{"92017bb45618a464046d18172821ed99b3524022": [["Contents lists available at ScienceDirectArchives of Psychiatric Nursing journal homepage: www.elsevier.com/locate/apnuContents lists available at ScienceDirectThe Value of Uncertainty Joyce J. Fitzpatrick (Editor) As a result of a 2018 study of neurocognitive results of experiments with monkeys, Yale researcher Lee concluded that we only learn from uncertainty (Yale News, 2018; Massi, Donahue, & Lee, 2018) .", [["monkeys", "ORGANISM", 289, 296]]], ["If that is truly the case with humans then the learning occurring today with the uncertainty surrounding the COVID-19 pandemic positions us for considerable intense and dramatic learning.", [["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37], ["dramatic", "OBSERVATION_MODIFIER", 169, 177]]], ["The amount of information alone is overwhelming and the predictive models of future permutations of the virus leave most of us with uncertainty.", [["the virus", "TREATMENT", 100, 109], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["While some components of the pandemic are more certain than others, e.g., the value of wearing masks and social distancing, the more complex components continue to perplex even the most learned epidemiologists.Contents lists available at ScienceDirectFor mental health researchers and clinicians uncertainty is a key factor, not only, but especially in the current environment.", [["the pandemic", "PROBLEM", 25, 37], ["wearing masks", "TREATMENT", 87, 100], ["pandemic", "OBSERVATION", 29, 37]]], ["The premise that more learning occurs with uncertainty is a core component of our interventions, helping others (and ourselves) acknowledge the uncertainty and build opportunities to learn and grow.Contents lists available at ScienceDirectAs mental health nurse researchers there are many additional opportunities for us.", [["our interventions", "TREATMENT", 78, 95]]], ["While much of the neurocognitive research is ongoing, there also is considerable nursing research focused on outcomes of uncertainty, particularly related to illness, and initiated through the early and continuing work of Merle Mishel.", [["illness", "DISEASE", 158, 165]]], ["Mishel's (1981) early research on uncertainty in illness began empirically through efforts at measurement (Mishel, 1981) .", [["illness", "DISEASE", 49, 56], ["illness", "PROBLEM", 49, 56]]], ["Her presentation of the uncertainty in illness theory first occurred in 1988, after she had conducted several studies of the phenomena; she then re-conceptualized the uncertainty in illness theory in 1990 (Mishel, 1988 (Mishel, , 1990 .", [["illness", "DISEASE", 39, 46], ["illness", "DISEASE", 182, 189], ["the phenomena", "PROBLEM", 121, 134]]], ["Several applications or the theory and the related references are detailed in the work of Clayton, Dean, and MIshel (2018) .Contents lists available at ScienceDirectThe theoretical perspective of Mishel, and the neuroscience research of Massi and colleagues (2018) , holds promise for research on outcomes of uncertainty in the COVID-19 pandemic.", [["Several applications", "TREATMENT", 0, 20], ["the COVID", "TEST", 324, 333], ["pandemic", "PROBLEM", 337, 345]]], ["The antecedents of uncertainty are present as are challenges for forming a new life perspective.", [["new", "OBSERVATION_MODIFIER", 75, 78]]], ["The rather constant discussion in the midst of the pandemic is adjusting to the new normal.", [["constant", "OBSERVATION_MODIFIER", 11, 19], ["new", "OBSERVATION_MODIFIER", 80, 83], ["normal", "OBSERVATION", 84, 90]]], ["Our potential is great for change during this challenging time.", [["great", "OBSERVATION_MODIFIER", 17, 22]]]], "69cc14915ab5b7184d9ec5cdb0be98279ccee0a5": [["Gain-of-function (GOF) research typically involves mutations that confer altered functionality of a protein or other molecule.", [["Gain", "TEST", 0, 4], ["mutations", "PROBLEM", 51, 60]]], ["These types of mutations have been used as powerful tools to understand basic bacterial and viral biology and pathogenhost interactions.", [["mutations", "PROBLEM", 15, 24]]], ["In recent years, a public discussion has surfaced, centering on the application of GOF research to highly pathogenic and potentially lethal viruses [1] .", [["lethal viruses", "PROBLEM", 133, 147]]], ["As the results from GOF research are salient to both the improved understanding of disease pathogenesis and the development of medical countermeasures to infectious diseases, the debate over its safety and value is of direct relevance to medical and public health practitioners.", [["infectious diseases", "DISEASE", 154, 173], ["disease pathogenesis", "PROBLEM", 83, 103], ["medical countermeasures", "TREATMENT", 127, 150], ["infectious diseases", "PROBLEM", 154, 173]]], ["This review article will provide a historical context for the current debate, describe the potential risks and benefits of this type of experimental study, and present some examples of how GOF research translates into tangible products of use to practicing clinicians.GOF: AN HISTORICAL PERSPECTIVEGenetic mutations can be classified in many ways, one of which is by their impact on protein function.", [["experimental study", "TEST", 136, 154], ["AN HISTORICAL PERSPECTIVEGenetic mutations", "PROBLEM", 273, 315]]], ["In the simplest terms, mutations can result in a protein's loss of function or GOF.", [["GOF", "GENE_OR_GENE_PRODUCT", 79, 82], ["GOF", "PROTEIN", 79, 82], ["mutations", "PROBLEM", 23, 32], ["a protein's loss of function", "PROBLEM", 47, 75], ["GOF", "PROBLEM", 79, 82]]], ["The distinction between the 2 phenotypes is not always clear.", [["not always", "UNCERTAINTY", 44, 54], ["clear", "OBSERVATION", 55, 60]]], ["GOF research, in this context, usually results in the introduction of changes to biological agents that might increase their ability to infect a host and cause disease by enhancing their transmissibility or pathogenicity [2] .", [["biological agents", "TREATMENT", 81, 98], ["disease", "PROBLEM", 160, 167], ["pathogenicity", "PROBLEM", 207, 220]]], ["DURC is a subset of microbiological research that, as defined by the US government, \"can be reasonably anticipated to provide knowledge, information, products, or technologies that could be directly misapplied to pose a significant threat with broad potential consequences to public health and safety, agricultural crops and other plants, animals, the environment, materiel, or national security\" [3, p.", [["DURC", "DISEASE", 0, 4]]], ["Some of the potential consequences of DURC that have been cited include the manipulation of pathogens for use as biological weapons and the development of mechanisms by which pathogens can evade countermeasures.", [["DURC", "GENE_OR_GENE_PRODUCT", 38, 42], ["DURC", "TREATMENT", 38, 42]]], ["DURC currently pertains to the select agents and toxins defined by the US Centers for Disease Prevention and Control and the US Department of Agriculture [4] .", [["DURC", "TREATMENT", 0, 4], ["toxins", "TREATMENT", 49, 55], ["Disease Prevention", "TREATMENT", 86, 104]]], ["Among these pathogens, highly pathogenic avian influenza virus (HPAI) is of high concern to both public health and agriculture authorities.GOF: AN HISTORICAL PERSPECTIVEPublic discourse on the controversies of influenza virus research is about a decade old, beginning in 2005 with the reconstitution of the 1918 influenza A(H1N1) [5] [6] [7] .", [["avian influenza virus", "DISEASE", 41, 62], ["HPAI", "DISEASE", 64, 68], ["influenza virus", "DISEASE", 210, 225], ["avian influenza virus", "ORGANISM", 41, 62], ["influenza virus", "ORGANISM", 210, 225], ["avian influenza virus", "SPECIES", 41, 62], ["HPAI", "SPECIES", 64, 68], ["these pathogens", "PROBLEM", 6, 21], ["highly pathogenic avian influenza virus", "PROBLEM", 23, 62], ["influenza virus", "PROBLEM", 210, 225], ["pathogens", "OBSERVATION", 12, 21]]], ["The more recent debates over the safety and merits of GOF research first surfaced in 2010, in the context of studies on the transmission dynamics of HPAI A(H5N1) (Figure 1 ).", [["HPAI", "DISEASE", 149, 153], ["HPAI A(H5N1)", "ORGANISM", 149, 161], ["HPAI A(H5N1)", "SPECIES", 149, 161]]], ["Laboratories at the University of Wisconsin (Madison) and Erasmus University Medical Center (EMC; Rotterdam, the Netherlands) performed a series of experiments [8, 9] that involved the mutation of 2 influenza A(H5N1) strains through multiple passaging.", [["2", "ORGANISM", 197, 198], ["influenza A(H5N1) strains", "ORGANISM", 199, 224], ["the mutation", "PROBLEM", 181, 193], ["2 influenza A(H5N1) strains", "PROBLEM", 197, 224], ["multiple passaging", "TREATMENT", 233, 251]]], ["The two laboratories identified specific amino acid changes that enhanced airborne transmissibility of the virus between ferrets-a standard animal influenza model that exhibits a natural history and pathology similar to what is observed in humans.", [["amino acid", "CHEMICAL", 41, 51], ["influenza", "DISEASE", 147, 156], ["amino acid", "CHEMICAL", 41, 51], ["amino acid", "AMINO_ACID", 41, 51], ["ferrets", "ORGANISM", 121, 128], ["humans", "ORGANISM", 240, 246], ["ferrets", "SPECIES", 121, 128], ["humans", "SPECIES", 240, 246], ["humans", "SPECIES", 240, 246], ["The two laboratories", "TEST", 0, 20], ["specific amino acid changes", "PROBLEM", 32, 59], ["the virus between ferrets", "PROBLEM", 103, 128], ["a standard animal influenza model", "PROBLEM", 129, 162], ["pathology", "PROBLEM", 199, 208], ["amino acid", "OBSERVATION", 41, 51], ["airborne transmissibility", "OBSERVATION", 74, 99]]], ["The potential translation from ferrets to humans raised concerns among funders (ie, the National Institutes of Health [NIH] ) and the broader biosecurity policy community that the research could be used for intentionally harmful purposes or result in an accidental release of pathogens from the laboratory into the general population.GOF: AN HISTORICAL PERSPECTIVEIn 2011, the Department of Health and Human Services (DHHS) convened the National Science Advisory Board for Biosecurity (NSABB)-an independent federal advisory committee chartered to provide advice on the biosecurity oversight of dual use research.", [["ferrets", "ORGANISM", 31, 38], ["humans", "ORGANISM", 42, 48], ["Human", "ORGANISM", 402, 407], ["humans", "SPECIES", 42, 48], ["Human", "SPECIES", 402, 407], ["humans", "SPECIES", 42, 48], ["pathogens", "PROBLEM", 276, 285]]], ["The NSABB was asked to weigh in on whether the GOF studies should be published in the public domain.", [["the GOF studies", "TEST", 43, 58]]], ["In March 2012, the NSABB recommended publication of both studies, with some minor changes to the EMC manuscript [11] .", [["both studies", "TEST", 52, 64]]], ["These deliberations led to the creation of a US framework for DURC studies [3, 12] and further stimulated a debate on GOF research within the scientific community [13] .GOF: AN HISTORICAL PERSPECTIVERecently, influenza virus researchers laid out a rationale for GOF experiments in the context of influenza A(H7N9) [14, 15] .", [["influenza A", "DISEASE", 296, 307], ["influenza virus", "ORGANISM", 209, 224], ["influenza A(H7N9)", "ORGANISM", 296, 313], ["a US framework", "TEST", 43, 57], ["DURC studies", "TEST", 62, 74], ["AN HISTORICAL PERSPECTIVERecently", "TREATMENT", 174, 207], ["influenza virus researchers", "TREATMENT", 209, 236], ["GOF experiments", "PROBLEM", 262, 277], ["influenza A", "PROBLEM", 296, 307]]], ["These arguments were met with some criticism [16] [17] [18] , especially with respect to the risks of accidental or intentional release of this HPAI.", [["HPAI", "DISEASE", 144, 148], ["this HPAI", "PROBLEM", 139, 148]]], ["Given the growing concern over this and other HPAI subtypes, the White House Office of Science and Technology Policy and the DHHS announced a moratorium, on 17 October 2014, on all new funding for GOF research on all influenza viruses, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) [2] .", [["HPAI", "DISEASE", 46, 50], ["influenza viruses", "DISEASE", 217, 234], ["acute respiratory syndrome coronavirus", "DISEASE", 243, 281], ["SARS-CoV)", "DISEASE", 283, 292], ["Middle East respiratory syndrome coronavirus", "DISEASE", 298, 342], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 236, 281], ["SARS-CoV", "ORGANISM", 283, 291], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 298, 342], ["MERS-CoV", "ORGANISM", 344, 352], ["severe acute respiratory syndrome coronavirus", "SPECIES", 236, 281], ["SARS-CoV", "SPECIES", 283, 291], ["Middle East respiratory syndrome coronavirus", "SPECIES", 298, 342], ["MERS-CoV", "SPECIES", 344, 352], ["GOF research", "PROBLEM", 197, 209], ["all influenza viruses", "PROBLEM", 213, 234], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 236, 281], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 298, 342], ["influenza viruses", "OBSERVATION", 217, 234], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["respiratory syndrome coronavirus", "OBSERVATION", 249, 281], ["Middle", "ANATOMY_MODIFIER", 298, 304], ["respiratory syndrome", "OBSERVATION", 310, 330]]], ["Additionally, the US government called for a voluntary moratorium on all such research, irrespective of funding source, while the risks and benefits of such experiments could be assessed.", [["the US government", "TEST", 14, 31], ["such experiments", "TREATMENT", 152, 168]]], ["On 15 and 16 December 2014, the National Academy of Sciences, National Research Council, and Institute of Medicine convened experts from the disciplines of infectious diseases, research ethics, and science policy to discuss the potential risks and benefits of GOF research in a public forum to help inform the federal government on how best to proceed in regulating GOF research on potentially dangerous biological agents [19] .Shortly after the meeting, the NIH notified a subset of researchers affected by the research pause that their work could resume [20] .", [["infectious diseases", "DISEASE", 156, 175], ["infectious", "OBSERVATION", 156, 166]]], ["Specifically, 5 research projects on MERS-CoV animal model development and 2 on HPAI were cleared to continue.GOF: AN HISTORICAL PERSPECTIVEThe discussion on the merits and risks of GOF research has not been limited to the United States, as the Dutch Court of Appeals recently handed down a verdict concerning EMC's objection to export license rules regarding the publication of HPAI GOF research [21] .", [["MERS-CoV", "ORGANISM", 37, 45], ["HPAI", "ORGANISM", 80, 84], ["MERS-CoV", "SPECIES", 37, 45], ["HPAI", "SPECIES", 80, 84], ["HPAI", "TREATMENT", 80, 84]]], ["Export licenses in the European Union are in place to prevent the proliferation of weapons of mass destruction and, thus, apply to specific biological agents, chemical agents, and technologies.", [["mass destruction", "PROBLEM", 94, 110], ["chemical agents", "TREATMENT", 159, 174], ["licenses", "OBSERVATION", 7, 15], ["mass", "OBSERVATION", 94, 98]]], ["Currently, all GOF research within the European Union requires export licenses for publication.GOF: AN HISTORICAL PERSPECTIVEA deliberative review process, headed by the NSABB, is currently underway [22] to evaluate the potential impacts of GOF research and to set criteria for what types of research can be conducted and made available in the public domain.", [["GOF", "OBSERVATION", 15, 18]]], ["A large part of the risk analysis will likely involve the potential for these pathogens to be misused either intentionally or accidentally.", [["the risk analysis", "TEST", 16, 33], ["these pathogens", "PROBLEM", 72, 87], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["The recent safety lapses at the Centers for Disease Control and Prevention and the NIH that could have resulted in exposure to anthrax and smallpox, respectively, have diminished public confidence in the ability of even high-containment laboratories to mitigate the risk of accidental release of pathogens of potential harm.", [["anthrax", "DISEASE", 127, 134], ["smallpox", "DISEASE", 139, 147], ["anthrax", "ORGANISM", 127, 134], ["The recent safety lapses", "PROBLEM", 0, 24], ["Disease Control", "TREATMENT", 44, 59], ["diminished", "OBSERVATION_MODIFIER", 168, 178]]], ["Though the actual risk of accidental release of highly pathogenic viruses may be low, public tolerance of that risk may be the ultimate determinant of what types of research are allowed to proceed.GOF: AN HISTORICAL PERSPECTIVEIncreasing attention has been brought to the use of alternative methods of investigation in areas that have historically been studied through GOF research.", [["highly pathogenic viruses", "PROBLEM", 48, 73], ["alternative methods", "TREATMENT", 279, 298]]], ["The relevance of these other methods is an important consideration for the scientific community, medical practitioners, and the general public, as the risks and benefits of each approach and the tangible outcomes they yield will vary according to the interests and needs of each sector.", [["each approach", "TREATMENT", 173, 186]]], ["As the GOF debate has transpired to date, the ramifications of this research for the practicing clinician have not been made clear.Animal ModelsThe development of novel prophylactic and therapeutic interventions invariably requires evaluation in animal models that, at least partially, recapitulate the disease in infected humans.", [["humans", "ORGANISM", 323, 329], ["humans", "SPECIES", 323, 329], ["humans", "SPECIES", 323, 329], ["novel prophylactic", "TREATMENT", 163, 181], ["therapeutic interventions", "TREATMENT", 186, 211], ["evaluation", "TEST", 232, 242], ["the disease in infected humans", "PROBLEM", 299, 329], ["novel", "OBSERVATION_MODIFIER", 163, 168], ["prophylactic", "OBSERVATION", 169, 181], ["disease", "OBSERVATION", 303, 310], ["infected", "OBSERVATION", 314, 322]]], ["Many emerging and reemerging zoonotic diseases lack relevant animal models that closely recapitulate human disease [27] .", [["zoonotic diseases", "DISEASE", 29, 46], ["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["reemerging zoonotic diseases", "PROBLEM", 18, 46]]], ["In these instances, GOF experiments are often needed to adapt virus isolates from humans to different, sometimes unnatural, mammalian hosts.", [["humans", "ORGANISM", 82, 88], ["humans", "SPECIES", 82, 88], ["humans", "SPECIES", 82, 88], ["GOF experiments", "PROBLEM", 20, 35], ["adapt virus isolates", "PROBLEM", 56, 76]]], ["Adaptation to a new host inherently involves the alteration of pathogens through mutation.", [["a new host", "PROBLEM", 14, 24], ["pathogens through mutation", "PROBLEM", 63, 89]]], ["As the development of appropriate animal models can be a rate-limiting step in the evaluation of prophylactic and therapeutic interventions, GOF modifications to viral strains can be an important tool toward accelerating the product development pipeline.Animal ModelsCoronaviruses such as SARS-CoV and MERS-CoV require meaningful small-animal models that elucidate viral pathogenesis and immunity.", [["SARS-CoV", "ORGANISM", 289, 297], ["MERS-CoV", "ORGANISM", 302, 310], ["SARS-CoV", "SPECIES", 289, 297], ["MERS-CoV", "SPECIES", 302, 310], ["the evaluation", "TEST", 79, 93], ["prophylactic and therapeutic interventions", "TREATMENT", 97, 139], ["GOF modifications", "TREATMENT", 141, 158], ["viral strains", "PROBLEM", 162, 175], ["Animal ModelsCoronaviruses", "PROBLEM", 254, 280], ["SARS", "PROBLEM", 289, 293], ["meaningful small-animal models", "PROBLEM", 319, 349], ["viral pathogenesis", "PROBLEM", 365, 383]]], ["The human isolates are manipulated either through natural evolution, targeted mutation, or repeated exposure to human factors in nonhuman hosts.", [["human", "ORGANISM", 4, 9], ["human", "ORGANISM", 112, 117], ["nonhuman", "ORGANISM", 129, 137], ["human factors", "PROTEIN", 112, 125], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 112, 117], ["The human isolates", "TREATMENT", 0, 18], ["targeted mutation", "PROBLEM", 69, 86]]], ["One of the more reliable SARS-CoV murine models was developed by modifying a human isolate through 15 serial passages, after which it was lethal to young mice [28] .", [["SARS-CoV", "ORGANISM", 25, 33], ["murine", "ORGANISM", 34, 40], ["human", "ORGANISM", 77, 82], ["mice", "ORGANISM", 154, 158], ["murine", "SPECIES", 34, 40], ["human", "SPECIES", 77, 82], ["mice", "SPECIES", 154, 158], ["SARS-CoV", "SPECIES", 25, 33], ["human", "SPECIES", 77, 82], ["mice", "SPECIES", 154, 158], ["a human isolate", "TREATMENT", 75, 90], ["SARS", "OBSERVATION", 25, 29]]], ["This mouse-adapted virus strain contained 6 coding mutations that conferred increased virulence, approximating many features of SARS-CoV disease in humans and thus providing a robust and reproducible challenge model for testing vaccines, antivirals, and other interventions [29] .", [["SARS-CoV disease", "DISEASE", 128, 144], ["mouse", "ORGANISM", 5, 10], ["SARS-CoV", "ORGANISM", 128, 136], ["humans", "ORGANISM", 148, 154], ["mouse", "SPECIES", 5, 10], ["humans", "SPECIES", 148, 154], ["mouse", "SPECIES", 5, 10], ["SARS-CoV", "SPECIES", 128, 136], ["humans", "SPECIES", 148, 154], ["adapted virus strain", "PROBLEM", 11, 31], ["6 coding mutations", "PROBLEM", 42, 60], ["increased virulence", "PROBLEM", 76, 95], ["SARS", "PROBLEM", 128, 132], ["CoV disease in humans", "PROBLEM", 133, 154], ["testing vaccines", "TREATMENT", 220, 236], ["antivirals", "TREATMENT", 238, 248], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["virulence", "OBSERVATION_MODIFIER", 86, 95], ["SARS", "OBSERVATION", 128, 132], ["CoV disease", "OBSERVATION", 133, 144]]], ["The development of an appropriate animal model for MERS-CoV, on the other hand, provides unique challenges because the viral receptor used for cell entry is radically different in mice.", [["cell", "ANATOMY", 143, 147], ["MERS-CoV", "ORGANISM", 51, 59], ["cell", "CELL", 143, 147], ["mice", "ORGANISM", 180, 184], ["viral receptor", "PROTEIN", 119, 133], ["mice", "SPECIES", 180, 184], ["MERS-CoV", "SPECIES", 51, 59], ["mice", "SPECIES", 180, 184], ["unique challenges", "TREATMENT", 89, 106], ["the viral receptor", "TREATMENT", 115, 133], ["cell entry", "PROBLEM", 143, 153]]], ["Models thus far have included transient transfection [30] and transgenic mice [31] , although it is still unclear whether these models accurately recapitulate human infection.", [["infection", "DISEASE", 165, 174], ["mice", "ORGANISM", 73, 77], ["human", "ORGANISM", 159, 164], ["mice", "SPECIES", 73, 77], ["human", "SPECIES", 159, 164], ["mice", "SPECIES", 73, 77], ["human", "SPECIES", 159, 164], ["transient transfection", "PROBLEM", 30, 52], ["human infection", "PROBLEM", 159, 174], ["infection", "OBSERVATION", 165, 174]]], ["Approximating human disease in these small-animal models might require further passaging in the presence of a humanized receptor, thus creating a potential for the development of GOF phenotypes.VaccinesMany live-attenuated vaccines, including some of the most successful vaccines ever developed, have been generated through GOF research.", [["human", "ORGANISM", 14, 19], ["GOF", "GENE_OR_GENE_PRODUCT", 179, 182], ["humanized receptor", "PROTEIN", 110, 128], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["Approximating human disease", "PROBLEM", 0, 27], ["further passaging", "TREATMENT", 71, 88], ["a humanized receptor", "TREATMENT", 108, 128], ["GOF phenotypes", "PROBLEM", 179, 193], ["Vaccines", "TREATMENT", 194, 202], ["attenuated vaccines", "TREATMENT", 212, 231], ["disease", "OBSERVATION", 20, 27], ["small", "OBSERVATION_MODIFIER", 37, 42], ["GOF phenotypes", "OBSERVATION", 179, 193]]], ["From polio to smallpox to influenza, liveattenuated vaccines elicit immunity against authentic epitopes on whole pathogens without causing disease.", [["smallpox", "DISEASE", 14, 22], ["influenza", "DISEASE", 26, 35], ["smallpox", "TREATMENT", 14, 22], ["influenza", "PROBLEM", 26, 35], ["liveattenuated vaccines", "TREATMENT", 37, 60], ["authentic epitopes", "PROBLEM", 85, 103], ["whole pathogens", "PROBLEM", 107, 122], ["disease", "PROBLEM", 139, 146]]], ["The live-attenuated measles vaccine was created by passaging the virus until mutations arose that altered virus tropism-a technique that could be considered, by current definitions, GOF research [32] .", [["measles", "ORGANISM", 20, 27], ["The live-attenuated measles vaccine", "TREATMENT", 0, 35], ["the virus", "PROBLEM", 61, 70], ["mutations", "PROBLEM", 77, 86], ["altered virus tropism", "PROBLEM", 98, 119]]], ["New research on highly pathogenic viruses has emphasized the different ways GOF mutations can generate even-more-effective live-attenuated vaccines.", [["GOF", "GENE_OR_GENE_PRODUCT", 76, 79], ["New research on highly pathogenic viruses", "PROBLEM", 0, 41], ["attenuated vaccines", "TREATMENT", 128, 147], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["pathogenic", "OBSERVATION_MODIFIER", 23, 33], ["viruses", "OBSERVATION", 34, 41]]], ["Mutations within RNA virus polymerases, for example, modify replication fidelity to generate higher or lower mutation rates during viral replication.", [["RNA virus polymerases", "PROTEIN", 17, 38], ["Mutations within RNA virus polymerases", "PROBLEM", 0, 38], ["lower mutation rates", "PROBLEM", 103, 123], ["viral replication", "TREATMENT", 131, 148]]], ["These fidelity mutants could potentially alter viral tropism, modify key antigens, and increase resistance against novel therapeutic interventions or antibody responses, but they could also lead to a virus that is less fit [33, 34] .", [["viral tropism", "PROBLEM", 47, 60], ["novel therapeutic interventions", "TREATMENT", 115, 146], ["antibody responses", "PROBLEM", 150, 168], ["a virus", "PROBLEM", 198, 205]]], ["These particular types of experiments have been carried out on a range of viruses, including alphaviruses [35, 36] and picornaviruses [37] .", [["alphaviruses", "PROBLEM", 93, 105], ["picornaviruses", "PROBLEM", 119, 133]]], ["The introduction of GOF mutations not only attenuates the virus but also provides improved understanding of the mechanics of viral replication, thus potentially uncovering new strategies in the development of vaccines against emerging pathogens.Therapeutic InterventionsThe generation of escape mutants in the presence of an investigational agent is common practice for the evaluation of antibiotics, antivirals, and other monoclonal antibodies.", [["GOF", "GENE_OR_GENE_PRODUCT", 20, 23], ["GOF", "DNA", 20, 23], ["monoclonal antibodies", "PROTEIN", 423, 444], ["GOF mutations", "PROBLEM", 20, 33], ["the virus", "PROBLEM", 54, 63], ["viral replication", "TREATMENT", 125, 142], ["vaccines", "TREATMENT", 209, 217], ["emerging pathogens", "PROBLEM", 226, 244], ["Therapeutic Interventions", "TREATMENT", 245, 270], ["escape mutants", "PROBLEM", 288, 302], ["an investigational agent", "TREATMENT", 322, 346], ["the evaluation", "TEST", 370, 384], ["antibiotics", "TREATMENT", 388, 399], ["antivirals", "TREATMENT", 401, 411], ["other monoclonal antibodies", "TEST", 417, 444], ["viral replication", "OBSERVATION", 125, 142], ["escape mutants", "OBSERVATION", 288, 302]]], ["GOF experiments with HPAIs and highly pathogenic human influenza viruses, for example, have identified specific mutations that can confer multidrug resistance [38, 39] .", [["HPAIs", "CHEMICAL", 21, 26], ["influenza viruses", "DISEASE", 55, 72], ["HPAIs", "GENE_OR_GENE_PRODUCT", 21, 26], ["human", "ORGANISM", 49, 54], ["influenza viruses", "ORGANISM", 55, 72], ["human", "SPECIES", 49, 54], ["influenza viruses", "SPECIES", 55, 72], ["human influenza viruses", "SPECIES", 49, 72], ["HPAIs", "PROBLEM", 21, 26], ["highly pathogenic human influenza viruses", "PROBLEM", 31, 72], ["specific mutations", "PROBLEM", 103, 121]]], ["GOF experiments are necessary in this context because naturally occurring resistant strains may not yet exist or the complex background of naturally occurring mutations may preclude identification of the amino acid residues that are critical to resistance [40] .", [["amino acid", "CHEMICAL", 204, 214], ["amino acid", "CHEMICAL", 204, 214], ["amino acid", "AMINO_ACID", 204, 214], ["GOF experiments", "PROBLEM", 0, 15], ["resistant strains", "PROBLEM", 74, 91], ["naturally occurring mutations", "PROBLEM", 139, 168], ["the amino acid residues", "PROBLEM", 200, 223]]], ["These GOF studies are equally important in research on antivirals and antibiotics and can help inform the development of combination therapies.", [["These GOF studies", "TEST", 0, 17], ["antivirals", "TREATMENT", 55, 65], ["antibiotics", "TREATMENT", 70, 81], ["combination therapies", "TREATMENT", 121, 142]]], ["Passive immunotherapy, which often includes a combination of products, is particularly dependent on GOF experiments for evaluating efficacy [41] [42] [43] , as seen in the current Ebola outbreak that has prompted a robust program to evaluate combination monoclonal antibody therapies [44, 45] .Disease SurveillanceIn the past half-century, GOF research has contributed to an improved understanding of the epidemiology of emerging pathogens and has informed efforts to conduct surveillance for future outbreaks.", [["Ebola", "DISEASE", 180, 185], ["Ebola", "ORGANISM", 180, 185], ["Passive immunotherapy", "TREATMENT", 0, 21], ["a combination of products", "TREATMENT", 44, 69], ["monoclonal antibody therapies", "TREATMENT", 254, 283], ["Disease", "PROBLEM", 294, 301], ["surveillance", "TEST", 476, 488]]], ["In the context of influenza, data, derived from GOF research, on the relative transmissibility of hemagglutinin mutations has aided in the interpretation of molecular surveillance data [46] .", [["influenza", "DISEASE", 18, 27], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 98, 111], ["influenza", "PROBLEM", 18, 27], ["hemagglutinin mutations", "PROBLEM", 98, 121], ["molecular surveillance data", "TEST", 157, 184], ["influenza", "OBSERVATION", 18, 27]]], ["Specifically, the initial influenza A(H5N1) [8, 9] and later influenza A(H7N9) experiments identified amino acid changes in influenza virus hemagglutinin or RNA polymerase through viral passaging or site-directed mutagenesis.", [["amino acid", "CHEMICAL", 102, 112], ["amino acid", "CHEMICAL", 102, 112], ["influenza A(H5N1)", "ORGANISM", 26, 43], ["influenza A", "ORGANISM", 61, 72], ["amino acid", "AMINO_ACID", 102, 112], ["influenza virus hemagglutinin", "ORGANISM", 124, 153], ["influenza virus hemagglutinin", "PROTEIN", 124, 153], ["RNA polymerase", "PROTEIN", 157, 171], ["influenza virus hemagglutinin", "SPECIES", 124, 153], ["H7N9", "SPECIES", 73, 77], ["influenza virus", "SPECIES", 124, 139], ["the initial influenza A(H5N1)", "TEST", 14, 43], ["later influenza A(H7N9) experiments", "PROBLEM", 55, 90], ["amino acid changes", "PROBLEM", 102, 120], ["influenza virus hemagglutinin", "TREATMENT", 124, 153], ["RNA polymerase", "TREATMENT", 157, 171], ["viral passaging", "TREATMENT", 180, 195], ["amino acid", "OBSERVATION", 102, 112]]], ["This research elucidated mechanisms by which naturally occurring influenza virus strains might evolve to replicate more efficiently and transmit more easily within mammalian hosts [47, 48] .", [["influenza virus", "ORGANISM", 65, 80], ["influenza virus strains", "PROBLEM", 65, 88]]], ["The results of these experiments can be used to cross-reference traits found among circulating strains and help predict transmission patterns and pathogenicity [49] .", [["these experiments", "TEST", 15, 32], ["circulating strains", "PROBLEM", 83, 102], ["pathogenicity", "PROBLEM", 146, 159]]], ["As the field of disease surveillance evolves to accommodate a growing repository of viral sequences, GOF research will also play an important role in assessing the public health significance of genotypic variation.Disease SurveillanceThough current understanding of the relationship between genotypic data and phenotypic expression is suboptimal, the increasing reliance by the clinical community on molecular diagnostic tools may help to reduce that uncertainty.", [["viral sequences", "DNA", 84, 99], ["disease surveillance", "TEST", 16, 36], ["viral sequences", "TEST", 84, 99], ["Disease", "PROBLEM", 214, 221], ["genotypic data", "TEST", 291, 305], ["disease", "OBSERVATION", 16, 23]]], ["As costs of whole-genome sequencing continue to decrease, data from these techniques are likely to become more central to disease surveillance programs.", [["whole-genome sequencing", "TREATMENT", 12, 35], ["these techniques", "TEST", 68, 84]]], ["The results of GOF experimentation can also help inform decisions about countermeasure selection and stockpiling, particularly in the context of influenza surveillance programs [50] .", [["influenza", "DISEASE", 145, 154], ["GOF experimentation", "TREATMENT", 15, 34], ["countermeasure selection", "TREATMENT", 72, 96], ["stockpiling", "TREATMENT", 101, 112], ["influenza surveillance programs", "TREATMENT", 145, 176]]], ["The improved understanding of how HPAIs evolve to transmit more efficiently has also factored into decisions about the creation of prepandemic vaccine stockpiles.THE ROLE OF CLINICIANS IN THE GOF RESEARCH DEBATEThe world has been witness to a number of emerging infectious disease pandemics over the past several decades.", [["infectious disease pandemics", "DISEASE", 262, 290], ["HPAIs", "GENE_OR_GENE_PRODUCT", 34, 39], ["prepandemic vaccine stockpiles", "TREATMENT", 131, 161], ["emerging infectious disease pandemics", "PROBLEM", 253, 290], ["infectious", "OBSERVATION", 262, 272]]], ["Each time, clinical and public health practitioners were on the front lines, providing care and treatment and finding ways to interrupt transmission, and were ultimately responsible for containing the outbreak.", [["treatment", "TREATMENT", 96, 105]]], ["Healthcare providers require effective medical countermeasures and epidemiologic information to assess risk and support decisions about treatment and prevention.", [["effective medical countermeasures", "TREATMENT", 29, 62], ["treatment", "TREATMENT", 136, 145]]], ["Recent outbreaks of infection due to Ebola virus, MERS-CoV, and pandemic influenza virus, however, continue to demonstrate that medical and public health readiness for emerging infections is not always optimal and could benefit from more research and development.", [["infection", "DISEASE", 20, 29], ["Ebola virus", "DISEASE", 37, 48], ["influenza virus", "DISEASE", 73, 88], ["infections", "DISEASE", 177, 187], ["Ebola virus", "ORGANISM", 37, 48], ["MERS-CoV", "ORGANISM", 50, 58], ["pandemic influenza virus", "ORGANISM", 64, 88], ["Ebola virus", "SPECIES", 37, 48], ["pandemic influenza virus", "SPECIES", 64, 88], ["Ebola virus", "SPECIES", 37, 48], ["MERS-CoV", "SPECIES", 50, 58], ["pandemic influenza virus", "SPECIES", 64, 88], ["infection", "PROBLEM", 20, 29], ["Ebola virus", "PROBLEM", 37, 48], ["MERS", "PROBLEM", 50, 54], ["CoV", "PROBLEM", 55, 58], ["pandemic influenza virus", "PROBLEM", 64, 88], ["emerging infections", "PROBLEM", 168, 187], ["infection", "OBSERVATION", 20, 29], ["Ebola virus", "OBSERVATION", 37, 48], ["influenza virus", "OBSERVATION", 73, 88]]], ["As outlined above, GOF research plays a significant role in ensuring that clinicians have the tools they need to respond to infectious disease outbreaks.", [["infectious disease outbreaks", "PROBLEM", 124, 152]]], ["As recent lapses at highprofile laboratories have illustrated, there remains the potential that bacterial and viral strains can escape even the most secure environments.", [["recent lapses at highprofile laboratories", "PROBLEM", 3, 44], ["bacterial and viral strains", "PROBLEM", 96, 123], ["bacterial", "OBSERVATION_MODIFIER", 96, 105], ["viral strains", "OBSERVATION", 110, 123]]]], "PMC7334151": [["A large body of research has demonstrated that asking certain types of questions can increase student engagement and it is an important factor of student achievement [1, 2, 16, 20, 27, 32].", [["large", "OBSERVATION_MODIFIER", 2, 7], ["body", "OBSERVATION_MODIFIER", 8, 12]]], ["Asking questions has become a central component of teachers\u2019 dialogic instructions and often serves as a catalyst for in-depth classroom discussions [21, 26, 28].IntroductionA large spectrum of approaches have been developed and successfully applied in generating classroom feedback to evaluate teachers\u2019 performances and help them improve their pedagogical techniques [15, 19, 26, 28, 31].", [["IntroductionA large spectrum of approaches", "TREATMENT", 162, 204]]], ["For example, the Nystrand and Gamoran coding scheme provides a general template for recording teachers\u2019 activities, which are used by trained human judges to manually assess teachers\u2019 classroom practices [15, 26].", [["human", "ORGANISM", 142, 147], ["Nystrand and Gamoran coding scheme", "DNA", 17, 51], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["the Nystrand and Gamoran coding scheme", "TREATMENT", 13, 51], ["a general template", "TREATMENT", 61, 79]]], ["By automatically analyzing when teachers ask questions and the corresponding question types, we are able to evaluate the question impact on teaching achievements and help teachers make adjustments to improve their pedagogical techniques.", [["teaching achievements", "TREATMENT", 140, 161]]], ["Previous endeavors have been conducted to tackle this problem using traditional machine learning (ML) algorithms [4\u20136, 12, 29].", [["traditional machine learning", "TREATMENT", 68, 96]]], ["However, the majority of these methods are not sufficient for teacher question detection due to the following challenges:Question type variation.", [["type variation", "PROBLEM", 130, 144]]], ["Traditional methods fail to perform a deep semantic understanding on natural languages, which is necessary for detecting questions of various types.Subject and speaker variability.", [["Traditional methods", "TREATMENT", 0, 19]]], ["Teaching materials and styles vary dramatically for different subjects and teachers, which leads to significantly distinguished classroom question sentences.", [["Teaching materials", "TREATMENT", 0, 18]]], ["Traditional methods show poor adaptability.", [["Traditional methods", "TEST", 0, 19], ["poor adaptability", "OBSERVATION", 25, 42]]]], "d66e36d869252432d6dd9ca4065c7051ac36f055": [["Sepsis is defined as life-threatening organ dysfunction as a consequence of a dysregulated host immune response to infection and is the leading cause of mortality across the globe [1] .", [["organ", "ANATOMY", 38, 43], ["Sepsis", "DISEASE", 0, 6], ["organ dysfunction", "DISEASE", 38, 55], ["infection", "DISEASE", 115, 124], ["organ", "ORGAN", 38, 43], ["Sepsis", "PROBLEM", 0, 6], ["threatening organ dysfunction", "PROBLEM", 26, 55], ["a dysregulated host immune response", "PROBLEM", 76, 111], ["infection", "PROBLEM", 115, 124], ["infection", "OBSERVATION", 115, 124], ["globe", "ANATOMY", 174, 179]]], ["Septic organ dysfunction leads to a 2-25 times greater risk of death, and patients that progress to septic shock have hospital mortality rates greater than 40%.", [["organ", "ANATOMY", 7, 12], ["Septic organ dysfunction", "DISEASE", 0, 24], ["death", "DISEASE", 63, 68], ["septic shock", "DISEASE", 100, 112], ["organ", "ORGAN", 7, 12], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Septic organ dysfunction", "PROBLEM", 0, 24], ["death", "PROBLEM", 63, 68], ["septic shock", "PROBLEM", 100, 112], ["hospital mortality rates", "TEST", 118, 142], ["organ", "ANATOMY", 7, 12], ["dysfunction", "OBSERVATION", 13, 24], ["septic", "OBSERVATION_MODIFIER", 100, 106]]], ["With few options available for prevention or treatment, antibiotics and supportive therapies are initiated empirically.", [["prevention", "TREATMENT", 31, 41], ["treatment", "TREATMENT", 45, 54], ["antibiotics", "TREATMENT", 56, 67], ["supportive therapies", "TREATMENT", 72, 92]]]], "182f97b5c1417220a7473fdf4fbf572a668a34c3": [["INTRODUCTIONLactate dehydrogenase (LDH) is a membrane associated enzyme and is released in extracellular environment during inflammation as a result of cellular injury.", [["membrane", "ANATOMY", 45, 53], ["extracellular", "ANATOMY", 91, 104], ["cellular", "ANATOMY", 152, 160], ["inflammation", "DISEASE", 124, 136], ["INTRODUCTIONLactate", "CHEMICAL", 0, 19], ["INTRODUCTIONLactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 33], ["LDH", "GENE_OR_GENE_PRODUCT", 35, 38], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["cellular", "CELL", 152, 160], ["INTRODUCTIONLactate dehydrogenase", "PROTEIN", 0, 33], ["LDH", "PROTEIN", 35, 38], ["membrane associated enzyme", "PROTEIN", 45, 71], ["INTRODUCTIONLactate dehydrogenase (LDH", "TEST", 0, 38], ["a membrane associated enzyme", "PROBLEM", 43, 71], ["inflammation", "PROBLEM", 124, 136], ["cellular injury", "PROBLEM", 152, 167], ["extracellular environment", "OBSERVATION", 91, 116], ["inflammation", "OBSERVATION", 124, 136], ["cellular injury", "OBSERVATION", 152, 167]]], ["[1] Few studies established direct correlation between concentrations of LDH and acute-phase cytokines.", [["LDH", "SIMPLE_CHEMICAL", 73, 76], ["LDH", "PROTEIN", 73, 76], ["acute-phase cytokines", "PROTEIN", 81, 102], ["Few studies", "TEST", 4, 15], ["LDH", "TEST", 73, 76], ["acute-phase cytokines", "PROBLEM", 81, 102], ["acute", "OBSERVATION_MODIFIER", 81, 86]]], ["LDH is a reliable biomarker of acute inflammatory injury associated with upper respiratory infections (URI).", [["respiratory", "ANATOMY", 79, 90], ["upper respiratory infections", "DISEASE", 73, 101], ["URI", "DISEASE", 103, 106], ["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["upper respiratory", "ORGANISM_SUBDIVISION", 73, 90], ["LDH", "TEST", 0, 3], ["acute inflammatory injury", "PROBLEM", 31, 56], ["upper respiratory infections", "PROBLEM", 73, 101], ["URI", "PROBLEM", 103, 106], ["reliable", "OBSERVATION_MODIFIER", 9, 17], ["biomarker", "OBSERVATION_MODIFIER", 18, 27], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["inflammatory", "OBSERVATION", 37, 49], ["upper", "ANATOMY_MODIFIER", 73, 78], ["respiratory", "ANATOMY", 79, 90], ["infections", "OBSERVATION", 91, 101]]], ["Unlike LDH, these cytokines in themselves do not directly represent cellular injury -the acute-phase cytokines are the mediators of inflammation, whereas LDH is the product of inflammatory injury.", [["cellular", "ANATOMY", 68, 76], ["inflammation", "DISEASE", 132, 144], ["LDH", "GENE_OR_GENE_PRODUCT", 7, 10], ["cellular", "CELL", 68, 76], ["LDH", "GENE_OR_GENE_PRODUCT", 154, 157], ["LDH", "PROTEIN", 7, 10], ["cytokines", "PROTEIN", 18, 27], ["acute-phase cytokines", "PROTEIN", 89, 110], ["LDH", "PROTEIN", 154, 157], ["LDH", "TEST", 7, 10], ["these cytokines", "TEST", 12, 27], ["cellular injury", "PROBLEM", 68, 83], ["the acute-phase cytokines", "PROBLEM", 85, 110], ["inflammation", "PROBLEM", 132, 144], ["LDH", "TEST", 154, 157], ["inflammatory injury", "PROBLEM", 176, 195], ["LDH", "OBSERVATION", 7, 10], ["cytokines", "OBSERVATION", 18, 27], ["do not directly represent", "UNCERTAINTY", 42, 67], ["cellular", "OBSERVATION_MODIFIER", 68, 76], ["injury", "OBSERVATION", 77, 83], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["-phase", "OBSERVATION_MODIFIER", 94, 100], ["inflammation", "OBSERVATION", 132, 144], ["inflammatory", "OBSERVATION_MODIFIER", 176, 188], ["injury", "OBSERVATION", 189, 195]]], ["[2] LDH is enzyme released in the bronchoalveolar space on damage of cytoplasmic cell membrane.", [["bronchoalveolar space", "ANATOMY", 34, 55], ["cytoplasmic cell membrane", "ANATOMY", 69, 94], ["[2] LDH", "SIMPLE_CHEMICAL", 0, 7], ["bronchoalveolar", "MULTI-TISSUE_STRUCTURE", 34, 49], ["cytoplasmic", "ORGANISM_SUBSTANCE", 69, 80], ["cell membrane", "CELLULAR_COMPONENT", 81, 94], ["LDH", "PROTEIN", 4, 7], ["enzyme", "PROTEIN", 11, 17], ["LDH is enzyme", "TEST", 4, 17], ["cytoplasmic cell membrane", "TREATMENT", 69, 94], ["bronchoalveolar space", "OBSERVATION", 34, 55], ["cytoplasmic cell membrane", "OBSERVATION", 69, 94]]], ["Elevated LDH is also indicator of underlying lung injury and inflammation.", [["lung", "ANATOMY", 45, 49], ["lung injury", "DISEASE", 45, 56], ["inflammation", "DISEASE", 61, 73], ["LDH", "GENE_OR_GENE_PRODUCT", 9, 12], ["lung", "ORGAN", 45, 49], ["LDH", "PROTEIN", 9, 12], ["Elevated LDH", "PROBLEM", 0, 12], ["underlying lung injury", "PROBLEM", 34, 56], ["inflammation", "PROBLEM", 61, 73], ["LDH", "OBSERVATION", 9, 12], ["also indicator of", "UNCERTAINTY", 16, 33], ["lung", "ANATOMY", 45, 49], ["injury", "OBSERVATION", 50, 56], ["inflammation", "OBSERVATION", 61, 73]]], ["[3] Serum LDH elevation had direct links to prognosis in this outbreak as well.", [["Serum", "ANATOMY", 4, 9], ["Serum", "ORGANISM_SUBSTANCE", 4, 9], ["LDH", "GENE_OR_GENE_PRODUCT", 10, 13], ["Serum LDH elevation", "TEST", 4, 23]]], ["Cohort of 138 cases of COVID-19 reported LDH elevation in 38% which had 4% mortality [7] whereas cohort of 99 cases reported having LDH elevation in 75% which had 11% mortality.", [["COVID", "DISEASE", 23, 28], ["LDH", "GENE_OR_GENE_PRODUCT", 41, 44], ["LDH", "GENE_OR_GENE_PRODUCT", 132, 135], ["COVID", "TEST", 23, 28], ["LDH elevation", "TEST", 41, 54], ["LDH elevation", "PROBLEM", 132, 145]]], ["Elevated LDH in the previous studies also was reported to be associated with bad prognosis as was seen in 2003 outbreak.", [["LDH", "GENE_OR_GENE_PRODUCT", 9, 12], ["LDH", "PROTEIN", 9, 12], ["Elevated LDH", "PROBLEM", 0, 12], ["the previous studies", "TEST", 16, 36], ["LDH", "OBSERVATION", 9, 12]]], ["[4] NASOPHARYNGEAL LDH, VIRAL URI, AND COVID-19INTRODUCTIONAbove discussion makes one thing clear that elevated LDH is a marker of viral cytolysis and poor prognosis.", [["LDH", "GENE_OR_GENE_PRODUCT", 112, 115], ["LDH", "PROTEIN", 112, 115], ["NASOPHARYNGEAL LDH", "TEST", 4, 22], ["VIRAL URI", "PROBLEM", 24, 33], ["elevated LDH", "PROBLEM", 103, 115], ["viral cytolysis", "PROBLEM", 131, 146], ["NASOPHARYNGEAL LDH", "ANATOMY", 4, 22], ["VIRAL URI", "OBSERVATION", 24, 33], ["viral cytolysis", "OBSERVATION", 131, 146]]], ["Now coming to viral URI and elevated LDH, in a study done on pediatric cases, elevated LDH in nasopharyngeal sample was associated with increased chances of acute otitis media (AOM).", [["nasopharyngeal sample", "ANATOMY", 94, 115], ["acute otitis media", "DISEASE", 157, 175], ["AOM", "DISEASE", 177, 180], ["LDH", "GENE_OR_GENE_PRODUCT", 37, 40], ["LDH", "GENE_OR_GENE_PRODUCT", 87, 90], ["nasopharyngeal sample", "CANCER", 94, 115], ["LDH", "PROTEIN", 87, 90], ["viral URI", "PROBLEM", 14, 23], ["elevated LDH", "PROBLEM", 28, 40], ["a study", "TEST", 45, 52], ["elevated LDH in nasopharyngeal sample", "PROBLEM", 78, 115], ["acute otitis media", "PROBLEM", 157, 175], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["URI", "OBSERVATION", 20, 23], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["LDH", "OBSERVATION", 37, 40], ["elevated", "OBSERVATION_MODIFIER", 78, 86], ["LDH", "OBSERVATION", 87, 90], ["nasopharyngeal", "ANATOMY", 94, 108], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["otitis", "OBSERVATION", 163, 169]]], ["LDH was indicator of nasopharyngeal injury and inflammation, leading to Eustachian tube damage which resulted in AOM.", [["nasopharyngeal", "ANATOMY", 21, 35], ["Eustachian tube", "ANATOMY", 72, 87], ["nasopharyngeal injury", "DISEASE", 21, 42], ["inflammation", "DISEASE", 47, 59], ["Eustachian tube damage", "DISEASE", 72, 94], ["AOM", "DISEASE", 113, 116], ["LDH", "GENE_OR_GENE_PRODUCT", 0, 3], ["nasopharyngeal", "ORGAN", 21, 35], ["Eustachian tube", "TISSUE", 72, 87], ["LDH", "TEST", 0, 3], ["nasopharyngeal injury", "PROBLEM", 21, 42], ["inflammation", "PROBLEM", 47, 59], ["Eustachian tube damage", "PROBLEM", 72, 94], ["AOM", "PROBLEM", 113, 116], ["indicator of", "UNCERTAINTY", 8, 20], ["nasopharyngeal", "ANATOMY", 21, 35], ["injury", "OBSERVATION", 36, 42], ["inflammation", "OBSERVATION", 47, 59], ["Eustachian", "OBSERVATION", 72, 82], ["tube damage", "OBSERVATION", 83, 94], ["AOM", "OBSERVATION", 113, 116]]], ["[2] COVID-19 starts as URI and in majority presents with same complaints few progresses onto lung injury and eventually ARDS.", [["lung", "ANATOMY", 93, 97], ["lung injury", "DISEASE", 93, 104], ["ARDS", "DISEASE", 120, 124], ["lung", "ORGAN", 93, 97], ["COVID", "TEST", 4, 9], ["URI", "PROBLEM", 23, 26], ["same complaints", "PROBLEM", 57, 72], ["lung injury", "PROBLEM", 93, 104], ["ARDS", "PROBLEM", 120, 124], ["lung", "ANATOMY", 93, 97], ["injury", "OBSERVATION", 98, 104], ["ARDS", "OBSERVATION", 120, 124]]], ["COVID-19 can be screened by doing nasopharyngeal LDH, even we can predict poor outcome on the basis of nasopharyngeal LDH and serum LDH.INTRODUCTIONBoth nasopharyngeal LDH and serum LDH are economical tests which can help our health-care personnel to segregate patient who can have stormy course of disease.", [["nasopharyngeal", "ANATOMY", 34, 48], ["nasopharyngeal", "ANATOMY", 103, 117], ["serum", "ANATOMY", 126, 131], ["nasopharyngeal", "ANATOMY", 153, 167], ["serum", "ANATOMY", 176, 181], ["nasopharyngeal", "ORGAN", 34, 48], ["LDH", "GENE_OR_GENE_PRODUCT", 49, 52], ["LDH", "GENE_OR_GENE_PRODUCT", 118, 121], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["LDH", "GENE_OR_GENE_PRODUCT", 168, 171], ["serum", "ORGANISM_SUBSTANCE", 176, 181], ["LDH", "GENE_OR_GENE_PRODUCT", 182, 185], ["patient", "ORGANISM", 261, 268], ["patient", "SPECIES", 261, 268], ["COVID", "TEST", 0, 5], ["nasopharyngeal LDH", "TEST", 34, 52], ["nasopharyngeal LDH", "TEST", 103, 121], ["serum LDH.INTRODUCTIONBoth nasopharyngeal LDH", "TEST", 126, 171], ["serum LDH", "TEST", 176, 185], ["economical tests", "TEST", 190, 206], ["disease", "PROBLEM", 299, 306], ["nasopharyngeal", "ANATOMY", 34, 48], ["nasopharyngeal LDH", "ANATOMY", 103, 121], ["nasopharyngeal LDH", "ANATOMY", 153, 171], ["disease", "OBSERVATION", 299, 306]]], ["Nasopharyngeal aspirate was used as a surrogate for the lower respiratory tract, as several studies confirm virus titers obtained in nasal washes correlate with disease activity in the lower airways.", [["Nasopharyngeal aspirate", "ANATOMY", 0, 23], ["lower respiratory tract", "ANATOMY", 56, 79], ["nasal", "ANATOMY", 133, 138], ["lower airways", "ANATOMY", 185, 198], ["Nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 23], ["lower", "ORGANISM_SUBDIVISION", 56, 61], ["respiratory tract", "ORGANISM_SUBDIVISION", 62, 79], ["nasal", "ORGANISM_SUBDIVISION", 133, 138], ["lower airways", "MULTI-TISSUE_STRUCTURE", 185, 198], ["Nasopharyngeal aspirate", "TEST", 0, 23], ["the lower respiratory tract", "PROBLEM", 52, 79], ["several studies", "TEST", 84, 99], ["virus titers", "TEST", 108, 120], ["nasal washes", "TREATMENT", 133, 145], ["disease activity in the lower airways", "PROBLEM", 161, 198], ["aspirate", "OBSERVATION", 15, 23], ["lower", "ANATOMY_MODIFIER", 56, 61], ["respiratory tract", "ANATOMY", 62, 79], ["disease", "OBSERVATION", 161, 168], ["lower", "ANATOMY_MODIFIER", 185, 190], ["airways", "ANATOMY", 191, 198]]], ["[8] In fact, cytopathic effects of respiratory syncytial viruses are detected earlier and are economical than isolation of virus itself.", [["respiratory syncytial viruses", "DISEASE", 35, 64], ["respiratory syncytial viruses", "ORGANISM", 35, 64], ["respiratory syncytial viruses", "SPECIES", 35, 64], ["cytopathic effects", "PROBLEM", 13, 31], ["respiratory syncytial viruses", "PROBLEM", 35, 64], ["virus itself", "PROBLEM", 123, 135], ["cytopathic", "OBSERVATION_MODIFIER", 13, 23], ["respiratory syncytial viruses", "OBSERVATION", 35, 64], ["virus", "OBSERVATION", 123, 128]]], ["[9] WHAT SHOULD BE THE IDEAL TECHNIQUE TO DETECT NASOPHARYNGEAL LDH?", [["NASOPHARYNGEAL LDH", "TEST", 49, 67], ["NASOPHARYNGEAL", "ANATOMY", 49, 63], ["LDH", "OBSERVATION", 64, 67]]], ["Nasal fluid is admixed with lacrimal fluid and water condenses at the mucosal surface during expiration can make an additional contribution.Various techniques to detect nasopharyngeal LDHNasal secretions contain minute amounts of cytokines and other inflammatory mediators expressed by various epithelial and non-epithelial cells.", [["Nasal fluid", "ANATOMY", 0, 11], ["lacrimal fluid", "ANATOMY", 28, 42], ["mucosal surface", "ANATOMY", 70, 85], ["nasopharyngeal LDHNasal secretions", "ANATOMY", 169, 203], ["epithelial", "ANATOMY", 294, 304], ["non-epithelial cells", "ANATOMY", 309, 329], ["Nasal fluid", "ORGANISM_SUBSTANCE", 0, 11], ["lacrimal fluid", "ORGANISM_SUBSTANCE", 28, 42], ["mucosal surface", "MULTI-TISSUE_STRUCTURE", 70, 85], ["epithelial", "CELL", 294, 304], ["non-epithelial cells", "CELL", 309, 329], ["cytokines", "PROTEIN", 230, 239], ["inflammatory mediators", "PROTEIN", 250, 272], ["epithelial and non-epithelial cells", "CELL_TYPE", 294, 329], ["Nasal fluid", "TREATMENT", 0, 11], ["lacrimal fluid", "PROBLEM", 28, 42], ["Various techniques", "TEST", 140, 158], ["nasopharyngeal LDHNasal secretions", "PROBLEM", 169, 203], ["cytokines", "PROBLEM", 230, 239], ["other inflammatory mediators", "PROBLEM", 244, 272], ["various epithelial and non-epithelial cells", "PROBLEM", 286, 329], ["fluid", "OBSERVATION", 6, 11], ["lacrimal", "ANATOMY", 28, 36], ["fluid", "OBSERVATION", 37, 42], ["water condenses", "OBSERVATION", 47, 62], ["mucosal", "ANATOMY", 70, 77], ["surface", "ANATOMY_MODIFIER", 78, 85], ["nasopharyngeal", "ANATOMY", 169, 183], ["LDHNasal secretions", "OBSERVATION", 184, 203], ["minute", "OBSERVATION_MODIFIER", 212, 218], ["amounts", "OBSERVATION_MODIFIER", 219, 226], ["cytokines", "OBSERVATION", 230, 239], ["inflammatory", "OBSERVATION_MODIFIER", 250, 262], ["various", "OBSERVATION_MODIFIER", 286, 293], ["epithelial", "ANATOMY_MODIFIER", 294, 304], ["non-epithelial cells", "OBSERVATION", 309, 329]]], ["Because cytokines play a dominant role in the pathophysiology of airway disease, interest has focused on cytokine determinations in nasal secretions.", [["airway", "ANATOMY", 65, 71], ["nasal secretions", "ANATOMY", 132, 148], ["airway disease", "DISEASE", 65, 79], ["airway", "MULTI-TISSUE_STRUCTURE", 65, 71], ["nasal secretions", "ORGANISM_SUBSTANCE", 132, 148], ["cytokines", "PROTEIN", 8, 17], ["cytokine", "PROTEIN", 105, 113], ["airway disease", "PROBLEM", 65, 79], ["cytokine determinations", "TEST", 105, 128], ["nasal secretions", "PROBLEM", 132, 148], ["dominant", "OBSERVATION_MODIFIER", 25, 33], ["airway", "ANATOMY", 65, 71], ["disease", "OBSERVATION", 72, 79], ["nasal", "ANATOMY", 132, 137], ["secretions", "OBSERVATION", 138, 148]]], ["Data on cytokine concentration obtained with different sampling techniques may differ by more than an order of magnitude.", [["cytokine", "PROTEIN", 8, 16], ["cytokine concentration", "TEST", 8, 30], ["different sampling techniques", "TREATMENT", 45, 74]]], ["[10] Polyurethane foam sampler technique is one of the most reliable and easy methods of detecting nasopharyngeal LDH.", [["nasopharyngeal", "ANATOMY", 99, 113], ["[10] Polyurethane", "CHEMICAL", 0, 17], ["nasopharyngeal", "CANCER", 99, 113], ["LDH", "GENE_OR_GENE_PRODUCT", 114, 117], ["Polyurethane foam sampler technique", "TREATMENT", 5, 40], ["nasopharyngeal LDH", "TEST", 99, 117], ["nasopharyngeal", "ANATOMY", 99, 113], ["LDH", "OBSERVATION", 114, 117]]], ["[11]CAN WE DO MASS SCREENING FOR COVID-19 WITH NASOPHARYNGEAL LDH?For a resource-constrained country like ours and considering the demography, the task of applying COVID-19 to all the residents of India will be a daunting task on health care workers, not only that but the cost of such herculean exercise will be exorbitant!", [["[11]CAN", "CHEMICAL", 0, 7], ["MASS SCREENING", "TEST", 14, 28], ["COVID", "TEST", 33, 38], ["NASOPHARYNGEAL LDH", "TEST", 47, 65], ["such herculean exercise", "TREATMENT", 281, 304], ["NASOPHARYNGEAL", "ANATOMY", 47, 61], ["LDH", "OBSERVATION", 62, 65]]], ["Our nation is being feared of entering Stage III of pandemic, i.e., community spread is highly likely.", [["pandemic", "PROBLEM", 52, 60], ["community spread", "PROBLEM", 68, 84], ["highly likely", "UNCERTAINTY", 88, 101]]], ["In such phase contact, tracing may not be possible for health-care system to track.", [["tracing", "TEST", 23, 30]]], ["In this phase, it is advisable to test each and every suspected case and isolate them and treat.CONCLUSIONBased on above discussion and evidences, we can apply nasopharyngeal LDH as economical option to do mass screening and it will also help us in segregation of cases requiring urgent health-care support.", [["nasopharyngeal", "ANATOMY", 160, 174], ["nasopharyngeal LDH", "TEST", 160, 178], ["economical option", "TREATMENT", 182, 199], ["mass screening", "TEST", 206, 220], ["urgent health-care support", "TREATMENT", 280, 306]]], ["No study has been done on nasopharyngeal LDH and COVID-19.CONCLUSIONHence, we do not know the false negativity of such approach, but given the cost of applying COVID-19 test kit on each and every suspected URI cases in India, we can give a serious thought to nasopharyngeal LDH.Declaration of patient consentPatient's consent not required as there are no patients in this study.Financial support and sponsorshipNil.Conflicts of interest\ue062ere are no conflicts of interest.Conflicts of interestbe COVID-19 positive as well.", [["nasopharyngeal", "ANATOMY", 26, 40], ["nasopharyngeal", "ANATOMY", 259, 273], ["nasopharyngeal LDH", "CANCER", 26, 44], ["nasopharyngeal", "CANCER", 259, 273], ["LDH", "GENE_OR_GENE_PRODUCT", 274, 277], ["patient", "ORGANISM", 293, 300], ["patients", "ORGANISM", 355, 363], ["patient", "SPECIES", 293, 300], ["Patient", "SPECIES", 308, 315], ["patients", "SPECIES", 355, 363], ["study", "TEST", 3, 8], ["nasopharyngeal LDH", "TEST", 26, 44], ["COVID", "TEST", 49, 54], ["COVID", "TEST", 160, 165], ["URI cases", "PROBLEM", 206, 215], ["nasopharyngeal LDH", "TEST", 259, 277], ["this study", "TEST", 367, 377], ["Financial support", "TREATMENT", 378, 395], ["sponsorshipNil", "TREATMENT", 400, 414], ["interestbe COVID", "TEST", 483, 499], ["nasopharyngeal", "ANATOMY", 259, 273], ["LDH", "OBSERVATION", 274, 277], ["no", "UNCERTAINTY", 445, 447], ["19 positive", "OBSERVATION_MODIFIER", 500, 511]]], ["While others may be having seasonal flu, without much damage, they may be very well treated at home, of course in home isolation. \ue062is will save lot of exchequers money and help the health-care systems to identify potential patients needing health-care assistance and ventilator support as well.", [["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["seasonal flu", "PROBLEM", 27, 39], ["much damage", "PROBLEM", 49, 60], ["home isolation", "TREATMENT", 114, 128], ["health-care assistance", "TREATMENT", 240, 262], ["ventilator support", "TREATMENT", 267, 285], ["flu", "OBSERVATION", 36, 39]]], ["Nasopharyngeal LDH -a marker of tissue damage can help us in finding and segregating patients of COVID-19, at much lesser cost as would have been incurred, had the COVID-19 kits applied on every person with URI.WHAT SHOULD BE THE CUTOFF OF NASOPHARYNGEAL LDH?For any screening test to be effective, false-negative rate should be minimal.", [["Nasopharyngeal", "ANATOMY", 0, 14], ["tissue", "ANATOMY", 32, 38], ["tissue damage", "DISEASE", 32, 45], ["Nasopharyngeal", "CANCER", 0, 14], ["LDH", "GENE_OR_GENE_PRODUCT", 15, 18], ["tissue", "TISSUE", 32, 38], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["person", "SPECIES", 195, 201], ["Nasopharyngeal LDH", "TEST", 0, 18], ["tissue damage", "PROBLEM", 32, 45], ["COVID", "TEST", 97, 102], ["the COVID-19 kits", "TREATMENT", 160, 177], ["URI", "PROBLEM", 207, 210], ["NASOPHARYNGEAL LDH", "TEST", 240, 258], ["any screening test", "TEST", 263, 281], ["false", "TEST", 299, 304], ["LDH", "OBSERVATION", 15, 18], ["marker of tissue", "OBSERVATION_MODIFIER", 22, 38], ["damage", "OBSERVATION", 39, 45], ["URI", "OBSERVATION", 207, 210], ["NASOPHARYNGEAL", "ANATOMY", 240, 254], ["LDH", "OBSERVATION", 255, 258], ["minimal", "OBSERVATION_MODIFIER", 329, 336]]], ["Based on the study done on nasopharyngeal secretion LDH and development of AOM, higher nasopharyngeal secretion LDH was associated with high chances of AOM, we suggest that LDH-3 and LDH-4 are higher in nasopharyngeal secretion.", [["nasopharyngeal", "ANATOMY", 27, 41], ["nasopharyngeal", "ANATOMY", 87, 101], ["nasopharyngeal", "ANATOMY", 203, 217], ["AOM", "DISEASE", 75, 78], ["AOM", "DISEASE", 152, 155], ["nasopharyngeal", "ORGAN", 27, 41], ["LDH", "GENE_OR_GENE_PRODUCT", 52, 55], ["AOM", "PATHOLOGICAL_FORMATION", 75, 78], ["nasopharyngeal", "ORGAN", 87, 101], ["LDH", "GENE_OR_GENE_PRODUCT", 112, 115], ["LDH-3", "GENE_OR_GENE_PRODUCT", 173, 178], ["LDH-4", "GENE_OR_GENE_PRODUCT", 183, 188], ["nasopharyngeal", "ORGAN", 203, 217], ["LDH", "PROTEIN", 173, 176], ["LDH", "PROTEIN", 183, 186], ["the study", "TEST", 9, 18], ["nasopharyngeal secretion LDH", "TEST", 27, 55], ["AOM", "PROBLEM", 75, 78], ["higher nasopharyngeal secretion LDH", "PROBLEM", 80, 115], ["AOM", "PROBLEM", 152, 155], ["LDH", "TEST", 173, 176], ["LDH", "TEST", 183, 186], ["nasopharyngeal secretion", "PROBLEM", 203, 227], ["AOM", "OBSERVATION", 75, 78], ["higher", "OBSERVATION_MODIFIER", 80, 86], ["nasopharyngeal", "ANATOMY", 87, 101], ["secretion LDH", "OBSERVATION", 102, 115], ["high", "OBSERVATION_MODIFIER", 136, 140], ["AOM", "OBSERVATION", 152, 155], ["higher", "OBSERVATION_MODIFIER", 193, 199], ["nasopharyngeal secretion", "OBSERVATION", 203, 227]]], ["[12] Furthermore, viral URI causes more rise in LDH as compared to bacterial.", [["LDH", "GENE_OR_GENE_PRODUCT", 48, 51], ["LDH", "PROTEIN", 48, 51], ["viral URI", "PROBLEM", 18, 27], ["LDH", "TEST", 48, 51], ["bacterial", "PROBLEM", 67, 76], ["rise", "OBSERVATION_MODIFIER", 40, 44], ["LDH", "ANATOMY", 48, 51]]], ["[13] Based on the study done by Ede Lin, 2013, [2] nasopharyngeal LDH and its association with various viruses are mentioned in Table 1 .", [["nasopharyngeal", "ANATOMY", 51, 65], ["the study", "TEST", 14, 23], ["nasopharyngeal LDH", "TEST", 51, 69], ["various viruses", "PROBLEM", 95, 110], ["nasopharyngeal LDH", "ANATOMY", 51, 69], ["viruses", "OBSERVATION", 103, 110]]], ["[2] If we study this Table 1 carefully then, you can find that the mean LDH and median LDH concentration in mU/ml was higher in coronavirus patients, we agree that the study population was small and hence is limitation but still given the severity of COVID-19, it is bound to have raised LDH at presentation.WHAT SHOULD BE THE CUTOFF OF NASOPHARYNGEAL LDH?Even the standard deviation is also lower, indicating that the Gaussian curve is steep in case of coronavirus as compared to other viruses.", [["coronavirus", "DISEASE", 128, 139], ["coronavirus", "DISEASE", 454, 465], ["COVID-19", "CHEMICAL", 251, 259], ["LDH", "GENE_OR_GENE_PRODUCT", 72, 75], ["LDH", "SIMPLE_CHEMICAL", 87, 90], ["coronavirus", "ORGANISM", 128, 139], ["patients", "ORGANISM", 140, 148], ["LDH", "GENE_OR_GENE_PRODUCT", 288, 291], ["coronavirus", "ORGANISM", 454, 465], ["LDH", "PROTEIN", 87, 90], ["LDH", "PROTEIN", 288, 291], ["patients", "SPECIES", 140, 148], ["the mean LDH", "TEST", 63, 75], ["median LDH concentration", "TEST", 80, 104], ["the study population", "TEST", 164, 184], ["COVID", "TEST", 251, 256], ["raised LDH", "PROBLEM", 281, 291], ["NASOPHARYNGEAL LDH", "TEST", 337, 355], ["the Gaussian curve", "TEST", 415, 433], ["coronavirus", "PROBLEM", 454, 465], ["small", "OBSERVATION_MODIFIER", 189, 194], ["NASOPHARYNGEAL", "ANATOMY", 337, 351], ["LDH", "OBSERVATION", 352, 355], ["standard deviation", "OBSERVATION", 365, 383], ["lower", "OBSERVATION_MODIFIER", 392, 397], ["coronavirus", "OBSERVATION", 454, 465]]]], "24f1963dabc7d28e1931ec44bba1ca425e6f0f99": [["Introducci\u00f3nLos coronavirus pertenecen a la familia Coronaviridae y son virus con envoltura cuyo genoma es de ARN de cadena sencilla con sentido positivo.", [["Introducci\u00f3nLos coronavirus", "ORGANISM", 0, 27], ["coronavirus", "SPECIES", 16, 27], ["Introducci\u00f3nLos coronavirus", "PROBLEM", 0, 27]]], ["Los coronavirus que afectan a los humanos son: coronavirus humano-229E (HCoV-229E), HCoV-NL63, HCoV-OC43, HCoV-HKU1, coronavirus del s\u00edndrome respiratorio agudo grave (SARS-CoV) y coronavirus del s\u00edndrome respiratorio de Oriente Medio (MERS-CoV); los dos \u00faltimos con tasas de mortalidad del 10% y el 35%, respectivamente 3 .Introducci\u00f3nEn diciembre de 2019, un nuevo coronavirus empez\u00f3 a circular entre los humanos, llamado ahora SARS-CoV-2, causante de la denominada enfermedad por coronavirus 2019 .", [["HCoV-229E", "CHEMICAL", 72, 81], ["SARS-CoV)", "DISEASE", 168, 177], ["coronavirus", "ORGANISM", 4, 15], ["coronavirus", "ORGANISM", 47, 58], ["humano-229E", "ORGANISM", 59, 70], ["HCoV-229E", "ORGANISM", 72, 81], ["HCoV-NL63", "CELL", 84, 93], ["HCoV-OC43", "CELL", 95, 104], ["HCoV-HKU1", "ORGANISM", 106, 115], ["coronavirus del s\u00edndrome", "ORGANISM", 117, 141], ["SARS-CoV", "ORGANISM", 168, 176], ["coronavirus", "SPECIES", 4, 15], ["coronavirus", "SPECIES", 47, 58], ["coronavirus", "SPECIES", 117, 128], ["coronavirus", "SPECIES", 180, 191], ["coronavirus", "SPECIES", 367, 378], ["coronavirus humano-229E (HCoV-229E)", "SPECIES", 47, 82], ["SARS-CoV) y coronavirus del s\u00edndrome respiratorio de Oriente Medio (MERS-CoV", "SPECIES", 168, 244], ["Los coronavirus", "TEST", 0, 15], ["coronavirus humano", "TEST", 47, 65], ["HCoV", "TEST", 72, 76], ["HCoV", "TEST", 84, 88], ["HCoV", "TEST", 95, 99], ["OC43", "TEST", 100, 104], ["HCoV", "TEST", 106, 110], ["HKU1", "TEST", 111, 115], ["coronavirus del s\u00edndrome", "TEST", 117, 141], ["respiratorio", "TEST", 142, 154], ["agudo", "TEST", 155, 160], ["grave (SARS", "PROBLEM", 161, 172], ["y coronavirus del s\u00edndrome", "PROBLEM", 178, 204], ["los dos \u00faltimos con tasas de mortalidad del", "TREATMENT", 247, 290], ["humanos", "TEST", 407, 414], ["coronavirus", "PROBLEM", 483, 494]]], ["Sus caracter\u00edsticas patog\u00e9nicas y de transmisi\u00f3n hicieron que la Organizaci\u00f3n Mundial de la Salud declarara una emergencia de salud p\u00fablica de inter\u00e9s internacional en enero de 2020, y el 11 de marzo, dada la propagaci\u00f3n y la gravedad de la COVID-19, declar\u00f3 que estas eran caracter\u00edsticas propias de una pandemia, la primera causada por un coronavirus 4 .Introducci\u00f3nEl SARS-CoV-2 produce un amplio espectro cl\u00ednico, que va desde casos asintom\u00e1ticos hasta neumon\u00eda grave e infecciones sist\u00e9micas con fallo multiorg\u00e1nica que pueden provocar la muerte 5 .", [["un coronavirus", "PROBLEM", 338, 352], ["Introducci\u00f3nEl SARS", "TEST", 356, 375], ["CoV", "TEST", 376, 379]]], ["Si bien en la mayor\u00eda de los casos la infecci\u00f3n por SARS-CoV-2 genera signos y s\u00edntomas en el aparato respiratorio, tambi\u00e9n se ha informado de episodios diarreicos con baja frecuencia 1, 6 .", [["Si", "CHEMICAL", 0, 2]]], ["Se ha estimado que alrededor del 80% de la poblaci\u00f3n con COVID-19 presenta signos y s\u00edntomas de leves a moderados que no requieren tratamiento 1 .", [["Se", "CHEMICAL", 0, 2], ["COVID", "TEST", 57, 62], ["requieren tratamiento", "TREATMENT", 121, 142]]], ["Respecto al periodo de gestaci\u00f3n, en una serie de casos que incluy\u00f3 43 mujeres embarazadas con COVID-19, el 86% tuvo enfermedad leve, el 9,3% enfermedad grave y el 4,7% enfermedad cr\u00edtica; porcentajes similares a los descritos en mujeres adultas no embarazadas con COVID-19.", [["COVID", "TEST", 95, 100], ["el", "TEST", 134, 136]]], ["Existe debate acerca de la posible transmisi\u00f3n vertical del SARS-CoV-2, y los consensos y las gu\u00edas internacionales sobre el manejo de las embarazadas con sospecha o confirmaci\u00f3n de infecci\u00f3n por SARS-CoV-2 difieren en las recomendaciones sobre el parto y la lactancia 10, 11 .", [["vertical del SARS", "PROBLEM", 47, 64], ["CoV", "TEST", 65, 68], ["CoV", "TEST", 201, 204]]], ["La primera de estas incluye 18 trabajos en ingl\u00e9s o chino publicados entre el 8 de diciembre de 2019 y el 1 de abril de 2020, con datos de 108 embarazos.", [["La", "TEST", 0, 2]]], ["Los autores concluyen que en la literatura analizada no se encuentra evidencia clara de transmisi\u00f3n vertical del SARS-CoV-2 de la madre al feto, pero no se puede excluir que se produzca 12 .", [["vertical del SARS", "TEST", 100, 117], ["CoV", "TEST", 118, 121]]], ["La segunda revisi\u00f3n incluye 12 trabajos publicados entre el 10 de febrero y el 4 de abril de 2020 que re\u00fanen 68 partos y 71 reci\u00e9n nacidos de madres con COVID-19, as\u00ed como 10 muestras cl\u00ednicas de l\u00edquido amni\u00f3tico, 5 de placenta y 10 de leche humana, las cuales dieron negativo para SARS-CoV-2 13 .Introducci\u00f3nEn el contexto de la pandemia por COVID-19 se ha generado nueva evidencia tras la publicaci\u00f3n de la gu\u00eda de la Organizaci\u00f3n Mundial de la Salud, el 13 de marzo de 2020 14 , por lo que efectuamos una revisi\u00f3n sistem\u00e1tica de la literatura en PubMed de estudios revisados por pares publicados entre el 27 de marzo y el 21 de mayo de 2020, enfoc\u00e1ndonos en aquellos trabajos que incluyeran an\u00e1lisis de muestras cl\u00ednicas de l\u00edquido amni\u00f3tico, placenta o membranas, sangre del cord\u00f3n umbilical y Se identificaron 107 registros, de los cuales dos condujeron a la misma referencia y uno indic\u00f3 una ruta de acceso no v\u00e1lida.", [["La segunda revisi\u00f3n", "TREATMENT", 0, 19], ["COVID", "TEST", 153, 158], ["para SARS", "TEST", 278, 287], ["CoV", "TEST", 288, 291], ["COVID", "TEST", 344, 349], ["enfoc\u00e1ndonos en aquellos trabajos", "TREATMENT", 646, 679], ["v\u00e1lida", "PROBLEM", 917, 923], ["placenta", "ANATOMY", 747, 755]]], ["Se revisaron 68 art\u00edculos originales y se excluyeron 50 por no cumplir con los criterios de inclusi\u00f3n y uno por no coincidir los datos de la tabla con el texto; finalmente, 17 estudios se incluyeron en el resumen cualitativo.Introducci\u00f3nEn los estudios incluidos se identific\u00f3 la etapa en que la madre tuvo la confirmaci\u00f3n de la infecci\u00f3n por SARS-CoV-2 o el diagn\u00f3stico cl\u00ednico de COVID-19, el pron\u00f3stico del binomio madre-hijo/a, los resultados del an\u00e1lisis de SARS-CoV-2 del beb\u00e9, y las muestras cl\u00ednicas de l\u00edquido amni\u00f3tico, placenta o membranas, sangre del cord\u00f3n umbilical o leche humana.", [["Se revisaron", "TEST", 0, 12], ["Introducci\u00f3nEn los estudios", "TREATMENT", 225, 252], ["la etapa en que la madre", "TREATMENT", 277, 301], ["CoV", "TEST", 468, 471], ["placenta", "ANATOMY", 530, 538], ["umbilical", "ANATOMY", 570, 579], ["leche humana", "ANATOMY", 582, 594]]], ["De acuerdo con la gu\u00eda GRADE, la calidad de todos los estudios incluidos en la s\u00edntesis cualitativa fue muy baja, debido a que tuvieron un dise\u00f1o observacional 16 .ResultadosSe incluyeron 17 estudios en el an\u00e1lisis cualitativo, todos con dise\u00f1o observacional y publicados en ingl\u00e9s 17-33 .", [["en la s\u00edntesis", "TREATMENT", 73, 87], ["ResultadosSe", "TEST", 164, 176]]], ["En ellos se identificaron 96 binomios madre-hijo/a, de los cuales 65 cumplieron con los criterios de inclusi\u00f3n (tabla 1).", [["cuales", "TEST", 59, 65]]], ["Se eliminaron 19, 10 y 2 binomios madre-hijo/a de los trabajos de Patan\u00e8 et al. 24 , Wu et al. 28 Yu et al. 32 reportan dos casos de mujeres embarazadas con diagn\u00f3stico de COVID-reportaron un producto de aborto que dio negativo para ARN de SARS-CoV-2, cuya madre dio positivo en muestras de hisopo nasofar\u00edngeo y de placenta.ResultadosEn un an\u00e1lisis retrospectivo realizado en 25 hospitales de China entre el 20 de enero y el 24 de marzo de 2020 se reporta un deceso neonatal, nacido de una madre con COVID-19 30 .", [["placenta", "ANATOMY", 316, 324], ["Se", "CHEMICAL", 0, 2], ["placenta", "ORGAN", 316, 324], ["CoV", "TEST", 245, 248], ["placenta", "ANATOMY", 316, 324]]], ["Este neonato fue un var\u00f3n nacido a las 35 + 2 semanas de gestaci\u00f3n mediante ces\u00e1rea que present\u00f3 asfixia grave, APGAR 1-1 al minuto y a los 5 minutos, fue tratado con ventilaci\u00f3n invasiva y muri\u00f3 en las 2 horas posteriores al nacimiento 30 .", [["APGAR", "TEST", 112, 117], ["fue tratado con ventilaci\u00f3n invasiva", "TREATMENT", 151, 187]]], ["Su madre desarroll\u00f3 neumon\u00eda grave y choque s\u00e9ptico, y requiri\u00f3 ingreso en la unidad de cuidados intensivos para ventilaci\u00f3n invasiva 30 .", [["para ventilaci\u00f3n invasiva", "TREATMENT", 108, 133]]], ["Este an\u00e1lisis retrospectivo incluye 116 embarazadas con COVID-19, 98 partos con producto \u00fanico y un parto gemelar; entre los/las 100 reci\u00e9n nacidos/as, a 86 se les efectuaron an\u00e1lisis para detectar ARN del SARS-CoV-2 en muestras far\u00edngeas, y en todos los casos los resultados fueron negativos; en diez casos se realizaron an\u00e1lisis de muestras de l\u00edquido amni\u00f3tico y de sangre del cord\u00f3n umbilical, cuyos resultados fueron negativos 30 .", [["embarazadas", "TEST", 40, 51], ["COVID", "TEST", 56, 61], ["del SARS", "TEST", 202, 210], ["CoV", "TEST", 211, 214], ["en diez casos", "TREATMENT", 294, 307], ["umbilical", "ANATOMY", 387, 396]]], ["En seis madres se analizaron muestras de secreci\u00f3n vaginal y fueron negativas, y 12 muestras de leche humana tambi\u00e9n fueron negativas 30 .ResultadosEntre los/las 65 neonatos/as identificados/as, ocho fueron positivos/as para SARS-CoV-2 en alg\u00fan momento 18, 19, 24, 27, 33 (tabla 1).", [["ResultadosEntre los/las 65 neonatos/as identificados/as, ocho fueron positivos/as para SARS-CoV", "SPECIES", 138, 233], ["En seis madres se analizaron muestras", "TREATMENT", 0, 37], ["para SARS", "TEST", 220, 229], ["CoV", "TEST", 230, 233]]], ["Zamaniyan et al. 33 describen el caso de una beb\u00e9 prematura nacida sin incidentes, con un peso de 2,350 kg y APGAR 8-8 muri\u00f3 el 26 de marzo.", [["beb\u00e9 prematura nacida sin incidentes, con un peso de 2,350 kg y APGAR 8-8 muri\u00f3 el 26 de marzo", "SPECIES", 45, 139], ["APGAR", "TEST", 109, 114]]], ["La muestra de l\u00edquido amni\u00f3tico que se tom\u00f3 antes de romper las membranas result\u00f3 positiva para el virus, pero la muestra de sangre del cord\u00f3n umbilical result\u00f3 negativa 33 .ResultadosHu et al. 19 reportan un caso de un neonato que a las 36 horas de vida tuvo resultado positivo de identificaci\u00f3n viral.", [["para el virus", "PROBLEM", 91, 104]]], ["Este ni\u00f1o fue aislado durante 14 d\u00edas, no desarroll\u00f3 s\u00edntomas cl\u00ednicos ni evidencia de la enfermedad, tuvo resultados normales en las pruebas bioqu\u00edmicas sistem\u00e1ticas y los recuentos de c\u00e9lulas sangu\u00edneas en el primer y el tercer d\u00edas de vida, as\u00ed como las radiograf\u00edas de t\u00f3rax y las ecograf\u00edas cerebrales realizadas el primer d\u00eda de vida, fueron normales.", [["desarroll\u00f3 s\u00edntomas", "PROBLEM", 42, 61]]], ["Estos autores mencionan que su madre tuvo labor de parto previa a la ces\u00e1rea, por lo que no se descarta la ruta transcervical; sin embargo, no se reporta el resultado de la identificaci\u00f3n viral en el cuello uterino.ResultadosSalvatori et al. 27 describen dos binomios con resultados positivos para SARS-CoV-2, tanto la madre como el infante, \u00abprobablemente infectados al mismo tiempo por una tercera persona\u00bb, cuyas muestras de leche humana resultaron negativas para el virus y ninguno necesit\u00f3 admisi\u00f3n en la unidad de cuidados intensivos.ResultadosEn 11 binomios madre-hijo/a analizados por Penfield et al. 25 se report\u00f3 una muestra de placenta y dos de membrana positivas para ARN del SARS-CoV-2.", [["labor", "PROBLEM", 42, 47], ["para SARS", "TEST", 293, 302], ["ResultadosEn", "TEST", 540, 552]]], ["Los autores sostienen que pudo haber ocurrido una mezcla de l\u00edquido y tejido materno-fetal en el momento del parto y que, por lo tanto, el origen del ARN del SARS-CoV-2 detectado en la placenta y las membranas no es claro y podr\u00eda representar contaminaci\u00f3n por sangre materna, l\u00edquido amni\u00f3tico o infecci\u00f3n por COVID-19 de las membranas y el saco amni\u00f3tico.ResultadosNinguno de los lactantes en este estudio dio positivo para SARS-CoV-2 entre el primer y el quinto d\u00edas de vida, y tampoco tuvieron s\u00edntomas de COVID-19.ResultadosLos estudios de Mulvey et al. 23Discusi\u00f3nEl SARS-CoV-2 es un virus de reciente circulaci\u00f3n en los humanos que ha generado una pandemia r\u00e1pidamente por su principal forma de transmisi\u00f3n, a trav\u00e9s de gotitas de las v\u00edas respiratorias 9 .", [["Los", "TEST", 0, 3], ["pudo", "TEST", 26, 30], ["del SARS", "TEST", 154, 162], ["CoV", "TEST", 163, 166], ["detectado", "TEST", 169, 178], ["lactantes", "TEST", 382, 391], ["para SARS", "TEST", 421, 430], ["CoV", "TEST", 578, 581]]], ["Inicialmente, la principal v\u00eda de entrada del SARS-CoV-2 al cuerpo humano se relacion\u00f3 con una enfermedad con signos y s\u00edntomas respiratorios.", [["Inicialmente", "TEST", 0, 12], ["CoV", "TEST", 51, 54], ["al cuerpo humano", "TREATMENT", 57, 73]]], ["Actualmente se conoce que la infecci\u00f3n, en algunos casos, puede ser m\u00e1s generalizada debido a la diseminaci\u00f3n del virus en el cuerpo 1,6 .", [["Actualmente", "TEST", 0, 11], ["a la diseminaci\u00f3n del virus en el cuerpo", "TREATMENT", 92, 132]]], ["Se requiere que en paralelo se investigue la presencia viral y la capacidad de replicaci\u00f3n de las part\u00edculas virales en muestras de l\u00edquido amni\u00f3tico, placenta o membranas, sangre del cord\u00f3n umbilical y leche humana, aplicando estrictas medidas de prevenci\u00f3n y control de infecciones durante el proceso de la toma de muestras, el transporte, el almacenamiento y el an\u00e1lisis.Discusi\u00f3nAl momento de escribir esta revisi\u00f3n, a diario se publica nueva informaci\u00f3n sobre la transmisi\u00f3n del SARS-CoV-2.", [["Se", "CHEMICAL", 0, 2], ["Se", "CHEMICAL", 0, 2], ["umbilical y leche humana", "TREATMENT", 191, 215], ["aplicando estrictas medidas", "TREATMENT", 217, 244], ["placenta", "ANATOMY", 151, 159]]], ["Mediante la t\u00e9cnica de hibridaci\u00f3n in situ con ARN viral se demostr\u00f3 la presencia de SARS-CoV-2 en placenta en el lado fetal 24 , lo que podr\u00eda sugerir que el virus se disemina del aparato respiratorio y podr\u00eda transmitirse de forma transplacentaria.Discusi\u00f3nConsiderando el sistema de clasificaci\u00f3n y definici\u00f3n de casos para la infecci\u00f3n por SARS-CoV-2 en las embarazadas, los fetos y los neonatos propuesto por Shah et al. 34 , el caso reportado por Zamaniyan et al. 33 , incluido en la s\u00edntesis cualitativa de esta revisi\u00f3n, cumple con uno de los tres criterios propuestos para ser clasificado como una infecci\u00f3n cong\u00e9nita confirmada.", [["Mediante la t\u00e9cnica", "TREATMENT", 0, 19], ["CoV", "TEST", 90, 93]]], ["Estos hallazgos indican la importancia de efectuar estudios que incluyan el seguimiento de los binomios madre-hijo/a clasificados por la etapa del embarazo en la que ocurra la infecci\u00f3n, as\u00ed como por la gravedad de esta, ya que la gravedad podr\u00eda ser un factor condicionante para la diseminaci\u00f3n viral y, en consecuencia, para la transmisi\u00f3n intrauterina.Discusi\u00f3nPor otro lado, en un reporte no revisado por pares disponible el 15 de mayo de 2020, los autores sostienen que han identificado el primer caso confirmado de transmisi\u00f3n transplacentaria de SARS-CoV-2 en una mujer embarazada durante el \u00faltimo trimestre, dado que el l\u00edquido amni\u00f3tico obtenido antes de la rotura de las membranas y durante la ces\u00e1rea, la placenta, los hisopos nasofar\u00edngeos y rectales neonatales obtenidos durante la primera hora de vida, y muestras de sangre y l\u00edquido de lavado broncoalveolar del neonato, resultaron positivos para los genes E y S del SARS-CoV-2 35 .", [["a clasificados por la etapa del embarazo", "TREATMENT", 115, 155], ["CoV", "TEST", 558, 561], ["del SARS", "TEST", 929, 937], ["CoV", "TEST", 938, 941], ["la placenta", "ANATOMY", 714, 725]]], ["El neonato prematuro con APGAR 4 y 2 al minuto y a los 5 minutos, respectivamente, necesit\u00f3 reanimaci\u00f3n y en el segundo d\u00eda de vida present\u00f3 irritabilidad, hiperton\u00eda axial y opist\u00f3tonos, y los autores sostienen es el primer caso de infecci\u00f3n cong\u00e9nita que se presenta con manifestaciones neurol\u00f3gicas despu\u00e9s de mostrar viremia neonatal 35 .", [["viremia", "DISEASE", 321, 328]]], ["Sin embargo, en este reporte no revisado por pares, seg\u00fan nuestra apreciaci\u00f3n, las curvas de amplificaci\u00f3n de las muestras de sangre del reci\u00e9n nacido y la de hisopo vaginal parecer\u00edan ser compatibles con curvas de amplificaci\u00f3n anormales 36 .Discusi\u00f3nUn art\u00edculo describe el caso de una embarazada positiva para SARS-CoV-2 y negativa para IgM/IgG, cuyo neonato fue aislado inmediatamente al nacer y result\u00f3 positivo para SARS-CoV-2 a las 16 horas posparto y negativo para IgM/IgG, aunque con la limitante de la falta de evaluaci\u00f3n del l\u00edquido amni\u00f3tico, de sangre del cord\u00f3n umbilical o de tejido placentario 37 .Discusi\u00f3nRespecto a la transmisi\u00f3n del SARS-CoV-2 por la leche materna, encontramos dos casos de mujeres con detecci\u00f3n positiva de ARN viral 18, 28 .", [["para SARS", "TEST", 308, 317], ["CoV", "TEST", 318, 321], ["para IgM", "TEST", 335, 343], ["IgG", "TEST", 344, 347], ["para SARS", "TEST", 417, 426], ["CoV", "TEST", 427, 430], ["a las", "TEST", 433, 438], ["para IgM", "TEST", 468, 476], ["IgG", "TEST", 477, 480], ["a la transmisi\u00f3n del SARS", "TEST", 632, 657], ["CoV", "TEST", 658, 661], ["la leche materna", "TREATMENT", 668, 684], ["vaginal", "ANATOMY", 166, 173]]], ["En relaci\u00f3n con otros virus de la familia Coronaviridae, una revisi\u00f3n de la literatura sostiene que no existe evidencia de transmisi\u00f3n vertical del SARS-CoV y que no se ha detectado el virus en la leche humana 38 .", [["En relaci\u00f3n con otros virus", "TREATMENT", 0, 27], ["vertical del SARS", "TEST", 135, 152]]], ["Dos estudios han indagado la presencia de ARN del SARS-CoV-2 y de anticuerpos en leche humana.", [["humana", "ANATOMY", 87, 93]]], ["El primero report\u00f3 la presencia de anticuerpos contra el SARS-CoV-2, pero no de ARN, en la leche de una mujer infectada a las 19 semanas de gestaci\u00f3n; sin embargo, se tom\u00f3 una sola muestra 131 d\u00edas despu\u00e9s de la aparici\u00f3n de s\u00edntomas, no se proporcionaron detalles sobre el m\u00e9todo de recogida y el beb\u00e9 no fue examinado para la infecci\u00f3n por SARS-CoV-2 39 .", [["ARN", "DISEASE", 80, 83], ["CoV", "TEST", 347, 350]]], ["El segundo estudio es un informe de un caso de una mujer infectada a las 7 semanas de gestaci\u00f3n, cuyas muestras de leche a los 12 y 30 d\u00edas posparto fueron negativas para anticuerpos contra el SARS-CoV-2 y el reci\u00e9n nacido dio negativo; sin embargo, se desconocen los detalles de la recogida de las muestras de leche 40 .", [["posparto", "TEST", 140, 148], ["fueron", "TEST", 149, 155], ["CoV", "TEST", 198, 201]]], ["El efecto protector de la leche humana es particularmente fuerte contra las enfermedades infecciosas que se previenen mediante la transferencia directa de anticuerpos y otros factores antiinfecciosos 46 .", [["El efecto protector", "TREATMENT", 0, 19]]], ["Un estudio no revisado por pares, disponible el 8 de mayo de 2020, describe la reactividad de 15 muestras de leche materna de mujeres recuperadas con diagn\u00f3stico previo de COVID-19 al receptor de dominio de uni\u00f3n de la prote\u00edna S del virus SARS-CoV-2, compar\u00e1ndolas con 10 muestras de leche materna obtenidas antes de la pandemia.", [["la prote\u00edna S del virus SARS", "TEST", 216, 244], ["CoV", "TEST", 245, 248], ["la pandemia", "OBSERVATION", 318, 329]]], ["Mediante ELISA se determinaron las IgA, IgG, IgM e IgA secretora 47 , y los resultados indican que el 80% de las muestras con diagn\u00f3stico previo de COVID-19 tuvieron reactividad para IgA e IgA secretora; los valores promedio de OD del grupo de COVID-19 fueron significativamente mayores para IgA, IgA secretora e IgG, pero no para IgM, en comparaci\u00f3n con los valores promedio del grupo prepand\u00e9mico 47 .", [["IgA", "PROTEIN", 35, 38], ["IgG", "PROTEIN", 40, 43], ["IgM", "PROTEIN", 45, 48], ["Mediante ELISA", "TEST", 0, 14], ["IgA", "TEST", 35, 38], ["IgG", "TEST", 40, 43], ["IgM", "TEST", 45, 48], ["que el", "TEST", 95, 101], ["COVID", "TEST", 148, 153], ["IgA", "TEST", 183, 186], ["COVID", "TEST", 244, 249], ["para IgA", "TEST", 287, 295], ["IgA", "TEST", 297, 300], ["para IgM", "TEST", 326, 334]]], ["Los autores concluyen que despu\u00e9s de la infecci\u00f3n, en la mayor\u00eda de los casos, existe una fuerte respuesta inmunitaria contra el SARS-CoV-2 mediada por la IgA secretora en la leche humana 47 .", [["contra el SARS", "TEST", 119, 133], ["CoV", "TEST", 134, 137]]], ["Es interesante que en modelos animales se ha demostrado que la lactancia materna previene la infecci\u00f3n por el coronavirus diarreico porcino debido al efecto protector de las IgA e IgG de la leche materna 48 .Discusi\u00f3nLa Organizaci\u00f3n Mundial de la Salud, en la gu\u00eda provisional del 13 de marzo de 2020, sostiene que las madres y los/las reci\u00e9n nacidos/as con sospecha o confirmaci\u00f3n de COVID-19 deben permanecer juntos, practicar la t\u00e9cnica del contacto piel con piel, el cuidado de la madre canguro e inmediatamente despu\u00e9s del nacimiento iniciar la lactancia materna 14 .", [["el coronavirus diarreico porcino debido", "TREATMENT", 107, 146], ["al efecto protector", "TREATMENT", 147, 166], ["COVID", "TEST", 385, 390]]], ["En algunos casos la separaci\u00f3n puede privar al reci\u00e9n nacido de los beneficios nutricionales e inmunitarios de la leche materna, aunque existe la opci\u00f3n de la extracci\u00f3n.", [["En algunos casos la separaci\u00f3n", "TREATMENT", 0, 30]]], ["De acuerdo con Tomori et al. 51 , la separaci\u00f3n de las madres con sospecha o confirmaci\u00f3n de SARS-CoV-2 y sus beb\u00e9s puede provocar \u00abun exceso de enfermedades y muertes prevenibles entre los beb\u00e9s y las mujeres alrededor del mundo\u00bb en el contexto de la pandemia.Discusi\u00f3nEn resumen, la informaci\u00f3n relacionada con la posible transmisi\u00f3n del SARS-CoV-2 durante el embarazo se ha reportado en estudios de peque\u00f1a escala.", [["del SARS", "PROBLEM", 336, 344], ["CoV", "TEST", 345, 348], ["durante el embarazo", "TREATMENT", 351, 370]]], ["De acuerdo con nuestros criterios de b\u00fasqueda, encontramos en la literatura un caso grave y fatal de una madre con COVID-19 en la que se detect\u00f3 ARN viral en el l\u00edquido amni\u00f3tico antes de romper las membranas, y el neonato result\u00f3 negativo para la presencia del virus al nacimiento y positivo a la semana 33 .", [["COVID", "TEST", 115, 120], ["a la semana", "TEST", 293, 304]]], ["Tambi\u00e9n se han reportado dos casos de detecci\u00f3n de ARN del SARS-CoV-2 en leche humana 18, 28 , pero en nuestro conocimiento no se ha probado la capacidad infectiva de esta.", [["CoV", "TEST", 64, 67]]], ["La transmisi\u00f3n vertical debe investigarse, idealmente utilizando t\u00e9cnicas de aislamiento que demuestren la capacidad infectiva de la part\u00edcula viral.Editora responsable del art\u00edculoMercedes Carrasco Porti\u00f1o.Contribuciones de autor\u00edaC.L. Sampieri realiz\u00f3 la concepci\u00f3n del estudio, el dise\u00f1o del trabajo, el an\u00e1lisis de los estudios, la interpretaci\u00f3n de los estudios y la escritura del art\u00edculo.", [["del art\u00edculoMercedes", "OBSERVATION", 169, 189]]], ["Ambas autoras J o u r n a l P r e -p r o o f 14 aprobaron la versi\u00f3n final para su publicaci\u00f3n y se hacen responsables y garantes de que todos los aspectos que integran el manuscrito han sido revisados y discutidos entre ellas con la finalidad de que sean expuestos con la m\u00e1xima precisi\u00f3n e integridad.Financiaci\u00f3nNinguna.Conflictos de interesesNinguno.", [["Ambas", "TEST", 0, 5], ["aprobaron", "TEST", 48, 57], ["Financiaci\u00f3nNinguna", "TREATMENT", 303, 322]]]], "e5eb156244a7c1ac71bc8338992a06ea120e31d7": [["IntroductionBoth pathogens and hosts require iron for several vital processes including oxygen binding, catalysis, and gene expression [1] .", [["iron", "CHEMICAL", 45, 49], ["oxygen", "CHEMICAL", 88, 94], ["iron", "CHEMICAL", 45, 49], ["oxygen", "CHEMICAL", 88, 94], ["iron", "SIMPLE_CHEMICAL", 45, 49], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["IntroductionBoth pathogens", "PROBLEM", 0, 26], ["iron", "TREATMENT", 45, 49], ["several vital processes", "PROBLEM", 54, 77], ["oxygen binding", "TREATMENT", 88, 102], ["catalysis", "TREATMENT", 104, 113]]], ["Demand for the same iron resources pressures the host and pathogen to coevolve competing systems to acquire and withhold iron [2] .", [["iron", "CHEMICAL", 20, 24], ["iron", "CHEMICAL", 121, 125], ["iron", "CHEMICAL", 20, 24], ["iron", "CHEMICAL", 121, 125], ["iron", "SIMPLE_CHEMICAL", 20, 24], ["iron", "SIMPLE_CHEMICAL", 121, 125], ["the same iron resources pressures", "TREATMENT", 11, 44], ["pathogen", "PROBLEM", 58, 66], ["iron", "TREATMENT", 121, 125]]], ["The host limits the free iron concentration with the iron transport and storage proteins transferrin and ferritin.", [["iron", "CHEMICAL", 25, 29], ["iron", "CHEMICAL", 53, 57], ["iron", "CHEMICAL", 25, 29], ["iron", "CHEMICAL", 53, 57], ["iron", "SIMPLE_CHEMICAL", 25, 29], ["iron", "SIMPLE_CHEMICAL", 53, 57], ["transferrin", "GENE_OR_GENE_PRODUCT", 89, 100], ["ferritin", "GENE_OR_GENE_PRODUCT", 105, 113], ["storage proteins", "PROTEIN", 72, 88], ["transferrin", "PROTEIN", 89, 100], ["ferritin", "PROTEIN", 105, 113], ["the free iron concentration", "TREATMENT", 16, 43], ["the iron transport", "TREATMENT", 49, 67], ["storage proteins transferrin", "TEST", 72, 100], ["ferritin", "TEST", 105, 113]]], ["Many bacteria acquire iron from the host by secreting siderophores that remove iron from the host proteins and carry it to the pathogen [3] .IntroductionIn response to siderophore-mediated iron acquisition, many animal hosts produce siderocalins.", [["iron", "CHEMICAL", 22, 26], ["iron", "CHEMICAL", 79, 83], ["iron", "CHEMICAL", 189, 193], ["iron", "CHEMICAL", 22, 26], ["iron", "CHEMICAL", 79, 83], ["iron", "CHEMICAL", 189, 193], ["siderocalins", "CHEMICAL", 233, 245], ["iron", "SIMPLE_CHEMICAL", 22, 26], ["iron", "SIMPLE_CHEMICAL", 79, 83], ["siderophore", "SIMPLE_CHEMICAL", 168, 179], ["iron", "SIMPLE_CHEMICAL", 189, 193], ["siderocalins", "GENE_OR_GENE_PRODUCT", 233, 245], ["Many bacteria", "PROBLEM", 0, 13], ["iron", "TREATMENT", 22, 26], ["secreting siderophores", "PROBLEM", 44, 66], ["iron", "TREATMENT", 79, 83], ["the host proteins", "TREATMENT", 89, 106], ["siderophore-mediated iron acquisition", "TREATMENT", 168, 205], ["bacteria", "OBSERVATION", 5, 13]]], ["Siderocalins are a siderophore-binding subset of the lipocalin family of proteins defined by the lipocalin fold, an eight-stranded anti-parallel beta-barrel that forms a calyx or binding pocket [4, 5] .", [["calyx", "ANATOMY", 170, 175], ["Siderocalins", "CHEMICAL", 0, 12], ["Siderocalins", "CHEMICAL", 0, 12], ["Siderocalins", "SIMPLE_CHEMICAL", 0, 12], ["lipocalin", "GENE_OR_GENE_PRODUCT", 53, 62], ["lipocalin", "GENE_OR_GENE_PRODUCT", 97, 106], ["lipocalin family", "PROTEIN", 53, 69], ["lipocalin fold", "PROTEIN", 97, 111], ["eight-stranded anti-parallel beta-barrel", "PROTEIN", 116, 156], ["an eight-stranded anti-parallel beta-barrel", "TREATMENT", 113, 156], ["binding pocket", "PROBLEM", 179, 193], ["lipocalin fold", "ANATOMY", 97, 111], ["calyx", "ANATOMY", 170, 175]]], ["Siderocalins limit pathogen growth by intercepting siderophores and preventing the delivery of iron to the pathogen [6] .", [["Siderocalins", "CHEMICAL", 0, 12], ["iron", "CHEMICAL", 95, 99], ["Siderocalins", "CHEMICAL", 0, 12], ["iron", "CHEMICAL", 95, 99], ["Siderocalins", "SIMPLE_CHEMICAL", 0, 12], ["iron", "SIMPLE_CHEMICAL", 95, 99], ["Siderocalins", "TREATMENT", 0, 12], ["intercepting siderophores", "TREATMENT", 38, 63], ["the delivery of iron", "TREATMENT", 79, 99]]], ["Siderocalins have recently been observed in several animals including humans, chickens, and quail.", [["Siderocalins", "CHEMICAL", 0, 12], ["Siderocalins", "CHEMICAL", 0, 12], ["Siderocalins", "GENE_OR_GENE_PRODUCT", 0, 12], ["humans", "ORGANISM", 70, 76], ["chickens", "ORGANISM", 78, 86], ["quail", "ORGANISM", 92, 97], ["Siderocalins", "PROTEIN", 0, 12], ["humans", "SPECIES", 70, 76], ["chickens", "SPECIES", 78, 86], ["quail", "SPECIES", 92, 97], ["humans", "SPECIES", 70, 76], ["chickens", "SPECIES", 78, 86], ["quail", "SPECIES", 92, 97]]], ["Subtle differences among the siderocalins suggest that each host has adapted to the most dangerous pathogens it encounters.IntroductionIn addition to pathogen defense, siderocalins function in many other processes.", [["siderocalins", "CHEMICAL", 168, 180], ["siderocalins", "GENE_OR_GENE_PRODUCT", 29, 41], ["siderocalins", "SIMPLE_CHEMICAL", 168, 180], ["Subtle differences", "PROBLEM", 0, 18], ["IntroductionIn", "TREATMENT", 123, 137], ["pathogen defense", "OBSERVATION", 150, 166]]], ["Cell differentiation, embryogenesis, inflammation, and cancer and other diseases have been associated with the expression of siderocalins.", [["Cell", "ANATOMY", 0, 4], ["cancer", "ANATOMY", 55, 61], ["inflammation", "DISEASE", 37, 49], ["cancer", "DISEASE", 55, 61], ["siderocalins", "CHEMICAL", 125, 137], ["Cell", "CELL", 0, 4], ["cancer", "CANCER", 55, 61], ["siderocalins", "GENE_OR_GENE_PRODUCT", 125, 137], ["siderocalins", "PROTEIN", 125, 137], ["Cell differentiation", "PROBLEM", 0, 20], ["embryogenesis", "PROBLEM", 22, 35], ["inflammation", "PROBLEM", 37, 49], ["cancer", "PROBLEM", 55, 61], ["other diseases", "PROBLEM", 66, 80], ["embryogenesis", "OBSERVATION_MODIFIER", 22, 35], ["inflammation", "OBSERVATION", 37, 49], ["cancer", "OBSERVATION", 55, 61]]], ["The role of the siderocalins in these processes is largely unknown, but the characterization of the siderophore binding properties provides the first molecular insights.", [["siderocalins", "CHEMICAL", 16, 28], ["siderocalins", "CHEMICAL", 16, 28], ["siderocalins", "GENE_OR_GENE_PRODUCT", 16, 28], ["the siderophore binding properties", "PROBLEM", 96, 130]]], ["The structure, function and properties of human Siderocalin (Scn), human tear lipocalin (TL), galline extracellular fatty-acid binding protein (Ex-FABP), and quail siderocalin (Q83) will be discussed in this review.SiderocalinThe antimicrobial human immunoprotein Siderocalin (Scn, also NGAL, Lcn2, HNL, 24p3) has garnered interest from a wide spectrum of scientists in recent years.", [["fatty-acid", "CHEMICAL", 116, 126], ["Siderocalin", "CHEMICAL", 215, 226], ["Siderocalin", "CHEMICAL", 264, 275], ["fatty-acid", "CHEMICAL", 116, 126], ["siderocalin", "CHEMICAL", 164, 175], ["Siderocalin", "CHEMICAL", 215, 226], ["human", "ORGANISM", 42, 47], ["Siderocalin", "GENE_OR_GENE_PRODUCT", 48, 59], ["Scn", "GENE_OR_GENE_PRODUCT", 61, 64], ["human", "ORGANISM", 67, 72], ["tear lipocalin", "GENE_OR_GENE_PRODUCT", 73, 87], ["TL", "GENE_OR_GENE_PRODUCT", 89, 91], ["galline extracellular fatty-acid binding protein", "GENE_OR_GENE_PRODUCT", 94, 142], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 144, 151], ["quail", "ORGANISM", 158, 163], ["siderocalin", "GENE_OR_GENE_PRODUCT", 164, 175], ["Q83", "GENE_OR_GENE_PRODUCT", 177, 180], ["Siderocalin", "SIMPLE_CHEMICAL", 215, 226], ["human", "ORGANISM", 244, 249], ["Siderocalin", "GENE_OR_GENE_PRODUCT", 264, 275], ["Scn", "GENE_OR_GENE_PRODUCT", 277, 280], ["NGAL", "GENE_OR_GENE_PRODUCT", 287, 291], ["Lcn2", "GENE_OR_GENE_PRODUCT", 293, 297], ["HNL", "GENE_OR_GENE_PRODUCT", 299, 302], ["human Siderocalin", "PROTEIN", 42, 59], ["Scn", "PROTEIN", 61, 64], ["human tear lipocalin", "PROTEIN", 67, 87], ["TL", "PROTEIN", 89, 91], ["galline extracellular fatty-acid binding protein", "PROTEIN", 94, 142], ["Ex", "PROTEIN", 144, 146], ["FABP", "PROTEIN", 147, 151], ["antimicrobial human immunoprotein", "PROTEIN", 230, 263], ["Siderocalin", "PROTEIN", 264, 275], ["Scn", "PROTEIN", 277, 280], ["NGAL", "PROTEIN", 287, 291], ["Lcn2", "PROTEIN", 293, 297], ["HNL", "PROTEIN", 299, 302], ["24p3", "PROTEIN", 304, 308], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 67, 72], ["quail", "SPECIES", 158, 163], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 244, 249], ["human Siderocalin (Scn)", "TREATMENT", 42, 65], ["human tear lipocalin (TL)", "TREATMENT", 67, 92], ["galline extracellular fatty-acid binding protein (Ex-FABP)", "TREATMENT", 94, 152], ["quail siderocalin", "TREATMENT", 158, 175], ["SiderocalinThe antimicrobial human immunoprotein Siderocalin (Scn", "TREATMENT", 215, 280]]], ["Arguably the most significant function of Scn is that it acts as part of the first line of defense against microbial invaders by intercepting bacterial siderophores [6] [7] [8] .", [["Scn", "GENE_OR_GENE_PRODUCT", 42, 45], ["Scn", "PROTEIN", 42, 45], ["microbial invaders", "PROBLEM", 107, 125], ["intercepting bacterial siderophores", "TEST", 129, 164], ["most significant", "OBSERVATION_MODIFIER", 13, 29]]], ["While it is also expressed in nondisease cases such as modulation of intracellular iron stores and iron delivery in early embryogenesis, Scn is also a biomarker that is upregulated in certain diseases such as acute kidney injury, psoriasis and ovarian and gastric cancers ( Figure 3 ) [9] [10] [11] [12] [13] [14] [15] .", [["intracellular", "ANATOMY", 69, 82], ["kidney", "ANATOMY", 215, 221], ["ovarian", "ANATOMY", 244, 251], ["gastric cancers", "ANATOMY", 256, 271], ["iron", "CHEMICAL", 83, 87], ["iron", "CHEMICAL", 99, 103], ["acute kidney injury", "DISEASE", 209, 228], ["psoriasis", "DISEASE", 230, 239], ["ovarian and gastric cancers", "DISEASE", 244, 271], ["iron", "CHEMICAL", 83, 87], ["iron", "CHEMICAL", 99, 103], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["iron", "SIMPLE_CHEMICAL", 83, 87], ["iron", "SIMPLE_CHEMICAL", 99, 103], ["Scn", "GENE_OR_GENE_PRODUCT", 137, 140], ["kidney", "ORGAN", 215, 221], ["ovarian", "ORGAN", 244, 251], ["gastric cancers", "CANCER", 256, 271], ["[9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 285, 318], ["Scn", "PROTEIN", 137, 140], ["intracellular iron stores", "TREATMENT", 69, 94], ["iron delivery", "TREATMENT", 99, 112], ["early embryogenesis", "PROBLEM", 116, 135], ["certain diseases", "PROBLEM", 184, 200], ["acute kidney injury", "PROBLEM", 209, 228], ["psoriasis", "PROBLEM", 230, 239], ["ovarian and gastric cancers", "PROBLEM", 244, 271], ["iron stores", "OBSERVATION", 83, 94], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["kidney", "ANATOMY", 215, 221], ["injury", "OBSERVATION", 222, 228], ["psoriasis", "OBSERVATION", 230, 239], ["ovarian", "ANATOMY", 244, 251], ["gastric", "ANATOMY", 256, 263], ["cancers", "OBSERVATION", 264, 271]]], ["Whether these functions are ligand-dependent or why Scn expression is upregulated in these cases is not fully understood [16] [17] [18] [19] [20] [21] [22] [23] [24] .SiderocalinA collection of crystallographic structures of Scn with bound ligands elucidated the role of the protein as an antimicrobial ligand scavenger.", [["SiderocalinA", "CHEMICAL", 167, 179], ["Scn", "CHEMICAL", 225, 228], ["[16] [17] [18] [19] [20] [21] [22] [23]", "CHEMICAL", 121, 160], ["SiderocalinA", "CHEMICAL", 167, 179], ["Scn", "GENE_OR_GENE_PRODUCT", 52, 55], ["[16] [17] [18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 121, 165], ["SiderocalinA", "SIMPLE_CHEMICAL", 167, 179], ["Scn", "SIMPLE_CHEMICAL", 225, 228], ["Scn", "PROTEIN", 52, 55], ["Scn", "PROTEIN", 225, 228], ["SiderocalinA collection of crystallographic structures of Scn", "PROBLEM", 167, 228], ["bound ligands", "PROBLEM", 234, 247], ["an antimicrobial ligand scavenger", "TREATMENT", 286, 319], ["crystallographic structures", "OBSERVATION", 194, 221], ["Scn", "ANATOMY", 225, 228], ["bound ligands", "OBSERVATION", 234, 247], ["antimicrobial ligand", "OBSERVATION", 289, 309]]], ["Scn has three rigid binding subpockets which are defined by the residue side chains that line them.", [["Scn", "CHEMICAL", 0, 3], ["Scn", "GENE_OR_GENE_PRODUCT", 0, 3], ["Scn", "PROTEIN", 0, 3], ["three rigid binding subpockets", "PROBLEM", 8, 38], ["rigid", "OBSERVATION_MODIFIER", 14, 19], ["binding subpockets", "OBSERVATION", 20, 38]]], ["The positively charged, polar residues Lys125, Lys134 and Arg81 are involved in cation-pi interactions necessary for molecular recognition by Scn [25] .", [["Lys125", "CHEMICAL", 39, 45], ["Lys134", "CHEMICAL", 47, 53], ["Arg81", "CHEMICAL", 58, 63], ["Lys125", "GENE_OR_GENE_PRODUCT", 39, 45], ["Lys134", "GENE_OR_GENE_PRODUCT", 47, 53], ["Arg81", "AMINO_ACID", 58, 63], ["cation", "SIMPLE_CHEMICAL", 80, 86]]], ["Tyr106 is key in stabilizing bound ligands by hydrogen bond stabilization [7] .", [["Tyr106", "CHEMICAL", 0, 6], ["hydrogen", "CHEMICAL", 46, 54], ["Tyr106", "GENE_OR_GENE_PRODUCT", 0, 6], ["Tyr106", "PROTEIN", 0, 6], ["hydrogen bond stabilization", "TREATMENT", 46, 73], ["hydrogen bond", "OBSERVATION", 46, 59]]], ["Several papers have shown the tris-catecholate siderophores, such as enterobactin from Escherichia coli and bacillibactin from Bacillus anthracis ( Figure 2 ) are bound tightly by Scn in vivo and in vitro with subnanomolar dissociation constants [7, 25, 4] .", [["tris-catecholate", "CHEMICAL", 30, 46], ["enterobactin", "CHEMICAL", 69, 81], ["tris-catecholate", "CHEMICAL", 30, 46], ["enterobactin", "CHEMICAL", 69, 81], ["tris-catecholate siderophores", "SIMPLE_CHEMICAL", 30, 59], ["enterobactin", "SIMPLE_CHEMICAL", 69, 81], ["Escherichia coli", "ORGANISM", 87, 103], ["bacillibactin", "GENE_OR_GENE_PRODUCT", 108, 121], ["Bacillus anthracis", "ORGANISM", 127, 145], ["Figure 2", "ORGANISM", 148, 156], ["Scn", "GENE_OR_GENE_PRODUCT", 180, 183], ["Scn", "PROTEIN", 180, 183], ["Escherichia coli", "SPECIES", 87, 103], ["Bacillus anthracis", "SPECIES", 127, 145], ["Escherichia coli", "SPECIES", 87, 103], ["Bacillus anthracis", "SPECIES", 127, 145], ["the tris-catecholate siderophores", "PROBLEM", 26, 59], ["enterobactin from Escherichia coli", "TREATMENT", 69, 103], ["bacillibactin from Bacillus anthracis", "PROBLEM", 108, 145], ["subnanomolar dissociation constants", "PROBLEM", 210, 245], ["Escherichia coli", "OBSERVATION", 87, 103], ["subnanomolar dissociation", "OBSERVATION", 210, 235]]], ["Siderophores bound by Scn are not limited to tris-catecholates.", [["tris-catecholates", "CHEMICAL", 45, 62], ["tris-catecholates", "CHEMICAL", 45, 62], ["Scn", "GENE_OR_GENE_PRODUCT", 22, 25], ["tris-catecholates", "SIMPLE_CHEMICAL", 45, 62], ["Siderophores bound", "PROBLEM", 0, 18], ["Scn", "ANATOMY", 22, 25]]], ["The carboxymycobactins of Mycobacterium tuberculosis ( Figure 2 ) bind iron with two hydroxamate and one phenyloxazoline moiety.", [["carboxymycobactins", "CHEMICAL", 4, 22], ["Mycobacterium tuberculosis", "DISEASE", 26, 52], ["iron", "CHEMICAL", 71, 75], ["hydroxamate", "CHEMICAL", 85, 96], ["phenyloxazoline", "CHEMICAL", 105, 120], ["iron", "CHEMICAL", 71, 75], ["hydroxamate", "CHEMICAL", 85, 96], ["phenyloxazoline", "CHEMICAL", 105, 120], ["carboxymycobactins", "SIMPLE_CHEMICAL", 4, 22], ["Mycobacterium tuberculosis", "ORGANISM", 26, 52], ["iron", "SIMPLE_CHEMICAL", 71, 75], ["hydroxamate", "SIMPLE_CHEMICAL", 85, 96], ["phenyloxazoline moiety", "SIMPLE_CHEMICAL", 105, 127], ["Mycobacterium tuberculosis", "SPECIES", 26, 52], ["Mycobacterium tuberculosis", "SPECIES", 26, 52], ["The carboxymycobactins of Mycobacterium tuberculosis ( Figure 2 ) bind iron", "TREATMENT", 0, 75], ["two hydroxamate", "TREATMENT", 81, 96], ["one phenyloxazoline moiety", "TREATMENT", 101, 127], ["Mycobacterium tuberculosis", "OBSERVATION", 26, 52]]], ["Several carboxymycobactins are secreted from M. tuberculosis, and differ from one another in fatty acid tail length [26] .", [["carboxymycobactins", "CHEMICAL", 8, 26], ["tuberculosis", "DISEASE", 48, 60], ["fatty acid", "CHEMICAL", 93, 103], ["fatty acid", "CHEMICAL", 93, 103], ["carboxymycobactins", "GENE_OR_GENE_PRODUCT", 8, 26], ["M. tuberculosis", "ORGANISM", 45, 60], ["carboxymycobactins", "PROTEIN", 8, 26], ["M. tuberculosis", "SPECIES", 45, 60], ["M. tuberculosis", "SPECIES", 45, 60], ["Several carboxymycobactins", "TREATMENT", 0, 26], ["M. tuberculosis", "PROBLEM", 45, 60], ["tuberculosis", "OBSERVATION", 48, 60]]], ["The phenyloxazoline unit of all carboxymycobactins is the singly aromatic unit of this siderophore that anchors the carboxymycobactin into Scn subpocket 1.", [["phenyloxazoline", "CHEMICAL", 4, 19], ["carboxymycobactins", "CHEMICAL", 32, 50], ["carboxymycobactin", "CHEMICAL", 116, 133], ["phenyloxazoline", "CHEMICAL", 4, 19], ["carboxymycobactins", "CHEMICAL", 32, 50], ["carboxymycobactin", "CHEMICAL", 116, 133], ["phenyloxazoline", "SIMPLE_CHEMICAL", 4, 19], ["carboxymycobactins", "SIMPLE_CHEMICAL", 32, 50], ["carboxymycobactin", "SIMPLE_CHEMICAL", 116, 133], ["Scn subpocket 1", "GENE_OR_GENE_PRODUCT", 139, 154], ["carboxymycobactin", "PROTEIN", 116, 133], ["Scn subpocket 1", "PROTEIN", 139, 154], ["The phenyloxazoline unit", "TREATMENT", 0, 24], ["all carboxymycobactins", "TREATMENT", 28, 50], ["this siderophore", "TREATMENT", 82, 98]]], ["Scn, however, binds only carboxymycobactins with n = 6-8 as well as corresponding ferric complexes.", [["Scn", "CHEMICAL", 0, 3], ["ferric", "CHEMICAL", 82, 88], ["carboxymycobactins", "CHEMICAL", 25, 43], ["ferric", "CHEMICAL", 82, 88], ["Scn", "GENE_OR_GENE_PRODUCT", 0, 3], ["carboxymycobactins", "SIMPLE_CHEMICAL", 25, 43], ["ferric complexes", "SIMPLE_CHEMICAL", 82, 98], ["ferric complexes", "PROTEIN", 82, 98], ["carboxymycobactins", "TREATMENT", 25, 43], ["ferric complexes", "OBSERVATION", 82, 98]]], ["Hoette et al. attribute the selectivity of Scn for carboxymycobactins n = 6-8 to the ability of longer carboxylate tails to tuck into a recess behind subpocket 2 [26] .", [["Scn", "CHEMICAL", 43, 46], ["carboxymycobactins", "CHEMICAL", 51, 69], ["carboxymycobactins", "CHEMICAL", 51, 69], ["carboxylate", "CHEMICAL", 103, 114], ["Scn", "SIMPLE_CHEMICAL", 43, 46], ["carboxymycobactins n", "TREATMENT", 51, 71], ["longer carboxylate tails", "TREATMENT", 96, 120]]], ["The shorter carboxylate tails of carboxymycobactins n = 3-5 protrude from subpocket 3 away from the calyx, thus diminishing Scn affinity for the siderophore [26] .", [["calyx", "ANATOMY", 100, 105], ["carboxylate", "CHEMICAL", 12, 23], ["carboxymycobactins n = 3-5", "CHEMICAL", 33, 59], ["Scn", "CHEMICAL", 124, 127], ["carboxylate", "CHEMICAL", 12, 23], ["carboxymycobactins", "CHEMICAL", 33, 51], ["calyx", "ORGANISM_SUBDIVISION", 100, 105], ["Scn", "SIMPLE_CHEMICAL", 124, 127], ["Scn", "PROTEIN", 124, 127], ["The shorter carboxylate tails of carboxymycobactins n", "TREATMENT", 0, 53], ["calyx", "ANATOMY", 100, 105]]], ["The 'tail-out' configuration of carboxymycobactin carboxylate tails can be viewed as a sort of stealth mechanism in which the bacterium produces several siderophores of varying lipophilicity and varying abilities to evade Scn sequestration.SiderocalinOther bacterial pathogens have capitalized on the strict Scn binding requirements to produce stealth siderophores, or iron chelators that are sterically or electronically incompatible with Scn.", [["carboxymycobactin carboxylate", "CHEMICAL", 32, 61], ["Scn", "CHEMICAL", 222, 225], ["SiderocalinOther", "CHEMICAL", 240, 256], ["iron", "CHEMICAL", 369, 373], ["carboxymycobactin carboxylate", "CHEMICAL", 32, 61], ["Scn", "CHEMICAL", 222, 225], ["iron", "CHEMICAL", 369, 373], ["carboxymycobactin carboxylate tails", "SIMPLE_CHEMICAL", 32, 67], ["Scn", "SIMPLE_CHEMICAL", 222, 225], ["stealth siderophores", "SIMPLE_CHEMICAL", 344, 364], ["iron chelators", "SIMPLE_CHEMICAL", 369, 383], ["Scn", "GENE_OR_GENE_PRODUCT", 440, 443], ["Scn", "PROTEIN", 440, 443], ["carboxymycobactin carboxylate tails", "TREATMENT", 32, 67], ["the bacterium", "PROBLEM", 122, 135], ["varying lipophilicity", "PROBLEM", 169, 190], ["Scn sequestration", "PROBLEM", 222, 239], ["SiderocalinOther bacterial pathogens", "PROBLEM", 240, 276], ["stealth siderophores", "PROBLEM", 344, 364], ["iron chelators", "TREATMENT", 369, 383], ["tail", "OBSERVATION_MODIFIER", 5, 9], ["bacterial", "OBSERVATION_MODIFIER", 257, 266], ["pathogens", "OBSERVATION", 267, 276]]], ["Salmochelins and aerobactin of E. coli are not Scn-bound due to sterics and lack of aromatic groups for cation-pi stabilization, respectively [27, 28] .", [["Salmochelins", "CHEMICAL", 0, 12], ["aerobactin", "CHEMICAL", 17, 27], ["Scn", "CHEMICAL", 47, 50], ["Salmochelins", "SIMPLE_CHEMICAL", 0, 12], ["aerobactin", "SIMPLE_CHEMICAL", 17, 27], ["E. coli", "ORGANISM", 31, 38], ["Scn", "GENE_OR_GENE_PRODUCT", 47, 50], ["cation-pi", "SIMPLE_CHEMICAL", 104, 113], ["E. coli", "SPECIES", 31, 38], ["E. coli", "SPECIES", 31, 38], ["Salmochelins", "TREATMENT", 0, 12], ["aerobactin", "TREATMENT", 17, 27], ["E. coli", "PROBLEM", 31, 38], ["sterics", "PROBLEM", 64, 71], ["cation-pi stabilization", "TREATMENT", 104, 127], ["E. coli", "OBSERVATION", 31, 38]]], ["Petrobactin of B. anthracis and its ferric complex clash with the Scn walls and thus are not bound ( Figure 2 ) [29, 30] .SiderocalinIn the medical sciences the role of Scn as a biomarker or a potential iron transport agent has been a topic of recent interest.", [["Petrobactin", "CHEMICAL", 0, 11], ["ferric", "CHEMICAL", 36, 42], ["SiderocalinIn", "CHEMICAL", 122, 135], ["Scn", "CHEMICAL", 169, 172], ["iron", "CHEMICAL", 203, 207], ["ferric", "CHEMICAL", 36, 42], ["Scn", "CHEMICAL", 66, 69], ["SiderocalinIn", "CHEMICAL", 122, 135], ["iron", "CHEMICAL", 203, 207], ["Petrobactin", "SIMPLE_CHEMICAL", 0, 11], ["B. anthracis", "ORGANISM", 15, 27], ["ferric", "SIMPLE_CHEMICAL", 36, 42], ["SiderocalinIn", "SIMPLE_CHEMICAL", 122, 135], ["Scn", "GENE_OR_GENE_PRODUCT", 169, 172], ["iron", "SIMPLE_CHEMICAL", 203, 207], ["Scn", "PROTEIN", 169, 172], ["B. anthracis", "SPECIES", 15, 27], ["B. anthracis", "SPECIES", 15, 27], ["Petrobactin", "TREATMENT", 0, 11], ["B. anthracis", "PROBLEM", 15, 27], ["its ferric complex clash", "PROBLEM", 32, 56], ["a potential iron transport agent", "TREATMENT", 191, 223], ["ferric", "OBSERVATION_MODIFIER", 36, 42], ["complex", "OBSERVATION_MODIFIER", 43, 50], ["clash", "OBSERVATION", 51, 56], ["Scn", "ANATOMY", 66, 69], ["walls", "ANATOMY_MODIFIER", 70, 75]]], ["Scn has been identified as an iron delivery agent in early embryogenesis, a relationship established from growth experiments with atransferrinemic mice ( Figure 3 ) [14, 31] .", [["Scn", "CHEMICAL", 0, 3], ["iron", "CHEMICAL", 30, 34], ["iron", "CHEMICAL", 30, 34], ["Scn", "GENE_OR_GENE_PRODUCT", 0, 3], ["iron", "SIMPLE_CHEMICAL", 30, 34], ["mice", "ORGANISM", 147, 151], ["Scn", "PROTEIN", 0, 3], ["mice", "SPECIES", 147, 151], ["an iron delivery agent", "TREATMENT", 27, 49]]], ["Scn has no measurable affinity for iron alone and requires an endogenous siderophore to traffic iron.SiderocalinBao and coworkers have shown that simple catechols can serve as the endogenous mammalian siderophore equivalent [13, 32] .", [["Scn", "CHEMICAL", 0, 3], ["iron", "CHEMICAL", 35, 39], ["iron", "CHEMICAL", 96, 100], ["SiderocalinBao", "CHEMICAL", 101, 115], ["catechols", "CHEMICAL", 153, 162], ["iron", "CHEMICAL", 35, 39], ["iron", "CHEMICAL", 96, 100], ["catechols", "CHEMICAL", 153, 162], ["Scn", "GENE_OR_GENE_PRODUCT", 0, 3], ["iron", "SIMPLE_CHEMICAL", 35, 39], ["iron", "SIMPLE_CHEMICAL", 96, 100], ["SiderocalinBao", "SIMPLE_CHEMICAL", 101, 115], ["catechols", "SIMPLE_CHEMICAL", 153, 162], ["iron", "TREATMENT", 35, 39], ["an endogenous siderophore", "TREATMENT", 59, 84], ["traffic iron", "TREATMENT", 88, 100], ["simple catechols", "TREATMENT", 146, 162], ["no", "UNCERTAINTY", 8, 10]]], ["Among the mammalian siderophore candidates isolated from mouse urine was 2, 3dihydroxybenzoic acid, the monomeric unit of enterobactin [13] .", [["urine", "ANATOMY", 63, 68], ["2, 3dihydroxybenzoic acid", "CHEMICAL", 73, 98], ["enterobactin", "CHEMICAL", 122, 134], ["2, 3dihydroxybenzoic acid", "CHEMICAL", 73, 98], ["enterobactin", "CHEMICAL", 122, 134], ["mouse", "ORGANISM", 57, 62], ["urine", "ORGANISM_SUBSTANCE", 63, 68], ["2, 3dihydroxybenzoic acid", "SIMPLE_CHEMICAL", 73, 98], ["enterobactin", "SIMPLE_CHEMICAL", 122, 134], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 57, 62], ["mouse urine", "TEST", 57, 68], ["3dihydroxybenzoic acid", "TREATMENT", 76, 98], ["the monomeric unit of enterobactin", "TREATMENT", 100, 134]]], ["All cofactors which can be classified as mammalian siderophores must obey the binding requirements of Scn.", [["Scn", "GENE_OR_GENE_PRODUCT", 102, 105], ["Scn", "PROTEIN", 102, 105], ["All cofactors", "PROBLEM", 0, 13]]], ["Claims that 2, 5-dihydroxybenzoic acid (25DHB), also known as gentisic acid and an isomer of 2,3dihydroxybenzoic acid, is a mammalian siderophore have been made [33] , but are inconsistent with the definition of mammalian siderophore.", [["2, 5-dihydroxybenzoic acid", "CHEMICAL", 12, 38], ["25DHB", "CHEMICAL", 40, 45], ["gentisic acid", "CHEMICAL", 62, 75], ["2,3dihydroxybenzoic acid", "CHEMICAL", 93, 117], ["2, 5-dihydroxybenzoic acid", "CHEMICAL", 12, 38], ["25DHB", "CHEMICAL", 40, 45], ["gentisic acid", "CHEMICAL", 62, 75], ["2,3dihydroxybenzoic acid", "CHEMICAL", 93, 117], ["2, 5-dihydroxybenzoic acid", "SIMPLE_CHEMICAL", 12, 38], ["25DHB", "SIMPLE_CHEMICAL", 40, 45], ["gentisic acid", "SIMPLE_CHEMICAL", 62, 75], ["2,3dihydroxybenzoic acid", "SIMPLE_CHEMICAL", 93, 117], ["[33]", "SIMPLE_CHEMICAL", 161, 165], ["dihydroxybenzoic acid", "TREATMENT", 17, 38], ["gentisic acid", "TEST", 62, 75], ["an isomer of 2,3dihydroxybenzoic acid", "TREATMENT", 80, 117], ["a mammalian siderophore", "TREATMENT", 122, 145], ["mammalian siderophore", "TREATMENT", 212, 233]]], ["Catechols form high affinity iron complexes due to the bidentate chelation by deprotonated ortho-hydroxyl groups to form a 5-membered ring.", [["Catechols", "CHEMICAL", 0, 9], ["iron", "CHEMICAL", 29, 33], ["ortho-hydroxyl", "CHEMICAL", 91, 105], ["Catechols", "CHEMICAL", 0, 9], ["iron", "CHEMICAL", 29, 33], ["ortho-hydroxyl", "CHEMICAL", 91, 105], ["Catechols", "SIMPLE_CHEMICAL", 0, 9], ["iron", "SIMPLE_CHEMICAL", 29, 33], ["deprotonated ortho-hydroxyl", "SIMPLE_CHEMICAL", 78, 105], ["5-membered ring", "SIMPLE_CHEMICAL", 123, 138], ["Catechols", "TEST", 0, 9], ["high affinity iron complexes", "PROBLEM", 15, 43], ["the bidentate chelation", "TREATMENT", 51, 74], ["deprotonated ortho-hydroxyl groups", "TREATMENT", 78, 112], ["a 5-membered ring", "TREATMENT", 121, 138]]], ["25DHB is not a catechol; it is a catechol isomer which binds iron via salicylate mode using one oxygen from the 2-hydroxyl group and one from the deprotonated carboxylic acid.", [["25DHB", "CHEMICAL", 0, 5], ["catechol", "CHEMICAL", 15, 23], ["catechol", "CHEMICAL", 33, 41], ["iron", "CHEMICAL", 61, 65], ["salicylate", "CHEMICAL", 70, 80], ["oxygen", "CHEMICAL", 96, 102], ["2-hydroxyl", "CHEMICAL", 112, 122], ["carboxylic acid", "CHEMICAL", 159, 174], ["25DHB", "CHEMICAL", 0, 5], ["catechol", "CHEMICAL", 15, 23], ["catechol", "CHEMICAL", 33, 41], ["iron", "CHEMICAL", 61, 65], ["salicylate", "CHEMICAL", 70, 80], ["oxygen", "CHEMICAL", 96, 102], ["2-hydroxyl", "CHEMICAL", 112, 122], ["carboxylic acid", "CHEMICAL", 159, 174], ["25DHB", "SIMPLE_CHEMICAL", 0, 5], ["catechol", "SIMPLE_CHEMICAL", 15, 23], ["catechol isomer", "SIMPLE_CHEMICAL", 33, 48], ["iron", "SIMPLE_CHEMICAL", 61, 65], ["salicylate", "SIMPLE_CHEMICAL", 70, 80], ["oxygen", "SIMPLE_CHEMICAL", 96, 102], ["2-hydroxyl", "SIMPLE_CHEMICAL", 112, 122], ["deprotonated carboxylic acid", "SIMPLE_CHEMICAL", 146, 174], ["a catechol", "PROBLEM", 13, 23], ["a catechol isomer", "TREATMENT", 31, 48], ["iron via salicylate mode", "TREATMENT", 61, 85], ["one oxygen", "TREATMENT", 92, 102], ["the 2-hydroxyl group", "TREATMENT", 108, 128], ["the deprotonated carboxylic acid", "TREATMENT", 142, 174], ["carboxylic acid", "OBSERVATION", 159, 174]]], ["Salicylate-siderophores are inherently weaker iron chelators.", [["Salicylate", "CHEMICAL", 0, 10], ["iron", "CHEMICAL", 46, 50], ["Salicylate", "CHEMICAL", 0, 10], ["iron", "CHEMICAL", 46, 50], ["Salicylate-siderophores", "SIMPLE_CHEMICAL", 0, 23], ["iron chelators", "SIMPLE_CHEMICAL", 46, 60], ["Salicylate", "TREATMENT", 0, 10], ["siderophores", "TREATMENT", 11, 23], ["iron chelators", "TREATMENT", 46, 60]]], ["Correnti et al. have performed solution thermodynamic analyses detailing the distribution of Fe(25DHB) 3 complexes in solution under various conditions only to find that either the bis or tris 25DHB ferric complexes exist at negligible concentrations.", [["Fe", "CHEMICAL", 93, 95], ["25DHB", "CHEMICAL", 96, 101], ["bis", "CHEMICAL", 181, 184], ["Fe(25DHB) 3", "CHEMICAL", 93, 104], ["bis or tris 25DHB ferric", "CHEMICAL", 181, 205], ["Fe(25DHB) 3 complexes", "SIMPLE_CHEMICAL", 93, 114], ["tris 25DHB ferric complexes", "SIMPLE_CHEMICAL", 188, 215], ["Fe(25DHB) 3 complexes", "PROTEIN", 93, 114], ["solution thermodynamic analyses", "TEST", 31, 62], ["Fe(25DHB)", "TREATMENT", 93, 102], ["the bis or tris 25DHB ferric complexes", "TREATMENT", 177, 215]]], ["The possibility that the Fe(25DHB) 3 complex form by ternary association in the Scn calyx is also implausible since the 5hydroxyl groups sterically clash with the calyx walls.", [["Scn calyx", "ANATOMY", 80, 89], ["calyx walls", "ANATOMY", 163, 174], ["Fe", "CHEMICAL", 25, 27], ["25DHB", "CHEMICAL", 28, 33], ["5hydroxyl", "CHEMICAL", 120, 129], ["Fe(25DHB) 3", "CHEMICAL", 25, 36], ["5hydroxyl", "CHEMICAL", 120, 129], ["Fe(25DHB) 3", "GENE_OR_GENE_PRODUCT", 25, 36], ["5hydroxyl", "SIMPLE_CHEMICAL", 120, 129], ["calyx walls", "MULTI-TISSUE_STRUCTURE", 163, 174], ["Fe(25DHB) 3 complex", "PROTEIN", 25, 44], ["the Fe(25DHB)", "TREATMENT", 21, 34], ["Scn calyx", "ANATOMY", 80, 89], ["calyx", "ANATOMY_MODIFIER", 163, 168], ["walls", "ANATOMY_MODIFIER", 169, 174]]], ["A hexadentate ligand based on 25DHB units was synthesized and tested in Scn binding assays to further illustrate the weak affinity Scn has for salicylate-mode chelators and/or for chelators with substituents on the 5 position of the aromatic ring [32] .SiderocalinUnfortunately, the misunderstanding about 25DHB as a mammalian siderophore has been the basis for other claims that the ternary Scn:Fe:25DHB complex can mediate apoptosis [33] .", [["hexadentate", "CHEMICAL", 2, 13], ["25DHB", "CHEMICAL", 30, 35], ["Scn", "CHEMICAL", 131, 134], ["salicylate", "CHEMICAL", 143, 153], ["25DHB", "CHEMICAL", 306, 311], ["Fe", "CHEMICAL", 396, 398], ["hexadentate", "CHEMICAL", 2, 13], ["25DHB", "CHEMICAL", 30, 35], ["salicylate", "CHEMICAL", 143, 153], ["25DHB", "CHEMICAL", 306, 311], ["Fe", "CHEMICAL", 396, 398], ["25DHB", "SIMPLE_CHEMICAL", 30, 35], ["Scn", "SIMPLE_CHEMICAL", 72, 75], ["Scn", "GENE_OR_GENE_PRODUCT", 131, 134], ["salicylate-mode chelators", "SIMPLE_CHEMICAL", 143, 168], ["chelators", "SIMPLE_CHEMICAL", 180, 189], ["25DHB", "SIMPLE_CHEMICAL", 306, 311], ["Scn", "GENE_OR_GENE_PRODUCT", 392, 395], ["Fe:25DHB", "SIMPLE_CHEMICAL", 396, 404], ["ternary Scn:Fe:25DHB complex", "PROTEIN", 384, 412], ["A hexadentate ligand", "TREATMENT", 0, 20], ["Scn binding assays", "TEST", 72, 90], ["salicylate-mode chelators", "TREATMENT", 143, 168], ["chelators", "TREATMENT", 180, 189], ["substituents", "TREATMENT", 195, 207], ["a mammalian siderophore", "TREATMENT", 315, 338]]], ["Repetitions of Scn:Fe:25DHB-mediated apoptosis experiments, followed by more direct and complementary apoptosis experiments, have shown that 25DHB-based siderophores do not chelate iron strongly enough to generate an apoptotic response in hematopoietic cell lines [32] .", [["hematopoietic cell lines", "ANATOMY", 239, 263], ["Scn", "CHEMICAL", 15, 18], ["Fe", "CHEMICAL", 19, 21], ["25DHB", "CHEMICAL", 22, 27], ["25DHB", "CHEMICAL", 141, 146], ["iron", "CHEMICAL", 181, 185], ["Fe", "CHEMICAL", 19, 21], ["25DHB", "CHEMICAL", 141, 146], ["iron", "CHEMICAL", 181, 185], ["Scn:Fe:25DHB", "SIMPLE_CHEMICAL", 15, 27], ["25DHB", "SIMPLE_CHEMICAL", 141, 146], ["iron", "SIMPLE_CHEMICAL", 181, 185], ["hematopoietic cell lines", "CELL", 239, 263], ["hematopoietic cell lines", "CELL_LINE", 239, 263], ["apoptosis experiments", "PROBLEM", 37, 58], ["hematopoietic cell lines", "TREATMENT", 239, 263], ["hematopoietic cell lines", "OBSERVATION", 239, 263]]], ["An important statement within the scope of this review is that Scn does not and cannot use 25DHB chelators as endogenous siderophores; 25DHB-based siderophores more likely resemble stealth siderophores due to the steric incompatibility of these molecules with Scn binding pockets.", [["25DHB", "CHEMICAL", 91, 96], ["25DHB", "CHEMICAL", 135, 140], ["Scn", "CHEMICAL", 260, 263], ["25DHB", "CHEMICAL", 91, 96], ["25DHB", "CHEMICAL", 135, 140], ["Scn", "CHEMICAL", 260, 263], ["Scn", "GENE_OR_GENE_PRODUCT", 63, 66], ["25DHB chelators", "SIMPLE_CHEMICAL", 91, 106], ["25DHB", "SIMPLE_CHEMICAL", 135, 140], ["Scn binding pockets", "SIMPLE_CHEMICAL", 260, 279], ["Scn binding pockets", "PROTEIN", 260, 279], ["25DHB chelators", "TREATMENT", 91, 106], ["endogenous siderophores", "TEST", 110, 133], ["stealth siderophores", "PROBLEM", 181, 201], ["the steric incompatibility of these molecules", "PROBLEM", 209, 254], ["Scn binding pockets", "PROBLEM", 260, 279], ["steric incompatibility", "OBSERVATION", 213, 235], ["binding pockets", "OBSERVATION", 264, 279]]], ["Cellular responses which are interpreted to be a result dependent on the Scn:Fe:25DHB interaction likely require alternative explanation or further study.Tear LipocalinTear lipocalin (TL, also known as Lipocalin1, von Ebner's gland protein, or human tear prealbumin) is the second-most concentrated protein in tears and protects the ocular surface by scavenging harmful lipid peroxidation products.", [["Cellular", "ANATOMY", 0, 8], ["gland", "ANATOMY", 226, 231], ["ocular surface", "ANATOMY", 333, 347], ["Fe", "CHEMICAL", 77, 79], ["Fe:25DHB", "CHEMICAL", 77, 85], ["Scn", "GENE_OR_GENE_PRODUCT", 73, 76], ["Fe", "SIMPLE_CHEMICAL", 77, 79], ["25DHB", "SIMPLE_CHEMICAL", 80, 85], ["Tear LipocalinTear lipocalin", "GENE_OR_GENE_PRODUCT", 154, 182], ["TL", "GENE_OR_GENE_PRODUCT", 184, 186], ["Lipocalin1", "GENE_OR_GENE_PRODUCT", 202, 212], ["von Ebner's gland protein", "GENE_OR_GENE_PRODUCT", 214, 239], ["human", "ORGANISM", 244, 249], ["tear prealbumin", "GENE_OR_GENE_PRODUCT", 250, 265], ["ocular surface", "TISSUE", 333, 347], ["lipid peroxidation products", "SIMPLE_CHEMICAL", 370, 397], ["Tear LipocalinTear lipocalin", "PROTEIN", 154, 182], ["TL", "PROTEIN", 184, 186], ["Lipocalin1", "PROTEIN", 202, 212], ["von Ebner's gland protein", "PROTEIN", 214, 239], ["human tear prealbumin", "PROTEIN", 244, 265], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 244, 249], ["Cellular responses", "TEST", 0, 18], ["further study", "TEST", 140, 153], ["Tear LipocalinTear lipocalin (TL", "TREATMENT", 154, 186], ["Lipocalin1", "TEST", 202, 212], ["human tear prealbumin", "TEST", 244, 265], ["concentrated protein in tears", "PROBLEM", 286, 315], ["harmful lipid peroxidation products", "TREATMENT", 362, 397], ["tears", "OBSERVATION", 310, 315], ["ocular", "ANATOMY", 333, 339], ["scavenging harmful", "OBSERVATION", 351, 369], ["lipid peroxidation", "OBSERVATION", 370, 388]]], ["More than an extracellular ligand delivery protein, TL is a catalytic endonuclease in tears which is important for the breakdown of invading viral or microbial DNA [34] .", [["extracellular", "ANATOMY", 13, 26], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["TL", "GENE_OR_GENE_PRODUCT", 52, 54], ["tears", "PATHOLOGICAL_FORMATION", 86, 91], ["DNA", "CELLULAR_COMPONENT", 160, 163], ["extracellular ligand delivery protein", "PROTEIN", 13, 50], ["TL", "PROTEIN", 52, 54], ["catalytic endonuclease", "PROTEIN", 60, 82], ["an extracellular ligand delivery protein", "TREATMENT", 10, 50], ["a catalytic endonuclease in tears", "PROBLEM", 58, 91], ["the breakdown", "PROBLEM", 115, 128], ["invading viral or microbial DNA", "PROBLEM", 132, 163], ["tears", "OBSERVATION", 86, 91]]], ["TL also disrupts bacterial or viral colonization in human tears by inhibiting microbial cysteine proteinases and intercepting bacterial siderophores [35] [36] [37] [38] .", [["tears", "ANATOMY", 58, 63], ["cysteine", "CHEMICAL", 88, 96], ["human", "ORGANISM", 52, 57], ["microbial cysteine proteinases", "GENE_OR_GENE_PRODUCT", 78, 108], ["[35] [36] [37] [38]", "SIMPLE_CHEMICAL", 149, 168], ["microbial cysteine proteinases", "PROTEIN", 78, 108], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["bacterial", "PROBLEM", 17, 26], ["viral colonization in human tears", "PROBLEM", 30, 63], ["inhibiting microbial cysteine proteinases", "PROBLEM", 67, 108], ["intercepting bacterial siderophores", "TEST", 113, 148], ["bacterial", "OBSERVATION_MODIFIER", 17, 26], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["colonization", "OBSERVATION_MODIFIER", 36, 48]]], ["In the early 1990's, TL was found in several other types of human mucosae, such as trachobroncheal, lingual, prostate and pituitary glandular mucosae [39] [40] [41] [42] .", [["mucosae", "ANATOMY", 66, 73], ["trachobroncheal", "ANATOMY", 83, 98], ["lingual", "ANATOMY", 100, 107], ["prostate", "ANATOMY", 109, 117], ["pituitary glandular mucosae", "ANATOMY", 122, 149], ["human", "ORGANISM", 60, 65], ["mucosae", "MULTI-TISSUE_STRUCTURE", 66, 73], ["trachobroncheal", "CANCER", 83, 98], ["lingual", "ORGAN", 100, 107], ["prostate", "CANCER", 109, 117], ["pituitary glandular mucosae", "TISSUE", 122, 149], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["human mucosae", "PROBLEM", 60, 73], ["trachobroncheal, lingual, prostate and pituitary glandular mucosae", "PROBLEM", 83, 149], ["human mucosae", "ANATOMY", 60, 73], ["lingual", "ANATOMY", 100, 107], ["prostate", "ANATOMY", 109, 117], ["pituitary glandular", "ANATOMY", 122, 141]]], ["The various roles of TL are attributed, in part, to its ligands.", [["TL", "GENE_OR_GENE_PRODUCT", 21, 23], ["TL", "PROTEIN", 21, 23], ["TL", "ANATOMY", 21, 23]]], ["TL accommodates ligands of strikingly different chemical structures.", [["ligands", "OBSERVATION_MODIFIER", 16, 23], ["strikingly", "OBSERVATION_MODIFIER", 27, 37], ["different", "OBSERVATION_MODIFIER", 38, 47], ["chemical structures", "OBSERVATION", 48, 67]]], ["Fatty acids with chains up to 18 carbons long or with aromatic moieties tethered to the end of the chain are bound by TL with high affinity [41, 45] .", [["Fatty acids", "CHEMICAL", 0, 11], ["Fatty acids", "CHEMICAL", 0, 11], ["carbons", "CHEMICAL", 33, 40], ["Fatty acids", "SIMPLE_CHEMICAL", 0, 11], ["TL", "PROTEIN", 118, 120], ["Fatty acids with chains", "PROBLEM", 0, 23], ["aromatic moieties", "PROBLEM", 54, 71], ["aromatic moieties", "OBSERVATION", 54, 71]]], ["TL also binds bacterial and fungal siderophores that are structurally quite different from fatty acids, such as enterobactin, aerobactin, DFOB, ferricrocin, ferrichrome, rhodotorulic acid, coprogen and triacetylfusarinine C [37] .Tear LipocalinUnlike other lipocalins, TL has a much bigger calyx that can also change cavity sizes and rigidity by rearrangement of residue side chains within the calyx (Figure 1) .", [["calyx", "ANATOMY", 290, 295], ["calyx", "ANATOMY", 394, 399], ["fatty acids", "CHEMICAL", 91, 102], ["enterobactin", "CHEMICAL", 112, 124], ["aerobactin", "CHEMICAL", 126, 136], ["DFOB", "CHEMICAL", 138, 142], ["ferricrocin", "CHEMICAL", 144, 155], ["ferrichrome", "CHEMICAL", 157, 168], ["rhodotorulic acid", "CHEMICAL", 170, 187], ["coprogen", "CHEMICAL", 189, 197], ["triacetylfusarinine", "CHEMICAL", 202, 221], ["rigidity", "DISEASE", 334, 342], ["fatty acids", "CHEMICAL", 91, 102], ["enterobactin", "CHEMICAL", 112, 124], ["aerobactin", "CHEMICAL", 126, 136], ["DFOB", "CHEMICAL", 138, 142], ["ferricrocin", "CHEMICAL", 144, 155], ["ferrichrome", "CHEMICAL", 157, 168], ["rhodotorulic acid", "CHEMICAL", 170, 187], ["coprogen", "CHEMICAL", 189, 197], ["triacetylfusarinine C", "CHEMICAL", 202, 223], ["TL", "GENE_OR_GENE_PRODUCT", 0, 2], ["fatty acids", "SIMPLE_CHEMICAL", 91, 102], ["enterobactin", "SIMPLE_CHEMICAL", 112, 124], ["aerobactin", "SIMPLE_CHEMICAL", 126, 136], ["DFOB", "SIMPLE_CHEMICAL", 138, 142], ["ferricrocin", "SIMPLE_CHEMICAL", 144, 155], ["ferrichrome", "SIMPLE_CHEMICAL", 157, 168], ["rhodotorulic acid", "SIMPLE_CHEMICAL", 170, 187], ["coprogen", "SIMPLE_CHEMICAL", 189, 197], ["triacetylfusarinine C [37]", "SIMPLE_CHEMICAL", 202, 228], ["lipocalins", "GENE_OR_GENE_PRODUCT", 257, 267], ["calyx", "ORGANISM_SUBDIVISION", 290, 295], ["calyx", "ORGANISM_SUBDIVISION", 394, 399], ["lipocalins", "PROTEIN", 257, 267], ["TL", "PROTEIN", 269, 271], ["binds bacterial and fungal siderophores", "PROBLEM", 8, 47], ["fatty acids", "TEST", 91, 102], ["enterobactin", "TREATMENT", 112, 124], ["aerobactin", "TREATMENT", 126, 136], ["DFOB", "TREATMENT", 138, 142], ["ferricrocin", "TREATMENT", 144, 155], ["ferrichrome", "TREATMENT", 157, 168], ["rhodotorulic acid", "TREATMENT", 170, 187], ["Tear LipocalinUnlike other lipocalins", "PROBLEM", 230, 267], ["rigidity", "PROBLEM", 334, 342], ["rearrangement of residue side chains", "TREATMENT", 346, 382], ["bacterial", "OBSERVATION_MODIFIER", 14, 23], ["fungal siderophores", "OBSERVATION", 28, 47], ["fatty acids", "OBSERVATION", 91, 102], ["lipocalins", "ANATOMY", 257, 267], ["TL", "ANATOMY", 269, 271], ["much bigger", "OBSERVATION_MODIFIER", 278, 289], ["calyx", "ANATOMY_MODIFIER", 290, 295], ["change", "OBSERVATION_MODIFIER", 310, 316], ["cavity", "OBSERVATION_MODIFIER", 317, 323], ["sizes", "OBSERVATION_MODIFIER", 324, 329], ["rigidity", "OBSERVATION_MODIFIER", 334, 342], ["residue", "OBSERVATION_MODIFIER", 363, 370], ["side", "OBSERVATION_MODIFIER", 371, 375], ["chains", "OBSERVATION_MODIFIER", 376, 382], ["calyx", "ANATOMY", 394, 399]]], ["A phenylalanine residue (Phe99) within the TL calyx can rearrange to reversibly form another beta-sheet that rigidifies the protein-ligand interaction [43] .", [["TL calyx", "ANATOMY", 43, 51], ["phenylalanine", "CHEMICAL", 2, 15], ["Phe99", "CHEMICAL", 25, 30], ["phenylalanine", "CHEMICAL", 2, 15], ["Phe99", "CHEMICAL", 25, 30], ["phenylalanine", "AMINO_ACID", 2, 15], ["Phe99", "AMINO_ACID", 25, 30], ["beta-sheet", "PROTEIN", 93, 103], ["A phenylalanine residue (Phe99) within the TL calyx", "TREATMENT", 0, 51], ["phenylalanine residue", "OBSERVATION", 2, 23]]], ["A methionine residue (Met39) can rearrange upon ligand binding to expand the calyx volume [44] .", [["calyx", "ANATOMY", 77, 82], ["methionine", "CHEMICAL", 2, 12], ["Met39", "CHEMICAL", 22, 27], ["methionine", "CHEMICAL", 2, 12], ["methionine", "AMINO_ACID", 2, 12], ["Met39", "AMINO_ACID", 22, 27], ["A methionine residue (Met39)", "TREATMENT", 0, 28], ["calyx", "ANATOMY", 77, 82]]], ["Furthermore, TL has 4 flexible loops that aid in ligand recognition [45] .These flexibility features demonstrate the multipurpose nature of TL.", [["TL", "PROTEIN", 13, 15], ["4 flexible loops", "TREATMENT", 20, 36], ["multipurpose nature", "OBSERVATION_MODIFIER", 117, 136]]], ["TL accommodates chemically different ligands and the resulting conformational changes of the protein are dependent on the identity of a ligand.", [["TL accommodates chemically different ligands", "PROBLEM", 0, 44], ["the resulting conformational changes of the protein", "PROBLEM", 49, 100], ["chemically", "OBSERVATION_MODIFIER", 16, 26], ["different ligands", "OBSERVATION", 27, 44], ["resulting", "OBSERVATION_MODIFIER", 53, 62], ["conformational", "OBSERVATION", 63, 77]]], ["For example, TL binding of a lipid results in \u03b2-structure formation and a rigidification of TL [41] .", [["lipid", "SIMPLE_CHEMICAL", 29, 34], ["\u03b2-structure", "SIMPLE_CHEMICAL", 46, 57]]], ["At various epithelial surfaces where TL is a scavenger, enzyme or enzyme inhibitor, the ultimate fate of one TL protein is determined by the bound ligand and the resulting TL conformational change.", [["epithelial surfaces", "ANATOMY", 11, 30], ["epithelial surfaces", "TISSUE", 11, 30], ["TL", "PROTEIN", 37, 39], ["TL protein", "PROTEIN", 109, 119], ["enzyme", "TEST", 56, 62], ["enzyme inhibitor", "TREATMENT", 66, 82], ["the resulting TL conformational change", "PROBLEM", 158, 196], ["epithelial", "ANATOMY_MODIFIER", 11, 21], ["surfaces", "OBSERVATION_MODIFIER", 22, 30]]], ["The fact that TL binds a vast array of ligands and is expressed in several types of cells suggests that TL is part of a general protective response for the human body.", [["cells", "ANATOMY", 84, 89], ["body", "ANATOMY", 162, 166], ["cells", "CELL", 84, 89], ["TL", "GENE_OR_GENE_PRODUCT", 104, 106], ["human", "ORGANISM", 156, 161], ["body", "ORGANISM_SUBDIVISION", 162, 166], ["TL", "PROTEIN", 14, 16], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 156, 161]]], ["Furthermore, other roles of TL such as its endonuclease role may be available in other physiological contexts beyond protection of ocular surfaces.Ex-FABPEx-FABP is a 21 kDa lipocalin found in chickens [4, 46] .", [["ocular surfaces", "ANATOMY", 131, 146], ["TL", "GENE_OR_GENE_PRODUCT", 28, 30], ["ocular surfaces", "MULTI-TISSUE_STRUCTURE", 131, 146], ["Ex-FABPEx-FABP", "GENE_OR_GENE_PRODUCT", 147, 161], ["lipocalin", "GENE_OR_GENE_PRODUCT", 174, 183], ["chickens", "ORGANISM", 193, 201], ["TL", "PROTEIN", 28, 30], ["endonuclease", "PROTEIN", 43, 55], ["FABPEx", "PROTEIN", 150, 156], ["FABP", "PROTEIN", 157, 161], ["21 kDa lipocalin", "PROTEIN", 167, 183], ["chickens", "SPECIES", 193, 201], ["chickens", "SPECIES", 193, 201], ["its endonuclease role", "TREATMENT", 39, 60], ["a 21 kDa lipocalin", "TREATMENT", 165, 183], ["ocular", "ANATOMY", 131, 137], ["FABP", "ANATOMY", 157, 161]]], ["The structural similarity to Scn, including a wide, positively charged calyx, prompted investigating the siderophore binding properties of Ex-FABP and the discovery that it is a siderocalin [47] (Figure 1 ).Ex-FABPThe calyx interacts with siderophores in a manner similar to Scn.", [["calyx", "ANATOMY", 71, 76], ["calyx", "ANATOMY", 218, 223], ["Scn", "CHEMICAL", 29, 32], ["siderocalin", "CHEMICAL", 178, 189], ["siderocalin", "CHEMICAL", 178, 189], ["Scn", "GENE_OR_GENE_PRODUCT", 29, 32], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 139, 146], ["Scn", "GENE_OR_GENE_PRODUCT", 275, 278], ["Ex-FABP", "PROTEIN", 139, 146], ["Scn", "PROTEIN", 275, 278], ["a wide, positively charged calyx", "PROBLEM", 44, 76], ["Ex-FABP", "TEST", 139, 146], ["wide", "OBSERVATION_MODIFIER", 46, 50]]], ["Three basic residues, Lys82, Arg101, and Arg112, give the calyx a positive charge and define three catecholbinding subpockets within the calyx.", [["calyx", "ANATOMY", 58, 63], ["calyx", "ANATOMY", 137, 142], ["Lys82", "CHEMICAL", 22, 27], ["Arg", "CHEMICAL", 29, 32], ["Arg112", "CHEMICAL", 41, 47], ["Lys82", "AMINO_ACID", 22, 27], ["Arg101", "AMINO_ACID", 29, 35], ["Arg112", "AMINO_ACID", 41, 47], ["calyx", "MULTI-TISSUE_STRUCTURE", 137, 142], ["catecholbinding subpockets", "PROTEIN", 99, 125], ["Three basic residues", "PROBLEM", 0, 20], ["Arg", "TEST", 29, 32], ["Arg112", "TREATMENT", 41, 47], ["three catecholbinding subpockets", "TREATMENT", 93, 125], ["basic residues", "OBSERVATION", 6, 20], ["calyx", "ANATOMY", 58, 63], ["calyx", "ANATOMY", 137, 142]]], ["Arg101 and Arg112 provide electrostatic interactions with bound catechols and Lys82 hydrogen bonds with the meta hydroxyl of the catechols in two of the subpockets.", [["catechols", "CHEMICAL", 64, 73], ["hydroxyl", "CHEMICAL", 113, 121], ["catechols", "CHEMICAL", 129, 138], ["Arg", "CHEMICAL", 0, 3], ["Arg112", "CHEMICAL", 11, 17], ["catechols", "CHEMICAL", 64, 73], ["Lys82", "CHEMICAL", 78, 83], ["hydrogen", "CHEMICAL", 84, 92], ["hydroxyl", "CHEMICAL", 113, 121], ["catechols", "CHEMICAL", 129, 138], ["Arg101", "AMINO_ACID", 0, 6], ["Arg112", "AMINO_ACID", 11, 17], ["catechols", "SIMPLE_CHEMICAL", 64, 73], ["Lys82 hydrogen bonds", "SIMPLE_CHEMICAL", 78, 98], ["catechols", "SIMPLE_CHEMICAL", 129, 138], ["Arg", "TEST", 0, 3], ["bound catechols", "TREATMENT", 58, 73], ["Lys82 hydrogen bonds", "TREATMENT", 78, 98], ["the meta hydroxyl of the catechols", "TREATMENT", 104, 138]]], ["Ex-FABP binds ferric enterobactin with a dissociation constant of 0.2 nM, comparable to the high affinity of Scn for ferric enterobactin.", [["ferric enterobactin", "CHEMICAL", 14, 33], ["Scn", "CHEMICAL", 109, 112], ["ferric enterobactin", "CHEMICAL", 117, 136], ["ferric enterobactin", "CHEMICAL", 14, 33], ["ferric enterobactin", "CHEMICAL", 117, 136], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 0, 7], ["ferric enterobactin", "SIMPLE_CHEMICAL", 14, 33], ["Scn", "SIMPLE_CHEMICAL", 109, 112], ["ferric enterobactin", "SIMPLE_CHEMICAL", 117, 136], ["Ex-FABP", "PROTEIN", 0, 7], ["Scn", "PROTEIN", 109, 112], ["FABP binds ferric enterobactin", "PROBLEM", 3, 33], ["a dissociation constant", "PROBLEM", 39, 62], ["ferric enterobactin", "TREATMENT", 117, 136]]], ["Ex-FABP also binds monoglucosylated enterobactin (MGE) with a subnanomolar dissociation constant, but it does not bind diglucosylated enterobactin (DGE) (Figure 2 ).", [["enterobactin", "CHEMICAL", 36, 48], ["MGE", "CHEMICAL", 50, 53], ["enterobactin", "CHEMICAL", 134, 146], ["monoglucosylated enterobactin", "CHEMICAL", 19, 48], ["diglucosylated enterobactin", "CHEMICAL", 119, 146], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 0, 7], ["monoglucosylated enterobactin", "SIMPLE_CHEMICAL", 19, 48], ["MGE", "SIMPLE_CHEMICAL", 50, 53], ["diglucosylated enterobactin", "SIMPLE_CHEMICAL", 119, 146], ["Ex-FABP", "PROTEIN", 0, 7], ["a subnanomolar dissociation constant", "PROBLEM", 60, 96], ["FABP", "ANATOMY", 3, 7], ["subnanomolar dissociation", "OBSERVATION", 62, 87]]], ["This is because one subpocket of Ex-FABP is extended to allow space for the single glucose subunit branching from a catechol of MGE.", [["glucose", "CHEMICAL", 83, 90], ["catechol", "CHEMICAL", 116, 124], ["glucose", "CHEMICAL", 83, 90], ["catechol", "CHEMICAL", 116, 124], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 33, 40], ["glucose", "SIMPLE_CHEMICAL", 83, 90], ["catechol", "SIMPLE_CHEMICAL", 116, 124], ["MGE", "SIMPLE_CHEMICAL", 128, 131], ["Ex-FABP", "PROTEIN", 33, 40], ["glucose subunit", "PROTEIN", 83, 98], ["Ex-FABP", "PROBLEM", 33, 40]]], ["The glucose would clash with the calyx wall of the corresponding subpocket in Scn [47] .Ex-FABPThe difference of binding MGE between Scn and Ex-FABP strongly suggests that chickens have developed a siderocalin defense specific to chicken pathogens.", [["calyx wall", "ANATOMY", 33, 43], ["glucose", "CHEMICAL", 4, 11], ["siderocalin", "CHEMICAL", 198, 209], ["glucose", "CHEMICAL", 4, 11], ["glucose", "SIMPLE_CHEMICAL", 4, 11], ["calyx wall", "MULTI-TISSUE_STRUCTURE", 33, 43], ["Scn", "GENE_OR_GENE_PRODUCT", 133, 136], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 141, 148], ["chickens", "ORGANISM", 172, 180], ["siderocalin", "GENE_OR_GENE_PRODUCT", 198, 209], ["chicken", "ORGANISM", 230, 237], ["Scn", "PROTEIN", 133, 136], ["Ex-FABP", "PROTEIN", 141, 148], ["chickens", "SPECIES", 172, 180], ["chicken", "SPECIES", 230, 237], ["chickens", "SPECIES", 172, 180], ["chicken", "SPECIES", 230, 237], ["The glucose", "TEST", 0, 11], ["Ex-FABP", "TEST", 141, 148], ["a siderocalin defense", "PROBLEM", 196, 217], ["chicken pathogens", "PROBLEM", 230, 247]]], ["MGE and DGE are members of a family of siderophores called salmochelins which also includes various hydrolysis products of MGE or DGE [28, 48] .", [["salmochelins", "CHEMICAL", 59, 71], ["MGE", "CELL", 0, 3], ["salmochelins", "GENE_OR_GENE_PRODUCT", 59, 71], ["MGE", "SIMPLE_CHEMICAL", 123, 126], ["MGE", "DNA", 0, 3], ["DGE", "DNA", 8, 11], ["salmochelins", "TREATMENT", 59, 71], ["various hydrolysis products", "TREATMENT", 92, 119]]], ["These siderophores are produced and transported by products of the iro gene locus found in Salmonella enterica and extraintestinal pathogenic E. coli, including avian pathogenic E. coli (APEC) [48] [49] [50] .", [["iro", "GENE_OR_GENE_PRODUCT", 67, 70], ["Salmonella enterica", "ORGANISM", 91, 110], ["extraintestinal pathogenic E. coli", "ORGANISM", 115, 149], ["E. coli", "ORGANISM", 178, 185], ["iro gene locus", "DNA", 67, 81], ["Salmonella enterica", "SPECIES", 91, 110], ["E. coli", "SPECIES", 142, 149], ["avian", "SPECIES", 161, 166], ["E. coli", "SPECIES", 178, 185], ["Salmonella enterica", "SPECIES", 91, 110], ["E. coli", "SPECIES", 142, 149], ["E. coli", "SPECIES", 178, 185], ["the iro gene locus", "TREATMENT", 63, 81], ["Salmonella enterica", "PROBLEM", 91, 110], ["extraintestinal pathogenic E. coli", "PROBLEM", 115, 149], ["avian pathogenic E. coli", "PROBLEM", 161, 185], ["Salmonella enterica", "OBSERVATION", 91, 110], ["E. coli", "OBSERVATION", 142, 149]]], ["In APEC, the enterobactin system alone is insufficient for virulence [50] presumably because the enterobactin is intercepted by Ex-FABP.", [["enterobactin", "CHEMICAL", 13, 25], ["enterobactin", "CHEMICAL", 97, 109], ["enterobactin", "CHEMICAL", 13, 25], ["enterobactin", "CHEMICAL", 97, 109], ["enterobactin", "SIMPLE_CHEMICAL", 13, 25], ["enterobactin", "SIMPLE_CHEMICAL", 97, 109], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 128, 135], ["Ex-FABP", "PROTEIN", 128, 135], ["the enterobactin system", "TREATMENT", 9, 32], ["virulence", "PROBLEM", 59, 68], ["the enterobactin", "TREATMENT", 93, 109]]], ["MGE is bound by Ex-FABP [47] and likely does not support virulence.", [["Ex-FABP", "GENE_OR_GENE_PRODUCT", 16, 23], ["MGE", "DNA", 0, 3]]], ["Unsurprisingly, DGE is secreted as well as MGE because it can circumvent the Ex-FABP defense [49, 50] .", [["FABP", "GENE_OR_GENE_PRODUCT", 80, 84], ["DGE", "DNA", 16, 19], ["DGE", "OBSERVATION", 16, 19]]], ["The iro locus remains a virulence factor in APEC that is significantly associated with pathogenicity and lethality [50, 51] .", [["iro", "GENE_OR_GENE_PRODUCT", 4, 7], ["APEC", "ORGANISM", 44, 48], ["iro locus", "DNA", 4, 13], ["virulence factor", "PROTEIN", 24, 40], ["APEC", "SPECIES", 44, 48], ["a virulence factor", "PROBLEM", 22, 40], ["APEC", "PROBLEM", 44, 48], ["pathogenicity", "PROBLEM", 87, 100], ["lethality", "PROBLEM", 105, 114], ["virulence", "OBSERVATION_MODIFIER", 24, 33]]], ["In addition to E. coli, pathogenic S. enterica isolated from chickens has the iro virulence factor [52] .Ex-FABPThe observed expression of Ex-FABP supports the siderocalin activity of the protein.", [["E. coli", "ORGANISM", 15, 22], ["S. enterica", "ORGANISM", 35, 46], ["chickens", "ORGANISM", 61, 69], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 139, 146], ["siderocalin", "GENE_OR_GENE_PRODUCT", 160, 171], ["iro virulence factor", "PROTEIN", 78, 98], ["Ex-FABP", "PROTEIN", 139, 146], ["siderocalin", "PROTEIN", 160, 171], ["E. coli", "SPECIES", 15, 22], ["S. enterica", "SPECIES", 35, 46], ["chickens", "SPECIES", 61, 69], ["E. coli", "SPECIES", 15, 22], ["S. enterica", "SPECIES", 35, 46], ["chickens", "SPECIES", 61, 69], ["E. coli", "PROBLEM", 15, 22], ["pathogenic S. enterica", "PROBLEM", 24, 46], ["Ex-FABP", "TEST", 139, 146], ["E. coli", "OBSERVATION_MODIFIER", 15, 22], ["enterica", "OBSERVATION_MODIFIER", 38, 46]]], ["It has been observed in the bacteriostatic hen egg [53] .", [["hen", "SPECIES", 43, 46], ["the bacteriostatic hen egg", "TEST", 24, 50]]], ["Granulocytes express it [54] .", [["Granulocytes", "ANATOMY", 0, 12], ["Granulocytes", "CELL", 0, 12], ["Granulocytes", "CELL_TYPE", 0, 12], ["Granulocytes", "TEST", 0, 12]]], ["Tracheal infection with infectious bronchitis coronavirus increases expression of the protein [55] , and the inflammatory signals IL6 and LPS, Gram-negative endotoxin, induce expression [56, 57] .Ex-FABPThe siderocalin activity of Ex-FABP is the most characterized function of the protein, but it plays a role in a variety of other processes.", [["Tracheal", "ANATOMY", 0, 8], ["Tracheal infection", "DISEASE", 0, 18], ["infectious bronchitis coronavirus", "DISEASE", 24, 57], ["Tracheal", "ORGAN", 0, 8], ["infectious bronchitis coronavirus", "ORGANISM", 24, 57], ["protein [55]", "GENE_OR_GENE_PRODUCT", 86, 98], ["IL6", "GENE_OR_GENE_PRODUCT", 130, 133], ["LPS", "GENE_OR_GENE_PRODUCT", 138, 141], ["Gram-negative endotoxin", "GENE_OR_GENE_PRODUCT", 143, 166], ["siderocalin", "GENE_OR_GENE_PRODUCT", 207, 218], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 231, 238], ["IL6", "PROTEIN", 130, 133], ["Gram-negative endotoxin", "PROTEIN", 143, 166], ["Ex-FABP", "PROTEIN", 231, 238], ["infectious bronchitis coronavirus", "SPECIES", 24, 57], ["infectious bronchitis coronavirus", "SPECIES", 24, 57], ["Tracheal infection", "PROBLEM", 0, 18], ["infectious bronchitis coronavirus", "PROBLEM", 24, 57], ["the protein", "TEST", 82, 93], ["the inflammatory signals IL6", "TEST", 105, 133], ["LPS", "TEST", 138, 141], ["infection", "OBSERVATION", 9, 18], ["infectious", "OBSERVATION_MODIFIER", 24, 34], ["inflammatory", "OBSERVATION_MODIFIER", 109, 121]]], ["Ex-FABP has been observed in differentiating cartilage cells of chicken embryos as well as skin, brain, heart, and muscle tissues [46, 54] .", [["cartilage cells", "ANATOMY", 45, 60], ["embryos", "ANATOMY", 72, 79], ["skin", "ANATOMY", 91, 95], ["brain", "ANATOMY", 97, 102], ["heart", "ANATOMY", 104, 109], ["muscle tissues", "ANATOMY", 115, 129], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 0, 7], ["cartilage cells", "CELL", 45, 60], ["chicken", "ORGANISM", 64, 71], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 72, 79], ["skin", "ORGAN", 91, 95], ["brain", "ORGAN", 97, 102], ["heart", "ORGAN", 104, 109], ["muscle tissues", "TISSUE", 115, 129], ["FABP", "PROTEIN", 3, 7], ["differentiating cartilage cells", "CELL_TYPE", 29, 60], ["chicken", "SPECIES", 64, 71], ["chicken", "SPECIES", 64, 71], ["chicken embryos", "PROBLEM", 64, 79], ["FABP", "ANATOMY", 3, 7], ["cartilage cells", "OBSERVATION", 45, 60], ["chicken embryos", "OBSERVATION", 64, 79], ["skin", "ANATOMY", 91, 95], ["brain", "ANATOMY", 97, 102], ["heart", "ANATOMY", 104, 109], ["muscle tissues", "ANATOMY", 115, 129]]], ["Expression increases during inflammation and acute phase response.", [["inflammation", "DISEASE", 28, 40], ["inflammation", "PROBLEM", 28, 40], ["acute phase response", "PROBLEM", 45, 65], ["inflammation", "OBSERVATION", 28, 40], ["acute phase", "OBSERVATION_MODIFIER", 45, 56]]], ["Pathological cartilage of dyschondroplastic and osteoarthritic chickens has an elevated amount of Ex-FABP [56] .", [["cartilage", "ANATOMY", 13, 22], ["cartilage", "TISSUE", 13, 22], ["chickens", "ORGANISM", 63, 71], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 98, 105], ["Ex", "PROTEIN", 98, 100], ["FABP", "PROTEIN", 101, 105], ["chickens", "SPECIES", 63, 71], ["chickens", "SPECIES", 63, 71], ["Pathological cartilage of dyschondroplastic", "PROBLEM", 0, 43], ["osteoarthritic chickens", "PROBLEM", 48, 71], ["cartilage", "OBSERVATION", 13, 22], ["dyschondroplastic", "OBSERVATION_MODIFIER", 26, 43], ["osteoarthritic", "OBSERVATION", 48, 62], ["elevated", "OBSERVATION_MODIFIER", 79, 87], ["amount", "OBSERVATION_MODIFIER", 88, 94]]], ["A review of the different process that involve Ex-FABP, and analogous processes that involve Scn in humans, has proposed that these proteins, in addition to being siderocalins, are stress proteins that function in tissues experiencing active remodeling or acute phase response [58] .Ex-FABPA breakthrough in the way Ex-FABP contributes to these different processes was uncovered while characterizing the structure of the Ex-FABP:siderophore complex.", [["tissues", "ANATOMY", 214, 221], ["Scn", "CHEMICAL", 93, 96], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 47, 54], ["Scn", "GENE_OR_GENE_PRODUCT", 93, 96], ["humans", "ORGANISM", 100, 106], ["siderocalins", "GENE_OR_GENE_PRODUCT", 163, 175], ["tissues", "TISSUE", 214, 221], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 316, 323], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 421, 428], ["siderophore complex", "GENE_OR_GENE_PRODUCT", 429, 448], ["Ex-FABP", "PROTEIN", 47, 54], ["Scn", "PROTEIN", 93, 96], ["siderocalins", "PROTEIN", 163, 175], ["stress proteins", "PROTEIN", 181, 196], ["Ex-FABP", "PROTEIN", 316, 323], ["Ex-FABP:siderophore complex", "PROTEIN", 421, 448], ["humans", "SPECIES", 100, 106], ["humans", "SPECIES", 100, 106], ["FABP", "TEST", 50, 54], ["analogous processes", "PROBLEM", 60, 79], ["these proteins", "PROBLEM", 126, 140], ["stress proteins", "PROBLEM", 181, 196], ["active remodeling", "PROBLEM", 235, 252], ["acute phase response", "PROBLEM", 256, 276], ["FABPA breakthrough", "PROBLEM", 286, 304], ["these different processes", "PROBLEM", 339, 364], ["acute", "OBSERVATION_MODIFIER", 256, 261]]], ["The beta-barrel forms a second binding site that extends from the siderophore binding pocket to the opposite side of the protein.", [["beta-barrel", "GENE_OR_GENE_PRODUCT", 4, 15], ["beta-barrel", "PROTEIN", 4, 15], ["siderophore binding pocket", "PROTEIN", 66, 92], ["a second binding site", "PROBLEM", 22, 43], ["beta-barrel", "OBSERVATION_MODIFIER", 4, 15], ["protein", "ANATOMY", 121, 128]]], ["Having two binding sites enables Ex-FABP to simultaneously bind two structurally, chemically, and physiologically distinct molecules.", [["Ex-FABP", "GENE_OR_GENE_PRODUCT", 33, 40], ["Ex-FABP", "PROTEIN", 33, 40], ["two binding sites", "PROBLEM", 7, 24], ["distinct", "OBSERVATION_MODIFIER", 114, 122], ["molecules", "OBSERVATION", 123, 132]]], ["The crystal structure shows a molecule of lysophosphatidic acid (LPA) bound in the long, narrow pocket while ferricenterobactin sits in the broad pocket near the surface (Figure 4) .", [["surface", "ANATOMY", 162, 169], ["lysophosphatidic acid", "CHEMICAL", 42, 63], ["LPA", "CHEMICAL", 65, 68], ["ferricenterobactin", "CHEMICAL", 109, 127], ["lysophosphatidic acid", "CHEMICAL", 42, 63], ["LPA", "CHEMICAL", 65, 68], ["ferricenterobactin", "CHEMICAL", 109, 127], ["lysophosphatidic acid", "SIMPLE_CHEMICAL", 42, 63], ["LPA", "SIMPLE_CHEMICAL", 65, 68], ["ferricenterobactin", "SIMPLE_CHEMICAL", 109, 127], ["surface", "CELLULAR_COMPONENT", 162, 169], ["lysophosphatidic acid (LPA) bound in the long, narrow pocket", "PROBLEM", 42, 102], ["ferricenterobactin sits", "TREATMENT", 109, 132], ["the broad pocket", "PROBLEM", 136, 152], ["molecule", "OBSERVATION_MODIFIER", 30, 38], ["lysophosphatidic acid", "OBSERVATION", 42, 63], ["LPA", "OBSERVATION_MODIFIER", 65, 68], ["long", "OBSERVATION_MODIFIER", 83, 87], ["narrow", "OBSERVATION_MODIFIER", 89, 95], ["pocket", "OBSERVATION_MODIFIER", 96, 102], ["ferricenterobactin sits", "OBSERVATION", 109, 132], ["broad", "OBSERVATION_MODIFIER", 140, 145], ["pocket", "OBSERVATION_MODIFIER", 146, 152], ["surface", "OBSERVATION_MODIFIER", 162, 169]]], ["LPA is signal for a variety of cellular processes, and Ex-FABP may serve as a LPA sensor.", [["cellular", "ANATOMY", 31, 39], ["LPA", "CHEMICAL", 0, 3], ["LPA", "CHEMICAL", 0, 3], ["LPA", "CHEMICAL", 78, 81], ["LPA", "SIMPLE_CHEMICAL", 0, 3], ["cellular", "CELL", 31, 39], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 55, 62], ["LPA", "SIMPLE_CHEMICAL", 78, 81], ["Ex-FABP", "PROTEIN", 55, 62], ["a variety of cellular processes", "PROBLEM", 18, 49], ["Ex-FABP", "TEST", 55, 62], ["a LPA sensor", "TEST", 76, 88], ["cellular processes", "OBSERVATION", 31, 49]]], ["Two reported instances have linked Ex-FABP to binding lipophilic molecules.", [["Ex-FABP", "GENE_OR_GENE_PRODUCT", 35, 42], ["Ex-FABP", "PROTEIN", 35, 42], ["binding lipophilic molecules", "PROTEIN", 46, 74], ["lipophilic molecules", "OBSERVATION", 54, 74]]], ["In adult chickens, polymorphisms of Ex-FABP are related to subcutaneous fat and skin thickness of cocks [59] .", [["subcutaneous fat", "ANATOMY", 59, 75], ["skin", "ANATOMY", 80, 84], ["chickens", "ORGANISM", 9, 17], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 36, 43], ["subcutaneous fat", "TISSUE", 59, 75], ["skin", "ORGAN", 80, 84], ["Ex-FABP", "PROTEIN", 36, 43], ["chickens", "SPECIES", 9, 17], ["chickens", "SPECIES", 9, 17], ["polymorphisms of Ex-FABP", "PROBLEM", 19, 43], ["adult", "OBSERVATION_MODIFIER", 3, 8], ["chickens", "OBSERVATION", 9, 17], ["subcutaneous fat", "ANATOMY", 59, 75], ["skin", "ANATOMY", 80, 84], ["thickness", "OBSERVATION_MODIFIER", 85, 94]]], ["The protein also protects the heart during acute phase response, possibly by fatty acid scavenging [57] .", [["heart", "ANATOMY", 30, 35], ["fatty acid", "CHEMICAL", 77, 87], ["fatty acid", "CHEMICAL", 77, 87], ["heart", "ORGAN", 30, 35], ["fatty acid", "SIMPLE_CHEMICAL", 77, 87], ["acute phase response", "PROBLEM", 43, 63], ["fatty acid scavenging", "PROBLEM", 77, 98], ["heart", "ANATOMY", 30, 35], ["acute phase", "OBSERVATION", 43, 54]]], ["As of now, it is unknown if each binding site operates independently, cooperatively, or both, but it is likely that the many functions of Ex-FABP depend on the status of each binding site.Q83Q83 is the quail homolog of Ex-FABP.", [["Ex-FABP", "GENE_OR_GENE_PRODUCT", 138, 145], ["quail", "ORGANISM", 202, 207], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 219, 226], ["Ex-FABP", "PROTEIN", 138, 145], ["Q83Q83", "DNA", 188, 194], ["Ex-FABP", "PROTEIN", 219, 226], ["quail", "SPECIES", 202, 207], ["Ex-FABP", "TEST", 138, 145]]], ["It was identified in avian fibroblasts transformed by the v-myc oncogene [60] .", [["fibroblasts", "ANATOMY", 27, 38], ["avian", "ORGANISM", 21, 26], ["fibroblasts", "CELL", 27, 38], ["v-myc", "GENE_OR_GENE_PRODUCT", 58, 63], ["avian fibroblasts", "CELL_TYPE", 21, 38], ["v-myc oncogene", "DNA", 58, 72], ["avian fibroblasts", "OBSERVATION", 21, 38]]], ["Q83 has 64% sequence similarity to Scn and 87% sequence similarity to Ex-FABP [60, 61] .", [["Q83", "CHEMICAL", 0, 3], ["Scn", "GENE_OR_GENE_PRODUCT", 35, 38], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 70, 77], ["Q83", "DNA", 0, 3], ["Scn", "DNA", 35, 38], ["Ex", "DNA", 70, 72], ["FABP", "PROTEIN", 73, 77], ["Scn", "TEST", 35, 38], ["FABP", "TEST", 73, 77]]], ["The structural similarity between Q83 and Ex-FABP is confirmed in the NMR structure of Q83.", [["Q83", "SIMPLE_CHEMICAL", 34, 37], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 42, 49], ["Q83", "DNA", 34, 37], ["Ex-FABP", "PROTEIN", 42, 49], ["Ex-FABP", "TEST", 42, 49]]], ["The typical beta-barrel forms a calyx containing the three basic residues Lys83, Arg102, and Arg113 ( Figure 1 ).", [["calyx", "ANATOMY", 32, 37], ["Lys83", "CHEMICAL", 74, 79], ["Arg", "CHEMICAL", 81, 84], ["Arg", "CHEMICAL", 93, 96], ["Arg102", "AMINO_ACID", 81, 87], ["Arg113", "AMINO_ACID", 93, 99], ["Arg", "TEST", 81, 84], ["Arg", "TEST", 93, 96], ["beta-barrel", "OBSERVATION_MODIFIER", 12, 23], ["calyx", "ANATOMY_MODIFIER", 32, 37]]], ["The basic triad provides the interactions to tightly bind enterobactin with a dissociation constant of 0.5 nM [61] , implying that it defends against pathogens that use enterobactin.", [["enterobactin", "CHEMICAL", 58, 70], ["enterobactin", "CHEMICAL", 169, 181], ["enterobactin", "CHEMICAL", 58, 70], ["enterobactin", "CHEMICAL", 169, 181], ["enterobactin", "SIMPLE_CHEMICAL", 58, 70], ["enterobactin", "SIMPLE_CHEMICAL", 169, 181], ["pathogens", "PROBLEM", 150, 159], ["enterobactin", "TREATMENT", 169, 181]]], ["It may have the same activity against avian pathogens as Ex-FABP by binding the salmochelin MGE, but the glucose subunit has not been modeled in the expanded subpocket 3 to verify this.Q83Similar to Ex-FABP, Q83 has a second binding pocket that extends through the core of the protein for binding arachidonic acid and other fatty acids with nanomolar dissociation constants ( Figure 4) .", [["glucose", "CHEMICAL", 105, 112], ["Ex-FABP", "CHEMICAL", 199, 206], ["Q83", "CHEMICAL", 208, 211], ["arachidonic acid", "CHEMICAL", 297, 313], ["fatty acids", "CHEMICAL", 324, 335], ["glucose", "CHEMICAL", 105, 112], ["arachidonic acid", "CHEMICAL", 297, 313], ["fatty acids", "CHEMICAL", 324, 335], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 57, 64], ["salmochelin", "GENE_OR_GENE_PRODUCT", 80, 91], ["glucose", "SIMPLE_CHEMICAL", 105, 112], ["arachidonic acid", "SIMPLE_CHEMICAL", 297, 313], ["fatty acids", "SIMPLE_CHEMICAL", 324, 335], ["Ex-FABP", "PROTEIN", 57, 64], ["salmochelin MGE", "DNA", 80, 95], ["glucose subunit", "PROTEIN", 105, 120], ["Ex-FABP", "PROTEIN", 199, 206], ["Q83", "DNA", 208, 211], ["Ex-FABP", "TEST", 57, 64], ["the glucose subunit", "TEST", 101, 120], ["a second binding pocket", "PROBLEM", 216, 239], ["binding arachidonic acid", "TEST", 289, 313], ["other fatty acids", "TEST", 318, 335], ["nanomolar dissociation constants", "PROBLEM", 341, 373], ["arachidonic acid", "OBSERVATION", 297, 313]]], ["NMR studies showed that the binding status of each binding site has an allosteric effect on the dynamics of the other binding site [62, 63] .", [["binding site", "DNA", 118, 130], ["NMR studies", "TEST", 0, 11], ["the binding status of each binding site", "PROBLEM", 24, 63], ["an allosteric effect", "PROBLEM", 68, 88], ["allosteric effect", "OBSERVATION", 71, 88]]], ["The dual binding capability of Q83 potentially links iron transport, antimicrobial activity, and fatty acid pathways.", [["Q83", "CHEMICAL", 31, 34], ["iron", "CHEMICAL", 53, 57], ["fatty acid", "CHEMICAL", 97, 107], ["iron", "CHEMICAL", 53, 57], ["fatty acid", "CHEMICAL", 97, 107], ["Q83", "SIMPLE_CHEMICAL", 31, 34], ["iron", "SIMPLE_CHEMICAL", 53, 57], ["fatty acid", "SIMPLE_CHEMICAL", 97, 107], ["iron transport", "TREATMENT", 53, 67], ["antimicrobial activity", "TREATMENT", 69, 91], ["fatty acid pathways", "TEST", 97, 116]]], ["The different roles of Q83 have not been investigated, but it is inferred to have pleiotropic functions similar to the other siderocalins.", [["siderocalins", "CHEMICAL", 125, 137], ["Q83", "GENE_OR_GENE_PRODUCT", 23, 26], ["siderocalins", "GENE_OR_GENE_PRODUCT", 125, 137], ["Q83", "PROTEIN", 23, 26], ["siderocalins", "PROTEIN", 125, 137], ["pleiotropic functions", "PROBLEM", 82, 103]]], ["The characterization of the dual binding sites of Q83 sheds light on how the siderocalins may participate in the variety of processes that have been identified.Concluding RemarksThe bacterial pilfering of the host iron supply is accomplished by a number of siderophores and the respective iron-uptake systems.", [["iron", "CHEMICAL", 214, 218], ["iron", "CHEMICAL", 214, 218], ["siderocalins", "GENE_OR_GENE_PRODUCT", 77, 89], ["iron", "SIMPLE_CHEMICAL", 214, 218], ["dual binding sites", "DNA", 28, 46], ["Q83", "DNA", 50, 53], ["siderocalins", "PROTEIN", 77, 89], ["the host iron supply", "TREATMENT", 205, 225], ["bacterial", "OBSERVATION_MODIFIER", 182, 191], ["pilfering", "OBSERVATION", 192, 201]]], ["Siderocalins are immunoproteins that incapacitate some bacterial iron uptake systems by intercepting bacterial siderophores.", [["Siderocalins", "CHEMICAL", 0, 12], ["iron", "CHEMICAL", 65, 69], ["Siderocalins", "CHEMICAL", 0, 12], ["iron", "CHEMICAL", 65, 69], ["Siderocalins", "SIMPLE_CHEMICAL", 0, 12], ["iron", "SIMPLE_CHEMICAL", 65, 69], ["Siderocalins", "TREATMENT", 0, 12], ["immunoproteins", "TREATMENT", 17, 31], ["some bacterial iron uptake systems", "PROBLEM", 50, 84], ["bacterial siderophores", "PROBLEM", 101, 123], ["bacterial", "OBSERVATION_MODIFIER", 55, 64], ["iron uptake", "OBSERVATION", 65, 76]]], ["The isolation and characterization of siderocalins from quail, chickens, and humans, suggests that siderocalins exist for all animals that suffer from microbial infections.", [["siderocalins", "CHEMICAL", 38, 50], ["siderocalins", "CHEMICAL", 99, 111], ["microbial infections", "DISEASE", 151, 171], ["siderocalins", "CHEMICAL", 99, 111], ["siderocalins", "SIMPLE_CHEMICAL", 38, 50], ["quail", "ORGANISM", 56, 61], ["chickens", "ORGANISM", 63, 71], ["humans", "ORGANISM", 77, 83], ["siderocalins", "SIMPLE_CHEMICAL", 99, 111], ["quail", "SPECIES", 56, 61], ["chickens", "SPECIES", 63, 71], ["humans", "SPECIES", 77, 83], ["quail", "SPECIES", 56, 61], ["chickens", "SPECIES", 63, 71], ["humans", "SPECIES", 77, 83], ["The isolation", "TREATMENT", 0, 13], ["siderocalins", "PROBLEM", 38, 50], ["microbial infections", "PROBLEM", 151, 171], ["microbial", "OBSERVATION_MODIFIER", 151, 160], ["infections", "OBSERVATION", 161, 171]]], ["It seems only a matter of time before siderocalins are identified for all forms of life that can be considered a host, thus enhancing our appreciation for the evolutionary pressure of host-pathogen interactions.", [["siderocalins", "CHEMICAL", 38, 50], ["siderocalins", "SIMPLE_CHEMICAL", 38, 50]]], ["The discovery of siderocalins will give an added perspective as to why certain species or individuals within a species are at higher risk of bacterial infections.", [["bacterial infections", "DISEASE", 141, 161], ["siderocalins", "CHEMICAL", 17, 29], ["siderocalins", "GENE_OR_GENE_PRODUCT", 17, 29], ["siderocalins", "TREATMENT", 17, 29], ["a species", "PROBLEM", 109, 118], ["bacterial infections", "PROBLEM", 141, 161], ["bacterial", "OBSERVATION_MODIFIER", 141, 150], ["infections", "OBSERVATION", 151, 161]]], ["Searching for new siderocalins may also reveal that a single host expresses a variety of location-specific siderocalins designed to manage the microbiome of the host by preventing an outbreak of pathogenic bacteria.Concluding RemarksWith regard to the multiple developmental and disease related functions of siderocalins, it is unknown if these functions coevolved with the siderophore-binding functions, or if the different functions developed independently.", [["siderocalins", "CHEMICAL", 308, 320], ["siderocalins", "GENE_OR_GENE_PRODUCT", 18, 30], ["siderocalins", "GENE_OR_GENE_PRODUCT", 107, 119], ["siderocalins", "GENE_OR_GENE_PRODUCT", 308, 320], ["new siderocalins", "PROBLEM", 14, 30], ["pathogenic bacteria", "PROBLEM", 195, 214], ["the multiple developmental and disease related functions of siderocalins", "PROBLEM", 248, 320], ["pathogenic bacteria", "OBSERVATION", 195, 214], ["disease", "OBSERVATION", 279, 286]]], ["Were these proteins originally developed for fatty acid binding and eventually customized by human evolution to sequester bacterial siderophores, or did the development follow another sequence?", [["fatty acid", "CHEMICAL", 45, 55], ["fatty acid", "CHEMICAL", 45, 55], ["fatty acid", "SIMPLE_CHEMICAL", 45, 55], ["human", "ORGANISM", 93, 98], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["fatty acid binding", "PROBLEM", 45, 63], ["bacterial siderophores", "PROBLEM", 122, 144]]], ["Furthermore, an evolutionary map of siderocalin development may indicate when a pathogen emerged since it appears that siderocalins evolved to bind siderophores secreted by the most threatening pathogens.", [["siderocalins", "CHEMICAL", 119, 131], ["siderocalin", "GENE_OR_GENE_PRODUCT", 36, 47], ["siderocalins", "SIMPLE_CHEMICAL", 119, 131], ["a pathogen", "PROBLEM", 78, 88], ["siderocalins", "PROBLEM", 119, 131], ["bind siderophores", "PROBLEM", 143, 160], ["the most threatening pathogens", "PROBLEM", 173, 203]]], ["Chemical structures of siderophores.", [["siderophores", "OBSERVATION", 23, 35]]], ["MGE and DGE are also referred to as salmochelins.", [["salmochelins", "CHEMICAL", 36, 48], ["MGE", "CELL", 0, 3], ["salmochelins", "GENE_OR_GENE_PRODUCT", 36, 48], ["MGE", "DNA", 0, 3], ["DGE", "DNA", 8, 11], ["DGE", "OBSERVATION", 8, 11]]], ["Scheme depicting intracellular Scn-mediated processes.", [["intracellular", "ANATOMY", 17, 30], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 30], ["intracellular Scn-mediated processes", "OBSERVATION", 17, 53]]], ["(1) Scn (shown in its apo form in step 1) binds its putative receptor, 24p3 or megalin.", [["(1) Scn", "CHEMICAL", 0, 7], ["Scn", "GENE_OR_GENE_PRODUCT", 4, 7], ["apo form in step 1", "GENE_OR_GENE_PRODUCT", 22, 40], ["24p3", "GENE_OR_GENE_PRODUCT", 71, 75], ["megalin", "GENE_OR_GENE_PRODUCT", 79, 86], ["apo form", "PROTEIN", 22, 30], ["24p3", "PROTEIN", 71, 75], ["megalin", "PROTEIN", 79, 86], ["megalin", "TREATMENT", 79, 86]]], ["Scn is endocytosed and secreted intracellularly (2) thus available to intercept (5) bacterial siderophores secreted (3) by an invading pathogen.", [["Scn", "CHEMICAL", 0, 3], ["Scn", "GENE_OR_GENE_PRODUCT", 0, 3], ["Scn", "PROTEIN", 0, 3], ["bacterial siderophores secreted", "PROBLEM", 84, 115], ["an invading pathogen", "PROBLEM", 123, 143], ["endocytosed", "OBSERVATION", 7, 18]]], ["The result is inhibition of bacterial growth (4) since the bacteria are rendered growth-limited by Scn.", [["Scn", "GENE_OR_GENE_PRODUCT", 99, 102], ["Scn", "PROTEIN", 99, 102], ["bacterial growth", "PROBLEM", 28, 44], ["the bacteria", "PROBLEM", 55, 67], ["bacterial", "OBSERVATION_MODIFIER", 28, 37], ["growth", "OBSERVATION_MODIFIER", 38, 44]]], ["The Scn:ferric siderophore complex is then trafficked to extracellular space.", [["extracellular space", "ANATOMY", 57, 76], ["Scn", "CHEMICAL", 4, 7], ["ferric", "CHEMICAL", 8, 14], ["ferric", "CHEMICAL", 8, 14], ["Scn", "GENE_OR_GENE_PRODUCT", 4, 7], ["ferric siderophore", "SIMPLE_CHEMICAL", 8, 26], ["extracellular space", "CELLULAR_COMPONENT", 57, 76], ["Scn:ferric siderophore complex", "PROTEIN", 4, 34], ["ferric siderophore complex", "PROBLEM", 8, 34], ["Scn", "ANATOMY", 4, 7], ["ferric", "OBSERVATION", 8, 14], ["siderophore complex", "OBSERVATION", 15, 34], ["extracellular space", "OBSERVATION", 57, 76]]], ["In a separate event, mediated by mammalian siderophores (6), a Scn:mammalian siderophore-iron complex can bind either 24p3 or megalin, and the ternary structure is endocytosed and trafficked to intracellular space (7) where the iron is released in acidic environments of the late endosome (8) .", [["intracellular", "ANATOMY", 194, 207], ["late endosome", "ANATOMY", 275, 288], ["Scn", "CHEMICAL", 63, 66], ["iron", "CHEMICAL", 89, 93], ["iron", "CHEMICAL", 228, 232], ["iron", "CHEMICAL", 89, 93], ["iron", "CHEMICAL", 228, 232], ["Scn", "GENE_OR_GENE_PRODUCT", 63, 66], ["iron", "SIMPLE_CHEMICAL", 89, 93], ["24p3", "GENE_OR_GENE_PRODUCT", 118, 122], ["megalin", "GENE_OR_GENE_PRODUCT", 126, 133], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 194, 207], ["iron", "SIMPLE_CHEMICAL", 228, 232], ["late endosome", "CELLULAR_COMPONENT", 275, 288], ["iron complex", "PROTEIN", 89, 101], ["24p3", "PROTEIN", 118, 122], ["megalin", "PROTEIN", 126, 133], ["ternary structure", "PROTEIN", 143, 160], ["mammalian siderophore-iron complex", "TREATMENT", 67, 101], ["megalin", "TREATMENT", 126, 133]]], ["This intracellular iron supply is used for growth, differentiation, or other cellular processes.", [["intracellular", "ANATOMY", 5, 18], ["cellular", "ANATOMY", 77, 85], ["iron", "CHEMICAL", 19, 23], ["iron", "CHEMICAL", 19, 23], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 5, 18], ["iron", "SIMPLE_CHEMICAL", 19, 23], ["cellular", "CELL", 77, 85], ["This intracellular iron supply", "TREATMENT", 0, 30], ["other cellular processes", "PROBLEM", 71, 95], ["cellular processes", "OBSERVATION", 77, 95]]], ["Dual binding pockets of Ex-FABP and Q83.", [["Ex-FABP", "GENE_OR_GENE_PRODUCT", 24, 31], ["Q83", "GENE_OR_GENE_PRODUCT", 36, 39], ["Ex-FABP", "PROTEIN", 24, 31], ["Q83", "PROTEIN", 36, 39], ["Ex-FABP", "TEST", 24, 31], ["pockets", "OBSERVATION_MODIFIER", 13, 20]]], ["Ex-FABP contains a red ferric dihydroxybenzoic acid molecule in the siderophore binding pocket and a yellow lysophosphatidic acid in the fatty acid binding pocket.", [["ferric dihydroxybenzoic acid", "CHEMICAL", 23, 51], ["lysophosphatidic acid", "CHEMICAL", 108, 129], ["fatty acid", "CHEMICAL", 137, 147], ["ferric dihydroxybenzoic acid", "CHEMICAL", 23, 51], ["lysophosphatidic acid", "CHEMICAL", 108, 129], ["fatty acid", "CHEMICAL", 137, 147], ["Ex-FABP", "GENE_OR_GENE_PRODUCT", 0, 7], ["ferric dihydroxybenzoic acid", "SIMPLE_CHEMICAL", 23, 51], ["yellow lysophosphatidic acid", "SIMPLE_CHEMICAL", 101, 129], ["fatty acid", "SIMPLE_CHEMICAL", 137, 147], ["Ex-FABP", "PROTEIN", 0, 7], ["red ferric dihydroxybenzoic acid molecule", "PROTEIN", 19, 60], ["siderophore binding pocket", "PROTEIN", 68, 94], ["fatty acid binding pocket", "PROTEIN", 137, 162], ["Ex-FABP", "TEST", 0, 7], ["a red ferric dihydroxybenzoic acid molecule", "PROBLEM", 17, 60], ["the siderophore binding pocket", "PROBLEM", 64, 94], ["a yellow lysophosphatidic acid in the fatty acid binding pocket", "PROBLEM", 99, 162], ["red ferric", "OBSERVATION_MODIFIER", 19, 29], ["dihydroxybenzoic acid molecule", "OBSERVATION", 30, 60], ["siderophore binding pocket", "OBSERVATION", 68, 94], ["yellow", "OBSERVATION_MODIFIER", 101, 107], ["lysophosphatidic acid", "OBSERVATION", 108, 129], ["fatty acid", "OBSERVATION", 137, 147], ["binding pocket", "OBSERVATION", 148, 162]]], ["Q83 contains a red ferric enterobactin molecule in the siderophore binding pocket and a yellow arachidonic acid molecule in the fatty acid binding pocket.", [["Q83", "CHEMICAL", 0, 3], ["ferric", "CHEMICAL", 19, 25], ["arachidonic acid", "CHEMICAL", 95, 111], ["fatty acid", "CHEMICAL", 128, 138], ["ferric", "CHEMICAL", 19, 25], ["arachidonic acid", "CHEMICAL", 95, 111], ["fatty acid", "CHEMICAL", 128, 138], ["yellow arachidonic acid", "SIMPLE_CHEMICAL", 88, 111], ["fatty acid", "SIMPLE_CHEMICAL", 128, 138], ["Q83", "PROTEIN", 0, 3], ["red ferric enterobactin molecule", "PROTEIN", 15, 47], ["siderophore binding pocket", "PROTEIN", 55, 81], ["yellow arachidonic acid molecule", "PROTEIN", 88, 120], ["fatty acid binding pocket", "PROTEIN", 128, 153], ["a red ferric enterobactin molecule", "TREATMENT", 13, 47], ["the siderophore binding pocket", "PROBLEM", 51, 81], ["a yellow arachidonic acid molecule", "PROBLEM", 86, 120], ["the fatty acid binding pocket", "PROBLEM", 124, 153], ["red ferric", "OBSERVATION_MODIFIER", 15, 25], ["enterobactin molecule", "OBSERVATION", 26, 47], ["siderophore binding pocket", "OBSERVATION", 55, 81], ["yellow", "OBSERVATION_MODIFIER", 88, 94], ["arachidonic acid molecule", "OBSERVATION", 95, 120], ["fatty acid", "OBSERVATION", 128, 138], ["binding pocket", "OBSERVATION", 139, 153]]]], "e12533c97ce060182f5da6e25dca21ed4b778b8b": [["INTRODUCTIONIn late December 2019, a newly identified coronavirus strain capable of crossing the species barrier and infecting humans was first reported in Wuhan, Hubei province, China, and was provisionally termed 2019 novel coronavirus Zhu et al., 2020) .", [["coronavirus", "ORGANISM", 54, 65], ["humans", "ORGANISM", 127, 133], ["coronavirus", "ORGANISM", 226, 237], ["humans", "SPECIES", 127, 133], ["humans", "SPECIES", 127, 133], ["a newly identified coronavirus strain", "PROBLEM", 35, 72], ["coronavirus strain", "OBSERVATION", 54, 72]]], ["This novel virus was later designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), owing to its genetic similarity with other coronavirus strains (Gorbalenya et al., 2020) .", [["acute respiratory syndrome coronavirus", "DISEASE", 48, 86], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 41, 88], ["SARS-CoV-2", "ORGANISM", 90, 100], ["coronavirus", "ORGANISM", 146, 157], ["severe acute respiratory syndrome coronavirus", "SPECIES", 41, 86], ["SARS-CoV-2", "SPECIES", 90, 100], ["This novel virus", "PROBLEM", 0, 16], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 41, 86], ["SARS-CoV", "TEST", 90, 98], ["other coronavirus strains", "PROBLEM", 140, 165], ["virus", "OBSERVATION", 11, 16], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome", "OBSERVATION", 54, 74]]], ["It is known to cause coronavirus disease 2019 , characterized by influenza-like mild or moderate respiratory symptoms including dry cough, fever, headache, and pneumonia, as well as severe lung injury and multi-organ failure, which eventually lead to death Huang C. et al., 2020) .", [["respiratory", "ANATOMY", 97, 108], ["lung", "ANATOMY", 189, 193], ["multi-organ", "ANATOMY", 205, 216], ["coronavirus disease", "DISEASE", 21, 40], ["influenza", "DISEASE", 65, 74], ["respiratory symptoms", "DISEASE", 97, 117], ["dry cough", "DISEASE", 128, 137], ["fever", "DISEASE", 139, 144], ["headache", "DISEASE", 146, 154], ["pneumonia", "DISEASE", 160, 169], ["lung injury", "DISEASE", 189, 200], ["multi-organ failure", "DISEASE", 205, 224], ["death", "DISEASE", 251, 256], ["coronavirus", "ORGANISM", 21, 32], ["lung", "ORGAN", 189, 193], ["multi-organ", "ORGAN", 205, 216], ["coronavirus disease", "PROBLEM", 21, 40], ["influenza", "PROBLEM", 65, 74], ["mild or moderate respiratory symptoms", "PROBLEM", 80, 117], ["dry cough", "PROBLEM", 128, 137], ["fever", "PROBLEM", 139, 144], ["headache", "PROBLEM", 146, 154], ["pneumonia", "PROBLEM", 160, 169], ["severe lung injury", "PROBLEM", 182, 200], ["multi-organ failure", "PROBLEM", 205, 224], ["known to cause", "UNCERTAINTY", 6, 20], ["coronavirus disease", "OBSERVATION", 21, 40], ["influenza", "OBSERVATION", 65, 74], ["mild", "OBSERVATION_MODIFIER", 80, 84], ["moderate", "OBSERVATION_MODIFIER", 88, 96], ["respiratory symptoms", "OBSERVATION", 97, 117], ["dry", "OBSERVATION_MODIFIER", 128, 131], ["cough", "OBSERVATION", 132, 137], ["pneumonia", "OBSERVATION", 160, 169], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["lung", "ANATOMY", 189, 193], ["injury", "OBSERVATION", 194, 200], ["multi-organ", "ANATOMY", 205, 216], ["failure", "OBSERVATION", 217, 224]]], ["The World Health Organization (WHO) officially declared COVID-19 as a pandemic on March 11, 2020 due to the rapid global dissemination of SARS-CoV-2.INTRODUCTIONAccording to the WHO, a total of 3,672,238 confirmed cases of COVID-19 and 254,045 deaths were recorded up to May 7, 2020 in over 200 countries.", [["COVID", "DISEASE", 223, 228], ["deaths", "DISEASE", 244, 250], ["COVID", "TEST", 223, 228], ["rapid", "OBSERVATION_MODIFIER", 108, 113], ["global", "OBSERVATION_MODIFIER", 114, 120], ["dissemination", "OBSERVATION", 121, 134]]], ["Moreover, effective antiviral therapeutic agents or vaccines are not yet available for COVID-19.", [["effective antiviral therapeutic agents", "TREATMENT", 10, 48], ["vaccines", "TREATMENT", 52, 60], ["COVID", "TEST", 87, 92]]], ["The repurposing of existing drugs designed for other viruses is the most practical strategy to treat patients with COVID-19 because they have already been tested for their safety.INTRODUCTIONAlthough de novo development of antivirals is a time-, cost-, and effort-intensive endeavor, it is important to generate specific antivirals for SARS-CoV-2 that directly target the viral or host proviral factors (Cascella et al., 2020; Senanayake, 2020) .INTRODUCTIONWith increasing structural data of key proteins in both SARS-CoV-2 and the host, such as the spike glycoprotein (S), the main protease (M pro ), RNA-dependent RNA polymerase (RdRp), and human angiotensin-converting enzyme 2 (hACE2), the structure-based design of new drugs has emerged as the most promising antiviral strategy.", [["angiotensin", "CHEMICAL", 650, 661], ["patients", "ORGANISM", 101, 109], ["SARS-CoV-2", "ORGANISM", 336, 346], ["SARS-CoV-2", "ORGANISM", 514, 524], ["spike glycoprotein", "GENE_OR_GENE_PRODUCT", 551, 569], ["M pro", "GENE_OR_GENE_PRODUCT", 594, 599], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 603, 631], ["RdRp", "GENE_OR_GENE_PRODUCT", 633, 637], ["human", "ORGANISM", 644, 649], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 650, 681], ["hACE2", "GENE_OR_GENE_PRODUCT", 683, 688], ["spike glycoprotein", "PROTEIN", 551, 569], ["S", "PROTEIN", 571, 572], ["protease", "PROTEIN", 584, 592], ["M pro", "PROTEIN", 594, 599], ["RNA-dependent RNA polymerase", "PROTEIN", 603, 631], ["RdRp", "PROTEIN", 633, 637], ["human angiotensin-converting enzyme 2", "PROTEIN", 644, 681], ["hACE2", "PROTEIN", 683, 688], ["patients", "SPECIES", 101, 109], ["human", "SPECIES", 644, 649], ["SARS-CoV", "SPECIES", 336, 344], ["SARS-CoV", "SPECIES", 514, 522], ["human", "SPECIES", 644, 649], ["existing drugs", "TREATMENT", 19, 33], ["other viruses", "PROBLEM", 47, 60], ["COVID", "TEST", 115, 120], ["antivirals", "TREATMENT", 223, 233], ["specific antivirals", "TREATMENT", 312, 331], ["SARS", "PROBLEM", 336, 340], ["key proteins", "PROBLEM", 493, 505], ["the main protease (M pro", "TREATMENT", 575, 599], ["RNA-dependent RNA polymerase", "PROBLEM", 603, 631], ["human angiotensin", "TREATMENT", 644, 661], ["new drugs", "TREATMENT", 721, 730]]], ["In this review, we have summarized the promising therapeutic potential of pre-existing drugs against COVID-19.", [["COVID-19", "CHEMICAL", 101, 109], ["pre-existing drugs", "TREATMENT", 74, 92], ["COVID", "TEST", 101, 106]]], ["In addition, the structural characterization of potentially therapeutic viral or host cellular targets associated with COVID-19 have been discussed to refine structure-based drug design strategies.SARS-CoV-2SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus and belongs to the genus Betacoronavirus, which also includes SARS-CoV and MERS-CoV (Andersen et al., 2020; Lu et al., 2020; Zhu et al., 2020) .", [["cellular", "ANATOMY", 86, 94], ["COVID-19", "CHEMICAL", 119, 127], ["SARS", "DISEASE", 197, 201], ["COVID-19", "CHEMICAL", 119, 127], ["cellular", "CELL", 86, 94], ["CoV-2", "GENE_OR_GENE_PRODUCT", 212, 217], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 302, 317], ["SARS-CoV", "ORGANISM", 339, 347], ["MERS-CoV", "ORGANISM", 352, 360], ["COVID-19", "DNA", 119, 127], ["SARS-CoV-2SARS-CoV-2", "DNA", 197, 217], ["SARS-CoV", "SPECIES", 339, 347], ["MERS-CoV", "SPECIES", 352, 360], ["therapeutic viral or host cellular targets", "PROBLEM", 60, 102], ["COVID", "TEST", 119, 124], ["SARS", "TEST", 197, 201], ["CoV", "TEST", 212, 215], ["single-stranded RNA virus", "PROBLEM", 251, 276], ["SARS", "PROBLEM", 339, 343]]], ["The genome sequence of SARS-CoV-2 is more closely related to that of SARS-CoV (79% identity) than with that of MERS-CoV (\u223c50%) .", [["SARS", "DISEASE", 23, 27], ["SARS", "DISEASE", 69, 73], ["SARS-CoV-2", "ORGANISM", 23, 33], ["SARS-CoV", "ORGANISM", 69, 77], ["MERS-CoV", "ORGANISM", 111, 119], ["SARS-CoV", "SPECIES", 23, 31], ["SARS-CoV", "SPECIES", 69, 77], ["MERS-CoV", "SPECIES", 111, 119], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["MERS", "TEST", 111, 115], ["CoV", "TEST", 116, 119]]], ["Notably, the S protein of SARS-CoV-2 and SARS-CoV are highly homologous with 76.5% amino acid sequence identity .", [["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 83, 93], ["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS-CoV", "ORGANISM", 41, 49], ["amino acid", "AMINO_ACID", 83, 93], ["S protein", "PROTEIN", 13, 22], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 41, 49], ["the S protein", "TEST", 9, 22], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["SARS-CoV", "TEST", 41, 49], ["amino acid sequence identity", "TEST", 83, 111]]], ["Consequently, SARS-CoV-2 and SARS-CoV are believed to bind to the same host cell entry receptor hACE2 Zhou et al., 2020) instead of human dipeptidyl peptidase 4 (hDPP4), which is used by MERS-CoV (Raj et al., 2013) .SARS-CoV-2SARS-CoV-2 has club-like spikes on its surface and a distinct replication strategy analogous to other coronaviruses.", [["cell", "ANATOMY", 76, 80], ["surface", "ANATOMY", 265, 272], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV", "ORGANISM", 29, 37], ["cell", "CELL", 76, 80], ["human", "ORGANISM", 132, 137], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 138, 160], ["hDPP4", "GENE_OR_GENE_PRODUCT", 162, 167], ["MERS-CoV", "ORGANISM", 187, 195], ["SARS-CoV-2SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 216, 236], ["surface", "CELLULAR_COMPONENT", 265, 272], ["coronaviruses", "ORGANISM", 328, 341], ["human dipeptidyl peptidase 4", "PROTEIN", 132, 160], ["hDPP4", "PROTEIN", 162, 167], ["SARS-CoV-2SARS-CoV-2", "DNA", 216, 236], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 29, 37], ["human", "SPECIES", 132, 137], ["MERS-CoV", "SPECIES", 187, 195], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["SARS", "PROBLEM", 29, 33], ["human dipeptidyl peptidase", "TREATMENT", 132, 158], ["SARS-CoV-2SARS", "TEST", 216, 230], ["club-like spikes", "PROBLEM", 241, 257]]], ["The life cycle and replication of SARS-CoV-2 is shown in Figure 1 .", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV", "SPECIES", 34, 42], ["The life cycle", "TREATMENT", 0, 14], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42]]], ["Viral infection is initiated by the interaction between the S protein and hACE2, followed by subsequent endocytosis or membrane fusion.", [["membrane", "ANATOMY", 119, 127], ["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["S protein", "GENE_OR_GENE_PRODUCT", 60, 69], ["hACE2", "GENE_OR_GENE_PRODUCT", 74, 79], ["membrane", "CELLULAR_COMPONENT", 119, 127], ["S protein", "PROTEIN", 60, 69], ["hACE2", "PROTEIN", 74, 79], ["Viral infection", "PROBLEM", 0, 15], ["the S protein", "TEST", 56, 69], ["membrane fusion", "TREATMENT", 119, 134], ["infection", "OBSERVATION", 6, 15], ["membrane fusion", "OBSERVATION", 119, 134]]], ["The S protein comprises two subunits: S1 and S2.", [["S2", "GENE_OR_GENE_PRODUCT", 45, 47], ["S protein", "PROTEIN", 4, 13], ["S1", "PROTEIN", 38, 40], ["S2", "PROTEIN", 45, 47], ["S1", "ANATOMY", 38, 40], ["S2", "ANATOMY", 45, 47]]], ["The S1 subunit contains the receptor binding domain (RBD) and binds to N-terminal hACE2, while the S2 subunit mediates virus-host membrane fusion.", [["membrane", "ANATOMY", 130, 138], ["N", "CHEMICAL", 71, 72], ["hACE2", "GENE_OR_GENE_PRODUCT", 82, 87], ["S2", "GENE_OR_GENE_PRODUCT", 99, 101], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["S1 subunit", "PROTEIN", 4, 14], ["receptor binding domain", "PROTEIN", 28, 51], ["RBD", "PROTEIN", 53, 56], ["N-terminal hACE2", "PROTEIN", 71, 87], ["S2 subunit", "PROTEIN", 99, 109], ["the receptor binding domain (RBD)", "PROBLEM", 24, 57], ["host membrane fusion", "TREATMENT", 125, 145], ["S1", "ANATOMY_MODIFIER", 4, 6], ["S2", "ANATOMY", 99, 101], ["virus", "OBSERVATION", 119, 124], ["host membrane fusion", "OBSERVATION", 125, 145]]], ["S proteins are cleaved by the host cell furin protease and transmembrane serine protease 2 (TMPRSS2) at the S1/S2 boundary and the S2 \u2032 position.", [["cell", "ANATOMY", 35, 39], ["serine", "CHEMICAL", 73, 79], ["host cell furin protease", "GENE_OR_GENE_PRODUCT", 30, 54], ["transmembrane serine protease 2", "GENE_OR_GENE_PRODUCT", 59, 90], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 92, 99], ["S proteins", "PROTEIN", 0, 10], ["host cell furin protease", "PROTEIN", 30, 54], ["transmembrane serine protease 2", "PROTEIN", 59, 90], ["TMPRSS2", "PROTEIN", 92, 99], ["S1", "PROTEIN", 108, 110], ["S2", "PROTEIN", 111, 113], ["S2", "PROTEIN", 131, 133], ["S proteins", "PROBLEM", 0, 10], ["the host cell furin protease", "TREATMENT", 26, 54], ["transmembrane serine protease", "TREATMENT", 59, 88], ["host cell", "OBSERVATION", 30, 39]]], ["Proteolytic cleavage at the S1/S2 boundary is thought to promote TMPRSS2-dependent entry into the target cells (Belouzard et al., 2009; Hoffmann et al., 2020; Walls et al., 2020) .", [["cells", "ANATOMY", 105, 110], ["S2", "GENE_OR_GENE_PRODUCT", 31, 33], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 65, 72], ["cells", "CELL", 105, 110], ["S1/S2 boundary", "DNA", 28, 42], ["TMPRSS2", "PROTEIN", 65, 72], ["target cells", "CELL_TYPE", 98, 110], ["Proteolytic cleavage", "PROBLEM", 0, 20], ["TMPRSS2", "TEST", 65, 72]]], ["After the release of the viral polycistronic RNA into the cytoplasm, the replicase gene comprising open reading frames (ORFs) 1a and 1ab is directly translated into either replicase polyprotein pp1a (\u223c450 kDa, nsp1-11) or pp1ab (\u223c750 kDa, nsp1-16) by a ribosomal\u22121 frameshift near the 3 \u2032 -end of ORF 1a and autoproteolytically cleaved into 16 non-structural proteins (nsp1-16) by two ORF1aencoded protease domains (Brierley et al., 1989; Herold et al., 1993; Thiel et al., 2001 Thiel et al., , 2003 Harcourt et al., 2004; Prentice et al., 2004; Ziebuhr, 2004) .", [["cytoplasm", "ANATOMY", 58, 67], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["open reading frames (ORFs) 1a", "GENE_OR_GENE_PRODUCT", 99, 128], ["1", "GENE_OR_GENE_PRODUCT", 133, 134], ["pp1a", "GENE_OR_GENE_PRODUCT", 194, 198], ["nsp1-11", "GENE_OR_GENE_PRODUCT", 210, 217], ["pp1ab", "GENE_OR_GENE_PRODUCT", 222, 227], ["nsp1-16", "GENE_OR_GENE_PRODUCT", 239, 246], ["ORF 1a", "GENE_OR_GENE_PRODUCT", 297, 303], ["nsp1-16", "GENE_OR_GENE_PRODUCT", 369, 376], ["viral polycistronic RNA", "RNA", 25, 48], ["replicase gene", "DNA", 73, 87], ["open reading frames", "DNA", 99, 118], ["ORFs", "DNA", 120, 124], ["replicase polyprotein pp1a", "PROTEIN", 172, 198], ["nsp1", "PROTEIN", 210, 214], ["pp1ab", "PROTEIN", 222, 227], ["nsp1", "PROTEIN", 239, 243], ["ribosomal\u22121 frameshift", "DNA", 253, 275], ["3 \u2032 -end", "DNA", 285, 293], ["ORF 1a", "DNA", 297, 303], ["16 non-structural proteins", "PROTEIN", 341, 367], ["nsp1-16", "PROTEIN", 369, 376], ["ORF1aencoded protease domains", "PROTEIN", 385, 414], ["the viral polycistronic RNA", "TREATMENT", 21, 48], ["the replicase gene", "TREATMENT", 69, 87], ["nsp1", "TEST", 210, 214], ["pp1ab", "TEST", 222, 227], ["kDa", "TEST", 234, 237], ["nsp1", "TEST", 239, 243], ["a ribosomal\u22121 frameshift", "PROBLEM", 251, 275], ["ORF 1a", "TEST", 297, 303], ["nsp1", "TEST", 369, 373], ["viral polycistronic RNA", "OBSERVATION", 25, 48]]], ["Furthermore, the main protease M pro (also called 3CL pro ) and papain-like protease (PL pro ) participate in this extensive proteolytic cleavage.", [["3CL pro", "GENE_OR_GENE_PRODUCT", 50, 57], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 64, 84], ["PL pro", "GENE_OR_GENE_PRODUCT", 86, 92], ["protease M pro", "PROTEIN", 22, 36], ["3CL pro", "PROTEIN", 50, 57], ["papain", "PROTEIN", 64, 70], ["protease", "PROTEIN", 76, 84], ["PL pro", "PROTEIN", 86, 92], ["the main protease M pro", "TREATMENT", 13, 36], ["papain", "TREATMENT", 64, 70], ["protease (PL pro )", "TREATMENT", 76, 94], ["this extensive proteolytic cleavage", "TREATMENT", 110, 145]]], ["The large pp1ab polyprotein has no <11 conserved cleavage sites that are mediated by M pro , which cleaves at Leu-Gln\u2193(Ser, Ala, Gly) (arrow indicates the cleavage site) (Ziebuhr et al., 2000; Hegyi and Ziebuhr, 2002) .", [["Gln\u2193", "CHEMICAL", 114, 118], ["Ser", "CHEMICAL", 119, 122], ["Ala", "CHEMICAL", 124, 127], ["Gly", "CHEMICAL", 129, 132], ["pp1ab", "GENE_OR_GENE_PRODUCT", 10, 15], ["M pro", "GENE_OR_GENE_PRODUCT", 85, 90], ["Ser", "AMINO_ACID", 119, 122], ["Ala, Gly", "AMINO_ACID", 124, 132], [")", "AMINO_ACID", 132, 133], ["pp1ab polyprotein", "PROTEIN", 10, 27], ["M pro", "PROTEIN", 85, 90], ["The large pp1ab polyprotein", "TREATMENT", 0, 27], ["Ser, Ala, Gly)", "TREATMENT", 119, 133], ["the cleavage site", "PROBLEM", 151, 168], ["large", "OBSERVATION_MODIFIER", 4, 9], ["pp1ab polyprotein", "OBSERVATION", 10, 27]]], ["Positive-strand RNA viruses usually form a cytoplasmic enzyme complex called replicase-transcriptase complex (RTC) that can mediate the synthesis of the full-length genome (replication) or discontinuous mRNAs (transcription) (Gorbalenya et al., 2006; Pasternak et al., 2006; Sawicki et al., 2007) .", [["cytoplasmic", "ANATOMY", 43, 54], ["cytoplasmic", "ORGANISM_SUBSTANCE", 43, 54], ["replicase-transcriptase complex", "GENE_OR_GENE_PRODUCT", 77, 108], ["RTC", "GENE_OR_GENE_PRODUCT", 110, 113], ["genome", "CELLULAR_COMPONENT", 165, 171], ["cytoplasmic enzyme complex", "PROTEIN", 43, 69], ["replicase-transcriptase complex", "PROTEIN", 77, 108], ["RTC", "PROTEIN", 110, 113], ["full-length genome", "DNA", 153, 171], ["discontinuous mRNAs", "RNA", 189, 208], ["strand RNA viruses", "PROBLEM", 9, 27], ["a cytoplasmic enzyme complex", "PROBLEM", 41, 69], ["replicase-transcriptase complex (RTC)", "TREATMENT", 77, 114], ["strand RNA viruses", "OBSERVATION", 9, 27]]], ["Structural and accessory proteins are subsequently translated from these transcripts, and new viruses assemble by budding into the lumen of the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and are eventually secreted (Klumperman et al., 1994; Hogue and Machamer, 2008) .ANTIVIRAL STRATEGIES AGAINST SARS-CoV-2Antivirals can be broadly divided into two categories: directacting antivirals (DAA) and indirect-acting antivirals (IAA).", [["lumen", "ANATOMY", 131, 136], ["endoplasmic reticulum", "ANATOMY", 144, 165], ["Golgi intermediate compartment", "ANATOMY", 166, 196], ["DAA", "CHEMICAL", 405, 408], ["IAA", "CHEMICAL", 442, 445], ["IAA", "CHEMICAL", 442, 445], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 136], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 144, 165], ["Golgi intermediate compartment", "CELLULAR_COMPONENT", 166, 196], ["SARS-CoV-2Antivirals", "ORGANISM", 315, 335], ["directacting antivirals", "SIMPLE_CHEMICAL", 380, 403], ["DAA", "SIMPLE_CHEMICAL", 405, 408], ["indirect-acting antivirals", "SIMPLE_CHEMICAL", 414, 440], ["IAA", "SIMPLE_CHEMICAL", 442, 445], ["accessory proteins", "PROTEIN", 15, 33], ["Structural and accessory proteins", "PROBLEM", 0, 33], ["new viruses", "PROBLEM", 90, 101], ["ANTIVIRAL STRATEGIES", "TREATMENT", 286, 306], ["2Antivirals", "TREATMENT", 324, 335], ["directacting antivirals (DAA", "TREATMENT", 380, 408], ["indirect-acting antivirals", "TREATMENT", 414, 440], ["accessory proteins", "OBSERVATION", 15, 33], ["new", "OBSERVATION_MODIFIER", 90, 93], ["viruses", "OBSERVATION", 94, 101], ["lumen", "ANATOMY_MODIFIER", 131, 136], ["endoplasmic reticulum", "ANATOMY", 144, 165], ["Golgi", "OBSERVATION", 166, 171], ["intermediate compartment", "OBSERVATION", 172, 196]]], ["DAAs directly target specific viral components, such as viral polymerase, or steps in the viral life cycle without affecting other host cellular processes.", [["cellular", "ANATOMY", 136, 144], ["DAAs", "SIMPLE_CHEMICAL", 0, 4], ["cellular", "CELL", 136, 144], ["DAAs", "PROTEIN", 0, 4], ["viral polymerase", "PROTEIN", 56, 72], ["DAAs", "TREATMENT", 0, 4], ["specific viral components", "PROBLEM", 21, 46], ["viral polymerase", "PROBLEM", 56, 72], ["viral components", "OBSERVATION", 30, 46], ["host cellular processes", "OBSERVATION", 131, 154]]], ["The development of DAAs can facilitate the treatment of patients with COVID-19.", [["COVID-19", "CHEMICAL", 70, 78], ["DAAs", "SIMPLE_CHEMICAL", 19, 23], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["DAAs", "TREATMENT", 19, 23], ["the treatment", "TREATMENT", 39, 52], ["COVID", "TEST", 70, 75], ["DAAs", "OBSERVATION", 19, 23]]], ["In contrast, IAAs target host proviral factors and indirectly inhibit viral infection or replication by impeding the function or interaction of these factors.", [["infection", "DISEASE", 76, 85], ["IAAs", "SIMPLE_CHEMICAL", 13, 17], ["IAAs", "PROTEIN", 13, 17], ["host proviral factors", "PROTEIN", 25, 46], ["IAAs", "TREATMENT", 13, 17], ["viral infection", "PROBLEM", 70, 85], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 76, 85]]], ["IAAs have an advantage over DAAs because they are not susceptible to viral mutations, which are frequently found in RNA viruses.", [["IAAs", "SIMPLE_CHEMICAL", 0, 4], ["DAAs", "SIMPLE_CHEMICAL", 28, 32], ["DAAs", "TREATMENT", 28, 32], ["viral mutations", "PROBLEM", 69, 84], ["RNA viruses", "PROBLEM", 116, 127], ["RNA viruses", "OBSERVATION", 116, 127]]], ["However, IAAs can alter the host cellular system and are not considered safe.", [["cellular", "ANATOMY", 33, 41], ["IAAs", "CHEMICAL", 9, 13], ["IAAs", "SIMPLE_CHEMICAL", 9, 13], ["cellular", "CELL", 33, 41], ["host cellular system", "OBSERVATION", 28, 48], ["not considered", "UNCERTAINTY", 57, 71]]], ["Therefore, DAAs targeting viral entry, proteases, and replication can serve as effective antivirals owing to their enhanced safety features.", [["DAAs", "CHEMICAL", 11, 15], ["DAAs", "SIMPLE_CHEMICAL", 11, 15], ["DAAs", "PROTEIN", 11, 15], ["proteases", "PROTEIN", 39, 48], ["DAAs", "TREATMENT", 11, 15], ["proteases", "TREATMENT", 39, 48], ["replication", "TREATMENT", 54, 65], ["effective antivirals", "TREATMENT", 79, 99]]], ["Drug repurposing of preexisting antiviral agents is considered one of the most practical strategies because there is no available approved antiviral drug or vaccine for COVID-19.", [["preexisting antiviral agents", "TREATMENT", 20, 48], ["antiviral drug", "TREATMENT", 139, 153], ["vaccine", "TREATMENT", 157, 164], ["COVID", "TEST", 169, 174], ["antiviral agents", "OBSERVATION", 32, 48], ["no", "UNCERTAINTY", 117, 119]]], ["Drug repurposing of several approved antivirals against COVID-19 has progressed into clinical trials (Table 1) .", [["COVID-19", "CHEMICAL", 56, 64], ["antivirals", "TREATMENT", 37, 47], ["COVID", "TEST", 56, 61]]], ["However, there is a potential risk of drug-resistant mutations with the use of DAA.", [["drug-resistant mutations", "PROBLEM", 38, 62], ["DAA", "TREATMENT", 79, 82], ["resistant mutations", "OBSERVATION", 43, 62]]], ["A combination of repurposed drugs can reduce the time, cost of treatment, and risk of drug-resistance, and increase therapeutic efficacy to facilitate progression into clinical trials (Cheng et al., 2019) .", [["repurposed drugs", "TREATMENT", 17, 33], ["treatment", "TREATMENT", 63, 72], ["drug-resistance", "PROBLEM", 86, 101]]], ["Moreover, due to the existence of crystal structures of viral and host cellular proteins associated with SARS-CoV-2, such as S protein, M pro , RdRp, and hACE2, structure-based drug design can be performed to develop more effective drugs with reduced off-target toxicity (Schomburg and Rarey, 2014 ).Viral EntryThe cryo-electron microscopy (CryoEM) structure of the extracellular domain of the S protein of SARS-CoV-2 revealed a homotrimeric conformation (Wrapp et al., 2020) .", [["cellular", "ANATOMY", 71, 79], ["extracellular", "ANATOMY", 366, 379], ["toxicity", "DISEASE", 262, 270], ["cellular", "CELL", 71, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 105, 115], ["S protein", "GENE_OR_GENE_PRODUCT", 125, 134], ["M pro", "GENE_OR_GENE_PRODUCT", 136, 141], ["RdRp", "GENE_OR_GENE_PRODUCT", 144, 148], ["hACE2", "GENE_OR_GENE_PRODUCT", 154, 159], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 366, 379], ["viral and host cellular proteins", "PROTEIN", 56, 88], ["S protein", "PROTEIN", 125, 134], ["M pro", "PROTEIN", 136, 141], ["RdRp", "PROTEIN", 144, 148], ["hACE2", "PROTEIN", 154, 159], ["extracellular domain", "PROTEIN", 366, 386], ["S protein", "PROTEIN", 394, 403], ["SARS-CoV", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 407, 415], ["crystal structures", "PROBLEM", 34, 52], ["viral and host cellular proteins", "PROBLEM", 56, 88], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113], ["S protein", "TEST", 125, 134], ["RdRp", "PROBLEM", 144, 148], ["hACE2", "TREATMENT", 154, 159], ["target toxicity", "PROBLEM", 255, 270], ["The cryo-electron microscopy", "TEST", 311, 339], ["the S protein", "TEST", 390, 403], ["SARS", "TEST", 407, 411], ["CoV", "TEST", 412, 415], ["viral", "OBSERVATION", 56, 61], ["host cellular proteins", "OBSERVATION", 66, 88]]], ["The binding of RBD-located in the S1 subunit-to hACE2 on the host cell surface initiates interaction between the virus and the host cell; therefore, the switching conformation of RBD is considered an important event for viral entry (Shang et al., 2020) .", [["cell surface", "ANATOMY", 66, 78], ["cell", "ANATOMY", 132, 136], ["RBD", "DISEASE", 179, 182], ["RBD", "GENE_OR_GENE_PRODUCT", 15, 18], ["S1", "GENE_OR_GENE_PRODUCT", 34, 36], ["hACE2", "GENE_OR_GENE_PRODUCT", 48, 53], ["cell surface", "CELLULAR_COMPONENT", 66, 78], ["host cell", "CELL", 127, 136], ["RBD", "GENE_OR_GENE_PRODUCT", 179, 182], ["RBD", "PROTEIN", 15, 18], ["S1 subunit", "PROTEIN", 34, 44], ["hACE2", "PROTEIN", 48, 53], ["RBD", "PROTEIN", 179, 182], ["The binding of RBD", "PROBLEM", 0, 18], ["the virus and the host cell", "PROBLEM", 109, 136], ["RBD", "PROBLEM", 179, 182], ["RBD", "OBSERVATION", 15, 18], ["S1", "ANATOMY", 34, 36], ["host cell", "OBSERVATION", 61, 70], ["surface", "OBSERVATION_MODIFIER", 71, 78], ["virus", "OBSERVATION", 113, 118], ["host cell", "OBSERVATION", 127, 136]]], ["CryoEM FIGURE 1 | Viral life cycle of SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["SARS-CoV", "SPECIES", 38, 46], ["CryoEM", "TEST", 0, 6], ["SARS", "TEST", 38, 42], ["CoV", "TEST", 43, 46]]], ["Interaction between the S protein of SARS-CoV-2 and hACE2 initiates SARS-CoV-2 infection.", [["infection", "DISEASE", 79, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["hACE2", "GENE_OR_GENE_PRODUCT", 52, 57], ["SARS-CoV-2", "ORGANISM", 68, 78], ["S protein", "PROTEIN", 24, 33], ["hACE2", "PROTEIN", 52, 57], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV-2", "SPECIES", 68, 78], ["the S protein", "TEST", 20, 33], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["SARS", "PROBLEM", 68, 72], ["2 infection", "PROBLEM", 77, 88], ["infection", "OBSERVATION", 79, 88]]], ["Following receptor binding, the virus enters the cell by acid-dependent proteolytic cleavage of the S protein by TMPRSS2 or other proteases.", [["cell", "ANATOMY", 49, 53], ["cell", "CELL", 49, 53], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 113, 120], ["S protein", "PROTEIN", 100, 109], ["TMPRSS2", "PROTEIN", 113, 120], ["proteases", "PROTEIN", 130, 139], ["receptor binding", "PROBLEM", 10, 26], ["the virus", "PROBLEM", 28, 37], ["the S protein", "TEST", 96, 109], ["other proteases", "PROBLEM", 124, 139], ["virus", "OBSERVATION", 32, 37]]], ["Upon fusion of the viral and host cell membranes, viral genomic RNA is released in the cytoplasm.", [["cell membranes", "ANATOMY", 34, 48], ["cytoplasm", "ANATOMY", 87, 96], ["cell membranes", "CELLULAR_COMPONENT", 34, 48], ["cytoplasm", "ORGANISM_SUBSTANCE", 87, 96], ["viral genomic RNA", "RNA", 50, 67], ["the viral and host cell membranes", "PROBLEM", 15, 48], ["viral genomic RNA", "PROBLEM", 50, 67], ["fusion", "OBSERVATION", 5, 11], ["viral", "OBSERVATION", 19, 24], ["host cell membranes", "OBSERVATION", 29, 48], ["viral genomic RNA", "OBSERVATION", 50, 67], ["cytoplasm", "OBSERVATION_MODIFIER", 87, 96]]], ["The viral RNA initiates translation of co-terminal polyproteins (pp1a/ab) by\u22121 frameshifting.", [["viral RNA", "RNA", 4, 13], ["co-terminal polyproteins", "PROTEIN", 39, 63], ["pp1a", "PROTEIN", 65, 69], ["The viral RNA", "PROBLEM", 0, 13], ["co-terminal polyproteins", "PROBLEM", 39, 63], ["pp1a/ab)", "TREATMENT", 65, 73], ["frameshifting", "PROBLEM", 79, 92], ["viral RNA", "OBSERVATION", 4, 13], ["co-terminal polyproteins", "OBSERVATION", 39, 63]]], ["These polyproteins are subsequently cleaved into nonstructural proteins (nsps) by M pro and PL pro .", [["nsps", "GENE_OR_GENE_PRODUCT", 73, 77], ["M pro", "GENE_OR_GENE_PRODUCT", 82, 87], ["PL pro", "GENE_OR_GENE_PRODUCT", 92, 98], ["nonstructural proteins", "PROTEIN", 49, 71], ["nsps", "PROTEIN", 73, 77], ["M pro", "PROTEIN", 82, 87], ["PL pro", "PROTEIN", 92, 98], ["These polyproteins", "PROBLEM", 0, 18], ["polyproteins", "OBSERVATION", 6, 18]]], ["Several nsp proteins interact with nsp12 (RdRp) to form the replicase-transcriptase complex (RTC), which is responsible for the synthesis of full-length viral genome (replication) and sub-genomic RNAs (transcription).", [["nsp", "GENE_OR_GENE_PRODUCT", 8, 11], ["nsp12", "GENE_OR_GENE_PRODUCT", 35, 40], ["RdRp", "GENE_OR_GENE_PRODUCT", 42, 46], ["replicase-transcriptase complex", "GENE_OR_GENE_PRODUCT", 60, 91], ["RTC", "GENE_OR_GENE_PRODUCT", 93, 96], ["nsp proteins", "PROTEIN", 8, 20], ["nsp12", "PROTEIN", 35, 40], ["RdRp", "PROTEIN", 42, 46], ["replicase-transcriptase complex", "PROTEIN", 60, 91], ["RTC", "PROTEIN", 93, 96], ["viral genome", "DNA", 153, 165], ["sub-genomic RNAs", "RNA", 184, 200], ["Several nsp proteins", "PROBLEM", 0, 20], ["nsp12 (RdRp", "TREATMENT", 35, 46], ["the replicase-transcriptase complex", "TREATMENT", 56, 91], ["full-length viral genome", "TREATMENT", 141, 165], ["sub-genomic RNAs", "TREATMENT", 184, 200]]], ["The viral structural proteins are expressed and translocated into the endoplasmic reticulum (ER).", [["endoplasmic reticulum", "ANATOMY", 70, 91], ["ER", "ANATOMY", 93, 95], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 70, 91], ["ER", "GENE_OR_GENE_PRODUCT", 93, 95], ["viral structural proteins", "PROTEIN", 4, 29], ["ER", "PROTEIN", 93, 95], ["The viral structural proteins", "PROBLEM", 0, 29], ["viral structural proteins", "OBSERVATION", 4, 29], ["endoplasmic reticulum", "OBSERVATION", 70, 91]]], ["The nucleocapsid (N) protein-encapsidated genomic RNA translocates with the structural proteins into the ER-Golgi intermediate compartment (ERGIC) for virion assembly.", [["ER-Golgi intermediate compartment", "ANATOMY", 105, 138], ["virion", "ANATOMY", 151, 157], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 4, 20], ["ER", "GENE_OR_GENE_PRODUCT", 105, 107], ["Golgi", "CELLULAR_COMPONENT", 108, 113], ["virion", "CELLULAR_COMPONENT", 151, 157], ["nucleocapsid (N) protein", "PROTEIN", 4, 28], ["encapsidated genomic RNA", "RNA", 29, 53], ["structural proteins", "PROTEIN", 76, 95], ["ER", "PROTEIN", 105, 107], ["ERGIC", "PROTEIN", 140, 145], ["The nucleocapsid (N) protein", "TEST", 0, 28], ["intermediate compartment", "OBSERVATION", 114, 138]]], ["The newly synthesized virions are budded through the cell membrane and exocytosed. studies revealed that the RBD in two out of three S proteins binds to the N-terminal domain (NTD) of the neighboring protomer of the S protein.", [["virions", "ANATOMY", 22, 29], ["cell membrane", "ANATOMY", 53, 66], ["RBD", "DISEASE", 109, 112], ["virions", "CELL", 22, 29], ["cell membrane", "CELLULAR_COMPONENT", 53, 66], ["RBD", "PROTEIN", 109, 112], ["S proteins", "PROTEIN", 133, 143], ["N-terminal domain", "PROTEIN", 157, 174], ["NTD", "PROTEIN", 176, 179], ["neighboring protomer", "PROTEIN", 188, 208], ["S protein", "PROTEIN", 216, 225], ["The newly synthesized virions", "TREATMENT", 0, 29], ["studies", "TEST", 83, 90], ["the RBD", "PROBLEM", 105, 112], ["synthesized virions", "OBSERVATION", 10, 29], ["cell membrane", "OBSERVATION", 53, 66], ["RBD", "OBSERVATION", 109, 112]]], ["These inter-molecular interactions result in a down (closed) conformation, wherein the hACE2 interaction interfaces are buried inside the structure.", [["hACE2", "GENE_OR_GENE_PRODUCT", 87, 92], ["hACE2", "PROTEIN", 87, 92], ["a down (closed) conformation", "PROBLEM", 45, 73]]], ["Moreover, the RBD in the third S protein forms an up (open) conformation to facilitate binding with the N-terminal region of hACE2 (Figure 2A ) (Wrapp et al., 2020) .", [["N", "CHEMICAL", 104, 105], ["RBD", "PROTEIN", 14, 17], ["third S protein", "PROTEIN", 25, 40], ["N-terminal region", "PROTEIN", 104, 121], ["hACE2", "PROTEIN", 125, 130], ["Figure 2A", "PROTEIN", 132, 141], ["RBD", "OBSERVATION", 14, 17], ["terminal", "ANATOMY_MODIFIER", 106, 114]]], ["The cryoEM study of SARS-CoV-2 S showed that single RBD formed an open conformation in an asymmetric trimer.", [["SARS", "DISEASE", 20, 24], ["RBD", "PROTEIN", 52, 55], ["The cryoEM study", "TEST", 0, 16], ["SARS", "TEST", 20, 24], ["CoV-2 S", "TEST", 25, 32], ["single RBD", "PROBLEM", 45, 55], ["open conformation", "OBSERVATION", 66, 83], ["asymmetric trimer", "OBSERVATION", 90, 107]]], ["The structural comparisons between the S protein of SARS-CoV (PDB ID 6CRZ) and SARS-CoV2 (PDB ID 6VSB) showed that the major structural differences came from RBD in a closed conformation.", [["SARS", "DISEASE", 52, 56], ["RBD", "DISEASE", 158, 161], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 79, 88], ["S protein", "PROTEIN", 39, 48], ["SARS-CoV", "PROTEIN", 52, 60], ["PDB ID 6CRZ", "PROTEIN", 62, 73], ["SARS", "PROTEIN", 79, 83], ["CoV2", "PROTEIN", 84, 88], ["PDB ID 6VSB", "PROTEIN", 90, 101], ["RBD", "PROTEIN", 158, 161], ["SARS-CoV", "SPECIES", 52, 60], ["the S protein", "TEST", 35, 48], ["SARS", "TEST", 52, 56], ["SARS", "TEST", 79, 83], ["PDB ID 6VSB", "TEST", 90, 101], ["the major structural differences", "PROBLEM", 115, 147], ["RBD", "PROBLEM", 158, 161], ["RBD", "OBSERVATION", 158, 161], ["closed conformation", "OBSERVATION", 167, 186]]], ["Although the RBD of S from SARS-CoV and SARS-CoV-2 were largely resembled, the SARS-CoV-2 RBD showed a higher binding affinity toward hACE2 than SARS-CoV RBD Shang et al., 2020) .", [["SARS", "DISEASE", 27, 31], ["SARS", "DISEASE", 40, 44], ["SARS", "DISEASE", 79, 83], ["SARS-CoV", "ORGANISM", 27, 35], ["SARS-CoV-2", "ORGANISM", 40, 50], ["RBD", "PROTEIN", 13, 16], ["SARS-CoV-2 RBD", "DNA", 79, 93], ["SARS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 145, 153], ["the RBD of S", "TEST", 9, 21], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["the SARS", "TEST", 75, 83], ["CoV", "TEST", 84, 87], ["a higher binding affinity", "PROBLEM", 101, 126], ["SARS", "PROBLEM", 145, 149]]], ["The CyroEM structure of full-length hACE2 revealed a homodimeric conformation, with each monomer of hACE2 binding to one RBD of the SARS-CoV-2 S protein ( Figure 2B ) .", [["hACE2", "GENE_OR_GENE_PRODUCT", 36, 41], ["hACE2", "SIMPLE_CHEMICAL", 100, 105], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 132, 144], ["CyroEM structure", "PROTEIN", 4, 20], ["hACE2", "PROTEIN", 36, 41], ["hACE2", "PROTEIN", 100, 105], ["RBD", "PROTEIN", 121, 124], ["SARS-CoV-2 S protein", "PROTEIN", 132, 152], ["Figure 2B", "PROTEIN", 155, 164], ["a homodimeric conformation", "PROBLEM", 51, 77], ["hACE2 binding", "PROBLEM", 100, 113], ["the SARS", "TEST", 128, 136], ["CoV", "TEST", 137, 140], ["full", "OBSERVATION_MODIFIER", 24, 28], ["homodimeric conformation", "OBSERVATION", 53, 77]]], ["The crystal structure of hACE2 in complex with SARS-CoV-2 RBD (PDB ID 6M0J and 6VW1) showed that SARS-CoV-2 RBD binds to the N-terminal region of hACE2 via S19, Q24, T27, F28, D30, K31, H34, E35, E37, D38, Y41, Q42, L45, L79, M82, Y83, Q325, N330, K353, D355, and R357 residues of hACE2 and K417, V445, G446, Y449, Y453, L455, F456, Y473, A475, G476, E484, F486, N487, Y489, Q493, G496, Q489, T500, N501, G502, V503, and Y505 residues of SARS-CoV-2 RBD ( Figure 2C ) (Shang et al., 2020; Wrapp et al., 2020) .", [["N-", "CHEMICAL", 125, 127], ["F28, D30, K31, H34, E35, E37, D38, Y41, Q42, L45, L79, M82, Y83, Q325, N330, K353, D355, and R357", "CHEMICAL", 171, 268], ["hACE2", "CHEMICAL", 281, 286], ["K417", "CHEMICAL", 291, 295], ["V445", "CHEMICAL", 297, 301], ["G446, Y449, Y453, L455, F456, Y473, A475, G476, E484, F486, N487, Y489, Q493, G496, Q489, T500, N501, G502, V503, and Y505", "CHEMICAL", 303, 425], ["hACE2", "GENE_OR_GENE_PRODUCT", 25, 30], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["PDB ID 6M0J", "GENE_OR_GENE_PRODUCT", 63, 74], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["hACE2", "GENE_OR_GENE_PRODUCT", 146, 151], ["S19", "GENE_OR_GENE_PRODUCT", 156, 159], ["Q24", "GENE_OR_GENE_PRODUCT", 161, 164], ["Y41", "GENE_OR_GENE_PRODUCT", 206, 209], ["hACE2", "GENE_OR_GENE_PRODUCT", 281, 286], ["hACE2", "PROTEIN", 25, 30], ["SARS-CoV-2 RBD", "PROTEIN", 47, 61], ["6M0J", "PROTEIN", 70, 74], ["6VW1", "PROTEIN", 79, 83], ["CoV", "PROTEIN", 102, 105], ["RBD", "PROTEIN", 108, 111], ["N-terminal region", "PROTEIN", 125, 142], ["hACE2", "PROTEIN", 146, 151], ["T27", "PROTEIN", 166, 169], ["F28", "PROTEIN", 171, 174], ["D30", "PROTEIN", 176, 179], ["K31", "PROTEIN", 181, 184], ["H34", "PROTEIN", 186, 189], ["E35", "PROTEIN", 191, 194], ["E37", "PROTEIN", 196, 199], ["D38", "PROTEIN", 201, 204], ["RBD", "PROTEIN", 449, 452], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["PDB ID 6M0J", "TEST", 63, 74], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["2 RBD binds", "PROBLEM", 106, 117], ["D30", "TEST", 176, 179], ["K31", "TEST", 181, 184], ["H34", "TEST", 186, 189], ["E35", "TEST", 191, 194], ["E37", "TEST", 196, 199], ["D38", "TEST", 201, 204], ["Y41", "TEST", 206, 209], ["L45", "TEST", 216, 219], ["L79", "TEST", 221, 224], ["M82", "TEST", 226, 229], ["Y83", "TEST", 231, 234], ["K353", "TEST", 248, 252], ["D355", "TEST", 254, 258], ["hACE2", "TEST", 281, 286], ["K417", "TEST", 291, 295], ["G446", "TEST", 303, 307], ["G502", "TEST", 405, 409], ["SARS", "TEST", 438, 442], ["CoV", "TEST", 443, 446], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["SARS", "OBSERVATION", 97, 101], ["N-", "ANATOMY_MODIFIER", 125, 127], ["terminal", "ANATOMY_MODIFIER", 127, 135], ["region", "ANATOMY_MODIFIER", 136, 142]]], ["Most of these interactions are mediated by \u03b11 of hACE2 ( Figure 2C) ; moreover, an N-glycosylation chain at N90 of hACE2 interacts with SARS-CoV-2 S protein (Shang et al., 2020) .", [["N", "CHEMICAL", 83, 84], ["\u03b11", "GENE_OR_GENE_PRODUCT", 43, 45], ["hACE2", "GENE_OR_GENE_PRODUCT", 49, 54], ["Figure 2C", "GENE_OR_GENE_PRODUCT", 57, 66], ["hACE2", "GENE_OR_GENE_PRODUCT", 115, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["\u03b11", "PROTEIN", 43, 45], ["hACE2", "PROTEIN", 49, 54], ["N-glycosylation chain", "PROTEIN", 83, 104], ["N90", "PROTEIN", 108, 111], ["hACE2", "PROTEIN", 115, 120], ["SARS-CoV-2 S protein", "PROTEIN", 136, 156], ["an N-glycosylation chain", "TREATMENT", 80, 104], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144]]], ["As mentioned earlier, the S1/S2 junction and S2 \u2032 site of the S protein are cleaved by furin and TMPRSS2, to enable efficient entry of SARS-CoV-2 into the host cell (Figure 2A) .", [["cell", "ANATOMY", 160, 164], ["SARS", "DISEASE", 135, 139], ["S2", "GENE_OR_GENE_PRODUCT", 29, 31], ["S2", "GENE_OR_GENE_PRODUCT", 45, 47], ["furin", "GENE_OR_GENE_PRODUCT", 87, 92], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 97, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["host cell", "CELL", 155, 164], ["Figure 2A", "CELL", 166, 175], ["S1/S2 junction and S2 \u2032 site", "DNA", 26, 54], ["S protein", "PROTEIN", 62, 71], ["furin", "PROTEIN", 87, 92], ["TMPRSS2", "PROTEIN", 97, 104], ["SARS-CoV-2", "PROTEIN", 135, 145], ["host cell", "CELL_TYPE", 155, 164], ["the S protein", "TEST", 58, 71], ["SARS", "TEST", 135, 139], ["CoV", "TEST", 140, 143], ["S1", "ANATOMY", 26, 28], ["S2 junction", "ANATOMY", 29, 40], ["S2", "ANATOMY", 45, 47], ["host cell", "ANATOMY", 155, 164]]], ["In addition to trypsin, cathepsin L, and elastase, TMPRSS2 is known to activate the S protein and induce virus-cell membrane fusion (Matsuyama et al., 2010) .", [["cell membrane", "ANATOMY", 111, 124], ["trypsin", "GENE_OR_GENE_PRODUCT", 15, 22], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 24, 35], ["elastase", "GENE_OR_GENE_PRODUCT", 41, 49], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 51, 58], ["cell membrane", "CELLULAR_COMPONENT", 111, 124], ["trypsin", "PROTEIN", 15, 22], ["cathepsin L", "PROTEIN", 24, 35], ["elastase", "PROTEIN", 41, 49], ["TMPRSS2", "PROTEIN", 51, 58], ["S protein", "PROTEIN", 84, 93], ["trypsin", "TEST", 15, 22], ["cathepsin L", "TREATMENT", 24, 35], ["elastase", "PROBLEM", 41, 49], ["TMPRSS2", "TEST", 51, 58], ["the S protein", "TEST", 80, 93], ["virus", "PROBLEM", 105, 110], ["cell membrane fusion", "TREATMENT", 111, 131], ["cell membrane fusion", "OBSERVATION", 111, 131]]], ["A recent study reported that TMPRSS2 is also essential for SARS-CoV-2 entry into target cells Matsuyama et al., 2020) .", [["cells", "ANATOMY", 88, 93], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 29, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["cells", "CELL", 88, 93], ["TMPRSS2", "PROTEIN", 29, 36], ["target cells", "CELL_TYPE", 81, 93], ["A recent study", "TEST", 0, 14], ["TMPRSS2", "TEST", 29, 36], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67]]], ["The overall structure reveals that human ACE2 forms a homodimer (orange and light-yellow) with B0AT1 (dark and light gray), which is located in the transmembrane region.", [["transmembrane region", "ANATOMY", 148, 168], ["human", "ORGANISM", 35, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["B0AT1", "GENE_OR_GENE_PRODUCT", 95, 100], ["transmembrane", "CELLULAR_COMPONENT", 148, 161], ["human ACE2", "PROTEIN", 35, 45], ["homodimer", "PROTEIN", 54, 63], ["B0AT1", "PROTEIN", 95, 100], ["dark and light gray", "PROTEIN", 102, 121], ["transmembrane region", "PROTEIN", 148, 168], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["B0AT1 (dark and light gray", "TREATMENT", 95, 121], ["transmembrane", "ANATOMY_MODIFIER", 148, 161], ["region", "ANATOMY_MODIFIER", 162, 168]]], ["The two SARS-CoV-2 RBDs are shown as dark and light green surfaces.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV-2 RBDs", "DNA", 8, 23], ["The two SARS", "TEST", 0, 12], ["two", "OBSERVATION_MODIFIER", 4, 7], ["SARS", "OBSERVATION", 8, 12], ["dark", "OBSERVATION_MODIFIER", 37, 41], ["light green", "OBSERVATION_MODIFIER", 46, 57], ["surfaces", "OBSERVATION_MODIFIER", 58, 66]]], ["(C) The interaction interface between RBD and ACE2 is shown (PDB ID 6M0J).", [["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["RBD", "PROTEIN", 38, 41], ["ACE2", "PROTEIN", 46, 50], ["ACE2", "TEST", 46, 50]]], ["The residues involved in the interaction between SARS-CoV-2 RBD and hACE2 are represented with stick models in green and orange, respectively.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["hACE2", "GENE_OR_GENE_PRODUCT", 68, 73], ["SARS-CoV-2 RBD", "DNA", 49, 63], ["hACE2", "PROTEIN", 68, 73], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["stick models", "TEST", 95, 107]]], ["Alpha helix 1 (\u03b11) of hACE2 is also labeled.", [["Alpha helix 1", "GENE_OR_GENE_PRODUCT", 0, 13], ["\u03b11", "GENE_OR_GENE_PRODUCT", 15, 17], ["hACE2", "GENE_OR_GENE_PRODUCT", 22, 27], ["Alpha helix 1", "PROTEIN", 0, 13], ["\u03b11", "PROTEIN", 15, 17], ["hACE2", "PROTEIN", 22, 27], ["Alpha helix", "TEST", 0, 11], ["helix", "ANATOMY_MODIFIER", 6, 11]]], ["(D) The overall structure of SARS-CoV-2 RBD in complex with its neutralizing antibody CR3022 (PDB ID 6W41).", [["SARS-CoV-2 RBD", "GENE_OR_GENE_PRODUCT", 29, 43], ["SARS-CoV-2 RBD", "PROTEIN", 29, 43], ["neutralizing antibody CR3022", "PROTEIN", 64, 92], ["PDB ID 6W41", "PROTEIN", 94, 105], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["2 RBD", "PROBLEM", 38, 43], ["its neutralizing antibody", "TEST", 60, 85], ["SARS", "OBSERVATION", 29, 33]]], ["The Fab regions of the heavy and light chains are shown in hot pink and pink, respectively.", [["Fab regions", "PROTEIN", 4, 15], ["heavy and light chains", "PROTEIN", 23, 45], ["Fab", "OBSERVATION", 4, 7], ["heavy", "OBSERVATION_MODIFIER", 23, 28], ["light chains", "OBSERVATION_MODIFIER", 33, 45], ["hot", "OBSERVATION_MODIFIER", 59, 62], ["pink", "OBSERVATION_MODIFIER", 63, 67], ["pink", "OBSERVATION_MODIFIER", 72, 76]]], ["SARS-CoV-2 RBD is shown in green.", [["SARS", "DISEASE", 0, 4], ["RBD", "DISEASE", 11, 14], ["SARS-CoV-2 RBD", "DNA", 0, 14], ["green", "OBSERVATION", 27, 32]]], ["(E) Structural comparison of interfaces between SARS-CoV-2 RBD and Nab or hACE2.", [["SARS-CoV-2 RBD", "GENE_OR_GENE_PRODUCT", 48, 62], ["Nab", "GENE_OR_GENE_PRODUCT", 67, 70], ["hACE2", "SIMPLE_CHEMICAL", 74, 79], ["SARS-CoV-2 RBD", "PROTEIN", 48, 62], ["Nab", "PROTEIN", 67, 70], ["hACE2", "PROTEIN", 74, 79], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56]]], ["The interaction interfaces with the light chain of CR3022, heavy chain of CR3022, and hACE2 are shown in pink, hot pink, and orange, respectively.", [["CR3022", "GENE_OR_GENE_PRODUCT", 51, 57], ["CR3022", "GENE_OR_GENE_PRODUCT", 74, 80], ["hACE2", "GENE_OR_GENE_PRODUCT", 86, 91], ["light chain", "PROTEIN", 36, 47], ["CR3022", "PROTEIN", 51, 57], ["heavy chain", "PROTEIN", 59, 70], ["CR3022", "PROTEIN", 74, 80], ["hACE2", "PROTEIN", 86, 91], ["CR3022", "TEST", 74, 80], ["heavy", "OBSERVATION_MODIFIER", 59, 64], ["chain", "OBSERVATION_MODIFIER", 65, 70], ["pink", "OBSERVATION_MODIFIER", 105, 109]]], ["(F) Hinge movement of hACE2 upon binding of the enzyme inhibitor.", [["hACE2", "GENE_OR_GENE_PRODUCT", 22, 27], ["hACE2", "PROTEIN", 22, 27], ["Hinge movement of hACE2", "PROBLEM", 4, 27], ["the enzyme inhibitor", "TREATMENT", 44, 64]]], ["The Apo form (PDB ID 1R42) and inhibitor-bound form (PDB ID 1R4L) are superimposed and shown in blue and red, respectively.Viral EntryAccordingly, targeting proteins that participate in SARS-CoV-2 entry can be a potential therapeutic strategy.", [["Apo", "GENE_OR_GENE_PRODUCT", 4, 7], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 186, 196], ["Apo form", "PROTEIN", 4, 12], ["PDB ID 1R42", "PROTEIN", 14, 25], ["inhibitor-bound form", "PROTEIN", 31, 51], ["PDB ID 1R4L", "PROTEIN", 53, 64], ["inhibitor", "TREATMENT", 31, 40], ["Viral EntryAccordingly", "PROBLEM", 123, 145], ["targeting proteins", "PROBLEM", 147, 165], ["SARS", "PROBLEM", 186, 190]]], ["The use of neutralizing antibodies (NAbs) against SARS-CoV-2's S protein is thought to be promising for the treatment of patients with COVID-19 (Pinto et al., 2020) .", [["SARS-CoV-2's S", "GENE_OR_GENE_PRODUCT", 50, 64], ["patients", "ORGANISM", 121, 129], ["neutralizing antibodies", "PROTEIN", 11, 34], ["NAbs", "PROTEIN", 36, 40], ["SARS-CoV-2's S protein", "PROTEIN", 50, 72], ["patients", "SPECIES", 121, 129], ["neutralizing antibodies", "TREATMENT", 11, 34], ["SARS-CoV", "PROBLEM", 50, 58], ["S protein", "TEST", 63, 72], ["COVID", "TEST", 135, 140]]], ["A Nab-CR3022-known to target SARS-CoV RBD and prevent lung pathology, can also bind to SARS-CoV-2 RBD (ter Meulen et al., 2006; Tian et al., 2020) .", [["lung", "ANATOMY", 54, 58], ["Nab-CR3022", "CHEMICAL", 2, 12], ["SARS", "DISEASE", 87, 91], ["Nab-CR3022", "GENE_OR_GENE_PRODUCT", 2, 12], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["lung", "ORGAN", 54, 58], ["SARS-CoV RBD", "PROTEIN", 29, 41], ["SARS-CoV", "SPECIES", 29, 37], ["A Nab", "TEST", 0, 5], ["CR3022", "TEST", 6, 12], ["target SARS", "PROBLEM", 22, 33], ["CoV RBD", "PROBLEM", 34, 41], ["lung pathology", "PROBLEM", 54, 68], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["prevent", "UNCERTAINTY", 46, 53], ["lung", "ANATOMY", 54, 58], ["pathology", "OBSERVATION", 59, 68]]], ["The crystal structure of SARS-CoV-2 RBD in complex with CR3022 revealed that CR3022 forms a distinct interaction interface with SARS-CoV-2 RBD, and does not overlap with the interaction interface between hACE2 and SARS-CoV-2 RBD (Figures 2D,E) .", [["CR3022", "CHEMICAL", 77, 83], ["CR3022", "CHEMICAL", 56, 62], ["CR3022", "CHEMICAL", 77, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["CR3022", "SIMPLE_CHEMICAL", 56, 62], ["CR3022", "SIMPLE_CHEMICAL", 77, 83], ["CoV", "PROTEIN", 30, 33], ["RBD", "PROTEIN", 36, 39], ["CR3022", "PROTEIN", 56, 62], ["CR3022", "PROTEIN", 77, 83], ["RBD", "PROTEIN", 139, 142], ["hACE2", "PROTEIN", 204, 209], ["RBD", "PROTEIN", 225, 228], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["CR3022", "TEST", 56, 62], ["SARS", "PROBLEM", 128, 132], ["CoV", "TEST", 133, 136], ["hACE2", "TEST", 204, 209], ["SARS", "TEST", 214, 218], ["CoV", "TEST", 219, 222], ["SARS", "OBSERVATION", 25, 29]]], ["Although CR3022 binds to SARS-CoV RBD and SARS-CoV-2 RBD with binding affinities (Kd) of 1 and 115 nM, respectively, it is unable to neutralize SARS-CoV-2 in vitro largely due to its inability to form the interaction interface and its low binding affinity (Pinto et al., 2020; Yuan et al., 2020) .", [["CR3022", "CHEMICAL", 9, 15], ["SARS", "DISEASE", 144, 148], ["CR3022", "SIMPLE_CHEMICAL", 9, 15], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 25, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 144, 154], ["CR3022", "PROTEIN", 9, 15], ["SARS-CoV RBD", "PROTEIN", 25, 37], ["SARS-CoV-2 RBD", "DNA", 42, 56], ["SARS-CoV", "SPECIES", 25, 33], ["CR3022 binds", "PROBLEM", 9, 21], ["SARS", "PROBLEM", 25, 29], ["CoV RBD", "PROBLEM", 30, 37], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["binding affinities", "TEST", 62, 80], ["Kd", "TEST", 82, 84], ["SARS", "TEST", 144, 148], ["CoV", "TEST", 149, 152]]], ["However, continuous efforts are being undertaken to identify potent NAbs by collecting plasma from infected individuals, and this has shown significant progress.", [["plasma", "ANATOMY", 87, 93], ["plasma", "ORGANISM_SUBSTANCE", 87, 93], ["NAbs", "PROTEIN", 68, 72], ["significant", "OBSERVATION_MODIFIER", 140, 151]]], ["The P2B-2F6 from SARS-CoV2 infected patients have overlapping residues, G446 and Y449, with higher RBD binding affinity than ACE2/RBD (5.14 and 4.70 nM respectively) (Ju et al., 2020) .", [["SARS-CoV2 infected", "DISEASE", 17, 35], ["P2B-2F6", "GENE_OR_GENE_PRODUCT", 4, 11], ["SARS-CoV2", "ORGANISM", 17, 26], ["patients", "ORGANISM", 36, 44], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["P2B", "PROTEIN", 4, 7], ["2F6", "PROTEIN", 8, 11], ["RBD", "PROTEIN", 99, 102], ["ACE2", "PROTEIN", 125, 129], ["RBD", "PROTEIN", 130, 133], ["patients", "SPECIES", 36, 44], ["The P2B", "TEST", 0, 7], ["SARS", "PROBLEM", 17, 21], ["overlapping residues", "PROBLEM", 50, 70], ["higher RBD binding affinity", "PROBLEM", 92, 119], ["ACE2/RBD", "TEST", 125, 133]]], ["Furthermore, the interaction interface of C105/RBD overlapped with the ACE2 binding region, and B38 share similar binding structures with prominent neutralizing effects (Barnes et al., 2020; Wu et al., 2020) .", [["C105", "GENE_OR_GENE_PRODUCT", 42, 46], ["RBD", "GENE_OR_GENE_PRODUCT", 47, 50], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["B38", "SIMPLE_CHEMICAL", 96, 99], ["C105", "PROTEIN", 42, 46], ["RBD", "PROTEIN", 47, 50], ["ACE2 binding region", "PROTEIN", 71, 90], ["B38", "PROTEIN", 96, 99], ["C105/RBD", "PROBLEM", 42, 50], ["prominent neutralizing effects", "PROBLEM", 138, 168], ["RBD", "OBSERVATION", 47, 50], ["prominent", "OBSERVATION_MODIFIER", 138, 147], ["neutralizing effects", "OBSERVATION", 148, 168]]], ["Also they showed recent concern of mutation in S (D614G) that might increase SARS-CoV-2's transmission rate and has a rare chance to affect the RBD-binding Mab C105, because of the distance between the RBD region and D614 (Barnes et al., 2020) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 77, 87], ["RBD-binding Mab C105", "GENE_OR_GENE_PRODUCT", 144, 164], ["RBD", "PROTEIN", 144, 147], ["Mab C105", "PROTEIN", 156, 164], ["RBD region", "PROTEIN", 202, 212], ["mutation in S", "PROBLEM", 35, 48], ["CoV", "TEST", 82, 85], ["transmission rate", "TEST", 90, 107], ["the RBD", "PROBLEM", 140, 147], ["RBD", "ANATOMY", 202, 205], ["region", "ANATOMY_MODIFIER", 206, 212]]], ["In addition to identifying NAbs targeting SARS-CoV-2's S protein, a pilot trial to use recombinant soluble human ACE2 in COVID-19 patients has been initiated (clinicaltrial.gov #NCT04287686).", [["SARS-CoV-2's S", "GENE_OR_GENE_PRODUCT", 42, 56], ["human", "ORGANISM", 107, 112], ["ACE2", "GENE_OR_GENE_PRODUCT", 113, 117], ["patients", "ORGANISM", 130, 138], ["NAbs", "PROTEIN", 27, 31], ["SARS-CoV-2's S protein", "PROTEIN", 42, 64], ["recombinant soluble human ACE2", "PROTEIN", 87, 117], ["human", "SPECIES", 107, 112], ["patients", "SPECIES", 130, 138], ["SARS-CoV", "SPECIES", 42, 50], ["human", "SPECIES", 107, 112], ["NAbs", "TEST", 27, 31], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["a pilot trial", "TREATMENT", 66, 79], ["recombinant soluble human ACE2 in COVID", "TREATMENT", 87, 126], ["NAbs", "OBSERVATION", 27, 31]]], ["However, this trial was recently withdrawn as it was not approved by the Center for Drug Evaluation (CDE).", [["Drug Evaluation", "TEST", 84, 99]]], ["Because ACE2 can counter the activation of renin-angiotensin-aldosterone system (RAAS) treatment with ACE2 inhibitors, it can increase ACE2 expression in some patients to compensate for the blocked ACE2 activity (Vaduganathan et al., 2020) .", [["angiotensin", "CHEMICAL", 49, 60], ["aldosterone", "CHEMICAL", 61, 72], ["aldosterone", "CHEMICAL", 61, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 43, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["patients", "ORGANISM", 159, 167], ["ACE2", "GENE_OR_GENE_PRODUCT", 198, 202], ["ACE2", "PROTEIN", 8, 12], ["renin", "PROTEIN", 43, 48], ["ACE2", "PROTEIN", 102, 106], ["ACE2", "PROTEIN", 135, 139], ["ACE2", "PROTEIN", 198, 202], ["patients", "SPECIES", 159, 167], ["ACE2", "TEST", 8, 12], ["renin-angiotensin-aldosterone system", "TREATMENT", 43, 79], ["RAAS) treatment", "TREATMENT", 81, 96], ["ACE2 inhibitors", "TREATMENT", 102, 117], ["ACE2 expression", "TREATMENT", 135, 150], ["the blocked ACE2 activity", "PROBLEM", 186, 211]]], ["In some animal studies, treatment of RAAS inhibitor resulted in increased expression of ACE2 in specific tissues (Ferrario et al., 2005; Soler et al., 2009) .", [["tissues", "ANATOMY", 105, 112], ["RAAS", "GENE_OR_GENE_PRODUCT", 37, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["tissues", "TISSUE", 105, 112], ["ACE2", "PROTEIN", 88, 92], ["some animal studies", "TEST", 3, 22], ["treatment of RAAS inhibitor", "TREATMENT", 24, 51], ["increased", "OBSERVATION_MODIFIER", 64, 73]]], ["In this regard, some researchers hypothesized that treatment of the RAAS inhibitor might enhance the accessibility of SARS-CoV-2 into cells and therefore increase the risk of severity in patients carrying COVID-19 (Fang et al., 2020; Watkins, 2020) .", [["cells", "ANATOMY", 134, 139], ["SARS", "DISEASE", 118, 122], ["RAAS", "GENE_OR_GENE_PRODUCT", 68, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 118, 128], ["cells", "CELL", 134, 139], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["SARS-CoV", "SPECIES", 118, 126], ["the RAAS inhibitor", "TREATMENT", 64, 82], ["SARS", "PROBLEM", 118, 122], ["CoV", "TEST", 123, 126]]], ["However, a recent case population study showed that there was no correlation between use of RAAS inhibitors and increased risk of COVID-19 (de Abajo et al., 2020) .", [["COVID-19", "CHEMICAL", 130, 138], ["RAAS", "GENE_OR_GENE_PRODUCT", 92, 96], ["a recent case population study", "TEST", 9, 39], ["RAAS inhibitors", "TREATMENT", 92, 107], ["COVID", "TEST", 130, 135]]], ["The Ramipril, ACE inhibitor showed cardiac protective effects without increased expression of ACE2 (Burchill et al., 2012) .", [["cardiac", "ANATOMY", 35, 42], ["Ramipril", "CHEMICAL", 4, 12], ["ACE inhibitor", "CHEMICAL", 14, 27], ["Ramipril", "CHEMICAL", 4, 12], ["Ramipril", "SIMPLE_CHEMICAL", 4, 12], ["ACE", "GENE_OR_GENE_PRODUCT", 14, 17], ["cardiac", "ORGAN", 35, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["ACE2", "PROTEIN", 94, 98], ["The Ramipril", "TREATMENT", 0, 12], ["ACE inhibitor", "TREATMENT", 14, 27], ["cardiac protective effects", "PROBLEM", 35, 61], ["cardiac", "ANATOMY", 35, 42], ["protective", "OBSERVATION", 43, 53]]], ["These contradictory results suggested that clinical validations of RAAS inhibitors are needed to demonstrate its effectiveness toward COVD-19.", [["COVD-19", "CHEMICAL", 134, 141], ["RAAS", "GENE_OR_GENE_PRODUCT", 67, 71], ["RAAS inhibitors", "TREATMENT", 67, 82], ["COVD", "TEST", 134, 138]]], ["The highresolution X-ray crystal structure of apo-hACE2 and hACE2 in complex with its enzymatic inhibitor MLN-4760 showed that inhibitor binding at the active site of hACE2 can cause large hinge-bending movement (Towler et al., 2004) (Figure 2F) .", [["MLN-4760", "CHEMICAL", 106, 114], ["MLN-4760", "CHEMICAL", 106, 114], ["apo-hACE2", "GENE_OR_GENE_PRODUCT", 46, 55], ["hACE2", "GENE_OR_GENE_PRODUCT", 60, 65], ["MLN-4760", "SIMPLE_CHEMICAL", 106, 114], ["hACE2", "SIMPLE_CHEMICAL", 167, 172], ["apo-hACE2", "PROTEIN", 46, 55], ["hACE2", "PROTEIN", 60, 65], ["hACE2", "PROTEIN", 167, 172], ["The highresolution X-ray crystal structure of apo-hACE2", "PROBLEM", 0, 55], ["its enzymatic inhibitor MLN", "TEST", 82, 109], ["inhibitor binding", "PROBLEM", 127, 144], ["large hinge-bending movement", "PROBLEM", 183, 211], ["large", "OBSERVATION_MODIFIER", 183, 188], ["hinge", "OBSERVATION_MODIFIER", 189, 194], ["bending movement", "OBSERVATION", 195, 211]]], ["Furthermore, a structure-based drug discovery study showed that an enzymatic hACE2 inhibitor can prevent SARS-CoV infection (Huentelman et al., 2004) .", [["SARS-CoV infection", "DISEASE", 105, 123], ["hACE2", "GENE_OR_GENE_PRODUCT", 77, 82], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["SARS-CoV", "SPECIES", 105, 113], ["a structure-based drug discovery study", "TEST", 13, 51], ["an enzymatic hACE2 inhibitor", "TREATMENT", 64, 92], ["SARS", "PROBLEM", 105, 109], ["CoV infection", "PROBLEM", 110, 123], ["CoV", "OBSERVATION_MODIFIER", 110, 113], ["infection", "OBSERVATION", 114, 123]]], ["Therefore, hACE2 inhibitors can potentially prevent SARS-CoV-2 infection.Viral EntryAlthough the structure of human TMPRSS2 is not available yet, homology modeling and in silico docking studies have demonstrated the molecular mechanisms of camostat mesylate, nafamostat, and bromhexine hydrochloride in inhibiting TMPRSS2 (Sonawane et al., 2020) .", [["SARS-CoV-2 infection", "DISEASE", 52, 72], ["camostat mesylate", "CHEMICAL", 240, 257], ["nafamostat", "CHEMICAL", 259, 269], ["bromhexine hydrochloride", "CHEMICAL", 275, 299], ["camostat mesylate", "CHEMICAL", 240, 257], ["nafamostat", "CHEMICAL", 259, 269], ["bromhexine hydrochloride", "CHEMICAL", 275, 299], ["hACE2", "SIMPLE_CHEMICAL", 11, 16], ["CoV-2", "ORGANISM", 57, 62], ["human", "ORGANISM", 110, 115], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 116, 123], ["camostat mesylate", "SIMPLE_CHEMICAL", 240, 257], ["nafamostat", "SIMPLE_CHEMICAL", 259, 269], ["bromhexine hydrochloride", "SIMPLE_CHEMICAL", 275, 299], ["TMPRSS2", "SIMPLE_CHEMICAL", 314, 321], ["human TMPRSS2", "PROTEIN", 110, 123], ["human", "SPECIES", 110, 115], ["SARS-CoV-2", "SPECIES", 52, 62], ["human", "SPECIES", 110, 115], ["hACE2 inhibitors", "TREATMENT", 11, 27], ["SARS", "PROBLEM", 52, 56], ["CoV-2 infection", "PROBLEM", 57, 72], ["human TMPRSS2", "TEST", 110, 123], ["homology modeling", "TEST", 146, 163], ["silico docking studies", "TEST", 171, 193], ["camostat mesylate", "TREATMENT", 240, 257], ["nafamostat", "TREATMENT", 259, 269], ["bromhexine hydrochloride", "TREATMENT", 275, 299], ["infection", "OBSERVATION", 63, 72]]], ["In this respect, active sitespecific inhibitors of TMPRSS2 can be used as potential antiviral agents against SARS-CoV-2.Viral ProteasesThe crystal structure of SARS-CoV M pro -a cysteine proteaseconsists of domains 1-3.", [["TMPRSS2", "CHEMICAL", 51, 58], ["SARS", "DISEASE", 109, 113], ["cysteine", "CHEMICAL", 178, 186], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 51, 58], ["SARS-CoV-2", "ORGANISM", 109, 119], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 160, 168], ["cysteine", "AMINO_ACID", 178, 186], ["TMPRSS2", "PROTEIN", 51, 58], ["Viral Proteases", "PROTEIN", 120, 135], ["SARS-CoV M pro", "PROTEIN", 160, 174], ["cysteine proteaseconsists of domains 1-3", "PROTEIN", 178, 218], ["SARS-CoV", "SPECIES", 109, 117], ["SARS-CoV", "SPECIES", 160, 168], ["active sitespecific inhibitors of TMPRSS2", "TREATMENT", 17, 58], ["antiviral agents", "TREATMENT", 84, 100], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["Viral Proteases", "TEST", 120, 135], ["SARS", "TEST", 160, 164], ["CoV M pro", "TEST", 165, 174], ["a cysteine proteaseconsists of domains", "TREATMENT", 176, 214]]], ["The catalytic processes of M pro are mediated by the non-canonical Cys-His catalytic dyad located between domains I and II (Anand et al., 2002 (Anand et al., , 2003 .", [["Cys", "CHEMICAL", 67, 70], ["His", "CHEMICAL", 71, 74], ["M pro", "GENE_OR_GENE_PRODUCT", 27, 32], ["M pro", "PROTEIN", 27, 32], ["non-canonical Cys-His catalytic dyad", "PROTEIN", 53, 89], ["I and II", "PROTEIN", 114, 122], ["His catalytic dyad", "PROBLEM", 71, 89]]], ["The M pro protein is highly conserved among SARS-CoV, MERS-CoV, and SARS-CoV-2, and it shares the common substrate recognition sequence consisting of LQ(S,A,G) (Ziebuhr et al., 2000; Hegyi and Ziebuhr, 2002; Dai et al., 2020) .", [["M pro", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS-CoV", "ORGANISM", 44, 52], ["MERS-CoV", "ORGANISM", 54, 62], ["SARS-CoV-2", "ORGANISM", 68, 78], ["M pro protein", "PROTEIN", 4, 17], ["SARS-CoV", "SPECIES", 44, 52], ["MERS-CoV", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 68, 76], ["The M pro protein", "TEST", 0, 17], ["CoV", "TEST", 49, 52], ["MERS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["SARS", "PROBLEM", 68, 72]]], ["Among them, the Gln in P1 of the substrate is an important common feature required for their catalytic activity.", [["Gln", "CHEMICAL", 16, 19], ["Gln", "CHEMICAL", 16, 19], ["Gln", "AMINO_ACID", 16, 19]]], ["Human proteases with a similar substrate specificity to that of M pro do not exist; therefore, development of M pro inhibitors is a potential therapeutic strategy for targeting SARS-CoV-2.Viral ProteasesSARS-CoV-2 M pro consists of three domains, analogous to that of M pro from other CoVs (Figure 3A ) (Dai et al., 2020; Jin et al., 2020; Zhang et al., 2020b) .", [["Human", "ORGANISM", 0, 5], ["M pro", "GENE_OR_GENE_PRODUCT", 64, 69], ["M pro", "GENE_OR_GENE_PRODUCT", 110, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 177, 187], ["Human proteases", "PROTEIN", 0, 15], ["M pro", "PROTEIN", 64, 69], ["Viral ProteasesSARS-CoV-2", "DNA", 188, 213], ["M pro", "PROTEIN", 214, 219], ["M pro", "PROTEIN", 268, 273], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human proteases", "PROBLEM", 0, 15], ["M pro inhibitors", "TREATMENT", 110, 126], ["a potential therapeutic strategy", "TREATMENT", 130, 162], ["Viral ProteasesSARS-CoV", "TEST", 188, 211]]], ["The crystal structure of M pro revealed that it forms homodimers (dimeric protomer) through interactions between domain II of protomer A and N-terminal residues of protomer B (Figure 3A ) (Zhang et al., 2020b) .", [["N", "CHEMICAL", 141, 142], ["M pro", "PROTEIN", 25, 30], ["homodimers", "PROTEIN", 54, 64], ["dimeric protomer", "PROTEIN", 66, 82], ["domain II", "PROTEIN", 113, 122], ["protomer A", "PROTEIN", 126, 136], ["N-terminal residues", "PROTEIN", 141, 160], ["protomer B", "PROTEIN", 164, 174], ["Figure 3A", "PROTEIN", 176, 185], ["homodimers (dimeric protomer", "TREATMENT", 54, 82], ["protomer A and N-terminal residues of protomer B", "TREATMENT", 126, 174]]], ["Homodimerization of M pro is required for its enzymatic activity.", [["M pro", "GENE_OR_GENE_PRODUCT", 20, 25], ["M pro", "PROTEIN", 20, 25], ["Homodimerization of M pro", "TREATMENT", 0, 25]]], ["Mutational studies on the dimeric interface, as well as crystal structure analysis, revealed that the interaction between two protomers is required to form the S1 pocket at the substrate binding site (Figure 3B ) (Anand et al., 2002; Lim et al., 2014; Zhang et al., 2020b) .", [["S1 pocket", "PROTEIN", 160, 169], ["substrate binding site", "PROTEIN", 177, 199], ["Mutational studies", "TEST", 0, 18], ["crystal structure analysis", "TEST", 56, 82], ["the S1 pocket", "PROBLEM", 156, 169], ["S1", "ANATOMY", 160, 162]]], ["The substrate binding site of SARS-CoV-2 consists of S1 \u2032 -S1-S2-S4 pockets lined with, H41, S46, M49, Y54, F140, L141, N142, G143, C145, H163, H164, M165, E166, L167, H172, F185, D187, Q189, T190, A191, and Q192 residues ( Figure 3B ) (Dai et al., 2020; Jin et al., 2020; Zhang et al., 2020b) .", [["H41, S46, M49, Y54, F140, L141, N142, G143, C145, H163, H164, M165, E166, L167, H172, F185, D187, Q189, T190, A191, and Q192", "CHEMICAL", 88, 212], ["substrate binding site", "DNA", 4, 26], ["SARS-CoV-2", "DNA", 30, 40], ["S1", "PROTEIN", 53, 55], ["S1", "PROTEIN", 59, 61], ["S2", "PROTEIN", 62, 64], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["S1", "TEST", 53, 55], ["H41", "TEST", 88, 91], ["M49", "TEST", 98, 101], ["Y54", "TEST", 103, 106], ["G143", "TEST", 126, 130], ["S1", "ANATOMY", 53, 55], ["S1", "ANATOMY", 59, 61], ["S2", "ANATOMY", 62, 64], ["S4", "ANATOMY", 65, 67], ["pockets", "ANATOMY_MODIFIER", 68, 75]]], ["Notably, the S2 pocket of CoVs is typically hydrophobic and can accommodate the bulky P2 fragment (Figure 3B) .", [["CoVs", "CHEMICAL", 26, 30], ["CoVs", "GENE_OR_GENE_PRODUCT", 26, 30], ["S2 pocket", "PROTEIN", 13, 22], ["CoVs", "PROTEIN", 26, 30], ["bulky P2 fragment", "PROTEIN", 80, 97], ["CoVs", "PROBLEM", 26, 30], ["the bulky P2 fragment", "PROBLEM", 76, 97], ["S2", "OBSERVATION_MODIFIER", 13, 15], ["pocket", "OBSERVATION_MODIFIER", 16, 22], ["CoVs", "OBSERVATION", 26, 30], ["hydrophobic", "OBSERVATION_MODIFIER", 44, 55], ["bulky", "OBSERVATION_MODIFIER", 80, 85], ["P2 fragment", "OBSERVATION", 86, 97]]], ["Several structure-based drug discovery studies have investigated the interaction of inhibitors in the substrate-binding pockets of SARS-CoV-2 M pro ( Figure 3C ) (Dai et al., 2020; Jin et al., 2020; Zhang et al., 2020b) .", [["inhibitors", "TREATMENT", 84, 94], ["SARS", "PROBLEM", 131, 135], ["CoV", "TEST", 136, 139]]], ["A previous study for developing broad spectrum inhibitors targeting CoV M pro showed that inhibitors of SARS-CoV-2 contain a (S)-\u03b3-lactam ring at P1 position to mimic glutamine and occupy the S1 pocket of SARS-CoV-2 M pro (Zhang et al., 2020a) .", [["\u03b3-lactam", "CHEMICAL", 129, 137], ["glutamine", "CHEMICAL", 167, 176], ["(S)-\u03b3-lactam", "CHEMICAL", 125, 137], ["glutamine", "CHEMICAL", 167, 176], ["CoV", "ORGANISM", 68, 71], ["SARS-CoV-2", "ORGANISM", 104, 114], ["(S)-\u03b3-lactam", "SIMPLE_CHEMICAL", 125, 137], ["glutamine", "AMINO_ACID", 167, 176], ["CoV M pro", "PROTEIN", 68, 77], ["S1 pocket", "PROTEIN", 192, 201], ["A previous study", "TEST", 0, 16], ["broad spectrum inhibitors", "TREATMENT", 32, 57], ["CoV M pro", "TEST", 68, 77], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["a (S)-\u03b3-lactam ring at P1 position", "TREATMENT", 123, 157], ["glutamine", "TREATMENT", 167, 176], ["SARS", "PROBLEM", 205, 209]]], ["A total of 103 structures of SARS-CoV-2 M pro in both apo and inhibitor complex forms are available in the protein data bank (PDB) database (https://www.rcsb. org/) until 27 April 2020.", [["SARS", "DISEASE", 29, 33], ["apo", "GENE_OR_GENE_PRODUCT", 54, 57], ["apo and inhibitor complex forms", "PROTEIN", 54, 85], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Zhang et al. (2020b) have developed peptidomimetic \u03b1-ketoamide inhibitors targeting SARS-CoV-2 M pro .", [["\u03b1-ketoamide", "CHEMICAL", 51, 62], ["\u03b1-ketoamide", "CHEMICAL", 51, 62], ["\u03b1-ketoamide", "SIMPLE_CHEMICAL", 51, 62], ["SARS-CoV-2 M pro", "PROTEIN", 84, 100], ["peptidomimetic \u03b1-ketoamide inhibitors", "TREATMENT", 36, 73]]], ["They also solved the crystal structure of M pro in complex with \u03b1-ketoamide 13b (PDB ID 6Y2G) and showed the presence of a \u03b3-lactam ring at P1 position and cyclopropyl at P2 position ( Figure 3D) .", [["\u03b1-ketoamide 13b", "CHEMICAL", 64, 79], ["\u03b3-lactam", "CHEMICAL", 123, 131], ["cyclopropyl", "CHEMICAL", 156, 167], ["\u03b1-ketoamide 13b", "CHEMICAL", 64, 79], ["\u03b3-lactam", "CHEMICAL", 123, 131], ["cyclopropyl", "CHEMICAL", 156, 167], ["\u03b1-ketoamide 13b", "SIMPLE_CHEMICAL", 64, 79], ["cyclopropyl", "SIMPLE_CHEMICAL", 156, 167], ["\u03b1-ketoamide 13b", "PROTEIN", 64, 79], ["\u03b1-ketoamide 13b", "TREATMENT", 64, 79], ["a \u03b3-lactam ring", "TREATMENT", 121, 136], ["cyclopropyl at P2 position", "TREATMENT", 156, 182]]], ["The biochemical IC 50 of SARS-CoV-2, SARS-CoV, and MERS-CoV M pro were found to be 0.67, 0.90, and 0.58 \u00b5M, respectively (Zhang et al., 2020b) .", [["SARS-CoV-2", "ORGANISM", 25, 35], ["SARS-CoV", "ORGANISM", 37, 45], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 51, 59], ["SARS-CoV", "SPECIES", 37, 45], ["MERS-CoV", "SPECIES", 51, 59], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["MERS", "TEST", 51, 55], ["CoV M pro", "TEST", 56, 65]]], ["Simultaneously, Dai et al. (2020) developed inhibitors with an aldehyde-substituted compound at warhead for occupying the S1 site and thus it covalently bonds with the catalytic cysteine of SARS-CoV-2 M pro (PDB ID 6LZE and 6MOK) (Dai et al., 2020) (Figure 3E) .", [["aldehyde", "CHEMICAL", 63, 71], ["aldehyde", "CHEMICAL", 63, 71], ["cysteine", "CHEMICAL", 178, 186], ["aldehyde", "SIMPLE_CHEMICAL", 63, 71], ["S1 site", "PROTEIN", 122, 129], ["inhibitors", "TREATMENT", 44, 54], ["an aldehyde", "TREATMENT", 60, 71], ["occupying the S1 site", "PROBLEM", 108, 129], ["SARS", "PROBLEM", 190, 194], ["CoV", "TEST", 195, 198], ["S1", "ANATOMY", 122, 124]]], ["These compounds showed high inhibition activity with IC 50 of 53 and 40 nM in vitro and reduced SARS-CoV-2 infection with FIGURE 3 | Structure of SARS-CoV-2 viral M pro and its complex with inhibitors.", [["infection", "DISEASE", 107, 116], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 146, 156], ["SARS-CoV-2 viral M pro", "PROTEIN", 146, 168], ["These compounds", "TEST", 0, 15], ["high inhibition activity", "PROBLEM", 23, 47], ["IC", "TEST", 53, 55], ["vitro", "TEST", 78, 83], ["reduced SARS", "PROBLEM", 88, 100], ["CoV", "TEST", 101, 104], ["2 infection", "PROBLEM", 105, 116], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["viral M pro", "TREATMENT", 157, 168], ["inhibitors", "TREATMENT", 190, 200], ["high inhibition", "OBSERVATION_MODIFIER", 23, 38], ["reduced", "OBSERVATION_MODIFIER", 88, 95], ["SARS", "OBSERVATION", 96, 100]]], ["(A) The crystal structure of SARS-CoV-2 M pro .", [["SARS", "PROBLEM", 29, 33]]], ["M pro is a cysteine protease that consists of three domains and two protomers.", [["cysteine", "CHEMICAL", 11, 19], ["M pro", "GENE_OR_GENE_PRODUCT", 0, 5], ["M pro", "PROTEIN", 0, 5], ["cysteine protease", "PROTEIN", 11, 28], ["a cysteine protease", "TREATMENT", 9, 28]]], ["Protomer B is shown in darker colors than protomer A and each domain is shown in different colors (sky blue, split pea, and violet represent domains 1, 2, and 3, respectively).", [["Protomer B", "GENE_OR_GENE_PRODUCT", 0, 10], ["pea", "ORGANISM_SUBDIVISION", 115, 118], ["Protomer B", "PROTEIN", 0, 10], ["protomer A", "PROTEIN", 42, 52], ["split pea", "OBSERVATION_MODIFIER", 109, 118]]], ["(B) Substrate binding site of SARS-CoV-2 M pro .", [["SARS-CoV-2 M pro", "PROTEIN", 30, 46], ["SARS", "PROBLEM", 30, 34]]], ["The substrate binding site of M pro is subdivided into S1, S1 \u2032 , S2, and S4 (shown in bold orange).", [["substrate binding site", "DNA", 4, 26], ["S1", "PROTEIN", 55, 57], ["S1", "PROTEIN", 59, 61], ["S2", "PROTEIN", 66, 68], ["S4", "PROTEIN", 74, 76], ["S1", "ANATOMY", 55, 57], ["S1", "ANATOMY", 59, 61], ["S2", "ANATOMY", 66, 68], ["S4", "ANATOMY", 74, 76]]], ["The inhibitors bind to 17 residues shown as yellow sticks (H41, S46, M49, Y56, F140, L141, N142, C145, H164, M165, E166 EC 50 of 0.53 and 0.72 \u00b5M in plaque reduction assay (Dai et al., 2020) .", [["plaque", "ANATOMY", 149, 155], ["H41, S46, M49, Y56, F140, L141, N142, C145, H164, M165", "CHEMICAL", 59, 113], ["plaque", "PATHOLOGICAL_FORMATION", 149, 155], ["The inhibitors bind", "TREATMENT", 0, 19], ["yellow sticks", "TEST", 44, 57], ["H41", "TEST", 59, 62], ["S46", "TEST", 64, 67], ["M49", "TEST", 69, 72], ["EC", "TEST", 120, 122], ["plaque reduction assay", "TEST", 149, 171]]], ["The crystal structure of SARS-CoV-2 M pro in complex with the inhibitor compound N3 (PDB ID 7BQY), previously designed to inhibit CoV M pro , revealed that N3 occupies the substrate binding pocket and forms a covalent bond with catalytic C145 of SARS-CoV-2 M pro .", [["N3", "CHEMICAL", 81, 83], ["N3", "CHEMICAL", 81, 83], ["N3", "CHEMICAL", 156, 158], ["PDB ID 7BQY", "SIMPLE_CHEMICAL", 85, 96], ["CoV M pro", "GENE_OR_GENE_PRODUCT", 130, 139], ["N3", "SIMPLE_CHEMICAL", 156, 158], ["SARS-CoV-2 M pro", "PROTEIN", 25, 41], ["CoV M pro", "PROTEIN", 130, 139], ["substrate binding pocket", "PROTEIN", 172, 196], ["catalytic C145 of SARS-CoV-2 M pro", "PROTEIN", 228, 262], ["SARS", "PROBLEM", 25, 29], ["CoV", "TEST", 30, 33], ["the inhibitor compound N3", "TREATMENT", 58, 83], ["the substrate binding pocket", "PROBLEM", 168, 196], ["SARS", "PROBLEM", 246, 250], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["N3", "OBSERVATION", 156, 158], ["binding pocket", "OBSERVATION", 182, 196]]], ["Consistently, the lactam ring at P1 position of N3 forms a hydrogen bond with H163 of SARS-CoV-2 M pro ( Figure 3F ) (Yang et al., 2005; Jin et al., 2020) .", [["lactam", "CHEMICAL", 18, 24], ["lactam", "CHEMICAL", 18, 24], ["N3", "CHEMICAL", 48, 50], ["hydrogen", "CHEMICAL", 59, 67], ["N3", "SIMPLE_CHEMICAL", 48, 50], ["H163", "SIMPLE_CHEMICAL", 78, 82], ["the lactam ring", "TREATMENT", 14, 29], ["a hydrogen bond", "TEST", 57, 72], ["SARS", "PROBLEM", 86, 90], ["CoV", "TEST", 91, 94]]], ["X77, a potential inhibitor of SARS-CoV-2 M pro , also occupies the substrate binding pocket; however, it does not form covalent bonds (PDB ID 6W63) ( Figure 3G ).Viral ProteasesIn conclusion, M pro of SARS-CoV-2 is a key protein that participates in the proteolytic processing of polyproteins and shows no overlapping substrate specificity with any of the known human proteases.", [["X77", "CHEMICAL", 0, 3], ["SARS", "DISEASE", 201, 205], ["X77", "SIMPLE_CHEMICAL", 0, 3], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 211], ["human", "ORGANISM", 362, 367], ["SARS-CoV-2 M pro", "PROTEIN", 30, 46], ["Viral Proteases", "PROTEIN", 162, 177], ["polyproteins", "PROTEIN", 280, 292], ["human proteases", "PROTEIN", 362, 377], ["human", "SPECIES", 362, 367], ["SARS-CoV", "SPECIES", 201, 209], ["human", "SPECIES", 362, 367], ["SARS", "PROBLEM", 30, 34], ["the substrate binding pocket", "PROBLEM", 63, 91], ["Viral Proteases", "PROBLEM", 162, 177], ["SARS", "PROBLEM", 201, 205], ["the proteolytic processing of polyproteins", "PROBLEM", 250, 292], ["overlapping substrate specificity", "PROBLEM", 306, 339], ["the known human proteases", "PROBLEM", 352, 377]]], ["Several potent inhibitors share common structural features, including covalent bond formation with catalytic cysteine and a lactam ring at P1 position.", [["cysteine", "CHEMICAL", 109, 117], ["lactam", "CHEMICAL", 124, 130], ["cysteine", "CHEMICAL", 109, 117], ["lactam", "CHEMICAL", 124, 130], ["cysteine", "AMINO_ACID", 109, 117], ["Several potent inhibitors", "TREATMENT", 0, 25], ["common structural features", "PROBLEM", 32, 58], ["covalent bond formation", "PROBLEM", 70, 93], ["catalytic cysteine", "TREATMENT", 99, 117], ["a lactam ring at P1 position", "TREATMENT", 122, 150], ["potent inhibitors", "OBSERVATION", 8, 25], ["covalent bond", "OBSERVATION", 70, 83]]], ["Because most inhibitors occupy the substrate binding pocket of SARS-CoV-2 FIGURE 4 | CryoEM structure of RdRp in complex with cofactors (nsp7 and nsp8), RNA template, and remdesivir.", [["remdesivir", "CHEMICAL", 171, 181], ["remdesivir", "CHEMICAL", 171, 181], ["nsp7", "GENE_OR_GENE_PRODUCT", 137, 141], ["nsp8", "GENE_OR_GENE_PRODUCT", 146, 150], ["remdesivir", "SIMPLE_CHEMICAL", 171, 181], ["RdRp", "PROTEIN", 105, 109], ["nsp7", "PROTEIN", 137, 141], ["nsp8", "PROTEIN", 146, 150], ["SARS", "PROBLEM", 63, 67], ["CoV", "TEST", 68, 71], ["RdRp", "PROBLEM", 105, 109], ["cofactors (nsp7 and nsp8", "TREATMENT", 126, 150], ["RNA template", "TREATMENT", 153, 165], ["remdesivir", "TREATMENT", 171, 181], ["pocket", "OBSERVATION_MODIFIER", 53, 59], ["RdRp", "OBSERVATION", 105, 109]]], ["(A) Surface representation of the CryoEM structure of SARS-CoV-2 RdRp in complex with its cofactors (two nsp8 and one nsp7) (PDB ID 6M71). nsp7 and nsp8 are shown in gray and pink, respectively.", [["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["nsp7", "GENE_OR_GENE_PRODUCT", 139, 143], ["nsp8", "GENE_OR_GENE_PRODUCT", 148, 152], ["CryoEM structure", "PROTEIN", 34, 50], ["SARS-CoV-2 RdRp", "PROTEIN", 54, 69], ["nsp8", "PROTEIN", 105, 109], ["nsp7", "PROTEIN", 118, 122], ["PDB ID 6M71", "PROTEIN", 125, 136], ["nsp7", "PROTEIN", 139, 143], ["nsp8", "PROTEIN", 148, 152], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["RdRp", "PROBLEM", 65, 69], ["its cofactors", "PROBLEM", 86, 99], ["SARS", "OBSERVATION", 54, 58], ["pink", "OBSERVATION_MODIFIER", 175, 179]]], ["The \u03b2-hairpin, NiRAN, interface, thumb, palm, and finger of SARS-CoV-2 RdRp are shown in cyan, yellow, green, orange, purple, and blue, respectively.", [["thumb", "ANATOMY", 33, 38], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 4, 13], ["NiRAN", "GENE_OR_GENE_PRODUCT", 15, 20], ["thumb", "ORGANISM_SUBDIVISION", 33, 38], ["palm", "ORGANISM_SUBDIVISION", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["\u03b2-hairpin", "PROTEIN", 4, 13], ["NiRAN", "PROTEIN", 15, 20], ["thumb, palm, and finger of SARS-CoV-2 RdRp", "PROTEIN", 33, 75], ["The \u03b2-hairpin", "TEST", 0, 13], ["CoV", "TEST", 65, 68], ["RdRp", "PROBLEM", 71, 75], ["thumb", "ANATOMY", 33, 38], ["palm", "ANATOMY", 40, 44], ["finger", "ANATOMY", 50, 56], ["SARS", "OBSERVATION", 60, 64], ["cyan", "OBSERVATION", 89, 93], ["yellow", "OBSERVATION_MODIFIER", 95, 101], ["green", "OBSERVATION_MODIFIER", 103, 108], ["purple", "OBSERVATION_MODIFIER", 118, 124]]], ["(B) A cartoon representation of the overall structure of SARS-CoV-2 RdRp in complex with the RNA template and its inhibitor remdesivir (PDB ID 7BV2).", [["SARS", "DISEASE", 57, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["remdesivir", "SIMPLE_CHEMICAL", 124, 134], ["PDB ID 7BV2", "GENE_OR_GENE_PRODUCT", 136, 147], ["SARS-CoV-2 RdRp", "PROTEIN", 57, 72], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["CoV-2 RdRp", "TREATMENT", 62, 72], ["the RNA template", "TREATMENT", 89, 105], ["its inhibitor remdesivir", "TREATMENT", 110, 134], ["SARS", "OBSERVATION", 57, 61]]], ["The RNA template and primer strand are shown in blue and red, respectively.", [["RNA template", "DNA", 4, 16], ["primer strand", "DNA", 21, 34], ["The RNA template and primer strand", "TREATMENT", 0, 34], ["RNA template", "OBSERVATION", 4, 16], ["primer strand", "OBSERVATION", 21, 34], ["blue", "OBSERVATION_MODIFIER", 48, 52]]], ["The red arrow indicated the direction of NTP entry.", [["NTP", "CHEMICAL", 41, 44], ["NTP", "CHEMICAL", 41, 44], ["NTP", "SIMPLE_CHEMICAL", 41, 44], ["NTP entry", "TREATMENT", 41, 50], ["red", "OBSERVATION", 4, 7]]], ["(C) magnified view of remdesivir monophosphate binding region.", [["remdesivir monophosphate", "CHEMICAL", 22, 46], ["remdesivir monophosphate", "CHEMICAL", 22, 46], ["remdesivir monophosphate", "GENE_OR_GENE_PRODUCT", 22, 46], ["remdesivir monophosphate binding region", "PROTEIN", 22, 61], ["remdesivir monophosphate binding region", "TREATMENT", 22, 61]]], ["Remdesivir covalently binds to the primer RNA strand and interacts with the template RNA.Viral ProteasesM pro , targeting this pocket could be an efficient and safe strategy in terms of toxicity.Viral ReplicationReplication of SARS-CoV-2 genomic RNA is mediated by a multiprotein complex consisting of several non-structural proteins, such as nsp7, nsp8, nsp12, and nsp14.", [["Remdesivir", "CHEMICAL", 0, 10], ["toxicity", "DISEASE", 186, 194], ["SARS", "DISEASE", 227, 231], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 227, 237], ["nsp7", "GENE_OR_GENE_PRODUCT", 343, 347], ["nsp8", "GENE_OR_GENE_PRODUCT", 349, 353], ["nsp12", "GENE_OR_GENE_PRODUCT", 355, 360], ["nsp14", "GENE_OR_GENE_PRODUCT", 366, 371], ["primer RNA strand", "RNA", 35, 52], ["template RNA", "RNA", 76, 88], ["Viral ProteasesM pro", "PROTEIN", 89, 109], ["SARS-CoV-2 genomic RNA", "RNA", 227, 249], ["multiprotein complex", "PROTEIN", 267, 287], ["non-structural proteins", "PROTEIN", 310, 333], ["nsp7", "PROTEIN", 343, 347], ["nsp8", "PROTEIN", 349, 353], ["nsp12", "PROTEIN", 355, 360], ["nsp14", "PROTEIN", 366, 371], ["SARS-CoV", "SPECIES", 227, 235], ["Remdesivir covalently binds", "TREATMENT", 0, 27], ["the template RNA", "TREATMENT", 72, 88], ["Viral ProteasesM pro", "TREATMENT", 89, 109], ["this pocket", "PROBLEM", 122, 133], ["toxicity", "PROBLEM", 186, 194], ["SARS", "PROBLEM", 227, 231], ["CoV-2 genomic RNA", "PROBLEM", 232, 249], ["several non-structural proteins", "PROBLEM", 302, 333], ["nsp7", "TEST", 343, 347], ["nsp8", "TEST", 349, 353], ["nsp12", "TEST", 355, 360], ["nsp14", "TEST", 366, 371], ["template RNA", "OBSERVATION", 76, 88], ["SARS", "OBSERVATION", 227, 231], ["several", "OBSERVATION_MODIFIER", 302, 309], ["non-structural proteins", "OBSERVATION", 310, 333]]], ["The functional core of this multiprotein complex consists of RNA-dependent RNA polymerase (RdRp, also called nsp12) .", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 61, 89], ["RdRp", "GENE_OR_GENE_PRODUCT", 91, 95], ["nsp12", "GENE_OR_GENE_PRODUCT", 109, 114], ["multiprotein complex", "PROTEIN", 28, 48], ["RNA-dependent RNA polymerase", "PROTEIN", 61, 89], ["RdRp", "PROTEIN", 91, 95], ["nsp12", "PROTEIN", 109, 114], ["RNA-dependent RNA polymerase", "PROBLEM", 61, 89], ["dependent", "OBSERVATION_MODIFIER", 65, 74], ["RNA polymerase", "OBSERVATION", 75, 89]]], ["SARS-CoV-2 RdRp plays an important role in the replication and transcription of viral genomic RNA (Figure 1 ) and its catalytic residues are highly conserved among CoVs (Venkataraman et al., 2018; .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["viral genomic RNA (Figure 1", "GENE_OR_GENE_PRODUCT", 80, 107], ["CoVs", "PATHOLOGICAL_FORMATION", 164, 168], ["SARS-CoV-2 RdRp", "DNA", 0, 15], ["viral genomic RNA", "RNA", 80, 97], ["the replication", "TREATMENT", 43, 58], ["viral genomic RNA", "PROBLEM", 80, 97], ["its catalytic residues", "PROBLEM", 114, 136]]], ["It is because of this that the nucleotide analog remdesivir (GS-5734, Gilead) was treated to target RdRp of MERS-CoV, SARS-CoV, and SARS-CoV-2 (Warren et al., 2016; Holshue et al., 2020; Wang M. et al., 2020) .", [["nucleotide", "CHEMICAL", 31, 41], ["remdesivir", "CHEMICAL", 49, 59], ["GS-5734", "CHEMICAL", 61, 68], ["nucleotide", "CHEMICAL", 31, 41], ["remdesivir", "CHEMICAL", 49, 59], ["GS-5734", "CHEMICAL", 61, 68], ["remdesivir", "SIMPLE_CHEMICAL", 49, 59], ["GS-5734", "SIMPLE_CHEMICAL", 61, 68], ["RdRp", "ORGANISM", 100, 104], ["MERS-CoV", "ORGANISM", 108, 116], ["SARS-CoV", "ORGANISM", 118, 126], ["SARS-CoV-2", "ORGANISM", 132, 142], ["RdRp", "PROTEIN", 100, 104], ["MERS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 118, 126], ["SARS-CoV", "SPECIES", 132, 140], ["the nucleotide analog remdesivir", "TEST", 27, 59], ["GS", "TEST", 61, 63]]], ["Although the viral RdRp is a core component of viral replication, nsp7 and nsp8 are still required for full-fill transcriptional activity of RdRp (Zhai et al., 2005; Venkataraman et al., 2018; Kirchdoerfer and Ward, 2019; Gao et al., 2020) .", [["nsp7", "GENE_OR_GENE_PRODUCT", 66, 70], ["nsp8", "GENE_OR_GENE_PRODUCT", 75, 79], ["viral RdRp", "PROTEIN", 13, 23], ["nsp7", "PROTEIN", 66, 70], ["nsp8", "PROTEIN", 75, 79], ["RdRp", "PROTEIN", 141, 145], ["the viral RdRp", "PROBLEM", 9, 23], ["viral replication", "TREATMENT", 47, 64], ["nsp7", "TEST", 66, 70], ["nsp8", "TEST", 75, 79], ["viral RdRp", "OBSERVATION", 13, 23], ["viral replication", "OBSERVATION", 47, 64]]], ["The cryoEM structure of nsp12 revealed an N-terminal \u03b2-hairpin (aa 31-50), extended nidovirus RdRpassociated nucleotidyl-transferase domain (NiRAN, aa 117-250), interface domain (aa 251-365), and RdRp domain (aa 366-920) consisting of finger, palm, and thumb subdomains (Gao et al., 2020; Yin et al., 2020) (Figure 4A ).", [["finger", "ANATOMY", 235, 241], ["N", "CHEMICAL", 42, 43], ["nucleotidyl", "CHEMICAL", 109, 120], ["nsp12", "GENE_OR_GENE_PRODUCT", 24, 29], ["RdRpassociated nucleotidyl-transferase", "GENE_OR_GENE_PRODUCT", 94, 132], ["finger", "ORGANISM_SUBDIVISION", 235, 241], ["palm", "ORGANISM_SUBDIVISION", 243, 247], ["nsp12", "PROTEIN", 24, 29], ["N-terminal \u03b2-hairpin", "PROTEIN", 42, 62], ["aa 31-50", "PROTEIN", 64, 72], ["nidovirus RdRpassociated nucleotidyl-transferase domain", "PROTEIN", 84, 139], ["NiRAN", "PROTEIN", 141, 146], ["aa 117-250", "PROTEIN", 148, 158], ["interface domain", "PROTEIN", 161, 177], ["aa 251-365", "PROTEIN", 179, 189], ["RdRp domain", "PROTEIN", 196, 207], ["aa 366-920", "PROTEIN", 209, 219], ["finger, palm, and thumb subdomains", "PROTEIN", 235, 269], ["The cryoEM structure", "TEST", 0, 20], ["nsp12", "TEST", 24, 29], ["aa", "TEST", 64, 66], ["NiRAN", "TEST", 141, 146], ["aa", "TEST", 148, 150], ["interface domain", "TEST", 161, 177], ["RdRp domain", "TEST", 196, 207], ["finger, palm", "TEST", 235, 247], ["terminal", "OBSERVATION_MODIFIER", 44, 52], ["finger", "ANATOMY", 235, 241], ["palm", "ANATOMY", 243, 247], ["thumb", "ANATOMY", 253, 258]]], ["Structural studies have demonstrated that nsp12 can recognize the RNA template in a sequence-independent manner, suggesting that the enzymatic activity of RdRp is largely sequence independent.", [["nsp12", "GENE_OR_GENE_PRODUCT", 42, 47], ["RdRp", "GENE_OR_GENE_PRODUCT", 155, 159], ["nsp12", "PROTEIN", 42, 47], ["RNA template", "DNA", 66, 78], ["RdRp", "PROTEIN", 155, 159], ["Structural studies", "TEST", 0, 18], ["the enzymatic activity of RdRp", "PROBLEM", 129, 159]]], ["The cryoEM structure of SARS-CoV-2 RdRp in complex with an RNA template or its small molecule inhibitor, remdesivir, (Figure 4B ) revealed the molecular inhibitory mechanism of remdesivir (Yin et al., 2020) .", [["remdesivir", "CHEMICAL", 105, 115], ["remdesivir", "CHEMICAL", 177, 187], ["remdesivir", "CHEMICAL", 105, 115], ["remdesivir", "CHEMICAL", 177, 187], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["remdesivir", "SIMPLE_CHEMICAL", 105, 115], ["remdesivir", "SIMPLE_CHEMICAL", 177, 187], ["SARS-CoV-2 RdRp", "PROTEIN", 24, 39], ["SARS", "PROBLEM", 24, 28], ["CoV", "TEST", 29, 32], ["RdRp", "PROBLEM", 35, 39], ["an RNA template", "TREATMENT", 56, 71], ["its small molecule inhibitor", "TREATMENT", 75, 103], ["SARS", "OBSERVATION", 24, 28]]], ["Remdesivir monophosphate interacts with the primer strand and uridine of the template strand by base stacking and hydrogen bonding, respectively, at the center of the catalytic active site of RdRp (Yin et al., 2020) (Figure 4C) .", [["Remdesivir monophosphate", "CHEMICAL", 0, 24], ["uridine", "CHEMICAL", 62, 69], ["Remdesivir monophosphate", "CHEMICAL", 0, 24], ["uridine", "CHEMICAL", 62, 69], ["hydrogen", "CHEMICAL", 114, 122], ["Remdesivir monophosphate", "SIMPLE_CHEMICAL", 0, 24], ["uridine", "SIMPLE_CHEMICAL", 62, 69], ["primer strand", "DNA", 44, 57], ["catalytic active site", "PROTEIN", 167, 188], ["Remdesivir monophosphate", "TREATMENT", 0, 24], ["the primer strand", "TREATMENT", 40, 57], ["uridine of the template strand", "TREATMENT", 62, 92], ["hydrogen bonding", "OBSERVATION", 114, 130]]], ["The covalent incorporation of remdesivir monophosphate into the primer strand blocks the entry of nucleotide triphosphates to the active site, and terminates the transcriptional activity of RdRp (Yin et al., 2020) (Figure 4B ).", [["remdesivir monophosphate", "CHEMICAL", 30, 54], ["nucleotide triphosphates", "CHEMICAL", 98, 122], ["remdesivir monophosphate", "CHEMICAL", 30, 54], ["nucleotide triphosphates", "CHEMICAL", 98, 122], ["remdesivir monophosphate", "SIMPLE_CHEMICAL", 30, 54], ["nucleotide triphosphates", "SIMPLE_CHEMICAL", 98, 122], ["primer strand", "DNA", 64, 77], ["RdRp", "PROTEIN", 190, 194], ["The covalent incorporation of remdesivir monophosphate", "TREATMENT", 0, 54], ["the primer strand blocks", "TREATMENT", 60, 84], ["nucleotide triphosphates", "TREATMENT", 98, 122], ["active", "OBSERVATION_MODIFIER", 130, 136], ["site", "OBSERVATION_MODIFIER", 137, 141], ["transcriptional activity", "OBSERVATION", 162, 186]]], ["Other nucleotide analog compounds such as favipiravir, ribavirin, EIDD-1931, and EIDD-2801 may exhibit a similar mechanism of action as remdesivir to inhibit RdRp with non-obligate RNA chain termination (Elfiky, 2020; Sheahan et al., 2020; Wang Y. et al., 2020) .", [["nucleotide", "CHEMICAL", 6, 16], ["favipiravir", "CHEMICAL", 42, 53], ["ribavirin", "CHEMICAL", 55, 64], ["EIDD-1931", "CHEMICAL", 66, 75], ["EIDD-2801", "CHEMICAL", 81, 90], ["remdesivir", "CHEMICAL", 136, 146], ["nucleotide", "CHEMICAL", 6, 16], ["favipiravir", "CHEMICAL", 42, 53], ["ribavirin", "CHEMICAL", 55, 64], ["EIDD-1931", "CHEMICAL", 66, 75], ["EIDD-2801", "CHEMICAL", 81, 90], ["remdesivir", "CHEMICAL", 136, 146], ["favipiravir", "SIMPLE_CHEMICAL", 42, 53], ["ribavirin", "SIMPLE_CHEMICAL", 55, 64], ["EIDD-1931", "SIMPLE_CHEMICAL", 66, 75], ["EIDD-2801", "SIMPLE_CHEMICAL", 81, 90], ["remdesivir", "SIMPLE_CHEMICAL", 136, 146], ["RdRp", "PROTEIN", 158, 162], ["EIDD-2801", "SPECIES", 81, 90], ["Other nucleotide analog compounds", "TREATMENT", 0, 33], ["favipiravir", "TREATMENT", 42, 53], ["ribavirin", "TREATMENT", 55, 64]]], ["Although the U.S. Food and Drug Administration issued an emergency use authorization for remdesivir on May 1, 2020 for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe symptoms, the clinical efficacy of remdesivir against SARS-CoV-2 is not known yet.", [["remdesivir", "CHEMICAL", 262, 272], ["SARS", "DISEASE", 281, 285], ["remdesivir", "CHEMICAL", 262, 272], ["adults", "ORGANISM", 182, 188], ["children", "ORGANISM", 193, 201], ["remdesivir", "SIMPLE_CHEMICAL", 262, 272], ["SARS-CoV-2", "ORGANISM", 281, 291], ["children", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 281, 289], ["severe symptoms", "PROBLEM", 220, 235], ["SARS", "PROBLEM", 281, 285]]], ["Moreover, no significant clinical benefits of remdesivir against SARS-CoV-2 were observed in a recent randomized, double-blind, placebo-controlled, multicenter clinical trial (ClinicalTrials.gov, NCT04257656) .Viral ReplicationTaken together, compounds that target SARS-CoV-2 RdRp are largely nucleotide analogs because of their ability to form covalent bonds with the viral template RNA and block the catalytic active site of RdRp.CONCLUSIONSZoonotic coronavirus outbreaks such as COVID-19 can not only affect public health but also have a major impact on societies and the global economy.", [["remdesivir", "CHEMICAL", 46, 56], ["SARS", "DISEASE", 65, 69], ["nucleotide", "CHEMICAL", 293, 303], ["COVID-19", "CHEMICAL", 482, 490], ["remdesivir", "CHEMICAL", 46, 56], ["nucleotide", "CHEMICAL", 293, 303], ["remdesivir", "SIMPLE_CHEMICAL", 46, 56], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV-2", "ORGANISM", 265, 275], ["RdRp", "ORGANISM", 276, 280], ["RdRp.CONCLUSIONSZoonotic coronavirus", "ORGANISM", 427, 463], ["SARS-CoV-2 RdRp", "DNA", 265, 280], ["viral template RNA", "RNA", 369, 387], ["catalytic active site", "PROTEIN", 402, 423], ["SARS-CoV", "SPECIES", 65, 73], ["RdRp.CONCLUSIONSZoonotic coronavirus", "SPECIES", 427, 463], ["SARS", "PROBLEM", 65, 69], ["placebo", "TREATMENT", 128, 135], ["Viral ReplicationTaken", "TREATMENT", 210, 232], ["target SARS", "PROBLEM", 258, 269], ["CoV", "TEST", 270, 273], ["RdRp", "PROBLEM", 276, 280], ["largely nucleotide analogs", "TREATMENT", 285, 311], ["covalent bonds", "PROBLEM", 345, 359], ["the viral template RNA", "TREATMENT", 365, 387], ["block the catalytic active site", "PROBLEM", 392, 423], ["RdRp.CONCLUSIONSZoonotic coronavirus outbreaks", "PROBLEM", 427, 473], ["COVID", "TEST", 482, 487], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["viral template RNA", "OBSERVATION", 369, 387]]], ["Therefore, global cooperation among academic institutions, governments, and pharmaceutical companies is necessary to overcome COVID-19.CONCLUSIONSDespite intensive worldwide efforts undertaken by researchers to contain the spread of SARS-CoV-2, COVID-19 has attained pandemic status.", [["COVID-19.CONCLUSIONSDespite", "CHEMICAL", 126, 153], ["SARS", "DISEASE", 233, 237], ["COVID-19", "CHEMICAL", 245, 253], ["SARS-CoV-2", "ORGANISM", 233, 243], ["COVID-19", "ORGANISM", 245, 253], ["SARS-CoV", "SPECIES", 233, 241], ["COVID", "TEST", 126, 131], ["CoV", "TEST", 238, 241], ["COVID", "TEST", 245, 250]]], ["Considering that the development of an effective vaccine and new therapeutics are still in the early stages, repurposing FDA-approved and well-characterized drugs might be a pragmatic approach.", [["an effective vaccine", "TREATMENT", 36, 56], ["new therapeutics", "TREATMENT", 61, 77], ["drugs", "TREATMENT", 157, 162], ["a pragmatic approach", "TREATMENT", 172, 192], ["effective", "OBSERVATION_MODIFIER", 39, 48]]], ["Consequently, some of these drugs, such as remdesivir, have been approved for emergency use and some are being tested in clinical trials.", [["remdesivir", "CHEMICAL", 43, 53], ["remdesivir", "CHEMICAL", 43, 53], ["remdesivir", "SIMPLE_CHEMICAL", 43, 53], ["these drugs", "TREATMENT", 22, 33]]], ["In addition, combination treatment might be an approach which could achieve synergistic effects and reduce the risk of drug-resistant mutations.CONCLUSIONSA few studies have shown that some pre-existing drugs are effective for the treatment of patients with COVID-19.", [["COVID-19", "CHEMICAL", 258, 266], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 244, 252], ["combination treatment", "TREATMENT", 13, 34], ["an approach", "TREATMENT", 44, 55], ["synergistic effects", "PROBLEM", 76, 95], ["drug-resistant mutations", "PROBLEM", 119, 143], ["CONCLUSIONSA few studies", "TEST", 144, 168], ["some pre-existing drugs", "PROBLEM", 185, 208], ["COVID", "TEST", 258, 263], ["resistant mutations", "OBSERVATION", 124, 143], ["drugs", "OBSERVATION", 203, 208]]], ["In this review, we described the ongoing therapeutic strategies targeting various components of the SARS-CoV-2 life cycle ( Table 1 ).", [["SARS", "DISEASE", 100, 104], ["the SARS", "TEST", 96, 104], ["CoV", "TEST", 105, 108]]], ["In addition, we provided structural insights into the mechanism of action of well-characterized drugs targeting the interaction between hACE2 and the spike protein of SARS-CoV-2 for viral entry, as well as M pro and RdRp for viral replication.", [["hACE2", "GENE_OR_GENE_PRODUCT", 136, 141], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 167, 177], ["M pro", "GENE_OR_GENE_PRODUCT", 206, 211], ["RdRp", "GENE_OR_GENE_PRODUCT", 216, 220], ["hACE2", "PROTEIN", 136, 141], ["spike protein", "PROTEIN", 150, 163], ["SARS-CoV-2", "PROTEIN", 167, 177], ["M pro", "PROTEIN", 206, 211], ["RdRp", "PROTEIN", 216, 220], ["drugs", "TREATMENT", 96, 101], ["the interaction between hACE2", "PROBLEM", 112, 141], ["SARS", "PROBLEM", 167, 171], ["CoV", "TEST", 172, 175], ["viral entry", "PROBLEM", 182, 193], ["RdRp", "TREATMENT", 216, 220], ["viral replication", "TREATMENT", 225, 242], ["viral replication", "OBSERVATION", 225, 242]]], ["We believe that structural characterization can aid in developing an effective therapeutic strategy not only against COVID-19 but also other viral outbreaks in the future.AUTHOR CONTRIBUTIONSGJ and HS conceived, designed, did the literature review, provided, and wrote the manuscript.", [["COVID", "TEST", 117, 122]]]], "8c10cdea8b892f4e8824fa062b1a586db8246f19": [["IntroductionThe evolution rates of RNA viruses are amongst the highest of all organisms, making phylogenetic comparison between viral families often challenging.", [["RNA viruses", "PROBLEM", 35, 46], ["RNA viruses", "OBSERVATION", 35, 46]]], ["The Nidovirales order consists of four families that display broadly diverse features: from genome length spanning from 13 to 32 kb, to the set of encoded genes, or host range.", [["encoded genes", "DNA", 147, 160]]], ["Nonetheless, all nidoviruses share common characteristics such as the use of ribosomal frameshifting in order to translate a part of the nonstructural proteins, including the RNAdependent RNA polymerase and the helicase.", [["ribosomal", "ANATOMY", 77, 86], ["ribosomal", "CELLULAR_COMPONENT", 77, 86], ["nonstructural proteins", "PROTEIN", 137, 159], ["RNAdependent RNA polymerase", "PROTEIN", 175, 202], ["helicase", "PROTEIN", 211, 219], ["ribosomal frameshifting", "TREATMENT", 77, 100], ["the RNAdependent RNA polymerase", "TREATMENT", 171, 202], ["ribosomal frameshifting", "OBSERVATION", 77, 100]]], ["Moreover, they all code for a set of subgenomic (sg) mRNAs, and also for six essential enzyme/protein domains displaying the same linear organization along the genome: a 3C-like proteinase (3CLpro) flanked by 2 transmembrane domains (TM), then the RNA-dependent RNA polymerase (RdRp) and eventually a zinc-cluster binding domain (Zm) fused to a helicase belonging to superfamily 1 (HEL1).", [["zinc", "CHEMICAL", 301, 305], ["sg", "GENE_OR_GENE_PRODUCT", 49, 51], ["genome", "CELLULAR_COMPONENT", 160, 166], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 248, 276], ["helicase belonging to superfamily 1", "GENE_OR_GENE_PRODUCT", 345, 380], ["HEL1", "GENE_OR_GENE_PRODUCT", 382, 386], ["subgenomic (sg) mRNAs", "RNA", 37, 58], ["enzyme", "PROTEIN", 87, 93], ["protein domains", "PROTEIN", 94, 109], ["3C-like proteinase", "PROTEIN", 170, 188], ["3CLpro", "PROTEIN", 190, 196], ["transmembrane domains", "PROTEIN", 211, 232], ["TM", "PROTEIN", 234, 236], ["RNA-dependent RNA polymerase", "PROTEIN", 248, 276], ["RdRp", "PROTEIN", 278, 282], ["zinc-cluster binding domain", "PROTEIN", 301, 328], ["Zm", "PROTEIN", 330, 332], ["helicase", "PROTEIN", 345, 353], ["superfamily 1", "PROTEIN", 367, 380], ["HEL1", "PROTEIN", 382, 386], ["subgenomic (sg) mRNAs", "TREATMENT", 37, 58], ["six essential enzyme/protein domains", "TEST", 73, 109], ["a 3C-like proteinase (3CLpro)", "TREATMENT", 168, 197], ["the RNA", "TEST", 244, 251], ["a zinc-cluster binding domain (Zm)", "TREATMENT", 299, 333]]], ["This specific protein organization can be summarized as follows: Nter-TM2-3CLpro-TM3-RdRp-(Zm)-HEL1-Cter. two years after its discovery, counting at present (July 2014) 837 cases with the CFR of approximately 30%.", [["Nter", "PROTEIN", 65, 69], ["TM2", "PROTEIN", 70, 73], ["3CLpro", "PROTEIN", 74, 80], ["TM3", "PROTEIN", 81, 84], ["RdRp", "PROTEIN", 85, 89], ["Zm", "PROTEIN", 91, 93], ["HEL1", "PROTEIN", 95, 99], ["Cter", "PROTEIN", 100, 104], ["Nter", "TEST", 65, 69], ["TM2", "TEST", 70, 73], ["3CLpro", "TEST", 74, 80], ["TM3", "TEST", 81, 84], ["RdRp", "TEST", 85, 89], ["the CFR", "TEST", 184, 191]]], ["MERS-CoV seems to be also of a zoonotic origin, as antibodies against MERS-CoV have been detected in camels (Perera et al., 2013; Reusken et al., 2013) and a case of camel-to-human transmission has been recently reported (Azhar et al., 2014) .IntroductionThese two episodes confirm that few mutations allow zoonotic coronaviruses to jump the species barriers and threat human health worldwide.", [["camel-to-human transmission", "DISEASE", 166, 193], ["zoonotic coronaviruses", "DISEASE", 307, 329], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["camel", "ORGANISM", 166, 171], ["human", "ORGANISM", 175, 180], ["human", "ORGANISM", 370, 375], ["antibodies", "PROTEIN", 51, 61], ["MERS", "PROTEIN", 70, 74], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 370, 375], ["MERS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 70, 78], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 370, 375], ["CoV", "PROBLEM", 75, 78], ["few mutations", "PROBLEM", 287, 300], ["zoonotic coronaviruses", "PROBLEM", 307, 329], ["zoonotic", "OBSERVATION", 31, 39]]], ["To date, no specific treatment against CoVs is available.", [["CoVs", "CANCER", 39, 43], ["CoVs", "DNA", 39, 43], ["CoVs", "PROBLEM", 39, 43]]], ["A better understanding about how coronaviruses replicate in the host is therefore of critical importance to develop antiviral strategies aiming at controlling their spread and morbidity.IntroductionCoronavirus RNA replication and transcription are mediated by nonstructural proteins (nsps) encoded by two open reading frames, ORF1a and ORF1b (Fig. 1) .", [["coronaviruses", "ORGANISM", 33, 46], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 198, 209], ["nsps", "GENE_OR_GENE_PRODUCT", 284, 288], ["ORF1a", "GENE_OR_GENE_PRODUCT", 326, 331], ["ORF1b", "GENE_OR_GENE_PRODUCT", 336, 341], ["nonstructural proteins", "PROTEIN", 260, 282], ["nsps", "PROTEIN", 284, 288], ["open reading frames", "DNA", 305, 324], ["ORF1a", "DNA", 326, 331], ["ORF1b", "DNA", 336, 341], ["antiviral strategies", "TREATMENT", 116, 136], ["IntroductionCoronavirus RNA replication", "TREATMENT", 186, 225], ["ORF1a", "TREATMENT", 326, 331]]], ["These two ORFs are translated in a cap-dependent manner to yield two overlapping polyproteins referred as pp1a and pp1ab.", [["pp1a", "GENE_OR_GENE_PRODUCT", 106, 110], ["pp1ab", "GENE_OR_GENE_PRODUCT", 115, 120], ["ORFs", "DNA", 10, 14], ["pp1a", "PROTEIN", 106, 110], ["pp1ab", "PROTEIN", 115, 120], ["two overlapping polyproteins", "PROBLEM", 65, 93], ["polyproteins", "OBSERVATION", 81, 93]]], ["ORF1b is translated only upon a ribosomal frameshift (\u22121) near the 3 end of ORF1a, with \u223c30% efficacy (Snijder et al., 2003) .", [["ribosomal", "ANATOMY", 32, 41], ["ORF1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["ribosomal", "CELLULAR_COMPONENT", 32, 41], ["ORF1a", "GENE_OR_GENE_PRODUCT", 76, 81], ["ORF1b", "PROTEIN", 0, 5], ["ribosomal frameshift", "DNA", 32, 52], ["ORF1a", "DNA", 76, 81], ["a ribosomal frameshift", "TREATMENT", 30, 52], ["ribosomal frameshift", "OBSERVATION", 32, 52]]], ["Hence, the nsps encoded in ORF1b (nsp12 to nsp16) are expressed at lower levels compared to ORF1a-encoded products (nsp1 to nsp11).", [["nsps", "GENE_OR_GENE_PRODUCT", 11, 15], ["ORF1b", "GENE_OR_GENE_PRODUCT", 27, 32], ["nsp12", "GENE_OR_GENE_PRODUCT", 34, 39], ["nsp16", "GENE_OR_GENE_PRODUCT", 43, 48], ["ORF1a", "GENE_OR_GENE_PRODUCT", 92, 97], ["nsp1", "GENE_OR_GENE_PRODUCT", 116, 120], ["nsp11", "GENE_OR_GENE_PRODUCT", 124, 129], ["nsps", "DNA", 11, 15], ["ORF1b", "PROTEIN", 27, 32], ["nsp12", "PROTEIN", 34, 39], ["nsp16", "DNA", 43, 48], ["ORF1a", "PROTEIN", 92, 97], ["encoded products", "PROTEIN", 98, 114], ["nsp1", "PROTEIN", 116, 120], ["nsp11", "PROTEIN", 124, 129]]], ["After polyprotein maturation mediated by viral proteases, these nsps associate to form a large replicative/transcription complex (RTC) with yet unknown cellular factors.", [["cellular", "ANATOMY", 152, 160], ["nsps", "GENE_OR_GENE_PRODUCT", 64, 68], ["RTC", "GENE_OR_GENE_PRODUCT", 130, 133], ["cellular", "CELL", 152, 160], ["viral proteases", "PROTEIN", 41, 56], ["nsps", "PROTEIN", 64, 68], ["transcription complex", "PROTEIN", 107, 128], ["RTC", "PROTEIN", 130, 133], ["cellular factors", "PROTEIN", 152, 168], ["polyprotein maturation", "TREATMENT", 6, 28], ["viral proteases", "PROBLEM", 41, 56], ["a large replicative/transcription complex", "TREATMENT", 87, 128], ["viral proteases", "OBSERVATION", 41, 56], ["large", "OBSERVATION_MODIFIER", 89, 94], ["replicative", "OBSERVATION", 95, 106], ["cellular factors", "OBSERVATION", 152, 168]]], ["The RTC not only entails the synthesis of new viral genomes from a full-length negative-stranded template, but also a nested set of so-called subgenomic (sg) mRNAs encoding structural and accessory proteins ( Fig. 1 ) (Pasternak et al., 2006) .", [["RTC", "PROTEIN", 4, 7], ["viral genomes", "DNA", 46, 59], ["full-length negative-stranded template", "DNA", 67, 105], ["subgenomic (sg) mRNAs", "RNA", 142, 163], ["structural and accessory proteins", "PROTEIN", 173, 206], ["Fig. 1", "PROTEIN", 209, 215], ["new viral genomes", "PROBLEM", 42, 59], ["stranded template", "PROBLEM", 88, 105], ["new", "OBSERVATION_MODIFIER", 42, 45], ["viral genomes", "OBSERVATION", 46, 59], ["stranded template", "OBSERVATION_MODIFIER", 88, 105]]], ["Coronavirus genome encodes for a total of 16 nsps, many having predicted and/or experimentally established function, and some others with yet defined functions.IntroductionAmong them, the RNA-dependent RNA polymerase (RdRp) encoded by nsp12 plays a central role in both RNA replication and transcription of the viral RNA.", [["nsps", "GENE_OR_GENE_PRODUCT", 45, 49], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 188, 216], ["RdRp", "GENE_OR_GENE_PRODUCT", 218, 222], ["nsp12", "GENE_OR_GENE_PRODUCT", 235, 240], ["Coronavirus genome", "DNA", 0, 18], ["nsps", "PROTEIN", 45, 49], ["RNA-dependent RNA polymerase", "PROTEIN", 188, 216], ["RdRp", "PROTEIN", 218, 222], ["nsp12", "PROTEIN", 235, 240], ["viral RNA", "RNA", 311, 320], ["Coronavirus genome encodes", "PROBLEM", 0, 26], ["the RNA", "TEST", 184, 191], ["both RNA replication", "TREATMENT", 265, 285], ["the viral RNA", "PROBLEM", 307, 320], ["RNA replication", "OBSERVATION", 270, 285], ["viral RNA", "OBSERVATION", 311, 320]]], ["In general, RNA virus RdRps deal with genomes spanning from 5 to 15 kb in length.", [["RdRps", "GENE_OR_GENE_PRODUCT", 22, 27], ["RNA virus", "OBSERVATION", 12, 21]]], ["Coronavirus RdRps stand out as they not only replicate large RNA molecules (up to 32 kb) but also transcribe the nested set of sg mRNAs.", [["sg", "GENE_OR_GENE_PRODUCT", 127, 129], ["RdRps", "PROTEIN", 12, 17], ["RNA molecules", "RNA", 61, 74], ["sg mRNAs", "RNA", 127, 135], ["Coronavirus RdRps", "TREATMENT", 0, 17], ["large RNA molecules", "PROBLEM", 55, 74], ["sg mRNAs", "OBSERVATION", 127, 135]]], ["Coronaviruses also possess other activities typically found in (+) RNA viruses, such as helicase and capping enzymes.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["helicase and capping enzymes", "PROTEIN", 88, 116], ["Coronaviruses", "PROBLEM", 0, 13], ["RNA viruses", "PROBLEM", 67, 78], ["capping enzymes", "TEST", 101, 116]]], ["On the other hand, less common or even unique RNA-processing activities are associated with other nsps, such as two nuclease activities: a 3 -5 Exonuclease (ExoN) in the amino-terminal domain of nsp14 (Minskaia et al., 2006) , and an endoribonuclease (NendoU) in nsp15 (Ivanov et al., 2004a) .", [["nsps", "GENE_OR_GENE_PRODUCT", 98, 102], ["Exonuclease", "GENE_OR_GENE_PRODUCT", 144, 155], ["ExoN", "GENE_OR_GENE_PRODUCT", 157, 161], ["nsp14", "GENE_OR_GENE_PRODUCT", 195, 200], ["NendoU", "GENE_OR_GENE_PRODUCT", 252, 258], ["nsps", "PROTEIN", 98, 102], ["Exonuclease", "PROTEIN", 144, 155], ["ExoN", "PROTEIN", 157, 161], ["amino-terminal domain", "PROTEIN", 170, 191], ["nsp14", "PROTEIN", 195, 200], ["endoribonuclease", "PROTEIN", 234, 250], ["NendoU", "PROTEIN", 252, 258], ["nsp15", "PROTEIN", 263, 268], ["other nsps", "PROBLEM", 92, 102]]], ["While the role of the former begins to be well established in proofreading, the role of the latter is still unclear.IntroductionCoronaviruses also encode for another group of unique and interesting proteins: nsp7 to nsp10, which are all small proteins with no known protein homolog.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 128, 141], ["nsp7", "GENE_OR_GENE_PRODUCT", 208, 212], ["nsp10", "GENE_OR_GENE_PRODUCT", 216, 221], ["Coronaviruses", "PROTEIN", 128, 141], ["nsp7", "PROTEIN", 208, 212], ["nsp10", "PROTEIN", 216, 221], ["protein homolog", "PROTEIN", 266, 281], ["known protein homolog", "PROBLEM", 260, 281]]], ["Initially, they were all described as RNA binding proteins (Egloff et al., 2004; Su et al., 2006; Zhai et al., 2005) .", [["RNA binding proteins", "PROTEIN", 38, 58]]], ["In more recent works, three of them (nsp7, nsp8 and nsp10) were shown to act as activating co-factors of the polymerase (nsp7, nsp8), the 3 -5 ExoN (nsp10) and the 2 O-methyltransferase (MTase) (nsp10) activities.IntroductionIn this review, we present the current state of knowledge on SARS-CoV enzymes involved in RNA synthesis, proofreading, and capping.Formation of the replicative/transcription complex (RTC)In coronaviruses, replication refers to viral genome amplification, while transcription refers to the synthesis of nested set of sg mRNAs.", [["O", "CHEMICAL", 166, 167], ["nsp7", "GENE_OR_GENE_PRODUCT", 37, 41], ["nsp8", "GENE_OR_GENE_PRODUCT", 43, 47], ["nsp10", "GENE_OR_GENE_PRODUCT", 52, 57], ["nsp7", "GENE_OR_GENE_PRODUCT", 121, 125], ["nsp8", "GENE_OR_GENE_PRODUCT", 127, 131], ["3 -5", "GENE_OR_GENE_PRODUCT", 138, 142], ["ExoN", "GENE_OR_GENE_PRODUCT", 143, 147], ["nsp10", "GENE_OR_GENE_PRODUCT", 149, 154], ["2 O-methyltransferase", "GENE_OR_GENE_PRODUCT", 164, 185], ["MTase", "GENE_OR_GENE_PRODUCT", 187, 192], ["nsp10", "GENE_OR_GENE_PRODUCT", 195, 200], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 286, 294], ["sg", "GENE_OR_GENE_PRODUCT", 541, 543], ["nsp7", "PROTEIN", 37, 41], ["nsp8", "PROTEIN", 43, 47], ["nsp10", "PROTEIN", 52, 57], ["polymerase", "PROTEIN", 109, 119], ["nsp7", "PROTEIN", 121, 125], ["nsp8", "PROTEIN", 127, 131], ["ExoN", "PROTEIN", 143, 147], ["nsp10", "PROTEIN", 149, 154], ["2 O-methyltransferase", "PROTEIN", 164, 185], ["MTase", "PROTEIN", 187, 192], ["nsp10", "PROTEIN", 195, 200], ["SARS-CoV enzymes", "PROTEIN", 286, 302], ["replicative/transcription complex", "PROTEIN", 373, 406], ["RTC", "PROTEIN", 408, 411], ["sg mRNAs", "RNA", 541, 549], ["SARS-CoV", "SPECIES", 286, 294], ["the polymerase", "TEST", 105, 119], ["the 2 O-methyltransferase (MTase)", "TREATMENT", 160, 193], ["CoV enzymes", "TEST", 291, 302], ["RNA synthesis", "TREATMENT", 315, 328], ["capping", "TREATMENT", 348, 355], ["the replicative/transcription complex", "TREATMENT", 369, 406], ["coronaviruses", "PROBLEM", 415, 428], ["viral genome amplification", "TREATMENT", 452, 478], ["replicative", "OBSERVATION_MODIFIER", 373, 384], ["viral genome", "OBSERVATION", 452, 464]]], ["Both processes are mediated by the RTC, which is located in a membranous network, called reticulo-vesicular network, which arises from the rearrangements of endoplasmic reticulum (ER) membranes (Knoops et al., 2008) .", [["membranous network", "ANATOMY", 62, 80], ["reticulo-vesicular network", "ANATOMY", 89, 115], ["endoplasmic reticulum", "ANATOMY", 157, 178], ["ER) membranes", "ANATOMY", 180, 193], ["RTC", "GENE_OR_GENE_PRODUCT", 35, 38], ["membranous network", "MULTI-TISSUE_STRUCTURE", 62, 80], ["vesicular network", "MULTI-TISSUE_STRUCTURE", 98, 115], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 157, 178], ["ER", "CELLULAR_COMPONENT", 180, 182], ["membranes", "CELLULAR_COMPONENT", 184, 193], ["RTC", "PROTEIN", 35, 38], ["RTC", "OBSERVATION_MODIFIER", 35, 38], ["membranous", "OBSERVATION", 62, 72], ["vesicular network", "OBSERVATION", 98, 115], ["endoplasmic reticulum", "OBSERVATION", 157, 178]]], ["Nsp3, through its transmembrane domain and together with two transmembrane proteins (nsp4 and nsp6) contribute to the anchoring of the RTC to membranes.", [["transmembrane", "ANATOMY", 18, 31], ["transmembrane", "ANATOMY", 61, 74], ["membranes", "ANATOMY", 142, 151], ["Nsp3", "GENE_OR_GENE_PRODUCT", 0, 4], ["transmembrane", "CELLULAR_COMPONENT", 18, 31], ["transmembrane", "CELLULAR_COMPONENT", 61, 74], ["nsp4", "GENE_OR_GENE_PRODUCT", 85, 89], ["nsp6", "GENE_OR_GENE_PRODUCT", 94, 98], ["RTC", "GENE_OR_GENE_PRODUCT", 135, 138], ["membranes", "CELLULAR_COMPONENT", 142, 151], ["Nsp3", "PROTEIN", 0, 4], ["transmembrane domain", "PROTEIN", 18, 38], ["transmembrane proteins", "PROTEIN", 61, 83], ["nsp4", "PROTEIN", 85, 89], ["nsp6", "PROTEIN", 94, 98], ["RTC", "PROTEIN", 135, 138], ["Nsp3", "PROBLEM", 0, 4], ["two transmembrane proteins", "TEST", 57, 83], ["nsp4", "PROBLEM", 85, 89], ["RTC", "ANATOMY", 135, 138]]], ["It may be formed after viral replication cycles in order to hide replication intermediates (dsRNA) from innate immunity sensors (Knoops et al., 2008) .The replication/transcription complex catalytic coreAs for all (+) RNA viruses, the replication catalytic core contains at least a helicase and an RNA-dependent RNA polymerase (RdRp).The NTPase/helicase nsp13A helicase domain of superfamily 1 helicases is harbored in SARS-CoV nsp13 C-terminal half (Ivanov et al., 2004b) .", [["C", "CHEMICAL", 434, 435], ["NTPase", "GENE_OR_GENE_PRODUCT", 338, 344], ["transcription complex", "PROTEIN", 167, 188], ["catalytic coreAs", "PROTEIN", 189, 205], ["replication catalytic core", "DNA", 235, 261], ["helicase", "PROTEIN", 282, 290], ["RNA-dependent RNA polymerase", "PROTEIN", 298, 326], ["RdRp", "PROTEIN", 328, 332], ["NTPase", "PROTEIN", 338, 344], ["helicase nsp13A helicase domain", "PROTEIN", 345, 376], ["superfamily 1 helicases", "PROTEIN", 380, 403], ["SARS-CoV", "SPECIES", 419, 427], ["viral replication cycles", "TREATMENT", 23, 47], ["The replication/transcription complex catalytic coreAs", "TREATMENT", 151, 205], ["all (+) RNA viruses", "PROBLEM", 210, 229], ["the replication catalytic core", "TREATMENT", 231, 261], ["a helicase", "TREATMENT", 280, 290], ["an RNA", "TEST", 295, 301], ["The NTPase/helicase nsp", "TREATMENT", 334, 357], ["CoV nsp", "TEST", 424, 431], ["may be", "UNCERTAINTY", 3, 9], ["viral replication", "OBSERVATION", 23, 40], ["RNA viruses", "OBSERVATION", 218, 229]]], ["SARS-CoV nsp13 is able to unwind dsRNA (and dsDNA) in a 5 -3 direction and required energy obtained from the hydrolysis of any NTPs and dNTPs (Ivanov et al., 2004b; Lee et al., 2010; Tanner et al., 2003) .", [["SARS", "DISEASE", 0, 4], ["NTPs", "CHEMICAL", 127, 131], ["dNTPs", "CHEMICAL", 136, 141], ["NTPs", "CHEMICAL", 127, 131], ["dNTPs", "CHEMICAL", 136, 141], ["SARS-CoV nsp13", "GENE_OR_GENE_PRODUCT", 0, 14], ["dsDNA", "CELLULAR_COMPONENT", 44, 49], ["NTPs", "SIMPLE_CHEMICAL", 127, 131], ["dNTPs", "SIMPLE_CHEMICAL", 136, 141], ["SARS-CoV nsp13", "PROTEIN", 0, 14], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["any NTPs", "TREATMENT", 123, 131], ["dNTPs", "TREATMENT", 136, 141]]], ["The N-terminal region of nsp13 contains a zinc-binding domain forms of 12 conserved cysteine and histidine residues.", [["zinc", "CHEMICAL", 42, 46], ["histidine", "CHEMICAL", 97, 106], ["N", "CHEMICAL", 4, 5], ["zinc", "CHEMICAL", 42, 46], ["cysteine", "CHEMICAL", 84, 92], ["histidine", "CHEMICAL", 97, 106], ["nsp13", "GENE_OR_GENE_PRODUCT", 25, 30], ["cysteine", "AMINO_ACID", 84, 92], ["histidine", "AMINO_ACID", 97, 106], ["N-terminal region", "PROTEIN", 4, 21], ["nsp13", "PROTEIN", 25, 30], ["zinc-binding domain", "PROTEIN", 42, 61], ["The N-terminal region of nsp13", "PROBLEM", 0, 30], ["a zinc-binding domain forms", "TREATMENT", 40, 67], ["histidine residues", "TREATMENT", 97, 115], ["-terminal", "OBSERVATION_MODIFIER", 5, 14], ["histidine residues", "OBSERVATION", 97, 115]]], ["This domain is conserved in all nidoviruses and is critical for the human CoV-229E (HCoV-229E) helicase activity in vitro (Seybert et al., 2005) .", [["nidoviruses", "CANCER", 32, 43], ["human", "ORGANISM", 68, 73], ["CoV-229E", "GENE_OR_GENE_PRODUCT", 74, 82], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 84, 93], ["human", "SPECIES", 68, 73], ["human CoV-229E (HCoV-229E", "SPECIES", 68, 93], ["the human CoV", "TEST", 64, 77], ["HCoV", "TEST", 84, 88]]], ["In order to promote dsRNA unwinding, an RNA substrate of at least five nucleotides in length is required and an estimated unwinding rate of \u223c280 base-pairs per second has been calculated, which is similar to other helicases (Adedeji et al., 2012) .", [["nucleotides", "CHEMICAL", 71, 82], ["dsRNA unwinding", "TREATMENT", 20, 35], ["an RNA substrate", "TEST", 37, 53], ["an estimated unwinding rate", "TEST", 109, 136], ["dsRNA unwinding", "OBSERVATION", 20, 35]]], ["Interestingly, nsp13-mediated helicase activity has been reported to be stimulated 2-fold by nsp12 RdRp through direct protein/protein interaction (Adedeji et al., 2012) .Nsp12RdRp and its cofactors nsp7 and nsp8: a processive polymerase complexNsp12Nsp12 is an RNA-dependent RNA polymerase (RdRp) containing all conserved motifs (named with letters from A to F) of canonical RdRps (Poch et al., 1989) .", [["nsp13", "GENE_OR_GENE_PRODUCT", 15, 20], ["nsp12 RdRp", "GENE_OR_GENE_PRODUCT", 93, 103], ["Nsp12RdRp", "GENE_OR_GENE_PRODUCT", 171, 180], ["nsp7", "GENE_OR_GENE_PRODUCT", 199, 203], ["nsp8", "GENE_OR_GENE_PRODUCT", 208, 212], ["complexNsp12Nsp12", "GENE_OR_GENE_PRODUCT", 238, 255], ["RdRps", "GENE_OR_GENE_PRODUCT", 376, 381], ["nsp13", "PROTEIN", 15, 20], ["helicase", "PROTEIN", 30, 38], ["nsp12 RdRp", "PROTEIN", 93, 103], ["Nsp12RdRp", "PROTEIN", 171, 180], ["nsp7", "PROTEIN", 199, 203], ["nsp8", "PROTEIN", 208, 212], ["processive polymerase complexNsp12Nsp12", "PROTEIN", 216, 255], ["RNA-dependent RNA polymerase", "PROTEIN", 262, 290], ["RdRp", "PROTEIN", 292, 296], ["canonical RdRps", "PROTEIN", 366, 381], ["nsp13", "TEST", 15, 20], ["nsp", "PROBLEM", 93, 96], ["a processive polymerase complexNsp12Nsp12", "PROBLEM", 214, 255], ["an RNA-dependent RNA polymerase", "PROBLEM", 259, 290]]], ["The polymerase active site (Ser-Asp-Asp within motif C) is conserved in all nidoviruses.", [["Ser", "CHEMICAL", 28, 31], ["Asp", "CHEMICAL", 32, 35], ["Asp", "CHEMICAL", 36, 39], ["nidoviruses", "PATHOLOGICAL_FORMATION", 76, 87], ["polymerase active site", "DNA", 4, 26], ["motif C", "PROTEIN", 47, 54], ["The polymerase active site", "PROBLEM", 0, 26], ["Ser-Asp-Asp within motif C", "TEST", 28, 54], ["active", "OBSERVATION_MODIFIER", 15, 21], ["site", "OBSERVATION_MODIFIER", 22, 26]]], ["Nsp12 also carries the motif G (Gorbalenya et al., 2002) , which is a signature sequence of RdRps that initiate RNA synthesis in a primer-dependent manner (Te Velthuis et al., 2010) .", [["Nsp12", "GENE_OR_GENE_PRODUCT", 0, 5], ["RdRps", "GENE_OR_GENE_PRODUCT", 92, 97], ["Nsp12", "PROTEIN", 0, 5], ["RdRps", "PROTEIN", 92, 97], ["RNA synthesis", "TREATMENT", 112, 125]]], ["The in vitro nsp12 polymerase activity appeared weak and non processive (Cheng et al., 2005; Te Velthuis et al., 2010) , at odds with the efficient replication of the very large RNA genome in vivo.", [["nsp12", "GENE_OR_GENE_PRODUCT", 13, 18], ["nsp12 polymerase", "PROTEIN", 13, 29], ["RNA genome", "DNA", 178, 188], ["weak", "PROBLEM", 48, 52], ["weak", "OBSERVATION_MODIFIER", 48, 52], ["very", "OBSERVATION_MODIFIER", 167, 171], ["large", "OBSERVATION_MODIFIER", 172, 177], ["RNA genome", "OBSERVATION", 178, 188]]], ["Protein/protein interaction maps were established for SARS-CoV and among others, the nsp12/nsp8 interaction was recovered .", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["nsp12", "GENE_OR_GENE_PRODUCT", 85, 90], ["nsp8", "GENE_OR_GENE_PRODUCT", 91, 95], ["nsp12", "PROTEIN", 85, 90], ["nsp8", "PROTEIN", 91, 95], ["SARS-CoV", "SPECIES", 54, 62], ["Protein/protein interaction maps", "TEST", 0, 32], ["SARS", "PROBLEM", 54, 58], ["the nsp12", "TEST", 81, 90]]], ["The interaction between SARS-CoV nsp7 and nsp8 is also ascertained as they were co-crystallized and proposed to act as processivity factor for nsp12 (Zhai et al., 2005) .Nsp12In our lab, we tested this hypothesis and detected activation of the primer-dependent polymerase activity of nsp12 upon addition of nsp7 and nsp8 (Subissi et al., 2014b) .", [["SARS-CoV nsp7", "GENE_OR_GENE_PRODUCT", 24, 37], ["nsp8", "GENE_OR_GENE_PRODUCT", 42, 46], ["nsp12", "GENE_OR_GENE_PRODUCT", 143, 148], ["nsp12", "GENE_OR_GENE_PRODUCT", 284, 289], ["nsp7", "GENE_OR_GENE_PRODUCT", 307, 311], ["nsp8", "GENE_OR_GENE_PRODUCT", 316, 320], ["SARS-CoV nsp7", "PROTEIN", 24, 37], ["nsp8", "PROTEIN", 42, 46], ["processivity factor", "PROTEIN", 119, 138], ["nsp12", "PROTEIN", 284, 289], ["nsp7", "PROTEIN", 307, 311], ["nsp8", "PROTEIN", 316, 320], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "TEST", 24, 28], ["CoV nsp7", "TEST", 29, 37], ["the primer", "PROBLEM", 240, 250], ["nsp7", "PROBLEM", 307, 311]]], ["This nsp7/nsp8/nsp12 complex is also able to synthesize RNA de novo in a processive fashion at least up to 340 nucleotides.", [["nucleotides", "CHEMICAL", 111, 122], ["nsp7", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsp8", "GENE_OR_GENE_PRODUCT", 10, 14], ["nsp12", "GENE_OR_GENE_PRODUCT", 15, 20], ["nsp7", "PROTEIN", 5, 9], ["nsp8", "PROTEIN", 10, 14], ["nsp12 complex", "PROTEIN", 15, 28], ["This nsp7", "TEST", 0, 9], ["/nsp8/nsp12 complex", "PROBLEM", 9, 28]]], ["To better understand how nsp7 and nsp8 activate and confer processivity to the RNA-synthesizing activity of nsp12, we used biochemical assays and a reverse genetics approach.", [["nsp7", "GENE_OR_GENE_PRODUCT", 25, 29], ["nsp8", "GENE_OR_GENE_PRODUCT", 34, 38], ["nsp12", "GENE_OR_GENE_PRODUCT", 108, 113], ["nsp7", "PROTEIN", 25, 29], ["nsp8", "PROTEIN", 34, 38], ["nsp12", "PROTEIN", 108, 113], ["biochemical assays", "TEST", 123, 141], ["a reverse genetics approach", "TREATMENT", 146, 173]]], ["We identified three amino acids in SARS-CoV nsp7 (K7, H36, and N37) that confer RNA-binding properties to the polymerase complex and that are also important for virus replication in vivo.", [["amino acids", "CHEMICAL", 20, 31], ["amino acids", "CHEMICAL", 20, 31], ["amino acids", "AMINO_ACID", 20, 31], ["SARS-CoV nsp7", "GENE_OR_GENE_PRODUCT", 35, 48], ["K7", "GENE_OR_GENE_PRODUCT", 50, 52], ["K7", "PROTEIN", 50, 52], ["H36", "PROTEIN", 54, 57], ["N37", "PROTEIN", 63, 66], ["polymerase complex", "PROTEIN", 110, 128], ["SARS-CoV", "SPECIES", 35, 43], ["three amino acids", "TEST", 14, 31], ["SARS", "TEST", 35, 39], ["CoV nsp7", "TEST", 40, 48], ["H36", "TEST", 54, 57], ["RNA", "TEST", 80, 83], ["virus replication", "TREATMENT", 161, 178], ["amino acids", "OBSERVATION", 20, 31]]], ["Our study also pointed out three nsp8 residues (K58, P183, and R190) critical for SARS-CoV genome replication.", [["nsp8", "GENE_OR_GENE_PRODUCT", 33, 37], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["nsp8 residues", "PROTEIN", 33, 46], ["P183", "PROTEIN", 53, 57], ["R190", "PROTEIN", 63, 67], ["SARS-CoV", "SPECIES", 82, 90], ["Our study", "TEST", 0, 9], ["K58", "TEST", 48, 51], ["P183", "TEST", 53, 57], ["SARS", "PROBLEM", 82, 86], ["CoV genome replication", "TREATMENT", 87, 109]]], ["The first one is involved in the interaction of the polymerase complex with RNA, while the two others are essential for nsp8/nsp12 interaction.", [["nsp8", "GENE_OR_GENE_PRODUCT", 120, 124], ["nsp12", "GENE_OR_GENE_PRODUCT", 125, 130], ["polymerase complex", "PROTEIN", 52, 70], ["nsp8", "PROTEIN", 120, 124], ["nsp12", "PROTEIN", 125, 130], ["nsp8/nsp12 interaction", "TREATMENT", 120, 142]]], ["The two open reading frames (ORFs) of the genomic mRNA are translated by a cap-dependent mechanism, yielding two polyproteins, pp1a and pp1ab, the latter requiring \u22121 ribosomal frameshifting (FS) near the 3 end of ORF1a.", [["pp1a", "GENE_OR_GENE_PRODUCT", 127, 131], ["pp1ab", "GENE_OR_GENE_PRODUCT", 136, 141], ["ORF1a", "GENE_OR_GENE_PRODUCT", 214, 219], ["open reading frames", "DNA", 8, 27], ["ORFs", "DNA", 29, 33], ["genomic mRNA", "RNA", 42, 54], ["polyproteins", "PROTEIN", 113, 125], ["pp1a", "PROTEIN", 127, 131], ["pp1ab", "PROTEIN", 136, 141], ["ORF1a", "DNA", 214, 219], ["a cap-dependent mechanism", "PROBLEM", 73, 98], ["pp1a", "TEST", 127, 131], ["pp1ab", "TREATMENT", 136, 141], ["\u22121 ribosomal frameshifting", "TREATMENT", 164, 190], ["genomic mRNA", "OBSERVATION", 42, 54], ["ribosomal frameshifting", "OBSERVATION", 167, 190]]], ["Subsequently, the two polyproteins are cleaved by two or three ORF1a-encoded proteases to release a total of 16 nonstructural proteins (nsp1-nsp16).", [["ORF1a", "GENE_OR_GENE_PRODUCT", 63, 68], ["nsp1-nsp16", "GENE_OR_GENE_PRODUCT", 136, 146], ["ORF1a", "PROTEIN", 63, 68], ["proteases", "PROTEIN", 77, 86], ["16 nonstructural proteins", "PROTEIN", 109, 134], ["nsp1", "PROTEIN", 136, 140], ["nsp16", "PROTEIN", 141, 146], ["the two polyproteins", "TREATMENT", 14, 34], ["nsp1", "TEST", 136, 140], ["polyproteins", "OBSERVATION", 22, 34]]], ["Then, they assemble with modified intracellular membranes (Knoops et al., 2008) to form the replication/transcription complex (RTC).", [["intracellular membranes", "ANATOMY", 34, 57], ["intracellular membranes", "CELLULAR_COMPONENT", 34, 57], ["transcription complex", "PROTEIN", 104, 125], ["RTC", "PROTEIN", 127, 130], ["the replication/transcription complex", "TREATMENT", 88, 125]]], ["This huge RTC not only entails the synthesis of new genomes, but also produces a nested set of subgenomic (sg) mRNAs encoding structural and accessory proteins.", [["RTC", "PROTEIN", 10, 13], ["subgenomic (sg) mRNAs", "RNA", 95, 116], ["structural and accessory proteins", "PROTEIN", 126, 159], ["This huge RTC", "TREATMENT", 0, 13], ["a nested set of subgenomic (sg) mRNAs encoding structural and accessory proteins", "PROBLEM", 79, 159], ["new", "OBSERVATION_MODIFIER", 48, 51], ["genomes", "OBSERVATION", 52, 59]]], ["The gray ball represents the cap structure.", [["gray ball", "OBSERVATION", 4, 13], ["cap structure", "OBSERVATION", 29, 42]]], ["Nonstructural, structural and accessory genes are represented in blue, green and purple, respectively.Nsp123.3.", [["Nsp123.3", "CHEMICAL", 102, 110], ["Nonstructural, structural and accessory genes", "DNA", 0, 45], ["Nsp", "TEST", 102, 105], ["accessory genes", "OBSERVATION", 30, 45]]], ["Nsp7 and nsp8, priming and/or processivity factors for nsp12?Nsp12Nsp8 of SARS-CoV, feline CoV (FCoV) and HCoV-229E were previously shown to exhibit RNA polymerase activities (Imbert et al., 2006; Te Velthuis et al., 2010; Xiao et al., 2012) .", [["Nsp7", "GENE_OR_GENE_PRODUCT", 0, 4], ["nsp8", "GENE_OR_GENE_PRODUCT", 9, 13], ["nsp12", "GENE_OR_GENE_PRODUCT", 55, 60], ["Nsp12Nsp8", "GENE_OR_GENE_PRODUCT", 61, 70], ["SARS-CoV", "ORGANISM", 74, 82], ["feline CoV", "ORGANISM", 84, 94], ["FCoV", "GENE_OR_GENE_PRODUCT", 96, 100], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 106, 115], ["Nsp7", "PROTEIN", 0, 4], ["nsp8", "PROTEIN", 9, 13], ["processivity factors", "PROTEIN", 30, 50], ["nsp12", "PROTEIN", 55, 60], ["Nsp12Nsp8", "PROTEIN", 61, 70], ["FCoV", "PROTEIN", 96, 100], ["HCoV-229E", "DNA", 106, 115], ["RNA polymerase", "PROTEIN", 149, 163], ["feline CoV", "SPECIES", 84, 94], ["SARS-CoV", "SPECIES", 74, 82], ["feline CoV", "SPECIES", 84, 94], ["FCoV", "SPECIES", 96, 100], ["HCoV-229E", "SPECIES", 106, 115], ["Nsp7", "TEST", 0, 4], ["nsp8", "PROBLEM", 9, 13], ["processivity factors", "PROBLEM", 30, 50], ["nsp12", "PROBLEM", 55, 60], ["SARS", "PROBLEM", 74, 78], ["CoV", "TEST", 79, 82], ["HCoV", "TEST", 106, 110], ["RNA polymerase activities", "PROBLEM", 149, 174], ["SARS", "OBSERVATION", 74, 78]]], ["Moreover, the nsp8 N-terminal amino-acid composition appears to be important for this activity.", [["N-terminal amino-acid", "CHEMICAL", 19, 40], ["nsp8", "CHEMICAL", 14, 18], ["N", "CHEMICAL", 19, 20], ["amino-acid", "CHEMICAL", 30, 40], ["nsp8", "GENE_OR_GENE_PRODUCT", 14, 18], ["amino-acid", "AMINO_ACID", 30, 40], ["nsp8 N", "PROTEIN", 14, 20], ["the nsp8", "TEST", 10, 18], ["terminal amino-acid composition", "TREATMENT", 21, 52]]], ["Indeed, SARS-CoV nsp8 with an N-terminal His tag can synthesize only short oligonucleotides (<6 nt) , while SARS-CoV and FCoV nsp8 without this tag are able to synthesize much longer RNA (Te Velthuis et al., 2010; Xiao et al., 2012) .", [["N-", "CHEMICAL", 30, 32], ["His", "CHEMICAL", 41, 44], ["SARS-CoV nsp8", "GENE_OR_GENE_PRODUCT", 8, 21], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 108, 116], ["FCoV nsp8", "GENE_OR_GENE_PRODUCT", 121, 130], ["SARS-CoV nsp8", "PROTEIN", 8, 21], ["N-terminal His tag", "PROTEIN", 30, 48], ["SARS-CoV and FCoV nsp8", "DNA", 108, 130], ["SARS-CoV", "SPECIES", 8, 16], ["SARS-CoV", "SPECIES", 108, 116], ["short oligonucleotides", "PROBLEM", 69, 91], ["SARS", "PROBLEM", 108, 112], ["FCoV", "PROBLEM", 121, 125], ["this tag", "PROBLEM", 139, 147]]], ["Upon addition of nsp7 to these \"improved\" recombinant nsp8, the RNA polymerase activity is stimulated (Te Velthuis et al., 2010; Xiao et al., 2012) .", [["nsp7", "GENE_OR_GENE_PRODUCT", 17, 21], ["nsp8", "GENE_OR_GENE_PRODUCT", 54, 58], ["nsp7", "PROTEIN", 17, 21], ["nsp8", "PROTEIN", 54, 58], ["RNA polymerase", "PROTEIN", 64, 78], ["nsp7", "TREATMENT", 17, 21], ["the RNA polymerase activity", "PROBLEM", 60, 87]]], ["Notably, the processing intermediates nsp7-nsp10 of HCoV-229E is also able to synthesize oligoribonucleotides (Xiao et al., 2012) .Nsp12Since nsp12 likely synthesizes RNA in a primer-dependent manner (Gorbalenya et al., 2002) , nsp8 was proposed to act as a primase for nsp12.", [["HCoV-229E", "CHEMICAL", 52, 61], ["nsp7-nsp10", "GENE_OR_GENE_PRODUCT", 38, 48], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 52, 61], ["Nsp12Since", "GENE_OR_GENE_PRODUCT", 131, 141], ["nsp12", "GENE_OR_GENE_PRODUCT", 142, 147], ["nsp8", "GENE_OR_GENE_PRODUCT", 228, 232], ["nsp12", "GENE_OR_GENE_PRODUCT", 270, 275], ["nsp7", "PROTEIN", 38, 42], ["HCoV", "PROTEIN", 52, 56], ["229E", "PROTEIN", 57, 61], ["Nsp12Since", "PROTEIN", 131, 141], ["nsp12", "PROTEIN", 142, 147], ["nsp8", "PROTEIN", 228, 232], ["nsp12", "PROTEIN", 270, 275], ["HCoV-229E", "SPECIES", 52, 61], ["HCoV", "TEST", 52, 56], ["likely", "UNCERTAINTY", 148, 154], ["synthesizes RNA", "OBSERVATION", 155, 170]]], ["Moreover, SARS-CoV nsp8 crystal structure has been solved in complex with nsp7, showing a hexadecameric structure formed by eight molecules of nsp7 associated with eight nsp8 molecules (Zhai et al., 2005) .", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["nsp7", "GENE_OR_GENE_PRODUCT", 74, 78], ["nsp7", "GENE_OR_GENE_PRODUCT", 143, 147], ["nsp7", "PROTEIN", 74, 78], ["hexadecameric structure", "PROTEIN", 90, 113], ["nsp7", "PROTEIN", 143, 147], ["nsp8 molecules", "PROTEIN", 170, 184], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "PROBLEM", 10, 14], ["CoV nsp8 crystal structure", "PROBLEM", 15, 41], ["a hexadecameric structure", "PROBLEM", 88, 113], ["eight molecules", "OBSERVATION_MODIFIER", 124, 139]]], ["This structure is reminiscent of processivity factors such as the eukaryotic PCNA sliding clamp (Prelich et al., 1987) , and is able to accommodate a dsRNA in its central channel ( Fig. 2A ) (Zhai et al., 2005) .Nsp12However, when the nsp8 primase was assayed in the context of the highly active polymerase complex (nsp7/nsp8/nsp12), no short RNAs could be detected (Subissi et al., 2014b) .", [["PCNA", "GENE_OR_GENE_PRODUCT", 77, 81], ["Nsp12However", "GENE_OR_GENE_PRODUCT", 212, 224], ["nsp8", "GENE_OR_GENE_PRODUCT", 235, 239], ["nsp7", "GENE_OR_GENE_PRODUCT", 316, 320], ["nsp8", "GENE_OR_GENE_PRODUCT", 321, 325], ["nsp12", "GENE_OR_GENE_PRODUCT", 326, 331], ["processivity factors", "PROTEIN", 33, 53], ["PCNA", "PROTEIN", 77, 81], ["Fig. 2A", "PROTEIN", 181, 188], ["Nsp12However", "PROTEIN", 212, 224], ["nsp8 primase", "PROTEIN", 235, 247], ["polymerase complex", "PROTEIN", 296, 314], ["nsp7", "PROTEIN", 316, 320], ["nsp8", "PROTEIN", 321, 325], ["nsp12", "PROTEIN", 326, 331], ["short RNAs", "RNA", 337, 347], ["processivity factors", "PROBLEM", 33, 53], ["the eukaryotic PCNA sliding clamp", "TREATMENT", 62, 95], ["a dsRNA", "PROBLEM", 148, 155], ["the nsp8 primase", "TEST", 231, 247], ["the highly active polymerase complex (nsp7/nsp8/nsp12", "PROBLEM", 278, 331], ["short RNAs", "PROBLEM", 337, 347], ["dsRNA", "OBSERVATION", 150, 155], ["highly", "OBSERVATION_MODIFIER", 282, 288], ["active", "OBSERVATION_MODIFIER", 289, 295], ["polymerase", "OBSERVATION", 296, 306]]], ["A hypothesis of this discrepancy could be that nsp8 in complex with nsp7 and nsp12 adopted a structural conformation that prevented the synthesis of short RNAs.", [["nsp8", "GENE_OR_GENE_PRODUCT", 47, 51], ["nsp7", "GENE_OR_GENE_PRODUCT", 68, 72], ["nsp12", "GENE_OR_GENE_PRODUCT", 77, 82], ["nsp8", "PROTEIN", 47, 51], ["nsp7", "PROTEIN", 68, 72], ["nsp12", "PROTEIN", 77, 82], ["short RNAs", "RNA", 149, 159], ["nsp8 in complex with nsp7", "PROBLEM", 47, 72], ["nsp12", "TREATMENT", 77, 82], ["a structural conformation", "PROBLEM", 91, 116], ["the synthesis of short RNAs", "PROBLEM", 132, 159]]], ["In other words, nsp7/nsp8 may synthesize primers before associating with nsp12, or nsp7/nsp8-mediated primer synthesis may trigger the formation of the nsp7/nsp8/nsp12 polymerase complex.", [["nsp7", "GENE_OR_GENE_PRODUCT", 16, 20], ["nsp8", "GENE_OR_GENE_PRODUCT", 21, 25], ["nsp12", "GENE_OR_GENE_PRODUCT", 73, 78], ["nsp7", "GENE_OR_GENE_PRODUCT", 83, 87], ["nsp8", "GENE_OR_GENE_PRODUCT", 88, 92], ["nsp7", "GENE_OR_GENE_PRODUCT", 152, 156], ["nsp8", "GENE_OR_GENE_PRODUCT", 157, 161], ["nsp12", "GENE_OR_GENE_PRODUCT", 162, 167], ["nsp7", "PROTEIN", 16, 20], ["nsp8", "PROTEIN", 21, 25], ["nsp12", "PROTEIN", 73, 78], ["nsp7", "PROTEIN", 83, 87], ["nsp8", "PROTEIN", 88, 92], ["nsp7", "PROTEIN", 152, 156], ["nsp8", "PROTEIN", 157, 161], ["nsp12 polymerase complex", "PROTEIN", 162, 186], ["synthesize primers", "PROBLEM", 30, 48], ["nsp12", "TEST", 73, 78], ["nsp7/nsp8-mediated primer synthesis", "PROBLEM", 83, 118], ["the nsp7/nsp8/nsp12 polymerase complex", "PROBLEM", 148, 186]]], ["This possibility is to be examined in light of the tridimensional structure solved for nsp7 and nsp8 from FCoV (Xiao et al., 2012) .", [["nsp7", "GENE_OR_GENE_PRODUCT", 87, 91], ["nsp8", "GENE_OR_GENE_PRODUCT", 96, 100], ["nsp7", "PROTEIN", 87, 91], ["nsp8", "PROTEIN", 96, 100], ["nsp7", "PROBLEM", 87, 91]]], ["In this structure, FCoV nsp7 and nsp8 assemble into a heterotrimer formed by one nsp8 molecule associated to two nsp7 molecules, without any central channel (Fig. 2B ).", [["FCoV nsp7", "GENE_OR_GENE_PRODUCT", 19, 28], ["nsp8", "GENE_OR_GENE_PRODUCT", 33, 37], ["nsp8", "GENE_OR_GENE_PRODUCT", 81, 85], ["FCoV", "PROTEIN", 19, 23], ["nsp7", "PROTEIN", 24, 28], ["nsp8", "PROTEIN", 33, 37], ["heterotrimer", "PROTEIN", 54, 66], ["nsp8 molecule", "PROTEIN", 81, 94], ["nsp7 molecules", "PROTEIN", 113, 127], ["central channel", "PROTEIN", 141, 156], ["Fig. 2B", "PROTEIN", 158, 165], ["FCoV nsp7", "TEST", 19, 28], ["two nsp7 molecules", "PROBLEM", 109, 127], ["FCoV nsp7", "OBSERVATION", 19, 28]]], ["SARS-CoV and FCoV nsp8 monomer folds are the same, except the conformation of the N-terminal helical domain that differs due to rotation over one or perhaps two hinge regions in the long alpha-helix, which undergoes partial unfolding at these hinge regions ( Fig. 2C ) (Xiao et al., 2012; Zhai et al., 2005) .Nsp12Coronavirus nsp8 in association with nsp7 reveals a remarkable plasticity that may explain several functions triggered by the nature of their partnership and/or quaternary structure.The puzzling nsp9 RNA-binding proteinNsp9 is a small (13 kDa in SARS-CoV) protein unique to coronavirus (Snijder et al., 2003) .", [["SARS", "DISEASE", 0, 4], ["N", "CHEMICAL", 82, 83], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["FCoV nsp8", "GENE_OR_GENE_PRODUCT", 13, 22], ["Nsp12Coronavirus nsp8", "GENE_OR_GENE_PRODUCT", 309, 330], ["nsp7", "GENE_OR_GENE_PRODUCT", 351, 355], ["nsp9", "GENE_OR_GENE_PRODUCT", 509, 513], ["proteinNsp9", "GENE_OR_GENE_PRODUCT", 526, 537], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 560, 568], ["coronavirus", "ORGANISM", 588, 599], ["N-terminal helical domain", "PROTEIN", 82, 107], ["hinge regions", "PROTEIN", 161, 174], ["long alpha-helix", "PROTEIN", 182, 198], ["hinge regions", "PROTEIN", 243, 256], ["Nsp12Coronavirus nsp8", "PROTEIN", 309, 330], ["nsp7", "PROTEIN", 351, 355], ["nsp9 RNA-binding proteinNsp9", "PROTEIN", 509, 537], ["SARS-CoV) protein", "PROTEIN", 560, 577], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 560, 568], ["SARS", "TEST", 0, 4], ["FCoV nsp8 monomer folds", "TREATMENT", 13, 36], ["the N-terminal helical domain", "TREATMENT", 78, 107], ["partial unfolding", "PROBLEM", 216, 233], ["The puzzling nsp9 RNA", "TEST", 496, 517], ["a small (13 kDa in SARS", "PROBLEM", 541, 564], ["coronavirus", "PROBLEM", 588, 599], ["long alpha-helix", "OBSERVATION_MODIFIER", 182, 198], ["partial", "OBSERVATION_MODIFIER", 216, 223], ["unfolding", "OBSERVATION", 224, 233], ["hinge", "ANATOMY_MODIFIER", 243, 248], ["remarkable", "OBSERVATION_MODIFIER", 366, 376], ["plasticity", "OBSERVATION", 377, 387], ["may explain", "UNCERTAINTY", 393, 404], ["quaternary structure", "OBSERVATION", 475, 495], ["small", "OBSERVATION_MODIFIER", 543, 548]]], ["The two available crystal structures of the protein (Egloff et al., 2004; Sutton et al., 2004 ) reveal a novel fold made of an open six-stranded \u2424-barrel and an additional \u2423-helix that contains a GXXXG protein/protein interaction motif (Miknis et al., 2009) To the left of this panel, SARS-CoV nsp7 and the two conformations of nsp8 are colored in orange, cyan and dark blue, respectively.", [["GXXXG", "GENE_OR_GENE_PRODUCT", 196, 201], ["SARS-CoV nsp7", "GENE_OR_GENE_PRODUCT", 285, 298], ["nsp8", "GENE_OR_GENE_PRODUCT", 328, 332], ["open six-stranded \u2424-barrel", "PROTEIN", 127, 153], ["\u2423-helix", "PROTEIN", 172, 179], ["GXXXG protein", "PROTEIN", 196, 209], ["protein interaction motif", "PROTEIN", 210, 235], ["SARS-CoV nsp7", "DNA", 285, 298], ["nsp8", "DNA", 328, 332], ["SARS-CoV", "SPECIES", 285, 293], ["a novel fold", "PROBLEM", 103, 115], ["an open six", "TREATMENT", 124, 135], ["an additional \u2423-helix", "TREATMENT", 158, 179], ["a GXXXG protein/protein interaction motif", "TREATMENT", 194, 235], ["this panel", "TEST", 273, 283], ["SARS", "TEST", 285, 289], ["CoV nsp7", "TEST", 290, 298], ["left", "ANATOMY_MODIFIER", 265, 269], ["dark blue", "OBSERVATION", 365, 374]]], ["To the right of this panel, the surface is colored according to electrostatic potential (blue, positive charge; red, negative charge).", [["surface", "ANATOMY", 32, 39], ["surface", "CELLULAR_COMPONENT", 32, 39], ["this panel", "TEST", 16, 26], ["right", "ANATOMY_MODIFIER", 7, 12], ["surface", "OBSERVATION_MODIFIER", 32, 39], ["colored", "OBSERVATION", 43, 50]]], ["(B) Structure of the FCoV nsp7/nsp8 heterotrimer (left panel): two nsp7 molecules (in green) are associated to one molecule of nsp8 (in pink) (from Xiao et al., 2012; PDB 3UBO) .", [["FCoV", "GENE_OR_GENE_PRODUCT", 21, 25], ["nsp7", "GENE_OR_GENE_PRODUCT", 26, 30], ["nsp8", "GENE_OR_GENE_PRODUCT", 31, 35], ["nsp7", "GENE_OR_GENE_PRODUCT", 67, 71], ["nsp8", "GENE_OR_GENE_PRODUCT", 127, 131], ["FCoV nsp7", "PROTEIN", 21, 30], ["nsp8 heterotrimer", "PROTEIN", 31, 48], ["left panel", "PROTEIN", 50, 60], ["nsp7 molecules", "PROTEIN", 67, 81], ["nsp8", "PROTEIN", 127, 131], ["the FCoV nsp7", "TEST", 17, 30], ["two nsp7 molecules", "PROBLEM", 63, 81], ["nsp8", "PROBLEM", 127, 131], ["FCoV", "ANATOMY", 21, 25], ["left", "ANATOMY_MODIFIER", 50, 54]]], ["The right panel shows the surface colored according to electrostatic potential (blue, positive charge; red, negative charge).", [["surface", "ANATOMY", 26, 33], ["The right panel", "TEST", 0, 15], ["right", "ANATOMY_MODIFIER", 4, 9], ["surface", "OBSERVATION_MODIFIER", 26, 33]]], ["(C) C-terminal domain superimposition of the two SARS-CoV nsp8 forms (in cyan and dark blue) with FCoV nsp8 (in pink).", [["SARS", "DISEASE", 49, 53], ["FCoV nsp8", "GENE_OR_GENE_PRODUCT", 98, 107], ["SARS-CoV nsp8 forms", "PROTEIN", 49, 68], ["FCoV nsp8", "PROTEIN", 98, 107], ["(C) C-terminal domain superimposition", "PROBLEM", 0, 37], ["the two SARS", "TEST", 41, 53], ["CoV nsp8 forms", "TEST", 54, 68], ["dark blue", "PROBLEM", 82, 91], ["FCoV nsp8", "PROBLEM", 98, 107], ["FCoV nsp8", "OBSERVATION", 98, 107]]], ["The amino-terminal domain of nsp8 is very flexible, even in association with nsp7.", [["amino-terminal", "CHEMICAL", 4, 18], ["amino", "CHEMICAL", 4, 9], ["nsp8", "GENE_OR_GENE_PRODUCT", 29, 33], ["nsp7", "GENE_OR_GENE_PRODUCT", 77, 81], ["amino-terminal domain", "PROTEIN", 4, 25], ["nsp8", "PROTEIN", 29, 33], ["nsp7", "PROTEIN", 77, 81], ["The amino-terminal domain of nsp8", "TREATMENT", 0, 33], ["nsp7", "PROBLEM", 77, 81], ["very", "OBSERVATION_MODIFIER", 37, 41], ["flexible", "OBSERVATION", 42, 50]]], ["Images were generated using PYMOL.The puzzling nsp9 RNA-binding proteinIn addition, SARS-CoV nsp9 binds ssRNA without sequence specificity (Egloff et al., 2004) , and has been shown to interact with nsp8 (Sutton et al., 2004) .", [["nsp9", "GENE_OR_GENE_PRODUCT", 47, 51], ["SARS-CoV nsp9", "GENE_OR_GENE_PRODUCT", 84, 97], ["nsp8", "GENE_OR_GENE_PRODUCT", 199, 203], ["PYMOL", "PROTEIN", 28, 33], ["nsp9 RNA-binding proteinIn", "PROTEIN", 47, 73], ["SARS-CoV nsp9", "PROTEIN", 84, 97], ["nsp8", "PROTEIN", 199, 203], ["SARS-CoV", "SPECIES", 84, 92], ["Images", "TEST", 0, 6], ["The puzzling nsp9 RNA", "TEST", 34, 55], ["SARS", "PROBLEM", 84, 88], ["sequence specificity", "TEST", 118, 138]]], ["The DNA replication catalytic core is formed, at least, by the association of a polymerase and its processivity factor, a helicase, and a single-strand DNA-binding protein (SSB).", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["DNA replication catalytic core", "DNA", 4, 34], ["polymerase", "PROTEIN", 80, 90], ["processivity factor", "PROTEIN", 99, 118], ["helicase", "PROTEIN", 122, 130], ["single-strand DNA-binding protein", "PROTEIN", 138, 171], ["SSB", "PROTEIN", 173, 176], ["a polymerase", "PROBLEM", 78, 90], ["its processivity factor", "PROBLEM", 95, 118], ["a helicase", "TEST", 120, 130], ["a single-strand DNA", "TEST", 136, 155], ["replication", "OBSERVATION_MODIFIER", 8, 19], ["catalytic", "OBSERVATION_MODIFIER", 20, 29], ["core", "OBSERVATION_MODIFIER", 30, 34]]], ["In the case of SARS-CoV, the first three actors were identified in nsp12, nsp8/nsp7 and nsp13, respectively.", [["SARS", "DISEASE", 15, 19], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 15, 23], ["nsp12", "GENE_OR_GENE_PRODUCT", 67, 72], ["nsp8", "GENE_OR_GENE_PRODUCT", 74, 78], ["nsp7", "GENE_OR_GENE_PRODUCT", 79, 83], ["nsp13", "GENE_OR_GENE_PRODUCT", 88, 93], ["nsp12", "DNA", 67, 72], ["nsp8", "DNA", 74, 78], ["nsp7", "DNA", 79, 83], ["nsp13", "DNA", 88, 93], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["nsp12", "TEST", 67, 72], ["nsp8", "TEST", 74, 78], ["nsp13", "TEST", 88, 93]]], ["Regarding the nsp9 structural features, we can hypothesis that this protein may act as an SSB-like molecule thus protecting the CoV RNA genome from degradation during replication.Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?The study of the coronavirus RNA repair machinery began with the discovery, by A.E. Gorbalenya and co-workers of nuclease motifs in ORF1b of the coronavirus genome.", [["nsp9", "GENE_OR_GENE_PRODUCT", 14, 18], ["CoV", "ORGANISM", 128, 131], ["nsp14", "GENE_OR_GENE_PRODUCT", 203, 208], ["coronavirus", "ORGANISM", 253, 264], ["ORF1b", "GENE_OR_GENE_PRODUCT", 368, 373], ["coronavirus", "ORGANISM", 381, 392], ["nsp9", "PROTEIN", 14, 18], ["SSB", "PROTEIN", 90, 93], ["CoV RNA genome", "DNA", 128, 142], ["3 -5 exonuclease", "PROTEIN", 186, 202], ["nsp14", "PROTEIN", 203, 208], ["RNA proofreading enzyme", "PROTEIN", 212, 235], ["nuclease motifs", "PROTEIN", 349, 364], ["ORF1b", "PROTEIN", 368, 373], ["coronavirus genome", "DNA", 381, 399], ["coronavirus", "SPECIES", 381, 392], ["the nsp9 structural features", "PROBLEM", 10, 38], ["an SSB-like molecule", "PROBLEM", 87, 107], ["the CoV RNA genome", "PROBLEM", 124, 142], ["The study", "TEST", 236, 245], ["the coronavirus RNA repair", "TREATMENT", 249, 275], ["nuclease motifs", "TREATMENT", 349, 364], ["the coronavirus genome", "PROBLEM", 377, 399], ["CoV RNA genome", "OBSERVATION", 128, 142], ["coronavirus genome", "OBSERVATION", 381, 399]]], ["The discovery was published as part of the full analysis of the SARS-CoV genome (Snijder et al., 2003) .", [["SARS", "DISEASE", 64, 68], ["SARS-CoV genome", "DNA", 64, 79], ["SARS-CoV", "SPECIES", 64, 72]]], ["Amongst other RNA processing enzymes, the authors reported that nsp14 N-terminal domain is an RNA 3 -5 exonuclease (ExoN) from the DEDD superfamily (Zuo and Deutscher, 2001) .Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?They proposed the ExoN activity to be related to RNA proofreading, repair, and/or recombination.", [["nsp14", "GENE_OR_GENE_PRODUCT", 64, 69], ["5", "GENE_OR_GENE_PRODUCT", 101, 102], ["ExoN", "GENE_OR_GENE_PRODUCT", 116, 120], ["DEDD", "GENE_OR_GENE_PRODUCT", 131, 135], ["nsp14", "GENE_OR_GENE_PRODUCT", 199, 204], ["ExoN", "GENE_OR_GENE_PRODUCT", 250, 254], ["RNA processing enzymes", "PROTEIN", 14, 36], ["nsp14 N-terminal domain", "PROTEIN", 64, 87], ["RNA 3 -5 exonuclease", "PROTEIN", 94, 114], ["ExoN", "PROTEIN", 116, 120], ["DEDD superfamily", "PROTEIN", 131, 147], ["3 -5 exonuclease", "PROTEIN", 182, 198], ["nsp14", "PROTEIN", 199, 204], ["RNA proofreading enzyme", "PROTEIN", 208, 231], ["ExoN", "PROTEIN", 250, 254], ["nsp14 N-terminal domain", "PROBLEM", 64, 87], ["an RNA", "TREATMENT", 91, 97], ["the ExoN activity", "PROBLEM", 246, 263], ["RNA proofreading", "TREATMENT", 281, 297], ["repair", "TREATMENT", 299, 305]]], ["These hypotheses were based on DNA organisms, which have developed mechanisms for their large DNA genome biosynthesis and maintenance.Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?Ubiquitously spread in large-genome viruses, genes encoding homologs of coronavirus nsp14 ExoN are found in all nidoviruses (toro and roniviruses, with respectively 28 and 26 kb genomes), and mesoniviruses (a recently discovered related viral family with a 20 kb genome) (Zirkel et al., 2011) .", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["nsp14", "GENE_OR_GENE_PRODUCT", 158, 163], ["coronavirus nsp14", "ORGANISM", 263, 280], ["ExoN", "GENE_OR_GENE_PRODUCT", 281, 285], ["toro", "CANCER", 316, 320], ["mesoniviruses", "GENE_OR_GENE_PRODUCT", 383, 396], ["3 -5 exonuclease", "PROTEIN", 141, 157], ["nsp14", "PROTEIN", 158, 163], ["RNA proofreading enzyme", "PROTEIN", 167, 190], ["coronavirus nsp14 ExoN", "DNA", 263, 285], ["20 kb genome", "DNA", 448, 460], ["coronavirus nsp", "SPECIES", 263, 278], ["DNA organisms", "PROBLEM", 31, 44], ["their large DNA genome biosynthesis", "TREATMENT", 82, 117], ["Ubiquitously spread", "PROBLEM", 191, 210], ["large-genome viruses", "PROBLEM", 214, 234], ["coronavirus nsp", "PROBLEM", 263, 278], ["genome biosynthesis", "OBSERVATION", 98, 117], ["large", "OBSERVATION_MODIFIER", 214, 219], ["genome viruses", "OBSERVATION", 220, 234]]], ["Small genome nidoviruses (arteriviruses, 13-15 kb) do not possess such ExoN activity (reviewed in, Gorbalenya et al., 2006) .", [["arteriviruses", "ANATOMY", 26, 39], ["arteriviruses", "CANCER", 26, 39], ["ExoN", "GENE_OR_GENE_PRODUCT", 71, 75], ["ExoN", "PROTEIN", 71, 75], ["Small genome nidoviruses", "PROBLEM", 0, 24], ["arteriviruses", "TEST", 26, 39], ["genome nidoviruses", "OBSERVATION", 6, 24]]], ["Outside nidoviruses, nsp14 ExoN homologs are rare, and have been solely identified in arenaviruses so far.", [["nidoviruses", "GENE_OR_GENE_PRODUCT", 8, 19], ["nsp14", "GENE_OR_GENE_PRODUCT", 21, 26], ["ExoN", "GENE_OR_GENE_PRODUCT", 27, 31], ["nidoviruses", "PROTEIN", 8, 19], ["nsp14 ExoN homologs", "DNA", 21, 40], ["arenaviruses", "OBSERVATION", 86, 98]]], ["In this last case, the ExoN activity is likely involved in counteracting the antiviral innate immunity (Hastie et al., 2011) .Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?The seminal discovery of the CoV 3 -5 ExoN activity was followed by sequential findings confirming its validity and raised great interest in various fields such as evolution, drug design and drug resistance.", [["seminal", "ANATOMY", 187, 194], ["ExoN", "GENE_OR_GENE_PRODUCT", 23, 27], ["nsp14", "GENE_OR_GENE_PRODUCT", 150, 155], ["seminal", "MULTI-TISSUE_STRUCTURE", 187, 194], ["CoV 3 -5", "ORGANISM", 212, 220], ["ExoN", "GENE_OR_GENE_PRODUCT", 221, 225], ["ExoN", "PROTEIN", 23, 27], ["3 -5 exonuclease", "PROTEIN", 133, 149], ["nsp14", "PROTEIN", 150, 155], ["RNA proofreading enzyme", "PROTEIN", 159, 182], ["CoV 3 -5 ExoN", "DNA", 212, 225], ["the CoV", "TEST", 208, 215], ["drug design and drug resistance", "PROBLEM", 358, 389], ["likely involved", "UNCERTAINTY", 40, 55], ["seminal", "ANATOMY_MODIFIER", 187, 194]]], ["The 3 -5 ExoN enzyme activity was subsequently demonstrated at the enzyme level (Minskaia et al., 2006) .", [["ExoN", "GENE_OR_GENE_PRODUCT", 9, 13], ["ExoN enzyme", "PROTEIN", 9, 20], ["ExoN enzyme activity", "TEST", 9, 29], ["the enzyme level", "TEST", 63, 79]]], ["These authors showed that mutations in the DEDD motif, usually leading to the inactivation of the exonuclease activity, allowed recovering viable viruses that exhibit a 15-20-fold increase in replication errors.", [["DEDD", "GENE_OR_GENE_PRODUCT", 43, 47], ["DEDD motif", "DNA", 43, 53], ["exonuclease", "PROTEIN", 98, 109], ["mutations in the DEDD motif", "PROBLEM", 26, 53], ["the exonuclease activity", "TREATMENT", 94, 118], ["replication errors", "PROBLEM", 192, 210], ["replication errors", "OBSERVATION", 192, 210]]], ["The study was conducted in MHV, a betacoronavirus-like SARS-CoV.", [["SARS", "DISEASE", 55, 59], ["MHV", "ORGANISM", 27, 30], ["SARS-CoV", "ORGANISM", 55, 63], ["MHV", "SPECIES", 27, 30], ["SARS-CoV", "SPECIES", 55, 63], ["The study", "TEST", 0, 9], ["a betacoronavirus", "TEST", 32, 49]]], ["Several significant complements and refinements of these studies appeared subsequently (Eckerle et al., 2010) .", [["these studies", "TEST", 51, 64], ["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["Whereas less than one mutation per sequenced genome was observed for wild-type SARS-CoV (corresponding to an error frequency of 2 \u00d7 10 \u22125 ), the SARS-CoV ExoN(\u2212) showed 10 mutations per sequenced genome (error frequency = 3 \u00d7 10 \u22124 ) (Eckerle et al., 2010) .", [["SARS", "DISEASE", 79, 83], ["wild-type SARS-CoV", "ORGANISM", 69, 87], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 145, 153], ["SARS-CoV ExoN", "DNA", 145, 158], ["SARS-CoV", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 145, 153], ["one mutation", "PROBLEM", 18, 30], ["wild-type SARS", "PROBLEM", 69, 83], ["an error frequency", "TEST", 106, 124], ["the SARS", "TEST", 141, 149], ["10 mutations", "PROBLEM", 169, 181], ["error frequency", "TEST", 204, 219]]], ["The same group recently showed that coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis (Smith et al., 2013) .", [["coronaviruses", "ORGANISM", 36, 49], ["exoribonuclease", "GENE_OR_GENE_PRODUCT", 58, 73], ["exoribonuclease", "PROTEIN", 58, 73], ["coronaviruses lacking exoribonuclease activity", "PROBLEM", 36, 82], ["lethal mutagenesis", "PROBLEM", 102, 120], ["coronaviruses", "OBSERVATION", 36, 49], ["exoribonuclease activity", "OBSERVATION", 58, 82]]], ["Indeed, they demonstrated that 5-fluorouracil (5FU) is incorporated into SARS-CoV and MHV RNA genomes, driving increased mutagenesis in ExoN(\u2212) viruses (Smith et al., 2013) .", [["5-fluorouracil", "CHEMICAL", 31, 45], ["5FU", "CHEMICAL", 47, 50], ["5-fluorouracil", "CHEMICAL", 31, 45], ["5FU", "CHEMICAL", 47, 50], ["5-fluorouracil", "SIMPLE_CHEMICAL", 31, 45], ["5FU", "SIMPLE_CHEMICAL", 47, 50], ["SARS-CoV", "ORGANISM", 73, 81], ["MHV", "ORGANISM", 86, 89], ["ExoN", "GENE_OR_GENE_PRODUCT", 136, 140], ["SARS-CoV and MHV RNA genomes", "DNA", 73, 101], ["SARS-CoV", "SPECIES", 73, 81], ["MHV", "SPECIES", 86, 89], ["fluorouracil (5FU", "TREATMENT", 33, 50], ["SARS", "PROBLEM", 73, 77], ["CoV", "PROBLEM", 78, 81], ["MHV RNA genomes", "TREATMENT", 86, 101], ["driving increased mutagenesis", "PROBLEM", 103, 132], ["SARS", "OBSERVATION", 73, 77], ["MHV", "OBSERVATION_MODIFIER", 86, 89], ["RNA genomes", "OBSERVATION", 90, 101]]], ["In addition, ribavirin, a guanosine analog, was also tested on a MHV ExoN(\u2212) strain exhibiting up to 300-fold increased in sensitivity to this compound.Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?At the enzyme level, mechanistic studies showed that nsp14 ExoN activity is strongly enhanced (>35-fold) by the addition of nsp10 (Bouvet et al., 2012) .", [["ribavirin", "CHEMICAL", 13, 22], ["guanosine", "CHEMICAL", 26, 35], ["ribavirin", "CHEMICAL", 13, 22], ["guanosine", "CHEMICAL", 26, 35], ["ribavirin", "SIMPLE_CHEMICAL", 13, 22], ["guanosine", "SIMPLE_CHEMICAL", 26, 35], ["MHV", "ORGANISM", 65, 68], ["ExoN", "GENE_OR_GENE_PRODUCT", 69, 73], ["nsp14", "GENE_OR_GENE_PRODUCT", 176, 181], ["nsp14", "GENE_OR_GENE_PRODUCT", 262, 267], ["ExoN", "GENE_OR_GENE_PRODUCT", 268, 272], ["nsp10", "GENE_OR_GENE_PRODUCT", 333, 338], ["3 -5 exonuclease", "PROTEIN", 159, 175], ["nsp14", "PROTEIN", 176, 181], ["RNA proofreading enzyme", "PROTEIN", 185, 208], ["nsp14", "PROTEIN", 262, 267], ["ExoN", "PROTEIN", 268, 272], ["nsp10", "PROTEIN", 333, 338], ["MHV", "SPECIES", 65, 68], ["ribavirin", "TREATMENT", 13, 22], ["a guanosine analog", "TREATMENT", 24, 42], ["a MHV ExoN", "TEST", 63, 73], ["strain", "PROBLEM", 77, 83], ["the enzyme level", "TEST", 212, 228], ["mechanistic studies", "TEST", 230, 249], ["nsp", "TEST", 262, 265], ["ExoN activity", "TEST", 268, 281], ["ribavirin", "OBSERVATION", 13, 22], ["enhanced", "OBSERVATION_MODIFIER", 294, 302]]], ["The nsp10/nsp14 ExoN complex was shown to be dsRNA-specific, but also able to excise one 3 mismatched nucleotide mimicking a polymerase-mediated nucleotide misincorporation product (Bouvet et al., 2012) .", [["nucleotide", "CHEMICAL", 102, 112], ["nucleotide", "CHEMICAL", 145, 155], ["nucleotide", "CHEMICAL", 102, 112], ["nucleotide", "CHEMICAL", 145, 155], ["nsp10", "GENE_OR_GENE_PRODUCT", 4, 9], ["p14", "GENE_OR_GENE_PRODUCT", 12, 15], ["ExoN", "GENE_OR_GENE_PRODUCT", 16, 20], ["nsp10/nsp14 ExoN complex", "PROTEIN", 4, 28], ["The nsp10", "TEST", 0, 9], ["dsRNA", "PROBLEM", 45, 50], ["a polymerase", "TREATMENT", 123, 135], ["nucleotide misincorporation product", "TREATMENT", 145, 180]]], ["It is however unclear which enzyme state, nsp10/14 complex or nsp14 alone is involved in the aforementioned effects on RNA replication errors.Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?Evidences accumulate in favor of an RNA proofreading system versus a post-replicative mismatch repair.", [["nsp10/14", "GENE_OR_GENE_PRODUCT", 42, 50], ["nsp14", "GENE_OR_GENE_PRODUCT", 62, 67], ["nsp14", "GENE_OR_GENE_PRODUCT", 166, 171], ["nsp10/14 complex", "PROTEIN", 42, 58], ["nsp14", "PROTEIN", 62, 67], ["3 -5 exonuclease", "PROTEIN", 149, 165], ["nsp14", "PROTEIN", 166, 171], ["RNA proofreading enzyme", "PROTEIN", 175, 198], ["an RNA proofreading system", "PROBLEM", 232, 258], ["a post-replicative mismatch repair", "TREATMENT", 266, 300], ["RNA replication", "OBSERVATION", 119, 134], ["RNA proofreading", "OBSERVATION", 235, 251], ["mismatch repair", "OBSERVATION", 285, 300]]], ["The latter generally involves a strand recognition system (e.g., neosynthesized ssRNA methylation) to determine which nucleotide has to be corrected in a mismatch-bearing dsRNA.", [["nucleotide", "CHEMICAL", 118, 128], ["nucleotide", "CHEMICAL", 118, 128], ["neosynthesized ssRNA methylation", "TREATMENT", 65, 97], ["a mismatch-bearing dsRNA", "PROBLEM", 152, 176], ["bearing dsRNA", "OBSERVATION", 163, 176]]], ["Then, a succession of enzymatic activities are required to replace the mismatched nucleotide: dsRNA endonucleolytic cleavage, RNA re-synthesis, and RNA ligation.", [["nucleotide", "CHEMICAL", 82, 92], ["nucleotide", "CHEMICAL", 82, 92], ["enzymatic activities", "TREATMENT", 22, 42], ["the mismatched nucleotide", "TREATMENT", 67, 92], ["dsRNA endonucleolytic cleavage", "TREATMENT", 94, 124], ["RNA re-synthesis", "TREATMENT", 126, 142], ["RNA ligation", "TREATMENT", 148, 160], ["RNA ligation", "OBSERVATION", 148, 160]]], ["Although several of these activities are embedded in the coronavirus ORF1ab, both strand recognition and ligase activities remain to be determined.", [["coronavirus", "ORGANISM", 57, 68], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 69, 75], ["coronavirus ORF1ab", "PROTEIN", 57, 75], ["coronavirus", "SPECIES", 57, 68], ["the coronavirus ORF1ab", "TREATMENT", 53, 75], ["ligase activities", "TEST", 105, 122]]], ["In contrast, RNA proofreading generally involves a minimal set of activities of the polymerase dealing with the mismatched nucleotide and, a single 3 -5 exonuclease activity vicinal to the active RNA polymerase.Is the 3 -5 exonuclease nsp14 an RNA proofreading enzyme?To formally demonstrate the occurrence of RNA proofreading by nsp14, several questions have to be addressed, some of which have already been answered.", [["nucleotide", "CHEMICAL", 123, 133], ["nucleotide", "CHEMICAL", 123, 133], ["nsp14", "GENE_OR_GENE_PRODUCT", 235, 240], ["nsp14", "GENE_OR_GENE_PRODUCT", 330, 335], ["polymerase", "PROTEIN", 84, 94], ["exonuclease", "PROTEIN", 153, 164], ["active RNA polymerase", "PROTEIN", 189, 210], ["3 -5 exonuclease", "PROTEIN", 218, 234], ["nsp14", "PROTEIN", 235, 240], ["RNA proofreading enzyme", "PROTEIN", 244, 267], ["nsp14", "PROTEIN", 330, 335], ["RNA proofreading", "PROBLEM", 13, 29], ["the polymerase", "TREATMENT", 80, 94], ["the mismatched nucleotide", "TREATMENT", 108, 133], ["a single 3 -5 exonuclease activity vicinal", "TREATMENT", 139, 181], ["active", "OBSERVATION_MODIFIER", 189, 195], ["RNA polymerase", "OBSERVATION", 196, 210]]], ["First, nsp14 has to be made available to nsp12, and both should exhibit activities.", [["nsp14", "GENE_OR_GENE_PRODUCT", 7, 12], ["nsp12", "GENE_OR_GENE_PRODUCT", 41, 46], ["nsp14", "PROTEIN", 7, 12], ["nsp12", "PROTEIN", 41, 46]]], ["This has been demonstrated in Subissi et al. (2014b) , with the association of nsp12 and nsp14 into an active complex.", [["nsp12", "GENE_OR_GENE_PRODUCT", 79, 84], ["nsp14", "GENE_OR_GENE_PRODUCT", 89, 94], ["nsp12", "PROTEIN", 79, 84], ["nsp14", "PROTEIN", 89, 94], ["active complex", "PROTEIN", 103, 117], ["nsp12", "TEST", 79, 84], ["active", "OBSERVATION_MODIFIER", 103, 109], ["complex", "OBSERVATION", 110, 117]]], ["Second, the RNA mismatch clearance pathway should be reconstituted in vitro.", [["the RNA mismatch clearance pathway", "TREATMENT", 8, 42], ["RNA", "OBSERVATION", 12, 15], ["mismatch clearance", "OBSERVATION", 16, 34]]], ["That is, not only mismatch formation by nsp12 should be documented (nature and frequency), but also mismatch extension vs mismatch excision, yielding an estimate of the mismatch fixation into the RNA genome.Coronavirus cap formation pathwayEukaryotic messenger RNA translation can be initiated by 2 different signals at the 5 -end, either by a cap structure or by a highly specific RNA tertiary structure named internal ribosome entry site (IRES).Coronavirus cap formation pathwayNidovirus genomes possess a cap structure at their 5 -end (Lai and Stohlman, 1981; Van Vliet et al., 2002) .", [["ribosome", "ANATOMY", 420, 428], ["nsp12", "GENE_OR_GENE_PRODUCT", 40, 45], ["nsp12", "PROTEIN", 40, 45], ["RNA genome", "DNA", 196, 206], ["Eukaryotic messenger RNA", "RNA", 240, 264], ["5 -end", "DNA", 324, 330], ["internal ribosome entry site", "DNA", 411, 439], ["IRES", "DNA", 441, 445], ["Nidovirus genomes", "DNA", 480, 497], ["mismatch formation", "PROBLEM", 18, 36], ["mismatch extension", "PROBLEM", 100, 118], ["mismatch excision", "TREATMENT", 122, 139], ["the mismatch fixation", "TREATMENT", 165, 186], ["Coronavirus cap formation", "TREATMENT", 207, 232], ["Eukaryotic messenger RNA translation", "PROBLEM", 240, 276], ["a highly specific RNA tertiary structure", "PROBLEM", 364, 404], ["Coronavirus cap formation pathway", "PROBLEM", 447, 480], ["a cap structure", "PROBLEM", 506, 521], ["not only", "UNCERTAINTY", 9, 17], ["mismatch", "OBSERVATION", 18, 26], ["mismatch excision", "OBSERVATION", 122, 139], ["mismatch fixation", "OBSERVATION", 169, 186], ["RNA genome", "OBSERVATION", 196, 206], ["Eukaryotic", "OBSERVATION_MODIFIER", 240, 250], ["messenger RNA", "OBSERVATION", 251, 264], ["internal", "OBSERVATION_MODIFIER", 411, 419], ["ribosome entry", "OBSERVATION", 420, 434], ["cap", "OBSERVATION_MODIFIER", 508, 511]]], ["The cap is composed of a methylated guanosine at position N7 and linked to the first transcribed nucleotide of the RNA by a 5 -5 triphosphate bridge, called \"cap-0\" ( 7m GpppN) (Fig. 3) .", [["guanosine", "CHEMICAL", 36, 45], ["5 -5 triphosphate", "CHEMICAL", 124, 141], ["guanosine", "CHEMICAL", 36, 45], ["nucleotide", "CHEMICAL", 97, 107], ["5 -5 triphosphate", "CHEMICAL", 124, 141], ["guanosine", "SIMPLE_CHEMICAL", 36, 45], ["5 -5 triphosphate", "SIMPLE_CHEMICAL", 124, 141], ["RNA", "RNA", 115, 118], ["a methylated guanosine at position N7", "TREATMENT", 23, 60], ["a 5 -5 triphosphate bridge", "TREATMENT", 122, 148], ["cap", "TEST", 158, 161], ["cap", "OBSERVATION_MODIFIER", 4, 7]]], ["A \"cap-0\" structure can then be converted into \"cap-1\" ( 7m Gppp m2 N) by the addition of a methyl group to the 2 position of the first RNA nucleotide (Furuichi and Shatkin, 2000) (Fig. 3) .", [["methyl", "CHEMICAL", 92, 98], ["nucleotide", "CHEMICAL", 140, 150], ["N", "CHEMICAL", 68, 69], ["methyl", "CHEMICAL", 92, 98], ["nucleotide", "CHEMICAL", 140, 150], ["a methyl group", "TREATMENT", 90, 104], ["the first RNA nucleotide (Furuichi and Shatkin", "TREATMENT", 126, 172]]], ["The cap structure is then recognized by the eukaryotic initiation factor 4E (eIF4E), which, in association with other eIFs, recruit the small ribosomal subunit 40S (for review, Decroly et al., 2012) .", [["eukaryotic initiation factor 4E", "GENE_OR_GENE_PRODUCT", 44, 75], ["eIF4E", "GENE_OR_GENE_PRODUCT", 77, 82], ["eIFs", "GENE_OR_GENE_PRODUCT", 118, 122], ["eukaryotic initiation factor 4E", "PROTEIN", 44, 75], ["eIF4E", "PROTEIN", 77, 82], ["eIFs", "PROTEIN", 118, 122], ["small ribosomal subunit 40S", "PROTEIN", 136, 163], ["cap structure", "OBSERVATION_MODIFIER", 4, 17], ["small", "OBSERVATION_MODIFIER", 136, 141]]], ["Another cap function was described as protecting the mRNA from cellular 5 -3 ExoN degradation (Furuichi et al., 1977) .", [["cellular", "ANATOMY", 63, 71], ["cellular", "CELL", 63, 71], ["ExoN", "GENE_OR_GENE_PRODUCT", 77, 81], ["mRNA", "RNA", 53, 57], ["Another cap function", "TEST", 0, 20], ["cap", "OBSERVATION_MODIFIER", 8, 11], ["function", "OBSERVATION", 12, 20]]], ["Recently, it has been shown that the 2 -O-methylation of the viral cap prevents viral genome recognition by the innate immune system of the host cell (Z\u00fcst et al., 2011) .Coronavirus cap formation pathwayGenerally, cap formation requires three successive steps (Fig. 4 ) (Furuichi et al., 1976) : (i) an RNA 5 -triphosphatase (RTPase) hydrolyses the 5 \u2425-phosphate of the nascent mRNA; (ii) a guanylyltransferase (GTase) catalyses the transfer of a guanosine monophosphate (GMP) to the diphosphate mRNA 5 end; (iii) an RNA methyltransferase (MTase) adds a methyl group at the N7 position of the cap guanine.", [["cell", "ANATOMY", 145, 149], ["cap", "ANATOMY", 183, 186], ["5 \u2425-phosphate", "CHEMICAL", 350, 363], ["guanosine monophosphate", "CHEMICAL", 448, 471], ["GMP", "CHEMICAL", 473, 476], ["diphosphate", "CHEMICAL", 485, 496], ["methyl", "CHEMICAL", 555, 561], ["guanine", "CHEMICAL", 598, 605], ["2 -O", "CHEMICAL", 37, 41], ["5 \u2425-phosphate", "CHEMICAL", 350, 363], ["guanosine monophosphate", "CHEMICAL", 448, 471], ["GMP", "CHEMICAL", 473, 476], ["diphosphate", "CHEMICAL", 485, 496], ["methyl", "CHEMICAL", 555, 561], ["N7", "CHEMICAL", 575, 577], ["guanine", "CHEMICAL", 598, 605], ["host cell", "CELL", 140, 149], ["cap", "CELLULAR_COMPONENT", 215, 218], ["RNA 5 -triphosphatase", "GENE_OR_GENE_PRODUCT", 304, 325], ["RTPase", "GENE_OR_GENE_PRODUCT", 327, 333], ["5 \u2425-phosphate", "SIMPLE_CHEMICAL", 350, 363], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 392, 411], ["GTase", "GENE_OR_GENE_PRODUCT", 413, 418], ["guanosine monophosphate", "SIMPLE_CHEMICAL", 448, 471], ["GMP", "SIMPLE_CHEMICAL", 473, 476], ["diphosphate", "SIMPLE_CHEMICAL", 485, 496], ["RNA methyltransferase", "GENE_OR_GENE_PRODUCT", 518, 539], ["MTase", "GENE_OR_GENE_PRODUCT", 541, 546], ["methyl", "SIMPLE_CHEMICAL", 555, 561], ["cap guanine", "SIMPLE_CHEMICAL", 594, 605], ["viral cap", "PROTEIN", 61, 70], ["RNA 5 -triphosphatase", "PROTEIN", 304, 325], ["RTPase", "PROTEIN", 327, 333], ["nascent mRNA", "RNA", 371, 383], ["guanylyltransferase", "PROTEIN", 392, 411], ["GTase", "PROTEIN", 413, 418], ["guanosine monophosphate", "PROTEIN", 448, 471], ["diphosphate mRNA 5 end", "RNA", 485, 507], ["RNA methyltransferase", "PROTEIN", 518, 539], ["MTase", "PROTEIN", 541, 546], ["N7 position", "PROTEIN", 575, 586], ["cap guanine", "PROTEIN", 594, 605], ["the viral cap", "TREATMENT", 57, 70], ["viral genome recognition", "PROBLEM", 80, 104], ["Coronavirus cap formation pathway", "PROBLEM", 171, 204], ["an RNA", "TEST", 301, 307], ["hydrolyses", "TEST", 335, 345], ["the nascent mRNA", "TREATMENT", 367, 383], ["a guanylyltransferase (GTase)", "TREATMENT", 390, 419], ["a guanosine monophosphate (GMP)", "TREATMENT", 446, 477], ["the diphosphate mRNA", "TREATMENT", 481, 501], ["an RNA methyltransferase (MTase)", "TREATMENT", 515, 547], ["a methyl group", "TREATMENT", 553, 567], ["the cap guanine", "TREATMENT", 590, 605], ["viral cap", "OBSERVATION_MODIFIER", 61, 70], ["prevents", "UNCERTAINTY", 71, 79], ["viral genome", "OBSERVATION", 80, 92], ["host cell", "OBSERVATION", 140, 149], ["cap", "OBSERVATION_MODIFIER", 215, 218], ["cap guanine", "OBSERVATION", 594, 605]]], ["As previously mentioned, CoV cap is a \"cap-1\", and thus another MTase transfers a methyl group to the 2 O position of the first mRNA nucleotide and this enzyme is so called 2 -O-MTase.", [["methyl", "CHEMICAL", 82, 88], ["nucleotide", "CHEMICAL", 133, 143], ["methyl", "CHEMICAL", 82, 88], ["O", "CHEMICAL", 104, 105], ["nucleotide", "CHEMICAL", 133, 143], ["CoV", "ORGANISM", 25, 28], ["cap-1", "GENE_OR_GENE_PRODUCT", 39, 44], ["MTase", "GENE_OR_GENE_PRODUCT", 64, 69], ["methyl", "SIMPLE_CHEMICAL", 82, 88], ["2 -O-MTase", "GENE_OR_GENE_PRODUCT", 173, 183], ["CoV cap", "PROTEIN", 25, 32], ["MTase", "PROTEIN", 64, 69], ["O-MTase", "PROTEIN", 176, 183], ["this enzyme", "TEST", 148, 159]]], ["As already mentioned, RNA cap methylation is a very important process, \"hiding\" the viral mRNA from innate immunity sensors but also preventing the pyrophosphorolytic reversal of the Fig. 4 .", [["viral mRNA", "RNA", 84, 94], ["RNA cap methylation", "PROBLEM", 22, 41], ["innate immunity sensors", "TREATMENT", 100, 123], ["the pyrophosphorolytic reversal", "TREATMENT", 144, 175]]], ["SARS-CoV RNA capping pathway.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV RNA", "RNA", 0, 12], ["SARS-CoV", "SPECIES", 0, 8], ["CoV RNA capping pathway", "TREATMENT", 5, 28]]], ["SARS-CoV uses a canonical capping pathway.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["a canonical capping pathway", "TREATMENT", 14, 41]]], ["The 5 -end \u2425-phosphate of the RNA is hydrolyzed by the nsp13 RTPase activity.", [["5 -end \u2425-phosphate", "CHEMICAL", 4, 22], ["5 -end \u2425-phosphate", "CHEMICAL", 4, 22], ["5 -end \u2425-phosphate", "SIMPLE_CHEMICAL", 4, 22], ["nsp13", "GENE_OR_GENE_PRODUCT", 55, 60], ["5 -end \u2425-phosphate", "DNA", 4, 22], ["RTPase", "PROTEIN", 61, 67], ["RNA", "OBSERVATION", 30, 33]]], ["Then, the still unknown RNA GTase transfers a GMP to the 5 -diphosphate RNA end, forming a 5 -5 triphosphate bond.", [["GMP", "CHEMICAL", 46, 49], ["5 -diphosphate", "CHEMICAL", 57, 71], ["5 -5 triphosphate", "CHEMICAL", 91, 108], ["GMP", "CHEMICAL", 46, 49], ["5 -diphosphate", "CHEMICAL", 57, 71], ["5 -5 triphosphate", "CHEMICAL", 91, 108], ["GMP", "SIMPLE_CHEMICAL", 46, 49], ["5 -diphosphate", "SIMPLE_CHEMICAL", 57, 71], ["5 -5 triphosphate", "SIMPLE_CHEMICAL", 91, 108], ["RNA GTase", "PROTEIN", 24, 33], ["5 -diphosphate RNA end", "RNA", 57, 79], ["a GMP", "TREATMENT", 44, 49]]], ["Next, the nsp14 N7-MTase transfers a methyl group from the SAM donor to the N7-position of the cap, forming the \"cap-0\" structure.", [["N7", "CHEMICAL", 16, 18], ["methyl", "CHEMICAL", 37, 43], ["methyl", "CHEMICAL", 37, 43], ["N7", "CHEMICAL", 76, 78], ["methyl", "SIMPLE_CHEMICAL", 37, 43], ["nsp14 N7-MTase", "PROTEIN", 10, 24], ["the nsp14 N7", "TREATMENT", 6, 18], ["a methyl group", "TREATMENT", 35, 49], ["the SAM donor", "TREATMENT", 55, 68], ["cap", "OBSERVATION_MODIFIER", 95, 98]]], ["Lastly, the nsp16/nsp10 2 O-MTase methylates the first RNA nucleotide in the 2 O position, to form the \"cap-1\" structure. guanylyltransfer reaction (Furuichi et al., 1977; Shuman, 2001) .", [["nucleotide", "CHEMICAL", 59, 69], ["nucleotide", "CHEMICAL", 59, 69], ["guanylyltransfer", "CHEMICAL", 122, 138], ["O-MTase", "GENE_OR_GENE_PRODUCT", 26, 33], ["guanylyltransfer", "SIMPLE_CHEMICAL", 122, 138], ["nsp16/nsp10 2 O-MTase", "DNA", 12, 33], ["MTase methylates", "TREATMENT", 28, 44], ["guanylyltransfer reaction", "PROBLEM", 122, 147]]], ["Knocking-out cap methylation genes in SARS-CoV is lethal if not detrimental for virus replication (Almaz\u00e1n et al., 2006; Chen et al., 2009) .Coronavirus cap formation pathwaySARS-CoV replicates in the cytoplasm, without access to the nuclear host-cell machinery for mRNA capping.", [["cytoplasm", "ANATOMY", 201, 210], ["nuclear", "ANATOMY", 234, 241], ["cell", "ANATOMY", 247, 251], ["SARS", "DISEASE", 38, 42], ["SARS-CoV", "ORGANISM", 38, 46], ["pathwaySARS-CoV", "GENE_OR_GENE_PRODUCT", 167, 182], ["cytoplasm", "ORGANISM_SUBSTANCE", 201, 210], ["nuclear", "CELLULAR_COMPONENT", 234, 241], ["cap methylation genes", "DNA", 13, 34], ["Coronavirus cap formation pathwaySARS-CoV", "PROTEIN", 141, 182], ["SARS-CoV", "SPECIES", 38, 46], ["cap methylation genes in SARS", "PROBLEM", 13, 42], ["Coronavirus cap formation pathwaySARS", "TEST", 141, 178], ["mRNA capping", "TREATMENT", 266, 278], ["mRNA capping", "OBSERVATION", 266, 278]]], ["Therefore, SARS-CoV has two options for capping its mRNAs: either the virus can hijack the cellular machinery or it has to produce its own RNAcapping enzymes (Mao and Shuman, 1994) .", [["cellular", "ANATOMY", 91, 99], ["SARS", "DISEASE", 11, 15], ["SARS-CoV", "ORGANISM", 11, 19], ["cellular", "CELL", 91, 99], ["mRNAs", "RNA", 52, 57], ["RNAcapping enzymes", "PROTEIN", 139, 157], ["Mao", "PROTEIN", 159, 162], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "PROBLEM", 11, 15], ["capping its mRNAs", "TREATMENT", 40, 57], ["the virus", "PROBLEM", 66, 75]]], ["So far, out of the four necessary activities involved in mRNA capping, three were identified in the CoV ORF1b (Figs.", [["CoV", "ORGANISM", 100, 103], ["ORF1b", "GENE_OR_GENE_PRODUCT", 104, 109], ["CoV ORF1b", "PROTEIN", 100, 109], ["mRNA capping", "TREATMENT", 57, 69]]], ["Current knowledge regarding the 4 steps of cap formation is more fully described in Sections 5.1-5.4.", [["cap", "ANATOMY", 43, 46], ["cap", "MULTI-TISSUE_STRUCTURE", 43, 46], ["cap formation", "PROBLEM", 43, 56], ["Sections", "TEST", 84, 92], ["more fully", "OBSERVATION_MODIFIER", 60, 70]]], ["Unless otherwise specified, all data were shown for the SARS-CoV.The RNA 5 -triphosphatase (RTPase)RTPase catalyses the cleavage of the interphosphate bond between the \u2424and the \u2425-phosphates at the 5 -end of a triphosphorylated mRNA.", [["SARS", "DISEASE", 56, 60], ["interphosphate", "CHEMICAL", 136, 150], ["interphosphate", "CHEMICAL", 136, 150], ["\u2425-phosphates", "CHEMICAL", 177, 189], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 56, 64], ["RNA 5 -triphosphatase", "GENE_OR_GENE_PRODUCT", 69, 90], ["RTPase", "GENE_OR_GENE_PRODUCT", 92, 98], ["RTPase", "GENE_OR_GENE_PRODUCT", 99, 105], ["interphosphate", "SIMPLE_CHEMICAL", 136, 150], ["\u2425-phosphates", "SIMPLE_CHEMICAL", 177, 189], ["RNA 5 -triphosphatase (RTPase)RTPase", "PROTEIN", 69, 105], ["5 -end", "DNA", 197, 203], ["triphosphorylated mRNA", "RNA", 209, 231], ["SARS-CoV", "SPECIES", 56, 64], ["The RNA", "TEST", 65, 72], ["triphosphatase (RTPase", "TEST", 76, 98], ["RTPase", "TEST", 99, 105], ["the interphosphate bond", "TEST", 132, 155], ["a triphosphorylated mRNA", "TREATMENT", 207, 231], ["triphosphorylated mRNA", "OBSERVATION", 209, 231]]], ["Biochemical assays indicate that this function, together with a helicase activity might be played by nsp13 (as described in paragraph 3.1) (Ivanov et al., 2004b) .", [["nsp13", "GENE_OR_GENE_PRODUCT", 101, 106], ["nsp13", "PROTEIN", 101, 106], ["Biochemical assays", "TEST", 0, 18], ["a helicase activity", "PROBLEM", 62, 81]]], ["The combination of RTPase and helicase activities carried by the same protein has already been observed for many RNA viruses (Wengler and Wengler, 1993; Bisaillon et al., 1997; Vasiljeva et al., 2000; Li et al., 2001; Benarroch et al., 2004b) .", [["RTPase", "GENE_OR_GENE_PRODUCT", 19, 25], ["RTPase", "PROTEIN", 19, 25], ["RTPase", "TREATMENT", 19, 25], ["helicase activities", "PROBLEM", 30, 49], ["many RNA viruses", "PROBLEM", 108, 124]]], ["Nevertheless, the exact RTPase mechanism as well as the high-resolution structure of nsp13 are still unknown.The guanylyltransferase (GTase)The guanylyltransferase (GTase) enzyme allows the transfer of GMP to the 5 -diphosphate mRNA end (Fig. 4) (Roth and Hurwitz, 1984) .", [["GMP", "CHEMICAL", 202, 205], ["5 -diphosphate", "CHEMICAL", 213, 227], ["GMP", "CHEMICAL", 202, 205], ["5 -diphosphate", "CHEMICAL", 213, 227], ["RTPase", "GENE_OR_GENE_PRODUCT", 24, 30], ["nsp13", "GENE_OR_GENE_PRODUCT", 85, 90], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 113, 132], ["GTase", "GENE_OR_GENE_PRODUCT", 134, 139], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 144, 163], ["GTase", "GENE_OR_GENE_PRODUCT", 165, 170], ["GMP", "SIMPLE_CHEMICAL", 202, 205], ["5 -diphosphate", "GENE_OR_GENE_PRODUCT", 213, 227], ["RTPase", "PROTEIN", 24, 30], ["nsp13", "PROTEIN", 85, 90], ["guanylyltransferase", "PROTEIN", 113, 132], ["GTase", "PROTEIN", 134, 139], ["guanylyltransferase (GTase) enzyme", "PROTEIN", 144, 178], ["5 -diphosphate mRNA end", "RNA", 213, 236], ["the exact RTPase mechanism", "TEST", 14, 40], ["The guanylyltransferase (GTase)", "TREATMENT", 109, 140], ["The guanylyltransferase (GTase) enzyme", "TREATMENT", 140, 178], ["GMP", "TEST", 202, 205]]], ["Most GTase proteins were shown to create covalent links with GMP before its subsequent transfer onto the diphosphate end of the RNA (Ahola and Ahlquist, 1999) .The guanylyltransferase (GTase)Many efforts have been made to identify the SARS-CoV GTase, unsuccessfully so far.", [["GMP", "CHEMICAL", 61, 64], ["diphosphate", "CHEMICAL", 105, 116], ["GMP", "CHEMICAL", 61, 64], ["diphosphate", "CHEMICAL", 105, 116], ["GTase", "GENE_OR_GENE_PRODUCT", 5, 10], ["GMP", "SIMPLE_CHEMICAL", 61, 64], ["diphosphate", "SIMPLE_CHEMICAL", 105, 116], ["guanylyltransferase", "GENE_OR_GENE_PRODUCT", 164, 183], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 235, 243], ["GTase proteins", "PROTEIN", 5, 19], ["diphosphate end", "PROTEIN", 105, 120], ["guanylyltransferase", "PROTEIN", 164, 183], ["GTase", "PROTEIN", 185, 190], ["SARS-CoV GTase", "PROTEIN", 235, 249], ["SARS-CoV", "SPECIES", 235, 243], ["Most GTase proteins", "PROBLEM", 0, 19], ["GMP", "TREATMENT", 61, 64], ["The guanylyltransferase (GTase)", "TREATMENT", 160, 191]]], ["No GMP covalent link was found for nsp7, nsp8, nsp10/nsp16, nsp12, nsp13, nsp14 or nsp15 (Jin et al., 2013) .", [["GMP", "CHEMICAL", 3, 6], ["GMP", "CHEMICAL", 3, 6], ["GMP", "SIMPLE_CHEMICAL", 3, 6], ["nsp7", "GENE_OR_GENE_PRODUCT", 35, 39], ["nsp8", "GENE_OR_GENE_PRODUCT", 41, 45], ["nsp10", "GENE_OR_GENE_PRODUCT", 47, 52], ["nsp16", "GENE_OR_GENE_PRODUCT", 53, 58], ["nsp12", "GENE_OR_GENE_PRODUCT", 60, 65], ["nsp13", "GENE_OR_GENE_PRODUCT", 67, 72], ["nsp14", "GENE_OR_GENE_PRODUCT", 74, 79], ["nsp15", "GENE_OR_GENE_PRODUCT", 83, 88], ["nsp7", "PROTEIN", 35, 39], ["nsp8", "PROTEIN", 41, 45], ["nsp10", "PROTEIN", 47, 52], ["nsp16", "PROTEIN", 53, 58], ["nsp12", "PROTEIN", 60, 65], ["nsp13", "PROTEIN", 67, 72], ["nsp14", "PROTEIN", 74, 79], ["nsp15", "PROTEIN", 83, 88], ["GMP covalent link", "PROBLEM", 3, 20], ["nsp7", "TEST", 35, 39], ["nsp8", "TEST", 41, 45], ["nsp10", "TEST", 47, 52], ["nsp16", "TEST", 53, 58], ["nsp12", "TEST", 60, 65], ["nsp13", "TEST", 67, 72], ["nsp14", "TEST", 74, 79], ["GMP", "OBSERVATION", 3, 6], ["covalent link", "OBSERVATION", 7, 20]]], ["Yeast trans-complementation experiments, that had allowed discovery of the N7-MTase activity (see Section 5.3), did not allow the identification of the SARS-CoV GTase activity (Chen et al., 2009 ).", [["SARS", "DISEASE", 152, 156], ["MTase", "PROTEIN", 78, 83], ["Yeast", "SPECIES", 0, 5], ["SARS-CoV", "SPECIES", 152, 160], ["the SARS", "PROBLEM", 148, 156]]], ["This function remains elusive.The N7-methyltransferase (N7-MTase)The methylation of the mRNA at the N7 position of the cap is the third step of cap formation and leads to a \"cap-0\" ( 7m GpppN) (Fig. 3) .", [["cap", "ANATOMY", 144, 147], ["N7", "CHEMICAL", 34, 36], ["N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 34, 54], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 56, 64], ["cap", "CELLULAR_COMPONENT", 144, 147], ["N7-methyltransferase", "PROTEIN", 34, 54], ["N7", "PROTEIN", 56, 58], ["MTase", "PROTEIN", 59, 64], ["mRNA", "RNA", 88, 92], ["N7 position", "PROTEIN", 100, 111], ["The N7-methyltransferase (N7-MTase", "TREATMENT", 30, 64], ["The methylation of the mRNA", "TREATMENT", 65, 92], ["a \"cap", "TEST", 171, 177], ["cap", "OBSERVATION_MODIFIER", 119, 122]]], ["N7-MTases are S-adenosyl-l-methionine (SAM) dependent enzymes.", [["S-adenosyl-l-methionine", "CHEMICAL", 14, 37], ["SAM", "CHEMICAL", 39, 42], ["S-adenosyl-l-methionine", "CHEMICAL", 14, 37], ["SAM", "CHEMICAL", 39, 42], ["N7-MTases", "SIMPLE_CHEMICAL", 0, 9], ["S-adenosyl-l-methionine", "SIMPLE_CHEMICAL", 14, 37], ["SAM", "SIMPLE_CHEMICAL", 39, 42], ["S-adenosyl-l-methionine (SAM) dependent enzymes", "PROTEIN", 14, 61], ["S-adenosyl", "TREATMENT", 14, 24], ["methionine (SAM) dependent enzymes", "TREATMENT", 27, 61]]], ["A methyl group is transferred from the SAM to the cap-RNA, producing also S-adenosyl-homocysteine (SAH) as byproduct.The N7-methyltransferase (N7-MTase)Functional screenings in yeast have revealed that SARS-CoV nsp14 is able to complement the deletion of the cellular cap N7-MTase (Chen et al., 2009) .", [["cellular", "ANATOMY", 259, 267], ["methyl", "CHEMICAL", 2, 8], ["S-adenosyl-homocysteine", "CHEMICAL", 74, 97], ["SAH", "DISEASE", 99, 102], ["methyl", "CHEMICAL", 2, 8], ["S-adenosyl-homocysteine", "CHEMICAL", 74, 97], ["SAH", "CHEMICAL", 99, 102], ["N7", "CHEMICAL", 121, 123], ["methyl", "SIMPLE_CHEMICAL", 2, 8], ["S-adenosyl-homocysteine", "SIMPLE_CHEMICAL", 74, 97], ["SAH", "SIMPLE_CHEMICAL", 99, 102], ["N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 121, 141], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 143, 151], ["SARS-CoV", "ORGANISM", 202, 210], ["nsp14", "GENE_OR_GENE_PRODUCT", 211, 216], ["cellular", "CELL", 259, 267], ["SAM", "PROTEIN", 39, 42], ["cap-RNA", "RNA", 50, 57], ["N7-methyltransferase", "PROTEIN", 121, 141], ["N7", "PROTEIN", 143, 145], ["MTase", "PROTEIN", 146, 151], ["SARS-CoV nsp14", "PROTEIN", 202, 216], ["MTase", "PROTEIN", 275, 280], ["yeast", "SPECIES", 177, 182], ["yeast", "SPECIES", 177, 182], ["SARS-CoV", "SPECIES", 202, 210], ["S-adenosyl-homocysteine (SAH)", "TREATMENT", 74, 103], ["The N7-methyltransferase (N7-MTase", "TREATMENT", 117, 151], ["Functional screenings in yeast", "TEST", 152, 182], ["SARS", "PROBLEM", 202, 206], ["CoV nsp14", "TEST", 207, 216], ["cap", "ANATOMY", 50, 53]]], ["Furthermore, this activity was demonstrated by biochemical analysis.", [["biochemical analysis", "TEST", 47, 67]]], ["Nsp14 is able to methylate the N7 position in presence of SAM without any sequence specificity (Chen et al., 2009; Bouvet et al., 2010) .", [["N7", "CHEMICAL", 31, 33], ["SAM", "CHEMICAL", 58, 61], ["Nsp14", "GENE_OR_GENE_PRODUCT", 0, 5], ["Nsp14", "PROTEIN", 0, 5], ["N7 position", "DNA", 31, 42], ["SAM", "PROTEIN", 58, 61]]], ["Indeed, nsp14 N7-MTase is active on different types of substrates: GTP and dGTP as well as cap analogs (GpppG, GpppA and m7 GpppG) (Jin et al., 2013) .", [["GTP", "CHEMICAL", 67, 70], ["dGTP", "CHEMICAL", 75, 79], ["GTP", "CHEMICAL", 67, 70], ["dGTP", "CHEMICAL", 75, 79], ["nsp14 N7-MTase", "GENE_OR_GENE_PRODUCT", 8, 22], ["GTP", "SIMPLE_CHEMICAL", 67, 70], ["dGTP", "SIMPLE_CHEMICAL", 75, 79], ["cap analogs", "SIMPLE_CHEMICAL", 91, 102], ["GpppG", "GENE_OR_GENE_PRODUCT", 104, 109], ["GpppA", "GENE_OR_GENE_PRODUCT", 111, 116], ["m7 GpppG", "GENE_OR_GENE_PRODUCT", 121, 129], ["nsp14", "PROTEIN", 8, 13], ["MTase", "PROTEIN", 17, 22], ["GpppG", "PROTEIN", 104, 109], ["GpppA", "PROTEIN", 111, 116], ["m7 GpppG", "PROTEIN", 121, 129], ["GTP and dGTP", "TREATMENT", 67, 79], ["cap analogs", "TEST", 91, 102], ["GpppG", "TEST", 104, 109], ["GpppA", "TEST", 111, 116], ["active", "OBSERVATION_MODIFIER", 26, 32]]], ["By sequence alignment and comparison of conserved motifs, the N7-MTase activity was attributed to the C-terminal domain of nsp14.", [["C", "CHEMICAL", 102, 103], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 62, 70], ["nsp14", "GENE_OR_GENE_PRODUCT", 123, 128], ["MTase", "PROTEIN", 65, 70], ["C-terminal domain", "PROTEIN", 102, 119], ["nsp14", "PROTEIN", 123, 128], ["the C-terminal domain of nsp14", "TREATMENT", 98, 128]]], ["Biochemical analysis revealed that both nsp14 enzymatic activities (ExoN and N7-MTase) are functionally distinct.", [["nsp14", "GENE_OR_GENE_PRODUCT", 40, 45], ["ExoN", "GENE_OR_GENE_PRODUCT", 68, 72], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 77, 85], ["nsp14", "PROTEIN", 40, 45], ["ExoN", "PROTEIN", 68, 72], ["N7", "PROTEIN", 77, 79], ["MTase", "PROTEIN", 80, 85], ["Biochemical analysis", "TEST", 0, 20], ["ExoN and N7-MTase)", "TREATMENT", 68, 86], ["distinct", "OBSERVATION_MODIFIER", 104, 112]]], ["However, based on deletion mutation analysis the two functional domains seem structurally linked (Chen et al., 2009 ) and a large region of nsp14 (aa 62 to 527) is essential for both N7-MTase and ExoN activities.", [["nsp14", "GENE_OR_GENE_PRODUCT", 140, 145], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 183, 191], ["ExoN", "GENE_OR_GENE_PRODUCT", 196, 200], ["nsp14", "DNA", 140, 145], ["aa 62 to 527", "DNA", 147, 159], ["MTase", "PROTEIN", 186, 191], ["ExoN", "PROTEIN", 196, 200], ["deletion mutation analysis", "TEST", 18, 44], ["a large region of nsp14", "PROBLEM", 122, 145], ["N7-MTase", "TREATMENT", 183, 191], ["large", "OBSERVATION_MODIFIER", 124, 129]]], ["The N7-MTase activity is strongly dependent on the N-terminal domain.", [["N7-MTase", "GENE_OR_GENE_PRODUCT", 4, 12], ["MTase", "PROTEIN", 7, 12], ["N-terminal domain", "PROTEIN", 51, 68], ["The N7-MTase activity", "TREATMENT", 0, 21], ["MTase activity", "OBSERVATION", 7, 21], ["dependent", "OBSERVATION_MODIFIER", 34, 43]]], ["However, the N-terminal ExoN domain is not involved in substrate binding for the N7-MTase activity .", [["N7-MTase", "GENE_OR_GENE_PRODUCT", 81, 89], ["N-terminal ExoN domain", "PROTEIN", 13, 35], ["MTase", "PROTEIN", 84, 89], ["the N-terminal ExoN domain", "PROBLEM", 9, 35]]], ["Nsp10, which was shown to strongly enhance the nsp14 ExoN activity (Bouvet et al., 2012) , has no effect on the nsp14 N7-MTase activity .The N7-methyltransferase (N7-MTase)The most conserved motif among N7-MTases is the SAMbinding site with a specific sequence signature \"D/ExGxGxG\" (where x refers to any amino acid) (Martin and McMillan, 2002) .", [["Nsp10", "CHEMICAL", 0, 5], ["amino acid", "CHEMICAL", 306, 316], ["N7", "CHEMICAL", 141, 143], ["amino acid", "CHEMICAL", 306, 316], ["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["nsp14", "GENE_OR_GENE_PRODUCT", 47, 52], ["nsp14 N7-MTase", "GENE_OR_GENE_PRODUCT", 112, 126], ["N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 141, 161], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 163, 171], ["N7-MTases", "GENE_OR_GENE_PRODUCT", 203, 212], ["amino acid", "AMINO_ACID", 306, 316], ["Nsp10", "PROTEIN", 0, 5], ["nsp14", "PROTEIN", 47, 52], ["ExoN", "PROTEIN", 53, 57], ["MTase", "PROTEIN", 121, 126], ["N7-methyltransferase", "PROTEIN", 141, 161], ["N7", "PROTEIN", 163, 165], ["MTase", "PROTEIN", 166, 171], ["N7-MTases", "PROTEIN", 203, 212], ["SAMbinding site", "DNA", 220, 235], ["The N7-methyltransferase (N7-MTase)", "TREATMENT", 137, 172], ["N7-MTases", "TREATMENT", 203, 212], ["the SAMbinding site", "PROBLEM", 216, 235], ["any amino acid", "TREATMENT", 302, 316], ["no", "UNCERTAINTY", 95, 97], ["effect", "OBSERVATION_MODIFIER", 98, 104]]], ["According to CoV nsp14 sequence alignments, the motif DxGx-PxG/A (aa 331 to 337) may represent the SAM-binding site of the nsp14 N7-MTase (Chen et al., 2009; Bouvet et al., 2010) .", [["CoV", "ORGANISM", 13, 16], ["CoV nsp14 sequence alignments", "DNA", 13, 42], ["DxGx", "DNA", 54, 58], ["PxG", "DNA", 59, 62], ["aa 331 to 337", "DNA", 66, 79], ["SAM-binding site", "DNA", 99, 115], ["nsp14 N7-MTase", "DNA", 123, 137], ["CoV nsp14 sequence alignments", "TEST", 13, 42], ["the motif DxGx", "TEST", 44, 58], ["PxG", "TEST", 59, 62]]], ["Moreover, two more regions, the first ranging from aa 310 to 428, overlapping with the core domain of N7-MTase, and the second ranging from aa 73 to 86, located at the N-terminus of the ExoN domain were found to be essential for nsp14 N7-MTase activity .The N7-methyltransferase (N7-MTase)The SAM-dependent MTase family exhibits low sequence conservation but possesses a highly conserved structural fold, named Rossmann-like fold (Martin and McMillan, 2002; Schubert et al., 2003) .", [["N", "CHEMICAL", 168, 169], ["N7", "CHEMICAL", 258, 260], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 102, 110], ["ExoN", "GENE_OR_GENE_PRODUCT", 186, 190], ["N7-methyltransferase", "GENE_OR_GENE_PRODUCT", 258, 278], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 280, 288], ["MTase", "GENE_OR_GENE_PRODUCT", 307, 312], ["aa 310 to 428", "DNA", 51, 64], ["N7", "PROTEIN", 102, 104], ["MTase", "PROTEIN", 105, 110], ["N-terminus", "PROTEIN", 168, 178], ["ExoN domain", "PROTEIN", 186, 197], ["nsp14 N7", "PROTEIN", 229, 237], ["MTase", "PROTEIN", 238, 243], ["N7-methyltransferase", "PROTEIN", 258, 278], ["N7", "PROTEIN", 280, 282], ["MTase", "PROTEIN", 283, 288], ["SAM", "PROTEIN", 293, 296], ["MTase family", "PROTEIN", 307, 319], ["Rossmann", "PROTEIN", 411, 419], ["nsp", "PROBLEM", 229, 232], ["The N7-methyltransferase (N7-MTase)", "TREATMENT", 254, 289], ["The SAM-dependent MTase family", "TREATMENT", 289, 319], ["low sequence conservation", "PROBLEM", 329, 354], ["a highly conserved structural fold", "PROBLEM", 369, 403], ["structural fold", "OBSERVATION", 388, 403]]], ["This fold is an alternation of \u2424-stranded and \u2423-helical regions, with 7 strands forming a central relatively planar \u2424-sheet and a varying number of helices creating two layers, one on each side of the plane (Martin and McMillan, 2002) .", [["\u2424-stranded and \u2423-helical regions", "PROTEIN", 31, 63], ["an alternation of \u2424-stranded and \u2423-helical regions", "PROBLEM", 13, 63], ["\u2424-stranded", "OBSERVATION_MODIFIER", 31, 41], ["central", "ANATOMY_MODIFIER", 90, 97], ["varying", "OBSERVATION_MODIFIER", 130, 137], ["number", "OBSERVATION_MODIFIER", 138, 144], ["helices", "OBSERVATION_MODIFIER", 148, 155], ["two", "OBSERVATION_MODIFIER", 165, 168], ["layers", "OBSERVATION_MODIFIER", 169, 175], ["one", "OBSERVATION_MODIFIER", 177, 180]]], ["Based on the known structure of mRNA cap N7-MTase, a structural model of SARS-CoV nsp14 core N7-MTase was created .", [["SARS", "DISEASE", 73, 77], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 93, 101], ["mRNA", "RNA", 32, 36], ["MTase", "PROTEIN", 44, 49], ["SARS-CoV nsp14 core N7-MTase", "DNA", 73, 101], ["SARS-CoV", "SPECIES", 73, 81], ["SARS", "TEST", 73, 77]]], ["This model confirmed the implication of DxGxPxG/A motif in SAM binding.", [["DxGxPxG", "GENE_OR_GENE_PRODUCT", 40, 47], ["A", "GENE_OR_GENE_PRODUCT", 48, 49], ["SAM", "SIMPLE_CHEMICAL", 59, 62], ["DxGxPxG/A motif", "DNA", 40, 55], ["DxGxPxG", "TREATMENT", 40, 47], ["A motif in SAM binding", "TREATMENT", 48, 70]]], ["Nevertheless, the determination of the full-length nsp14 structure is required to better understand the functional mechanism of the N7-MTase activity.The 2 -O-methyltransferase (2 -O-MTase)A 2 -O-MTase transfers a methyl group from the SAM methyl donor to the first mRNA nucleotide.", [["2 -O-methyltransferase (2 -O", "CHEMICAL", 154, 182], ["methyl", "CHEMICAL", 214, 220], ["methyl", "CHEMICAL", 240, 246], ["nucleotide", "CHEMICAL", 271, 281], ["2 -O", "CHEMICAL", 154, 158], ["methyl", "CHEMICAL", 214, 220], ["SAM methyl", "CHEMICAL", 236, 246], ["nucleotide", "CHEMICAL", 271, 281], ["nsp14", "GENE_OR_GENE_PRODUCT", 51, 56], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 132, 140], ["2 -O-methyltransferase", "SIMPLE_CHEMICAL", 154, 176], ["2 -O-MTase)A 2 -O-MTase", "SIMPLE_CHEMICAL", 178, 201], ["methyl", "SIMPLE_CHEMICAL", 214, 220], ["SAM methyl", "SIMPLE_CHEMICAL", 236, 246], ["nsp14 structure", "PROTEIN", 51, 66], ["MTase", "PROTEIN", 135, 140], ["2 -O-methyltransferase (2 -O-MTase)A 2 -O-MTase", "PROTEIN", 154, 201], ["first mRNA nucleotide", "RNA", 260, 281], ["the full-length nsp14 structure", "TREATMENT", 35, 66], ["a methyl group", "TREATMENT", 212, 226], ["the SAM methyl donor", "TREATMENT", 232, 252], ["the first mRNA nucleotide", "TREATMENT", 256, 281]]], ["This step converts the \"cap-0\" to a \"cap-1\" structure ( 7m Gppp m2 N), this last form being found in all higher eukaryotes (Fig. 3) .", [["N", "CHEMICAL", 67, 68]]], ["Lower eukaryotes, including yeast, employ usually a \"cap-0\" ( 7m GpppN) structure.", [["yeast", "SPECIES", 28, 33], ["yeast", "SPECIES", 28, 33], ["Lower eukaryotes", "PROBLEM", 0, 16], ["yeast", "PROBLEM", 28, 33]]], ["Many RNA viruses have evolved to adopt the \"cap-1\" structure, yielding to \"cellularlike mRNA\".", [["cellularlike mRNA", "RNA", 75, 92], ["Many RNA viruses", "PROBLEM", 0, 16], ["RNA viruses", "OBSERVATION", 5, 16]]], ["Z\u00fcst et al. (2011) highlighted a biological role for viral mRNA 2 -O-methylation.", [["viral mRNA", "RNA", 53, 63], ["viral mRNA", "TEST", 53, 63]]], ["They showed that 2 -O-methylation subverts the induction of type I interferon, acting as a molecular signature to distinguish self and non-self mRNA.The 2 -O-methyltransferase (2 -O-MTase)2 -O-MTases belong to the same family as N7-MTase, with low sequence identity but a common Rossmann-like structural fold (see section 5.3) encompassing the canonical catalytic tetrad K-D-K-E (Bujnicki and Rychlewski, 2001; Ferron et al., 2002; Benarroch et al., 2004a) .", [["2 -O", "CHEMICAL", 17, 21], ["2 -O", "CHEMICAL", 153, 157], ["2 -O", "SIMPLE_CHEMICAL", 17, 21], ["type I interferon", "GENE_OR_GENE_PRODUCT", 60, 77], ["2 -O-methyltransferase", "SIMPLE_CHEMICAL", 153, 175], ["2 -O-MTase)2 -O-MTases", "SIMPLE_CHEMICAL", 177, 199], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 229, 237], ["type I interferon", "PROTEIN", 60, 77], ["self and non-self mRNA", "RNA", 126, 148], ["2 -O-methyltransferase (2 -O-MTase)2 -O-MTases", "PROTEIN", 153, 199], ["N7", "PROTEIN", 229, 231], ["MTase", "PROTEIN", 232, 237], ["Rossmann", "PROTEIN", 279, 287], ["canonical catalytic tetrad K", "PROTEIN", 344, 372], ["type I interferon", "TREATMENT", 60, 77], ["methyltransferase (2 -O-MTase)", "TREATMENT", 158, 188], ["low sequence identity", "PROBLEM", 244, 265], ["a common Rossmann-like structural fold", "PROBLEM", 270, 308]]], ["The functional mechanism of the vaccinia virus (vv) 2 -O-MTase VP39 has been extensively described (Hodel et al., 1996; Lockless et al., 1998) .", [["vaccinia virus", "ORGANISM", 32, 46], ["2 -O-MTase", "GENE_OR_GENE_PRODUCT", 52, 62], ["vaccinia virus (vv) 2 -O-MTase VP39", "PROTEIN", 32, 67], ["vaccinia virus", "SPECIES", 32, 46], ["the vaccinia virus", "TREATMENT", 28, 46]]], ["The reaction mechanism seems to involve a bi-molecular nucleophilic substitution (S N 2 type) in which the nucleophilic ribose 2 -hydroxyl group of a lysine attacks the SAM methyl group, thus leading to the release of SAH .The 2 -O-methyltransferase (2 -O-MTase)Bioinformatics studies on the SARS-CoV have predicted a SAM-dependent 2 -O-MTase harbored by nsp16 (Von Grotthuss et al., 2003) .", [["ribose 2 -hydroxyl", "CHEMICAL", 120, 138], ["lysine", "CHEMICAL", 150, 156], ["SAM methyl", "CHEMICAL", 169, 179], ["SAH", "DISEASE", 218, 221], ["ribose 2 -hydroxyl", "CHEMICAL", 120, 138], ["lysine", "CHEMICAL", 150, 156], ["SAM methyl", "CHEMICAL", 169, 179], ["2 -O", "CHEMICAL", 227, 231], ["ribose 2 -hydroxyl", "SIMPLE_CHEMICAL", 120, 138], ["lysine", "AMINO_ACID", 150, 156], ["SAM methyl", "SIMPLE_CHEMICAL", 169, 179], ["SAH", "SIMPLE_CHEMICAL", 218, 221], ["2 -O-methyltransferase", "SIMPLE_CHEMICAL", 227, 249], ["2 -O-MTase", "SIMPLE_CHEMICAL", 251, 261], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 292, 300], ["MTase", "PROTEIN", 256, 261], ["SAM-dependent 2 -O-MTase", "PROTEIN", 318, 342], ["nsp16", "PROTEIN", 355, 360], ["SARS-CoV", "SPECIES", 292, 300], ["The reaction mechanism", "PROBLEM", 0, 22], ["a bi-molecular nucleophilic substitution", "PROBLEM", 40, 80], ["the nucleophilic ribose", "TREATMENT", 103, 126], ["a lysine attacks the SAM methyl group", "TREATMENT", 148, 185], ["SAH", "PROBLEM", 218, 221], ["Bioinformatics studies", "TEST", 262, 284], ["the SARS", "TEST", 288, 296], ["nucleophilic substitution", "OBSERVATION", 55, 80], ["SAH", "OBSERVATION", 218, 221]]], ["This activity was confirmed in vitro for FCoV nsp16 (Decroly et al., 2008) and, with a lower activity for SARS-CoV nsp16.", [["SARS-CoV", "SPECIES", 106, 114], ["FCoV nsp", "TEST", 41, 49], ["SARS", "PROBLEM", 106, 110], ["CoV nsp", "TEST", 111, 118]]], ["Bouvet et al. (2010) showed evidences that SARS-CoV nsp16 2 -O-MTase activity is stimulated by the addition of nsp10 through direct protein/protein interaction.", [["SARS", "DISEASE", 43, 47], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 43, 51], ["2 -O-MTase", "SIMPLE_CHEMICAL", 58, 68], ["nsp10", "GENE_OR_GENE_PRODUCT", 111, 116], ["MTase", "PROTEIN", 63, 68], ["nsp10", "PROTEIN", 111, 116], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "PROBLEM", 43, 47], ["CoV ns", "TREATMENT", 48, 54], ["nsp10", "TREATMENT", 111, 116], ["direct protein/protein interaction", "TREATMENT", 125, 159], ["SARS", "OBSERVATION", 43, 47]]], ["They found out that the nsp10/nsp16 complex can methylate the 2 O position of the first mRNA nucleotide only if the cap is already methylated at the N7 position.", [["nucleotide", "CHEMICAL", 93, 103], ["nucleotide", "CHEMICAL", 93, 103], ["nsp10", "GENE_OR_GENE_PRODUCT", 24, 29], ["nsp16", "GENE_OR_GENE_PRODUCT", 30, 35], ["nsp10", "PROTEIN", 24, 29], ["nsp16 complex", "PROTEIN", 30, 43], ["2 O position", "DNA", 62, 74], ["first mRNA nucleotide", "RNA", 82, 103], ["N7 position", "DNA", 149, 160], ["the nsp10/nsp16 complex", "PROBLEM", 20, 43], ["the first mRNA nucleotide", "TREATMENT", 78, 103], ["the cap", "PROBLEM", 112, 119]]], ["Using a mutational approach, K 46 -D 130 -K 170 -E 203 residues were identified as the catalytic tetrad (Fig. 5) .", [["K", "CHEMICAL", 29, 30], ["K 46 -D 130 -K 170", "DNA", 29, 47], ["a mutational approach", "TEST", 6, 27], ["K", "TEST", 29, 30], ["K", "TEST", 42, 43]]], ["The 2 -O-MTase activity is completely abolished by any single mutation of this catalytic tetrad, demonstrating that although nsp10 stimulates the nsp16 2 -O-MTase activity, the catalytic site itself resides in nsp16 .", [["2 -O-MTase", "GENE_OR_GENE_PRODUCT", 4, 14], ["nsp10", "GENE_OR_GENE_PRODUCT", 125, 130], ["nsp", "GENE_OR_GENE_PRODUCT", 146, 149], ["nsp16", "GENE_OR_GENE_PRODUCT", 210, 215], ["MTase", "PROTEIN", 9, 14], ["nsp10", "PROTEIN", 125, 130], ["MTase", "PROTEIN", 157, 162], ["catalytic site", "DNA", 177, 191], ["nsp16", "PROTEIN", 210, 215]]], ["Noteworthy, a similar activation of MTase activity was previously reported for the vaccinia virus capping enzyme (Mao and Shuman, 1994) .", [["MTase", "GENE_OR_GENE_PRODUCT", 36, 41], ["vaccinia virus", "ORGANISM", 83, 97], ["MTase", "PROTEIN", 36, 41], ["vaccinia virus capping enzyme", "PROTEIN", 83, 112], ["vaccinia virus", "SPECIES", 83, 97], ["a similar activation of MTase activity", "PROBLEM", 12, 50], ["the vaccinia virus capping enzyme", "TREATMENT", 79, 112]]], ["The structure of the co-factor nsp10 was first solved and revealed a novel fold with a pair of antiparallel Nterminal \u2423-helices stacked against an irregular \u2424-sheet, a coil-rich C-terminus and two Zn fingers (Joseph et al., 2006; Su et al., 2006) .", [["C", "CHEMICAL", 178, 179], ["Zn", "CHEMICAL", 197, 199], ["nsp10", "GENE_OR_GENE_PRODUCT", 31, 36], ["nsp10", "PROTEIN", 31, 36], ["antiparallel Nterminal \u2423-helices", "PROTEIN", 95, 127], ["coil-rich C-terminus", "PROTEIN", 168, 188], ["Zn fingers", "PROTEIN", 197, 207], ["a novel fold", "PROBLEM", 67, 79], ["a coil", "TREATMENT", 166, 172], ["irregular", "OBSERVATION_MODIFIER", 147, 156]]], ["The crystal structure of SARS-CoV nsp16 in complex with nsp10 was determined in 2011 by 2 groups (Fig. 5) (Chen et al., 2011; Decroly et al., 2011) .", [["SARS", "DISEASE", 25, 29], ["SARS-CoV nsp16", "GENE_OR_GENE_PRODUCT", 25, 39], ["nsp10", "GENE_OR_GENE_PRODUCT", 56, 61], ["SARS-CoV nsp16", "PROTEIN", 25, 39], ["nsp10", "PROTEIN", 56, 61], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "PROBLEM", 25, 29], ["nsp10", "TREATMENT", 56, 61], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["structure", "OBSERVATION_MODIFIER", 12, 21], ["SARS", "OBSERVATION", 25, 29], ["CoV", "OBSERVATION_MODIFIER", 30, 33]]], ["The nsp10 overall structure in complex with nsp16 remains quite similar to the one determined for the free nsp10.", [["nsp10", "GENE_OR_GENE_PRODUCT", 4, 9], ["nsp16", "GENE_OR_GENE_PRODUCT", 44, 49], ["nsp10", "GENE_OR_GENE_PRODUCT", 107, 112], ["nsp10", "PROTEIN", 4, 9], ["nsp16", "PROTEIN", 44, 49], ["nsp10", "PROTEIN", 107, 112], ["nsp16", "TEST", 44, 49], ["the free nsp10", "TREATMENT", 98, 112], ["overall", "OBSERVATION_MODIFIER", 10, 17], ["structure", "OBSERVATION_MODIFIER", 18, 27], ["complex", "OBSERVATION_MODIFIER", 31, 38]]], ["Nsp16 adopts a canonical SAM-dependent MTase fold with two binding domains, one for the methyl donor SAM and another for the methyl acceptor substrate (capped-RNA).", [["Nsp16", "CHEMICAL", 0, 5], ["methyl", "CHEMICAL", 88, 94], ["methyl", "CHEMICAL", 125, 131], ["methyl", "CHEMICAL", 88, 94], ["SAM", "CHEMICAL", 101, 104], ["methyl", "CHEMICAL", 125, 131], ["Nsp16", "GENE_OR_GENE_PRODUCT", 0, 5], ["SAM", "SIMPLE_CHEMICAL", 101, 104], ["methyl acceptor substrate", "SIMPLE_CHEMICAL", 125, 150], ["Nsp16", "PROTEIN", 0, 5], ["SAM", "PROTEIN", 25, 28], ["MTase", "PROTEIN", 39, 44], ["binding domains", "PROTEIN", 59, 74], ["methyl donor SAM", "PROTEIN", 88, 104], ["methyl acceptor substrate", "PROTEIN", 125, 150], ["capped-RNA", "RNA", 152, 162], ["a canonical SAM-dependent MTase fold", "TREATMENT", 13, 49], ["the methyl donor SAM", "TREATMENT", 84, 104], ["the methyl acceptor substrate (capped-RNA", "TREATMENT", 121, 162]]], ["Nsp16 fold is a central \u2424sheet of 7 strands surrounded by five \u2423-helices.", [["Nsp16", "GENE_OR_GENE_PRODUCT", 0, 5], ["Nsp16", "PROTEIN", 0, 5], ["central", "ANATOMY_MODIFIER", 16, 23]]], ["Compared to the MTase canonical fold, two \u2423-helices are absent in the SAM binding region of nsp16, but the complex formed with nsp10 seems to compensate and stabilize the overall structure of nsp16.", [["nsp10", "CHEMICAL", 127, 132], ["nsp16", "GENE_OR_GENE_PRODUCT", 92, 97], ["nsp10", "GENE_OR_GENE_PRODUCT", 127, 132], ["nsp16", "GENE_OR_GENE_PRODUCT", 192, 197], ["MTase", "PROTEIN", 16, 21], ["SAM binding region", "PROTEIN", 70, 88], ["nsp16", "PROTEIN", 92, 97], ["nsp10", "PROTEIN", 127, 132], ["nsp16", "PROTEIN", 192, 197], ["nsp10", "TREATMENT", 127, 132], ["absent", "OBSERVATION", 56, 62], ["overall", "OBSERVATION_MODIFIER", 171, 178], ["structure", "OBSERVATION_MODIFIER", 179, 188]]], ["Whereas earlier reports claimed that Mg 2+ was necessary for the nsp10/nsp16 2 -O-MTase activity , no cation was observed in the active site.", [["Mg", "CHEMICAL", 37, 39], ["Mg 2+", "CHEMICAL", 37, 42], ["Mg 2+", "SIMPLE_CHEMICAL", 37, 42], ["2 -O-MTase", "SIMPLE_CHEMICAL", 77, 87], ["cation", "SIMPLE_CHEMICAL", 102, 108], ["nsp10", "PROTEIN", 65, 70], ["MTase", "PROTEIN", 82, 87], ["Mg", "TEST", 37, 39], ["cation", "PROBLEM", 102, 108], ["active site", "OBSERVATION", 129, 140]]], ["However, the structure shows a Mg 2+ located far from the SAM-binding site (Fig. 5) .", [["Mg", "CHEMICAL", 31, 33], ["Mg 2+", "CHEMICAL", 31, 36], ["Mg 2+", "SIMPLE_CHEMICAL", 31, 36], ["Mg 2", "PROTEIN", 31, 35], ["SAM-binding site", "DNA", 58, 74], ["SAM", "OBSERVATION_MODIFIER", 58, 61], ["binding site", "OBSERVATION", 62, 74]]], ["It is thus possible that divalent cations play a structural role in the nsp16 structure in stabilizing the general fold.", [["cations", "SIMPLE_CHEMICAL", 34, 41], ["nsp16", "GENE_OR_GENE_PRODUCT", 72, 77], ["nsp16 structure", "PROTEIN", 72, 87], ["divalent cations", "TREATMENT", 25, 41], ["thus possible", "UNCERTAINTY", 6, 19], ["general fold", "ANATOMY", 107, 119]]], ["The organization of the active site is in agreement with the current 2 -O-MTase mechanism described above, transferring the methyl group of SAM to capped-RNA.", [["methyl", "CHEMICAL", 124, 130], ["2 -O", "CHEMICAL", 69, 73], ["methyl", "CHEMICAL", 124, 130], ["SAM", "CHEMICAL", 140, 143], ["methyl", "SIMPLE_CHEMICAL", 124, 130], ["SAM", "SIMPLE_CHEMICAL", 140, 143], ["MTase", "PROTEIN", 74, 79], ["SAM", "PROTEIN", 140, 143], ["capped-RNA", "RNA", 147, 157], ["the methyl group of SAM to capped-RNA", "TREATMENT", 120, 157], ["active", "OBSERVATION_MODIFIER", 24, 30], ["site", "OBSERVATION_MODIFIER", 31, 35]]], ["Although no RNA-bound structure is available to date, a putative RNA-binding groove was proposed based on the highly positively charged patch found on nsp16 at the proximity of the catalytic site (Fig. 6) (Chen et al., 2011; Decroly et al., 2011) .", [["nsp16", "GENE_OR_GENE_PRODUCT", 151, 156], ["nsp16", "PROTEIN", 151, 156], ["catalytic site", "PROTEIN", 181, 195], ["RNA-bound structure", "PROBLEM", 12, 31], ["a putative RNA-binding groove", "PROBLEM", 54, 83], ["no", "UNCERTAINTY", 9, 11]]], ["Nsp10 alone does not exhibit any enzyme activity but appears to be central for two distinct regulatory mechanisms (nsp14 ExoN and nsp16 2 -O-MTase).", [["Nsp10", "CHEMICAL", 0, 5], ["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["nsp14 ExoN", "GENE_OR_GENE_PRODUCT", 115, 125], ["nsp16 2 -O-MTase", "GENE_OR_GENE_PRODUCT", 130, 146], ["Nsp10", "PROTEIN", 0, 5], ["nsp14 ExoN", "PROTEIN", 115, 125], ["O", "PROTEIN", 139, 140], ["MTase", "PROTEIN", 141, 146], ["any enzyme activity", "PROBLEM", 29, 48], ["two distinct regulatory mechanisms", "PROBLEM", 79, 113], ["ExoN", "TEST", 121, 125], ["nsp", "TEST", 130, 133]]], ["Our group has determined the interaction surface of nsp10 with nsp14 and with nsp16 (Bouvet et al., 2014; Lugari et al., 2010) .", [["surface", "ANATOMY", 41, 48], ["nsp10", "GENE_OR_GENE_PRODUCT", 52, 57], ["nsp14", "GENE_OR_GENE_PRODUCT", 63, 68], ["nsp10", "PROTEIN", 52, 57], ["nsp14", "PROTEIN", 63, 68], ["nsp16", "PROTEIN", 78, 83], ["nsp14", "TREATMENT", 63, 68]]], ["These studies show that the same nsp10 interface is involved in complex formation with both nsp16 and nsp14.", [["nsp10", "GENE_OR_GENE_PRODUCT", 33, 38], ["nsp16", "GENE_OR_GENE_PRODUCT", 92, 97], ["nsp14", "GENE_OR_GENE_PRODUCT", 102, 107], ["nsp10", "PROTEIN", 33, 38], ["nsp16", "PROTEIN", 92, 97], ["nsp14", "PROTEIN", 102, 107], ["These studies", "TEST", 0, 13], ["nsp14", "TREATMENT", 102, 107]]], ["Comparison of SARS-CoV nsp10 interaction surface with nsp14 and with nsp16.", [["SARS-CoV nsp10", "GENE_OR_GENE_PRODUCT", 14, 28], ["nsp14", "GENE_OR_GENE_PRODUCT", 54, 59], ["SARS-CoV nsp10", "PROTEIN", 14, 28], ["nsp14", "PROTEIN", 54, 59], ["nsp16", "PROTEIN", 69, 74], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["nsp14", "TEST", 54, 59], ["nsp", "TEST", 69, 72]]], ["The SARS-CoV nsp10/nsp16 complex structure is presented with nsp10 solvent-accessible surface in gray, and nsp16 in yellow ribbon.", [["surface", "ANATOMY", 86, 93], ["SARS-CoV", "ORGANISM", 4, 12], ["nsp10", "GENE_OR_GENE_PRODUCT", 13, 18], ["nsp16", "GENE_OR_GENE_PRODUCT", 19, 24], ["surface", "CELLULAR_COMPONENT", 86, 93], ["nsp16", "GENE_OR_GENE_PRODUCT", 107, 112], ["SARS-CoV nsp10/nsp16 complex structure", "PROTEIN", 4, 42], ["nsp16", "PROTEIN", 107, 112], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV nsp10", "TEST", 9, 18], ["nsp10 solvent", "TREATMENT", 61, 74], ["surface", "OBSERVATION_MODIFIER", 86, 93], ["yellow ribbon", "OBSERVATION", 116, 129]]], ["Nsp10 residues involved in the interaction with nsp14 are depicted in green.", [["Nsp10", "GENE_OR_GENE_PRODUCT", 0, 5], ["nsp14", "GENE_OR_GENE_PRODUCT", 48, 53], ["Nsp10 residues", "PROTEIN", 0, 14], ["nsp14", "PROTEIN", 48, 53]]], ["The interaction surface of nsp10 with nsp16 and nsp14 overlaps, the latter being wider (Bouvet et al., 2014).", [["surface", "ANATOMY", 16, 23], ["nsp10", "GENE_OR_GENE_PRODUCT", 27, 32], ["nsp16", "GENE_OR_GENE_PRODUCT", 38, 43], ["nsp14", "GENE_OR_GENE_PRODUCT", 48, 53], ["nsp10", "PROTEIN", 27, 32], ["nsp16", "PROTEIN", 38, 43], ["nsp14", "PROTEIN", 48, 53], ["nsp16", "TREATMENT", 38, 43], ["nsp14 overlaps", "PROBLEM", 48, 62], ["surface", "OBSERVATION_MODIFIER", 16, 23]]], ["However, in the case of nsp10/nsp14, the interaction interface is substantially wider (Fig. 7) .", [["nsp10", "GENE_OR_GENE_PRODUCT", 24, 29], ["nsp14", "GENE_OR_GENE_PRODUCT", 30, 35], ["nsp10", "PROTEIN", 24, 29], ["nsp14", "PROTEIN", 30, 35], ["substantially", "OBSERVATION_MODIFIER", 66, 79], ["wider", "OBSERVATION_MODIFIER", 80, 85]]], ["As a consequence, nsp10 cannot interact simultaneously with both nsp14 and nsp16.", [["nsp10", "GENE_OR_GENE_PRODUCT", 18, 23], ["nsp14", "GENE_OR_GENE_PRODUCT", 65, 70], ["nsp16", "GENE_OR_GENE_PRODUCT", 75, 80], ["nsp10", "PROTEIN", 18, 23], ["nsp14", "PROTEIN", 65, 70], ["nsp16", "PROTEIN", 75, 80], ["nsp16", "TEST", 75, 80]]], ["Nevertheless, the two regulatory functions of nsp10 may still act simultaneously, since nsp10 is translated in stoichiometric excess compared to ORF1b-encoded nsp14 and nsp16 ( Fig. 1) (Snijder et al., 2003) .The 2 -O-methyltransferase (2 -O-MTase)Eukaryotic and viral mRNA capping systems show many differences (Furuichi and Shatkin, 2000) , and given the essential role fulfilled by these systems, each protein involved in this process should be considered as a potential antiviral target.", [["2 -O", "CHEMICAL", 213, 217], ["nsp10", "GENE_OR_GENE_PRODUCT", 46, 51], ["nsp10", "GENE_OR_GENE_PRODUCT", 88, 93], ["ORF1b", "GENE_OR_GENE_PRODUCT", 145, 150], ["nsp14", "GENE_OR_GENE_PRODUCT", 159, 164], ["nsp16", "GENE_OR_GENE_PRODUCT", 169, 174], ["2 -O-methyltransferase", "GENE_OR_GENE_PRODUCT", 213, 235], ["2 -O-MTase", "GENE_OR_GENE_PRODUCT", 237, 247], ["nsp10", "PROTEIN", 46, 51], ["nsp10", "PROTEIN", 88, 93], ["ORF1b", "PROTEIN", 145, 150], ["nsp14", "PROTEIN", 159, 164], ["nsp16", "PROTEIN", 169, 174], ["2 -O-methyltransferase (2 -O-MTase", "DNA", 213, 247], ["nsp10", "TREATMENT", 46, 51], ["stoichiometric excess", "PROBLEM", 111, 132], ["ORF1b", "TEST", 145, 150], ["The 2 -O-methyltransferase (2 -O-MTase)", "TREATMENT", 209, 248], ["Eukaryotic and viral mRNA capping systems", "TREATMENT", 248, 289], ["viral mRNA", "OBSERVATION", 263, 273]]], ["In particular, viral MTases seem to be good candidates (Dong et al., 2008; Bollati et al., 2010; Dong et al., 2010) .", [["viral MTases", "PROTEIN", 15, 27], ["viral MTases", "PROBLEM", 15, 27], ["viral MTases", "OBSERVATION", 15, 27]]], ["Indeed, mutations abolishing MTase activities have a detrimental effect on viral replication (Almaz\u00e1n et al., 2006; Ray et al., 2006; Chen et al., 2009) .", [["MTase", "GENE_OR_GENE_PRODUCT", 29, 34], ["MTase", "PROTEIN", 29, 34], ["mutations abolishing MTase activities", "PROBLEM", 8, 45], ["viral replication", "TREATMENT", 75, 92]]], ["In vitro, sinefungin and SAH (the by-product of the methyl transfer reaction) were found to inhibit both SARS-CoV MTase activities .", [["sinefungin", "CHEMICAL", 10, 20], ["SAH", "DISEASE", 25, 28], ["sinefungin", "CHEMICAL", 10, 20], ["SAH", "CHEMICAL", 25, 28], ["methyl", "CHEMICAL", 52, 58], ["sinefungin", "SIMPLE_CHEMICAL", 10, 20], ["SAH", "SIMPLE_CHEMICAL", 25, 28], ["methyl", "SIMPLE_CHEMICAL", 52, 58], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["SARS-CoV MTase", "PROTEIN", 105, 119], ["SARS-CoV", "SPECIES", 105, 113], ["sinefungin", "TREATMENT", 10, 20], ["SAH", "PROBLEM", 25, 28], ["the methyl transfer reaction", "TREATMENT", 48, 76]]], ["Furthermore, a crystal structure of the SARS-CoV nsp10/nsp16 complex with sinefungin was solved and revealed that the molecule is bound in the SAM-binding pocket and hence should inhibit nsp16 2 -O-MTase activity (Fig. 6 ).", [["SARS", "DISEASE", 40, 44], ["sinefungin", "CHEMICAL", 74, 84], ["sinefungin", "CHEMICAL", 74, 84], ["SARS-CoV", "ORGANISM", 40, 48], ["nsp10", "GENE_OR_GENE_PRODUCT", 49, 54], ["nsp16", "GENE_OR_GENE_PRODUCT", 55, 60], ["sinefungin", "SIMPLE_CHEMICAL", 74, 84], ["2 -O-MTase", "SIMPLE_CHEMICAL", 193, 203], ["SARS-CoV nsp10", "PROTEIN", 40, 54], ["nsp16 complex", "PROTEIN", 55, 68], ["sinefungin", "PROTEIN", 74, 84], ["SAM", "PROTEIN", 143, 146], ["MTase", "PROTEIN", 198, 203], ["SARS-CoV", "SPECIES", 40, 48], ["the SARS", "PROBLEM", 36, 44], ["CoV nsp10", "TEST", 45, 54], ["sinefungin", "TREATMENT", 74, 84], ["the molecule", "PROBLEM", 114, 126], ["binding pocket", "PROBLEM", 147, 161], ["binding pocket", "OBSERVATION", 147, 161]]], ["In addition, aurintricarboxylic acid (ATA), expected to bind MTase active site, inhibits SARS-CoV replication (He et al., 2004; Milani et al., 2009) .", [["aurintricarboxylic acid", "CHEMICAL", 13, 36], ["ATA", "CHEMICAL", 38, 41], ["aurintricarboxylic acid", "CHEMICAL", 13, 36], ["ATA", "CHEMICAL", 38, 41], ["aurintricarboxylic acid", "SIMPLE_CHEMICAL", 13, 36], ["ATA", "SIMPLE_CHEMICAL", 38, 41], ["MTase", "GENE_OR_GENE_PRODUCT", 61, 66], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 89, 97], ["MTase active site", "PROTEIN", 61, 78], ["SARS-CoV", "SPECIES", 89, 97], ["aurintricarboxylic acid (ATA", "TREATMENT", 13, 41], ["SARS", "PROBLEM", 89, 93]]], ["Biochemical assays demonstrated that ATA inhibits both nsp14 N7-MTase and nsp16 2 -O-MTase activities .", [["ATA", "CHEMICAL", 37, 40], ["ATA", "CHEMICAL", 37, 40], ["ATA", "SIMPLE_CHEMICAL", 37, 40], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 61, 69], ["2 -O-MTase", "SIMPLE_CHEMICAL", 80, 90], ["MTase", "PROTEIN", 64, 69], ["MTase", "PROTEIN", 85, 90], ["Biochemical assays", "TEST", 0, 18], ["ATA", "TEST", 37, 40], ["nsp", "TEST", 55, 58], ["ns", "TREATMENT", 74, 76]]], ["Recently, Sun et al. (2014) developed a yeast-based high-throughput antiviral screening system to find novel anti-coronavirus drugs.", [["yeast", "SPECIES", 40, 45], ["yeast", "SPECIES", 40, 45], ["a yeast", "PROBLEM", 38, 45], ["antiviral screening system", "TREATMENT", 68, 94], ["novel anti-coronavirus drugs", "TREATMENT", 103, 131]]], ["This study confirmed that sinefungin significantly suppresses the growth of yeast cells complemented with nsp14 N7-MTase gene.", [["yeast cells", "ANATOMY", 76, 87], ["sinefungin", "CHEMICAL", 26, 36], ["sinefungin", "CHEMICAL", 26, 36], ["sinefungin", "SIMPLE_CHEMICAL", 26, 36], ["yeast cells", "CELL", 76, 87], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 112, 120], ["yeast cells", "CELL_TYPE", 76, 87], ["nsp14 N7-MTase gene", "DNA", 106, 125], ["yeast", "SPECIES", 76, 81], ["yeast", "SPECIES", 76, 81], ["This study", "TEST", 0, 10], ["sinefungin", "PROBLEM", 26, 36], ["yeast cells", "PROBLEM", 76, 87], ["nsp14 N7-MTase gene", "TREATMENT", 106, 125], ["growth", "OBSERVATION_MODIFIER", 66, 72], ["yeast cells", "OBSERVATION", 76, 87]]], ["However, sinefungin is not a specific inhibitor as it also inhibits yeast and human MTases (Sun et al., 2014) .ConclusionCoronaviruses have only recently attracted a wider audience due to public health issues generated by SARS-and MERS-CoV emergences.", [["sinefungin", "CHEMICAL", 9, 19], ["SARS", "DISEASE", 222, 226], ["sinefungin", "CHEMICAL", 9, 19], ["sinefungin", "GENE_OR_GENE_PRODUCT", 9, 19], ["human", "ORGANISM", 78, 83], ["MERS-CoV", "ORGANISM", 231, 239], ["yeast", "SPECIES", 68, 73], ["human", "SPECIES", 78, 83], ["yeast", "SPECIES", 68, 73], ["human", "SPECIES", 78, 83], ["MERS-CoV", "SPECIES", 231, 239], ["a specific inhibitor", "TREATMENT", 27, 47], ["SARS", "PROBLEM", 222, 226]]], ["Although other viruses, such as Hepatitis C and Influenza viruses, might be better and sooner controlled through antiviral therapies, the study of coronaviruses may well accelerate our current understanding of RNA synthesis, evolution, capping, repair, as well as all novel implications arising from the combination and coordination of these RNA processing activities.", [["Hepatitis C", "DISEASE", 32, 43], ["Influenza viruses", "DISEASE", 48, 65], ["Hepatitis C", "ORGANISM", 32, 43], ["Influenza viruses", "ORGANISM", 48, 65], ["coronaviruses", "ORGANISM", 147, 160], ["Influenza", "SPECIES", 48, 57], ["Hepatitis C", "SPECIES", 32, 43], ["other viruses", "PROBLEM", 9, 22], ["Hepatitis C", "PROBLEM", 32, 43], ["Influenza viruses", "PROBLEM", 48, 65], ["antiviral therapies", "TREATMENT", 113, 132], ["the study", "TEST", 134, 143], ["coronaviruses", "PROBLEM", 147, 160], ["RNA synthesis", "PROBLEM", 210, 223], ["capping", "TREATMENT", 236, 243], ["repair", "TREATMENT", 245, 251], ["viruses", "OBSERVATION", 15, 22], ["Hepatitis", "OBSERVATION", 32, 41], ["Influenza viruses", "OBSERVATION", 48, 65], ["RNA synthesis", "OBSERVATION", 210, 223], ["repair", "OBSERVATION", 245, 251]]], ["Further experiments should open an entirely new field of research, since for viral RNA synthesis, very few data are available on these processes.", [["Further experiments", "TREATMENT", 0, 19], ["viral RNA synthesis", "PROBLEM", 77, 96]]], ["For example, it is possible to quantitate mismatch formation for some RNA viruses (Hepatitis C Virus (Powdrill et al., 2011) , Poliovirus (Korneeva and Cameron, 2007) , Dengue virus ) and sometimes only for a restricted set of nucleotides (Dengue virus ).ConclusionThe progress made on SARS-CoV RNA synthesis machinery comprehension will soon allow to measure, through genome sequencing, the RNA replication fidelity.", [["Hepatitis C Virus", "DISEASE", 83, 100], ["Dengue virus", "DISEASE", 169, 181], ["Dengue", "DISEASE", 240, 246], ["nucleotides", "CHEMICAL", 227, 238], ["Hepatitis C Virus", "ORGANISM", 83, 100], ["Dengue virus", "ORGANISM", 169, 181], ["Dengue virus", "ORGANISM", 240, 252], ["SARS-CoV", "ORGANISM", 286, 294], ["Hepatitis C Virus", "SPECIES", 83, 100], ["Dengue virus", "SPECIES", 169, 181], ["Hepatitis C Virus", "SPECIES", 83, 100], ["Dengue virus", "SPECIES", 169, 181], ["Dengue virus", "SPECIES", 240, 252], ["SARS-CoV", "SPECIES", 286, 294], ["mismatch formation", "PROBLEM", 42, 60], ["some RNA viruses", "PROBLEM", 65, 81], ["Hepatitis C Virus", "PROBLEM", 83, 100], ["Poliovirus", "PROBLEM", 127, 137], ["Dengue virus", "PROBLEM", 169, 181], ["nucleotides (Dengue virus", "PROBLEM", 227, 252], ["SARS", "PROBLEM", 286, 290], ["CoV RNA synthesis", "TREATMENT", 291, 308], ["mismatch", "OBSERVATION", 42, 50], ["RNA viruses", "OBSERVATION", 70, 81]]], ["This knowledge will likely open a Pandora box containing the coronavirus \"playbook\" exposing how they maintain the integrity of their large genomes, while generating the population diversity required for emergence and adaptation.", [["coronavirus", "ORGANISM", 61, 72], ["Pandora box", "DNA", 34, 45], ["a Pandora box", "TREATMENT", 32, 45], ["large", "OBSERVATION_MODIFIER", 134, 139], ["genomes", "OBSERVATION", 140, 147]]], ["Knowing in detail these mechanisms will provide new antiviral strategies.", [["new antiviral strategies", "TREATMENT", 48, 72]]]], "71f6c6b8a43555df8e7148c1ed5be1bb21d916e7": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted by exposure to asymptomatic carriers or patients with COVID-19.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["asymptomatic carriers", "PROBLEM", 103, 124], ["COVID", "TEST", 142, 147], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45]]], ["As cases of COVID-19 continue to rise globally, there are increasing concerns about the risks of SARS-CoV-2 transmission to healthcare workers involved in direct patient care.", [["SARS", "DISEASE", 97, 101], ["CoV-2", "ORGANISM", 102, 107], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["COVID", "TEST", 12, 17], ["SARS", "PROBLEM", 97, 101]]], ["During the SARS-CoV-1 outbreak, healthcare workers were disproportionately affected, comprising 21% of those infected [1] .", [["SARS-CoV-1 outbreak", "DISEASE", 11, 30], ["SARS-CoV-1", "SPECIES", 11, 21]]], ["Some of those at greatest risk were involved in aerosolgenerating procedures [2] .IntroductionThere are currently no prospective procedure-specific data during the current COVID-19 pandemic.IntroductionHowever, based on SARS-CoV-1 data, tracheal intubation is thought to pose the greatest risk of nosocomial transmission of COVID-19 to healthcare workers [3] .", [["tracheal", "ANATOMY", 237, 245], ["COVID-19", "CHEMICAL", 324, 332], ["tracheal", "ORGAN", 237, 245], ["prospective procedure", "TREATMENT", 117, 138], ["the current COVID", "TEST", 160, 177], ["pandemic", "PROBLEM", 181, 189], ["SARS", "TEST", 220, 224], ["CoV", "TEST", 225, 228], ["tracheal intubation", "TREATMENT", 237, 256], ["COVID", "TEST", 324, 329], ["tracheal", "ANATOMY", 237, 245], ["intubation", "OBSERVATION", 246, 256]]], ["In response, interventions such as the appropriate use of personal protective equipment (PPE) [4] and specific procedural techniques [5, 6] have been implemented.", [["interventions", "TREATMENT", 13, 26], ["personal protective equipment (PPE)", "TREATMENT", 58, 93], ["specific procedural techniques", "TREATMENT", 102, 132]]], ["Healthcare workers that develop suspected or confirmed COVID-19 require selfisolation and may need hospitalisation.", [["selfisolation", "TREATMENT", 72, 85]]], ["The magnitude of this risk is important to: inform clinicians in their daily practice [7] ; demonstrate the ramifications to clinical workforce; and consider the societal implications of nosocomial COVID-19 in healthcare workers.", [["nosocomial COVID", "TREATMENT", 187, 203]]], ["However, we currently lack data to estimate the scale of this risk.IntroductionTo better understand the hazards to healthcare workers caring for patients with suspected or confirmed COVID-19, we designed a self-reporting provider registry to collect data on nosocomial exposure, procedural performance, use of PPE, and subsequent COVID-19-related outcomes after tracheal intubation.", [["tracheal", "ANATOMY", 362, 370], ["patients", "ORGANISM", 145, 153], ["tracheal", "ORGAN", 362, 370], ["patients", "SPECIES", 145, 153], ["nosocomial exposure", "TREATMENT", 258, 277], ["PPE", "TREATMENT", 310, 313], ["COVID", "TEST", 330, 335], ["tracheal intubation", "TREATMENT", 362, 381], ["tracheal", "ANATOMY", 362, 370], ["intubation", "OBSERVATION", 371, 381]]], ["We aimed to determine the incidence and risk factors for developing COVID-19 in healthcare workers after their involvement in tracheal intubation.", [["tracheal", "ANATOMY", 126, 134], ["COVID-19", "CHEMICAL", 68, 76], ["tracheal", "ORGAN", 126, 134], ["tracheal intubation", "TREATMENT", 126, 145], ["tracheal", "ANATOMY", 126, 134], ["intubation", "OBSERVATION", 135, 145]]], ["These data can inform clinicians, policy-makers and the wider public of the potential hazards of tracheal intubation to the healthcare workforce and society.MethodsWe adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [8] .", [["tracheal", "ANATOMY", 97, 105], ["tracheal", "ORGAN", 97, 105], ["tracheal intubation", "TREATMENT", 97, 116], ["Observational Studies", "TEST", 213, 234], ["tracheal", "ANATOMY", 97, 105], ["intubation", "OBSERVATION", 106, 116]]], ["The intubateCOVID registry was launched on 23 March 2020 as an investigator-led, prospective multicentre cohort study recruiting healthcare workers performing or assisting in tracheal intubation of patients with suspected or confirmed COVID-19 across 17 countries.", [["tracheal", "ANATOMY", 175, 183], ["tracheal", "ORGAN", 175, 183], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["tracheal intubation", "TREATMENT", 175, 194], ["COVID", "TEST", 235, 240], ["tracheal", "ANATOMY", 175, 183]]], ["Information on the registry was disseminated via national and international professional organisations and social media.MethodsIndividual provider registration and subsequent data submission were completely voluntary, and allAccepted ArticleThis article is protected by copyright.", [["subsequent data submission", "TEST", 164, 190]]], ["All rights reserved participants gave consent for inclusion of their data in this study.", [["participants", "ORGANISM", 20, 32], ["participants", "SPECIES", 20, 32], ["their data", "TEST", 63, 73], ["this study", "TEST", 77, 87]]], ["Registry data were collected via a webbased database (Knack.com, Evenly Odd, Inc., Philadelphia, Pennsylvania, USA).", [["Registry data", "TEST", 0, 13]]], ["At registration, participants recorded their own baseline characteristics, and thereafter utilised the registry to record details of any tracheal intubation procedures they were involved in, and to self-report follow-up outcomes related to their COVID-19 infection status.", [["tracheal", "ANATOMY", 137, 145], ["infection", "DISEASE", 255, 264], ["tracheal", "ORGAN", 137, 145], ["participants", "SPECIES", 17, 29], ["any tracheal intubation procedures", "TREATMENT", 133, 167], ["their COVID-19 infection status", "PROBLEM", 240, 271], ["tracheal", "ANATOMY", 137, 145], ["intubation", "OBSERVATION", 146, 156], ["infection", "OBSERVATION", 255, 264]]], ["Details of all data variables collected in the registry are available online Appendix S1.", [["all data variables", "TEST", 11, 29]]], ["Data collection for the registry is ongoing, but the present analysis of data reported to date was undertaken to ensure timely dissemination of results that would potentially guide clinical practice during the COVID-19 pandemic.", [["Data collection", "TEST", 0, 15], ["the COVID", "TEST", 206, 215], ["pandemic", "PROBLEM", 219, 227]]], ["Due to international variation in patient testing and changing patient case definitions at different points during the pandemic, the COVID-19 status of patients requiring tracheal intubation (either suspected or confirmed) was reported by participants based on local convention.", [["tracheal", "ANATOMY", 171, 179], ["patient", "ORGANISM", 34, 41], ["patient", "ORGANISM", 63, 70], ["patients", "ORGANISM", 152, 160], ["tracheal", "ORGAN", 171, 179], ["patient", "SPECIES", 34, 41], ["patient", "SPECIES", 63, 70], ["patients", "SPECIES", 152, 160], ["participants", "SPECIES", 239, 251], ["patient testing", "TEST", 34, 49], ["changing patient case definitions", "PROBLEM", 54, 87], ["the COVID", "TEST", 129, 138], ["tracheal intubation", "TREATMENT", 171, 190], ["tracheal", "ANATOMY", 171, 179], ["intubation", "OBSERVATION", 180, 190]]], ["Other details of tracheal intubation procedures were also collected (online Appendix S1), including devices used, number of attempts at tracheal intubation and PPE used.Accepted ArticleEmails were sent each week to participants on Fridays at 0900 hrs GMT+1, reminding them to report their COVID-19 infection status as one of the following four options: laboratory-confirmed COVID-19; admission to hospital with COVID-19-related symptoms; self-isolation due to COVID-19-related symptoms; or no COVID-19 symptoms or diagnosis.", [["tracheal", "ANATOMY", 17, 25], ["tracheal", "ANATOMY", 136, 144], ["infection", "DISEASE", 298, 307], ["tracheal", "MULTI-TISSUE_STRUCTURE", 17, 25], ["tracheal", "MULTI-TISSUE_STRUCTURE", 136, 144], ["participants", "SPECIES", 215, 227], ["tracheal intubation procedures", "TREATMENT", 17, 47], ["devices", "TREATMENT", 100, 107], ["tracheal intubation", "TREATMENT", 136, 155], ["PPE", "TREATMENT", 160, 163], ["ArticleEmails", "TREATMENT", 178, 191], ["their COVID", "TEST", 283, 294], ["COVID", "TEST", 374, 379], ["COVID", "TEST", 411, 416], ["related symptoms", "PROBLEM", 420, 436], ["self-isolation", "PROBLEM", 438, 452], ["COVID", "TEST", 460, 465], ["related symptoms", "PROBLEM", 469, 485], ["COVID-19 symptoms", "PROBLEM", 493, 510], ["tracheal", "ANATOMY", 17, 25], ["tracheal", "ANATOMY", 136, 144], ["intubation", "OBSERVATION", 145, 155], ["infection", "OBSERVATION", 298, 307]]], ["Participants were encouraged to report their infection status on multiple occasions over time.", [["infection", "DISEASE", 45, 54], ["Participants", "SPECIES", 0, 12], ["their infection status", "PROBLEM", 39, 61], ["infection", "OBSERVATION", 45, 54]]], ["Data collection included the date of reported status, and the presence of any of the following symptoms: fatigue; cough; sore throat; headache; myalgia; fever; loss of smell or taste; breathlessness; diarrhoea; nausea or vomiting; abdominal pain; or photophobia.", [["abdominal", "ANATOMY", 231, 240], ["fatigue", "DISEASE", 105, 112], ["cough", "DISEASE", 114, 119], ["sore throat", "DISEASE", 121, 132], ["headache", "DISEASE", 134, 142], ["myalgia", "DISEASE", 144, 151], ["fever", "DISEASE", 153, 158], ["loss of smell or taste", "DISEASE", 160, 182], ["breathlessness", "DISEASE", 184, 198], ["diarrhoea", "DISEASE", 200, 209], ["nausea", "DISEASE", 211, 217], ["vomiting", "DISEASE", 221, 229], ["abdominal pain", "DISEASE", 231, 245], ["photophobia", "DISEASE", 250, 261], ["abdominal", "ORGANISM_SUBDIVISION", 231, 240], ["the following symptoms", "PROBLEM", 81, 103], ["fatigue", "PROBLEM", 105, 112], ["cough", "PROBLEM", 114, 119], ["sore throat", "PROBLEM", 121, 132], ["headache", "PROBLEM", 134, 142], ["myalgia", "PROBLEM", 144, 151], ["fever", "PROBLEM", 153, 158], ["loss of smell or taste", "PROBLEM", 160, 182], ["breathlessness", "PROBLEM", 184, 198], ["diarrhoea", "PROBLEM", 200, 209], ["nausea", "PROBLEM", 211, 217], ["vomiting", "PROBLEM", 221, 229], ["abdominal pain", "PROBLEM", 231, 245], ["photophobia", "PROBLEM", 250, 261], ["abdominal", "ANATOMY", 231, 240]]], ["As participants were enrolled at different times during the study, depending on when the registry opened in their respective countries and institutions, follow-up times were variable depending on enrolment date relativeAccepted ArticleThis article is protected by copyright.", [["participants", "SPECIES", 3, 15], ["the study", "TEST", 56, 65]]], ["All rights reserved to the date of data extraction.", [["data extraction", "TREATMENT", 35, 50]]], ["The primary endpoint of the study was a composite outcome of either new laboratory-confirmed COVID-19 or new COVID-19 symptoms requiring self-isolation or hospitalisation [9] . tracheal intubation characteristics and the primary endpoint were investigated using univariable and multivariable Cox proportional hazards models.", [["tracheal", "ANATOMY", 177, 185], ["tracheal", "MULTI-TISSUE_STRUCTURE", 177, 185], ["the study", "TEST", 24, 33], ["COVID", "TEST", 93, 98], ["new COVID-19 symptoms", "PROBLEM", 105, 126], ["self-isolation", "TREATMENT", 137, 151], ["tracheal intubation", "TREATMENT", 177, 196], ["intubation", "OBSERVATION", 186, 196]]], ["Since characteristics tended to differ between intubations within participants, procedural variables were included as time-updated covariates.", [["participants", "SPECIES", 66, 78], ["intubations", "TREATMENT", 47, 58], ["procedural variables", "TEST", 80, 100]]], ["We selected significant variables on univariable modelling to enter as covariates into our multivariable model.", [["univariable modelling", "TREATMENT", 37, 58], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["No adjustments were made for multiple testing and therefore all analyses should be considered exploratory.Accepted ArticleTo account for multiple tracheal intubations reported by participants, cumulative incidences were also plotted for time from every tracheal intubation, ignoring within-participant dependence, and time from the most recent tracheal intubation, with censoring at the participant's subsequent tracheal intubation.Accepted ArticleTo investigate whether performing an increased number of tracheal intubations led to a higher incidence of the primary endpoint, Kaplan-Meier curves from the first, second and third tracheal intubation were compared.", [["tracheal", "ANATOMY", 146, 154], ["tracheal", "ANATOMY", 253, 261], ["tracheal", "ANATOMY", 344, 352], ["tracheal", "ANATOMY", 412, 420], ["tracheal", "ANATOMY", 505, 513], ["tracheal", "ANATOMY", 630, 638], ["tracheal", "MULTI-TISSUE_STRUCTURE", 146, 154], ["tracheal", "ORGAN", 253, 261], ["tracheal", "ORGAN", 344, 352], ["tracheal", "ORGAN", 412, 420], ["tracheal", "MULTI-TISSUE_STRUCTURE", 505, 513], ["tracheal", "ORGAN", 630, 638], ["participants", "SPECIES", 179, 191], ["participant", "SPECIES", 387, 398], ["multiple testing", "TEST", 29, 45], ["all analyses", "TEST", 60, 72], ["multiple tracheal intubations", "TREATMENT", 137, 166], ["every tracheal intubation", "TREATMENT", 247, 272], ["recent tracheal intubation", "TREATMENT", 337, 363], ["censoring", "TREATMENT", 370, 379], ["tracheal intubation", "TREATMENT", 412, 431], ["tracheal intubations", "TREATMENT", 505, 525], ["Meier curves", "TEST", 584, 596], ["second and third tracheal intubation", "TREATMENT", 613, 649], ["tracheal", "ANATOMY", 146, 154], ["intubations", "OBSERVATION", 155, 166], ["tracheal", "ANATOMY", 253, 261], ["intubation", "OBSERVATION", 262, 272], ["tracheal", "ANATOMY", 344, 352], ["intubation", "OBSERVATION", 353, 363], ["tracheal", "ANATOMY", 412, 420], ["intubation", "OBSERVATION", 421, 431], ["increased", "OBSERVATION_MODIFIER", 485, 494], ["tracheal", "ANATOMY", 505, 513], ["intubations", "OBSERVATION", 514, 525], ["tracheal", "ANATOMY", 630, 638], ["intubation", "OBSERVATION", 639, 649]]], ["There were no missing data from our baseline covariates; missing outcomes were handled as censored outcome variables as is standard for time-to-event modelling.", [["missing data", "PROBLEM", 14, 26], ["missing outcomes", "PROBLEM", 57, 73], ["no", "UNCERTAINTY", 11, 13]]], ["No sample size calculation was performed prior to data collection and analysis, and a convenience sample was used.", [["sample size calculation", "TEST", 3, 26], ["data collection", "TEST", 50, 65], ["analysis", "TEST", 70, 78], ["a convenience sample", "TEST", 84, 104], ["size", "OBSERVATION_MODIFIER", 10, 14]]], ["All analyses were performed using Stata version 16.0 (StataCorp., Texas, USA) or R version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria).", [["All analyses", "TEST", 0, 12], ["Stata version", "TEST", 34, 47]]], ["Table S1 in Appendix S1).", [["Appendix S1", "ANATOMY", 12, 23]]], ["We analysed 5148 tracheal intubations by 1718 participants who recorded at least one tracheal intubation and one follow-up (Table 1 , Fig. 1 ).Accepted ArticleThis article is protected by copyright.", [["tracheal", "ANATOMY", 17, 25], ["tracheal", "ANATOMY", 85, 93], ["tracheal", "ORGAN", 17, 25], ["tracheal", "ORGAN", 85, 93], ["participants", "SPECIES", 46, 58], ["tracheal intubations", "TREATMENT", 17, 37], ["tracheal intubation", "TREATMENT", 85, 104], ["tracheal", "ANATOMY", 17, 25], ["tracheal", "ANATOMY", 85, 93], ["intubation", "OBSERVATION", 94, 104]]], ["All rights reservedAccepted ArticleThe three most frequently reported indications for performing tracheal intubation were respiratory failure (3666, 67.1%), general anaesthesia for surgery (714, 13.1%) and tracheal tube exchange (308, 5.6%).", [["tracheal", "ANATOMY", 97, 105], ["respiratory", "ANATOMY", 122, 133], ["tracheal tube", "ANATOMY", 206, 219], ["respiratory failure", "DISEASE", 122, 141], ["tracheal", "ORGAN", 97, 105], ["tracheal tube", "MULTI-TISSUE_STRUCTURE", 206, 219], ["performing tracheal intubation", "TREATMENT", 86, 116], ["respiratory failure", "PROBLEM", 122, 141], ["general anaesthesia", "TREATMENT", 157, 176], ["surgery", "TREATMENT", 181, 188], ["tracheal tube exchange", "TREATMENT", 206, 228], ["tracheal", "ANATOMY", 97, 105], ["respiratory failure", "OBSERVATION", 122, 141], ["tracheal", "ANATOMY", 206, 214], ["tube", "OBSERVATION", 215, 219]]], ["Approximately half of reported tracheal intubations were performed in critical care units (2783, 50.9%).", [["tracheal", "ANATOMY", 31, 39], ["tracheal", "ORGAN", 31, 39], ["tracheal intubations", "TREATMENT", 31, 51], ["tracheal", "ANATOMY", 31, 39], ["intubations", "OBSERVATION", 40, 51]]], ["Characteristics of reported tracheal intubations are summarised in Table 2 .Accepted ArticleThe majority (4800, 87.9%) of tracheal intubations were performed with participants wearing PPE conforming to World Health Organization (WHO) recommended minimum standards for aerosolgenerating procedures (gown, gloves, eye protection and respirator masks certified to N95 or FFP2 or FFP3 or equivalent standard) [10] .", [["tracheal", "ANATOMY", 28, 36], ["tracheal", "ANATOMY", 122, 130], ["eye", "ANATOMY", 312, 315], ["tracheal", "MULTI-TISSUE_STRUCTURE", 28, 36], ["tracheal", "ORGAN", 122, 130], ["eye", "ORGAN", 312, 315], ["N95", "PROTEIN", 361, 364], ["FFP2", "PROTEIN", 368, 372], ["FFP3", "PROTEIN", 376, 380], ["participants", "SPECIES", 163, 175], ["tracheal intubations", "TREATMENT", 28, 48], ["tracheal intubations", "TREATMENT", 122, 142], ["PPE", "TREATMENT", 184, 187], ["aerosolgenerating procedures", "TREATMENT", 268, 296], ["gown", "TREATMENT", 298, 302], ["gloves", "TREATMENT", 304, 310], ["eye protection", "TREATMENT", 312, 326], ["respirator masks", "TREATMENT", 331, 347], ["FFP2", "TREATMENT", 368, 372], ["FFP3", "TREATMENT", 376, 380], ["tracheal", "ANATOMY", 28, 36], ["intubations", "OBSERVATION", 37, 48], ["tracheal", "ANATOMY", 122, 130], ["eye", "ANATOMY", 312, 315]]], ["Specific PPE combinations varied across participants (Fig. 2) .", [["participants", "SPECIES", 40, 52], ["Specific PPE combinations", "TREATMENT", 0, 25]]], ["The use of respirator masks varied geographically, for example in the U.S., N95 respirator masks (71.6%) andAccepted ArticlePowered Air-Purifying Respirators (PAPRs) (43.4%) were used more commonly than in the UK, where participants more frequently used FFP3/N100 respirator masks (89.3%).", [["participants", "SPECIES", 220, 232], ["respirator masks", "TREATMENT", 11, 27], ["N95 respirator masks", "TREATMENT", 76, 96], ["FFP3", "TREATMENT", 254, 258], ["N100 respirator masks", "TREATMENT", 259, 280]]], ["Table S2 in Appendix S1) among those with a primary outcome were: fatigue (111, 60.3%); cough (102, 55.4%); and sore throat (100, 54.4%).", [["fatigue", "DISEASE", 66, 73], ["cough", "DISEASE", 88, 93], ["sore throat", "DISEASE", 112, 123], ["fatigue", "PROBLEM", 66, 73], ["cough", "TEST", 88, 93], ["sore throat", "PROBLEM", 112, 123], ["Appendix S1", "ANATOMY", 12, 23], ["sore throat", "ANATOMY", 112, 123]]], ["Breathlessness was reported infrequently (35, 19.0%).Accepted ArticleCumulative incidences of the outcomes for 7, 14, and 21 days after the first tracheal intubation episode are shown in Table 3 .", [["tracheal", "ANATOMY", 146, 154], ["Breathlessness", "DISEASE", 0, 14], ["tracheal", "ORGAN", 146, 154], ["Breathlessness", "PROBLEM", 0, 14], ["the first tracheal intubation episode", "TREATMENT", 136, 173], ["tracheal", "ANATOMY", 146, 154], ["intubation", "OBSERVATION", 155, 165]]], ["Cumulative incidence plots (Fig. 4) for the primary outcome from: first tracheal intubation; most recent tracheal intubation; and any tracheal intubation, showed similar incidence rates regardless of the starting point of follow-up.Accepted ArticleUnivariable associations using Cox-regression models indicated a significantly higher incidence of the primary endpoint of COVID-19 infection between countries, in females, and in assistants versus intubators (Table 4) , the latter which was attenuated in a multivariable analysis.", [["tracheal", "ANATOMY", 72, 80], ["tracheal", "ANATOMY", 105, 113], ["tracheal", "ANATOMY", 134, 142], ["infection", "DISEASE", 380, 389], ["tracheal", "ORGAN", 72, 80], ["tracheal", "ORGAN", 105, 113], ["tracheal", "ORGAN", 134, 142], ["COVID-19", "GENE_OR_GENE_PRODUCT", 371, 379], ["Cumulative incidence plots", "PROBLEM", 0, 26], ["first tracheal intubation", "TREATMENT", 66, 91], ["recent tracheal intubation", "TREATMENT", 98, 124], ["any tracheal intubation", "TREATMENT", 130, 153], ["Cox-regression models", "TEST", 279, 300], ["COVID-19 infection", "PROBLEM", 371, 389], ["a multivariable analysis", "TEST", 504, 528], ["tracheal", "ANATOMY", 72, 80], ["intubation", "OBSERVATION", 81, 91], ["tracheal", "ANATOMY", 105, 113], ["intubation", "OBSERVATION", 114, 124], ["tracheal", "ANATOMY", 134, 142], ["intubation", "OBSERVATION", 143, 153], ["infection", "OBSERVATION", 380, 389]]], ["In a multivariable model, betweencountry differences and increased hazards for developing the primary endpoint in females persisted.", [["increased hazards", "PROBLEM", 57, 74], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["primary", "OBSERVATION_MODIFIER", 94, 101]]], ["All rights reserved other significant associations were identified with other factors.", [["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["The hazard rate for the primary endpoint appeared reasonably constant over time from tracheal intubation.DiscussionWe report a unique study of 1718 healthcare workers performing tracheal intubations on COVID-19 patients across 503 hospitals in 17 countries.", [["tracheal", "ANATOMY", 85, 93], ["tracheal", "ANATOMY", 178, 186], ["tracheal", "ORGAN", 85, 93], ["tracheal", "ORGAN", 178, 186], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["The hazard rate", "TEST", 0, 15], ["tracheal intubation", "TREATMENT", 85, 104], ["tracheal intubations", "TREATMENT", 178, 198], ["COVID", "TREATMENT", 202, 207], ["constant", "OBSERVATION_MODIFIER", 61, 69], ["tracheal", "ANATOMY", 85, 93], ["intubation", "OBSERVATION", 94, 104], ["tracheal", "ANATOMY", 178, 186]]], ["After a median follow up of 32 days from the first tracheal intubation episode, 10.7% of participants reported self-isolation or hospitalisation with new symptoms, or laboratory-confirmation of COVID-19 after tracheal intubation episodes in patients with suspected or confirmed COVID-19.", [["tracheal", "ANATOMY", 51, 59], ["tracheal", "ANATOMY", 209, 217], ["tracheal", "ORGAN", 51, 59], ["participants", "ORGANISM", 89, 101], ["tracheal", "ORGAN", 209, 217], ["patients", "ORGANISM", 241, 249], ["participants", "SPECIES", 89, 101], ["patients", "SPECIES", 241, 249], ["the first tracheal intubation episode", "PROBLEM", 41, 78], ["new symptoms", "PROBLEM", 150, 162], ["COVID", "TEST", 194, 199], ["tracheal intubation episodes", "PROBLEM", 209, 237], ["COVID", "TEST", 278, 283], ["tracheal", "ANATOMY", 51, 59], ["intubation", "OBSERVATION", 60, 70], ["tracheal", "ANATOMY", 209, 217], ["intubation", "OBSERVATION", 218, 228]]], ["The incidence of our primary endpoint increased over time from 3.6% within 7 days, to 6.1% within 14 days, and 8.5% within 21 days of participants' first recorded tracheal intubation episodes.", [["tracheal", "ANATOMY", 163, 171], ["tracheal", "ORGAN", 163, 171], ["participants", "SPECIES", 134, 146], ["tracheal intubation episodes", "PROBLEM", 163, 191], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["tracheal", "ANATOMY", 163, 171], ["intubation", "OBSERVATION", 172, 182]]], ["The increased incidence of the primary endpoint in women, which persisted after multivariable adjustment in our modelling, supports future research into sex differences for COVID-19 transmission and disease severity.DiscussionTracheal intubation has previously been highlighted as a high-risk aerosol-generating procedure, with an OR of transmission of 6.6 for SARS-CoV-1 when compared with unexposed healthcare workers [2] .DiscussionHowever, the incidence of infection in healthcare workers involved in tracheal intubation of suspected or confirmed COVID-19 is unknown, and it is unclear which elements of the procedure may contribute to increased risk, if any.", [["Tracheal", "ANATOMY", 226, 234], ["tracheal", "ANATOMY", 505, 513], ["SARS", "DISEASE", 361, 365], ["infection", "DISEASE", 461, 470], ["women", "ORGANISM", 51, 56], ["Tracheal", "ORGAN", 226, 234], ["tracheal", "MULTI-TISSUE_STRUCTURE", 505, 513], ["women", "SPECIES", 51, 56], ["SARS-CoV-1", "SPECIES", 361, 371], ["COVID", "TEST", 173, 178], ["disease severity", "PROBLEM", 199, 215], ["Tracheal intubation", "TREATMENT", 226, 245], ["a high-risk aerosol-generating procedure", "TREATMENT", 281, 321], ["SARS", "PROBLEM", 361, 365], ["infection", "PROBLEM", 461, 470], ["tracheal intubation", "TREATMENT", 505, 524], ["COVID", "TEST", 551, 556], ["the procedure", "TREATMENT", 608, 621], ["increased risk", "PROBLEM", 640, 654], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["incidence", "OBSERVATION_MODIFIER", 14, 23], ["primary", "OBSERVATION_MODIFIER", 31, 38], ["endpoint", "OBSERVATION_MODIFIER", 39, 47], ["disease", "OBSERVATION", 199, 206], ["infection", "OBSERVATION", 461, 470], ["tracheal", "ANATOMY", 505, 513]]], ["In examining the procedure-related characteristics, we identified women as being at increased risk of reporting a COVID-19 outcome.", [["women", "ORGANISM", 66, 71], ["women", "SPECIES", 66, 71], ["the procedure", "TREATMENT", 13, 26], ["a COVID", "TEST", 112, 119]]], ["The reasons for this finding are unclear, and may point to biological differences between men and women, differences in symptom-reporting behaviour, or variations arising from heterogenous sex distributions in our sample.", [["men", "ORGANISM", 90, 93], ["women", "ORGANISM", 98, 103], ["men", "SPECIES", 90, 93], ["women", "SPECIES", 98, 103], ["symptom", "PROBLEM", 120, 127], ["heterogenous", "OBSERVATION_MODIFIER", 176, 188]]], ["Furthermore, we did not detect an association with the use of PPE in accordance with WHO standards, though perhaps the wide range of combinations of PPE reported may have hampered our ability to elucidate any relationship.", [["PPE", "TREATMENT", 62, 65], ["PPE", "PROBLEM", 149, 152]]], ["Regardless, a significant concern highlighted by the data is the insufficient utilisation of PPE in more than 12% of cases.", [["PPE", "PROBLEM", 93, 96]]], ["Although the reasons for deficiencies in PPE utilisation are beyond the scope of these data, this finding might reflect global concerns of PPE scarcity [11] [12] [13] .DiscussionWhilst we are unable to ascribe a causal relationship between tracheal intubation and a COVID-19 outcome, best estimates of population prevalence suggests that the outcomes reported herein may not be due solely to community exposure [4, [14] [15] [16] [17] [18] .", [["tracheal", "ANATOMY", 240, 248], ["tracheal", "ORGAN", 240, 248], ["[14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 415, 439], ["deficiencies in PPE utilisation", "PROBLEM", 25, 56], ["these data", "TEST", 81, 91], ["PPE scarcity", "PROBLEM", 139, 151], ["tracheal intubation", "TREATMENT", 240, 259], ["tracheal", "ANATOMY", 240, 248]]], ["There is little evidence that participant exposure wasAccepted ArticleThis article is protected by copyright.", [["little evidence", "UNCERTAINTY", 9, 24]]], ["Data from the UK estimated a 2-week community prevalence of laboratoryconfirmed COVID-19 of approximately 0.27% [18] , while population prevalence data estimates a US population infection rate of 0.7% and just 0.07% [16] in the European Union and UK.", [["infection", "DISEASE", 178, 187], ["laboratoryconfirmed COVID", "TEST", 60, 85], ["a US population infection rate", "TEST", 162, 192]]], ["Variability in national, regional, and local prevalence based on the disease spread geospatially and temporally [19] , as well as differences in testing and reporting, hampers our ability to make direct comparisons with aggregate population-level data.Accepted ArticleRegardless of the exposure source, our results have significant implications for individual healthcare workers, the workforce, and wider society.", [["the disease spread", "PROBLEM", 65, 83], ["testing", "TEST", 145, 152], ["aggregate population", "TEST", 220, 240], ["regional", "OBSERVATION_MODIFIER", 25, 33]]], ["Self-isolation due to symptoms or laboratory-confirmed COVID-19 of potentially a tenth of the workforce involved in tracheal intubation means that institutions should consider building capacity and resilience in workforce planning during this pandemic and thereafter [20] .", [["tracheal", "ANATOMY", 116, 124], ["tracheal", "ORGAN", 116, 124], ["Self-isolation", "TREATMENT", 0, 14], ["symptoms", "PROBLEM", 22, 30], ["COVID", "TEST", 55, 60], ["tracheal intubation", "TREATMENT", 116, 135], ["tracheal", "ANATOMY", 116, 124], ["intubation", "OBSERVATION", 125, 135]]], ["Diminishing the availability of vital, highly-trained health providers means that institutions may have a shortfall in their capacity to deliver essential healthcare services to both COVID-19 and non-COVID-19 patients.", [["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["COVID", "TEST", 183, 188]]], ["At a public health level, household members of these clinicians will also face the requirement for self-quarantine and are at risk of subsequently contracting the disease, thus amplifying the potential implications of healthcare worker infection.", [["infection", "DISEASE", 236, 245], ["self-quarantine", "TREATMENT", 99, 114], ["the disease", "PROBLEM", 159, 170], ["healthcare worker infection", "PROBLEM", 218, 245], ["disease", "OBSERVATION", 163, 170]]], ["Similarly, other patients and the public may also become exposed to clinicians who develop COVID-19, further perpetuating transmission beyond hospital walls.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["COVID", "TEST", 91, 96]]], ["Of note, 7% of healthcare workers have been shown to be asymptomatic viral carriers based on reverse transcriptase polymerase-chain-reaction testing [17] and up to 44% may be asymptomatic seroconverters of immunoglobulins to SARS-CoV-2 [21] .", [["SARS", "DISEASE", 225, 229], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 206, 221], ["reverse transcriptase", "PROTEIN", 93, 114], ["immunoglobulins", "PROTEIN", 206, 221], ["asymptomatic viral carriers", "PROBLEM", 56, 83], ["reverse transcriptase polymerase", "TEST", 93, 125], ["SARS", "TEST", 225, 229], ["CoV", "TEST", 230, 233]]], ["One potential interpretation of these findings could be that our results may be underestimating the infection rate in clinicians involved in tracheal intubation, as a proportion of those without reported COVID-19 outcomes in our study may be asymptomatic carriers.", [["tracheal", "ANATOMY", 141, 149], ["infection", "DISEASE", 100, 109], ["tracheal", "ORGAN", 141, 149], ["the infection rate", "PROBLEM", 96, 114], ["tracheal intubation", "TREATMENT", 141, 160], ["our study", "TEST", 225, 234], ["asymptomatic carriers", "PROBLEM", 242, 263], ["infection", "OBSERVATION", 100, 109], ["tracheal", "ANATOMY", 141, 149], ["intubation", "OBSERVATION", 150, 160]]], ["Therefore, policies for regular testing of those at greatest risk to personal and public health may be valuable.", [["regular testing", "TEST", 24, 39]]], ["This could identify both asymptomatic carriers [17] , as well as healthcare workers whose symptoms may be consistent with COVID-19 but are due to alternative pathology.Accepted ArticleOur study has several strengths.", [["symptoms", "PROBLEM", 90, 98], ["COVID", "TEST", 122, 127], ["alternative pathology", "PROBLEM", 146, 167], ["ArticleOur study", "TEST", 177, 193]]], ["Firstly, we draw data from the largest international prospective database of high-risk aerosol-generating procedures globally that continues to collect surveillance data that can help inform practice.", [["high-risk aerosol", "TREATMENT", 77, 94], ["generating procedures", "TREATMENT", 95, 116], ["surveillance data", "TEST", 152, 169]]], ["This may become increasingly relevant as further waves of COVID-19 outbreaks emerge, allowing a comparative understanding of changes in practice and risk of healthcare workers.", [["COVID", "TEST", 58, 63]]], ["The follow-up rate of participants after reporting tracheal intubation episodes in our cohort was high, providing validity to our findings.", [["tracheal", "ANATOMY", 51, 59], ["participants", "ORGANISM", 22, 34], ["tracheal", "MULTI-TISSUE_STRUCTURE", 51, 59], ["participants", "SPECIES", 22, 34], ["tracheal intubation episodes", "PROBLEM", 51, 79], ["tracheal", "ANATOMY", 51, 59], ["intubation", "OBSERVATION", 60, 70]]], ["All rights reserved clinicians and other healthcare workers likely to be involved in tracheal intubation.", [["tracheal", "ANATOMY", 85, 93], ["tracheal", "ORGAN", 85, 93], ["tracheal intubation", "TREATMENT", 85, 104], ["tracheal", "ANATOMY", 85, 93], ["intubation", "OBSERVATION", 94, 104]]], ["Finally, we report prospective data that has not been available from any pandemic or epidemic literature to date.", [["prospective data", "TEST", 19, 35]]], ["Firstly, as healthcare workers involved in tracheal intubation may be exposed to SARS-CoV-2 from other sources, direct causality linked to tracheal intubations per se cannot be demonstrated.", [["tracheal", "ANATOMY", 43, 51], ["tracheal", "ANATOMY", 139, 147], ["SARS", "DISEASE", 81, 85], ["tracheal", "ORGAN", 43, 51], ["tracheal", "MULTI-TISSUE_STRUCTURE", 139, 147], ["tracheal intubation", "TREATMENT", 43, 62], ["SARS", "PROBLEM", 81, 85], ["tracheal intubations", "TREATMENT", 139, 159], ["tracheal", "ANATOMY", 43, 51], ["tracheal", "ANATOMY", 139, 147], ["intubations", "OBSERVATION", 148, 159]]], ["Secondly, asymptomatic seroconversion was not accounted for.", [["asymptomatic seroconversion", "PROBLEM", 10, 37], ["asymptomatic", "OBSERVATION_MODIFIER", 10, 22], ["seroconversion", "OBSERVATION", 23, 37]]], ["Thus, the true incidence of infection may have been underestimated due to the prevalence of asymptomatic carrier states.", [["infection", "DISEASE", 28, 37], ["infection", "PROBLEM", 28, 37], ["asymptomatic carrier states", "PROBLEM", 92, 119], ["infection", "OBSERVATION", 28, 37]]], ["Similarly, the reporting of critical illness and death was not feasible in the registry, potentially leading to a source of bias.", [["illness", "DISEASE", 37, 44], ["death", "DISEASE", 49, 54], ["critical illness", "PROBLEM", 28, 44], ["death", "PROBLEM", 49, 54], ["critical", "OBSERVATION_MODIFIER", 28, 36], ["illness", "OBSERVATION", 37, 44]]], ["However, this possibility is minimised using fixed-choice questions, as well as highly motivated participants reporting their tracheal intubation episodes contemporaneously.", [["tracheal", "ANATOMY", 126, 134], ["tracheal", "ORGAN", 126, 134], ["participants", "SPECIES", 97, 109], ["their tracheal intubation episodes", "PROBLEM", 120, 154], ["tracheal", "ANATOMY", 126, 134], ["intubation", "OBSERVATION", 135, 145]]], ["Participants continued to document tracheal intubation episodes regularly and recorded weekly outcomes throughout the study duration.Accepted ArticleFourth, there is a risk of sampling bias stemming from the voluntary nature of study participation, and the healthcare providers engaging in this study may represent a small subset with clinical performance characteristics that are not representative of the larger community.", [["tracheal", "ANATOMY", 35, 43], ["tracheal", "ORGAN", 35, 43], ["Participants", "SPECIES", 0, 12], ["tracheal intubation episodes", "PROBLEM", 35, 63], ["the study duration", "TEST", 114, 132], ["this study", "TEST", 290, 300], ["tracheal", "ANATOMY", 35, 43], ["intubation", "OBSERVATION", 44, 54], ["small", "OBSERVATION_MODIFIER", 317, 322], ["larger", "OBSERVATION_MODIFIER", 407, 413]]], ["Therefore, cautious interpretation of these results is encouraged.Accepted ArticleIn conclusion, approximately 10% of healthcare workers in our sample were either diagnosed with new COVID-19 infection or required self-isolation or hospitalisation with new symptoms following involvement in tracheal intubation of patients with suspected or confirmed COVID-19.", [["tracheal", "ANATOMY", 290, 298], ["infection", "DISEASE", 191, 200], ["tracheal", "ORGAN", 290, 298], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["new COVID-19 infection", "PROBLEM", 178, 200], ["self-isolation", "TREATMENT", 213, 227], ["new symptoms", "PROBLEM", 252, 264], ["tracheal intubation", "TREATMENT", 290, 309], ["COVID", "TEST", 350, 355], ["infection", "OBSERVATION", 191, 200], ["tracheal", "ANATOMY", 290, 298]]], ["Future work should focus on screening and identifying interventions to reduce risks to healthcare workers providing care for COVID-19 patients.Accepted ArticleThis article is protected by copyright.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["screening", "TEST", 28, 37], ["interventions", "TREATMENT", 54, 67]]], ["2 Kaplan-Meier estimates, from the date of first tracheal intubation.", [["tracheal", "ANATOMY", 49, 57], ["tracheal", "ORGAN", 49, 57], ["first tracheal intubation", "TREATMENT", 43, 68], ["tracheal", "ANATOMY", 49, 57], ["intubation", "OBSERVATION", 58, 68]]], ["3 Lab-confirmed COVID-19 diagnosis, self-isolation due to symptoms, hospital admission with \u22651 symptomAccepted ArticleThis article is protected by copyright.", [["COVID", "TEST", 16, 21], ["self-isolation", "TREATMENT", 36, 50], ["symptoms", "PROBLEM", 58, 66]]], ["All rights reserved Where procedural characteristics are analysed as time-updated variables * analysing one variable at a time in a Cox model \u2020 including all variables simultaneously in a multivariable Cox modelSupporting InformationAdditional supporting information may be found online via the journal website.Accepted ArticleAppendix S1 Additional information regarding the study Total number of registered users -n = 4,502NAccepted ArticleParticipants with at least one intubation recorded -n = 2,182NAccepted ArticleExcluded: Users reporting no intubations -n = 2,320NAccepted ArticleParticipants included for analysis -n = 1,718NAccepted ArticleExcluded: Reporting no follow-up outcomes -n = 444N No follow-up outcomes after first intubation -n = 20N", [["a Cox model \u2020", "TREATMENT", 130, 143], ["the study", "TEST", 372, 381], ["analysis", "TEST", 614, 622]]]]}